

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1	(-)-(3aR,4S,7aR)-4-Hydroxy-4-m-tolyethynyl-octahydro-indole-1-carboxylic acid methyl ester	n/a	10/12/2011	Treatment of Fragile X syndrome	Novartis Pharmaceuticals Corp.
2	(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-broethyl) diamidophosphate	n/a	6/5/2013	Treatment of pancreatic cancer	EMD Serono
3	(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate	n/a	3/9/2012	Treatment of soft tissue sarcoma	Threshold Pharmaceuticals, Inc.
4	(1R,3R,4R,5S)-3-O-[2-O-benzoyl-3-O-(sodium(2S)-3-cyclohexyl-propanoate-	n/a	2/17/2009	Treatment of vaso-occlusive crisis in patients with sickle cell disease.	Pfizer, Inc.
5	(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride	n/a	8/13/2004	Treatment of acute lymphoblastic leukemia	Mundipharma Research Limited
6	(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride	n/a	1/29/2004	Treatment of T-cell non-Hodgkin's lymphoma	Mundipharma Research Limited
7	(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride	n/a	8/10/2004	Treatment of chronic lymphocytic leukemia and related leukemias to include prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia	Mundipharma Research Ltd.
8	(1S,3S)-3-amino-4-(difluoromethylene)cyclopentanecarboxylic acid hydrochloride, (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid hydrochloride	n/a	9/15/2010	Treatment of infantile spasms.	Catalyst Pharmaceutical Partners
9	(2E, 4E, 6Z, 8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl) nona-2,4,6,8-tetraen-1-yl acetate	n/a	12/2/2010	Treatment of retinitis pigmentosa	QLT Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
10	(2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenyl acetate 9-cis-retinyl acetate (API)	n/a	12/2/2010	Treatment of Leber congenital amaurosis (LCA) due to inherited mutations in RPE65 (encoding the protein retinal pigment epithelial protein 65) or LRAT (encoding the enzyme lecithin:retinol acyltransferase)genes.	QLT, Inc.
11	(2S)-2-[[[(2R)-2-[[[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- 1,2,5-benzothiadiazepin-8-yl]oxy}acetyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]butanoic acid	n/a	10/31/2012	Treatment of progressive familial intrahepatic cholestasis	Albireo AB
12	(2S)-2-[[[(2R)-2-[[[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- 1,2,5-benzothiadiazepin-8-yl]oxy}acetyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]butanoic acid	n/a	10/31/2012	Treatment of primary biliary cirrhosis	Albireo AB
13	(2Z)-2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-hepten-6-ynamide	Fk778	1/10/2005	Prevention of acute rejection following kidney, heart, and liver transplantation	Fujisawa Healthcare, Inc.
14	(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-yl amino) phenyl] benzamide	n/a	3/18/2011	Treatment of chronic myelogenous leukemia.	NATCO Pharma Limited
15	(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-yl amino) phenyl] benzamide	n/a	3/18/2011	Treatment of pancreatic cancer	NATCO Pharma Limited
16	(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-yl amino) phenyl] benzamideNRC-AN-019	n/a	3/18/2011	Treatment of Glioma	NATCO Pharma Limited
17	(3E,5E)-3,5-bis[(4-fluoro-3-nitrophenyl)methylidene]-1-(prop-2-enoyl)azepan-4-One	n/a	4/30/2014	Treatment of multiple myeloma	VivoLux AB

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
18	(3S)-3-(4-trifluoromethoxybenzyloxy)-6-nitro-2H-3,4-dihydroimidazo[2,1-b]oxazine	n/a	7/5/2007	Treatment of tuberculosis.	Global Alliance for TB Drug Development
19	(3S)-3-[(2S)-2-({N-[2-tert-butyl]phenyl}carbonyl)carbonylamino)propanoylamino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy) pentanoci acid	n/a	8/19/2003	Treatment of patients undergoing solid organ transplantation.	Pfizer Global Research and Development
20	(3S)-3-(4-[7-(aminocarbonyl)-2H-indazol-2-	(3s)-3-{4-[7-(Aminocarbonyl)-2	4/30/2010	Treatment of ovarian cancer	TESARO, Inc.
21	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy)methyl]phenyl)methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of primary sclerosing cholangitis	Lumena Pharmaceuticals' Inc.
22	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy)methyl]phenyl)methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of alagille syndrome	Lumena Pharmaceuticals, Inc.
23	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy)methyl]phenyl)methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of primary biliary cirrhosis	Lumena Pharmaceuticals, Inc.
24	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy)methyl]phenyl)methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of progressive familial intrahepatic cholestasis	Lumena Pharmaceuticals. Inc.
25	(5R)-5-(4-([2-fluorophenyl)methyl]oxy)phenyl)-L-prolinamide, hydrochloride	n/a	7/24/2013	Treatment of trigeminal neuralgia	Convergence Pharmaceuticals Ltd.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
26	(6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl]amino-L-glyceroB-L-manno-heptopyranosyl]amino-9H-purine)	n/a	2/21/2014	Parenteral treatment of painful, chronic, chemotherapy-induced peripheral neuropathy that is refractory to conventional analgesics	DARA BioSciences, Inc.
27	(6-maleimidocaproyl)hydrazone of doxorubicin	n/a	6/29/2011	Treatment of soft tissue sarcoma	CytRx Corporation
28	(6R,S)5,10-methylene-tetrahydrofolic acid	Cofactor	8/13/2004	For use in combination with 5-fluorouracil for the treatment of patients with pancreatic cancer	Adventrx Pharmaceuticals, Inc.
29	(9-[N-(3-morpholinopropyl)-sulfonyl]-5,6-dihydro-5-oxo-11-H-indeno [1,2-c] isoquinoline methanesulfonic acid	n/a	12/8/2004	Prevention of post-operative complications of aortic aneurysm surgical repair	Inotek Pharmaceuticals Corporation
30	(E)-4-carboxystyryl-4-chlorobenzyl-sulfone, sodium salt	Ex-Rad(R)	6/1/2012	Prevention of acute radiation toxicity, also known as Acute Radiation Syndrome (ARS)	Onconova Therapeutics, Inc.
31	(E)-4-carboxystyryl-4-chlorobenzyl-sulfone, sodium salt	Ex-Rad(R)	9/4/2012	Treatment of acute radiation syndrome	Onconova Therapeutics, Inc.
32	(N-[2,6-bis(1-methylethyl)-phenyl-N'-[[1-(4-dimethyl-amino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt	n/a	3/9/2012	Treatment of adrenocortical carcinoma	Atterocor, Inc.
33	(R)-1-(2,2-difluorobenzo [d][1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide	n/a	4/24/2014	Treatment of cystic fibrosis	Vertex Pharmaceuticals Inc.
34	(R)-1-phenylethyl-5-(4-biphenyl-4-cyclopropanecarboxylic acid)-3-methylisoxazole-4-yl carbamate sodium salt	n/a	4/15/2011	Treatment of idiopathic pulmonary fibrosis	Bristol-Myers Squibb Company
35	(R)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxy-methyl}-2,3-dihydroimidazo[2,1-b]oxazole	n/a	7/12/2007	Treatment of pulmonary tuberculosis.	Otsuka Pharmaceutical Company, Ltd

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
36	(R)-4-(3-morpholin-4-yl-1-phenylsulfanylmethyl-propylamino)-N-(4-{4-[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enylmethyl]-piperazin-1-yl}-benzoyl)-3-trifluoromethanesulfonylbenzenesulfonamide bis-hydrochloride	n/a	12/19/2007	Treatment of small cell lung cancer.	AbbVie, Inc
37	(R)-N-[2-(6-chloro-5-methoxy-1H-indol-3-yl)propyl]acetamide	n/a	10/3/2001	Treatment of circadian rhythm sleep disorders in blind people with no light perception	Phase 2 Discovery, Inc.
38	(R)-N-[2-(6-Chloro-methoxy-1H-indol-3yl)propyl]acetamide	n/a	7/3/2003	Treatment of neuroleptic-induced tardive dyskinesia in schizophrenia patients	Phase 2 Discovery, Inc.
39	(RS)-baclofen, naltrexone and D-sorbitol	n/a	3/17/2014	Treatment of Charcot-Marie-Tooth disease type 1A	Pharnext SAS
40	(S)-10-[(dimethylamino)methyl]-4-ethyl-9hydroxy-4-O-[a-(2",4",5",7"-tetranitro-9"-fluorenylideneaminoxy)propionyl]- 1H-pyrano[3',4',6',7',] indolizino [1,2-B]-quinoline-3, 14-(4H, 12H)-dione, hydrochloride	Lipotecan	10/6/2010	Treatment of hepatocellular carcinoma	TLC Biopharmaceuticals, Inc.
41	(S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one	n/a	8/1/2013	Treatment of follicular lymphoma	Infinity Pharmaceuticals, Inc.
42	(S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one	n/a	4/15/2013	Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma	Infinity Pharmaceuticals
43	(S)-4-(5-chloro-2-(isopropylamino)pyridin-4-yl)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1H-pyrrole-2-carboxamide hydrochloride	n/a	6/24/2013	Treatment of Stage IIb through Stage IV BRAF mutant melanoma	BioMed Valley Discoveries, Inc.
44	(S)-4,5-dihydro-2[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiaxolecarboxylic acid	n/a	2/4/2009	Treatment of chronic iron overload in patients with transfusion-dependent anemias	Ferrokin BioSciences, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
45	(UDU-stereoisomer of c-UJUn UNU-terminal UkUnhibitor)	n/a	3/28/2006	Treatment of acute sensorineural hearing loss	Auris Medical, Inc.
46	(Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(pyrazin-2-yl)acrylohydrazide	n/a	5/14/2014	Treatment of diffuse large B-cell lymphoma	Karyopharm Therapeutics, Inc.
47	(Z)-9-([2,2-bis-(hydroxymethyl)cyclopropylidene]methyl)guanine, cyclopropavir, ZSM-1-62 and NSC D745998	n/a	11/29/2010	Treatment of active cytomegalovirus infections.	Microbiotix, Inc.
48	[131I]-N-(2-(diethylamino) ethyl-4-(4-fluorobenzamido)-5-(iodo)-2-methoxybenzamide	n/a	9/17/2008	Treatment of metastatic melanoma, stages IIB, IIC, III and IV	Molecular Insight Pharmaceuticals, Inc.
49	[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine hydrochloride salt	n/a	2/14/2014	Treatment of pigmented villonodular synovitis/giant cell tumor of the tendon sheath	Plexxikon, Inc.
50	[5,10,15,20-tetrakis(1,3-diethylimidazolium-2-yl)porphyrinato] manganese(III)pentachloride	n/a	11/4/2003	Treatment of Amyotrophic Lateral Sclerosis	Aeolus Pharmaceuticals, Inc.
51	[AC3-yCD2(V)] and Flucytosine (5-FC XR)	n/a	1/12/2011	Treatment of glioblastoma multiforme	Tocagen, Inc.
52	[a-N-(2'succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-[epsilon-N-(2'succinyl-paclitaxel)Lys]-Arg-Asn-Asn-Phe-[epsilon-N-(2'succinyl-paclitaxel)Lys]-Thr-Glu-Glu-Tyr	n/a	5/14/2014	Treatment of glioblastoma multiforme	Angiochem, Inc.
53	[Lu-177]-DOTA-Tyr3-Octreotate	n/a	1/12/2009	Treatment of gastro-entero-pancreatic neuroendocrine tumors	BioSynthema, Inc.
54	[met5]-enkephalin	Opioid Growth Factor	1/24/2013	Treatment of pancreatic cancer	TNI BioTech, Inc.
55	[Nle4, D-Phe7]-a-melanocyte stimulating hormone	n/a	7/17/2008	Treatment of erythropoietic porphyrias	Clinuvel Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
56	{2-amino-8-[4-(pyrrolidinylcarbonyl)phenyl](3H-benzo[f]azepin-4-yl)}-N,N-dipropylcarboxamide	n/a	4/10/2014	Treatment of ovarian cancer	VentiRx Pharmaceuticals, Inc.
57	1-(2-C-cyano-2-deoxy-B-D-arabino-pentafuranosyl)-N4-palmitoylcytosine	Sapacitabine	6/24/2010	Treatment of myelodysplastic syndrome	Cyclacel Limited
58	1-(2-C-cyano-2-deoxy-B-D-arabino-pentafuranosyl)-N4-palmitoylcytosine	Sapacitabine	6/24/2010	Treatment of acute myelogenous leukemia	Cyclacel Limited
59	1-(3-chloro-5-[[4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]carbamoyl]-2-pyridyl) piperidine-4-carboxylic acid Monomaleate	n/a	9/1/2011	Treatment of idiopathic thrombocytopenic purpura	Eisai, Inc.
60	1-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridine-3-yl}phenyl)-3-(3-fluorophenyl)urea)	n/a	7/28/2011	Treatment of acute myelogenous leukemia	AbbVie, Inc.
61	1,2:5,6-Dianhydrogalactitol, NSC-132313	n/a	1/31/2012	Treatment of malignant gliomas	Del Mar Pharmaceuticals (BC), Ltd.
62	1,5-(Butylimino)-1,5 dideoxy,D-glucitol	n/a	5/12/1998	Treatment of Fabry's disease.	Oxford GlycoSciences
63	1-[(2-Chloro-4-methoxyphenoxy)methyl]-4-[(2,6-dichlorophenoxy) methyl]benzene	n/a	1/9/2012	Treatment of poliovirus infection.	ViroDefense, Inc.
64	1'-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[furo[2,3-f][1,3]benzodioxole-7,3'-indol]-2'(1'H)-one	n/a	11/19/2012	Treatment of erythromelalgia	Teva Pharmaceuticals
65	10 synthetic peptides targeting 5 tumor associated antigens	n/a	1/23/2013	Treatment of non-small cell lung cancer in patients expressing HLA-A2	Orphan Synergy Europe Pharma (OSE Pharma)
66	111Indium pentetreotide	Somatother	6/10/1999	Treatment of somatostatin receptor positive neuroendocrine tumors.	Louisiana State University Medical Center Foundation
67	12-A-p21 RAS(5-21). 12-C-p21 RAS(5-21). 12-D-p21 RAS(5-21). 12-Rp21 RAS(5-21). 12-S-p21 RAS(5-21). 12-V-p21 RAS(5-21). 13-D-p21 RAS(5-21)	n/a	6/7/2011	Treatment of pancreatic cancer	Targovax AS

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
68	14-amino acid peptide derived from wound growth factor	n/a	8/5/2010	Prevention of delayed graft function in renal transplant recipients	NephRx Corporation
69	14-amino acid peptide derived from wound growth factor	n/a	8/16/2010	Treatment of delayed graft function in renal transplant recipients	NephRx Corporation
70	17 amino acid peptide	n/a	1/29/2010	Prevention of ischemia reperfusion injury in the lung during lung transplantation	Apeptico
71	177Lu-tetraxetan-tetulumab	Betalutin	5/14/2014	Treatment of Follicular Lymphoma	Nordic Nanovector AS
72	17-allylamino-17-demethoxygeldanamycin (17-AGG)	n/a	9/3/2004	Treatment of chronic myelogenous leukemia	Bristol-Myers Squibb Company
73	18-(p-[124I]-iodophenyl)octadecyl phosphocholine	n/a	4/30/2014	Diagnostic for the management of glioma	Cellectar Biosciences, Inc.
74	1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]-urea	n/a	11/12/2009	Treatment of acute myeloid leukemia	Astex Therapeutics Ltd
75	2 dimethylbutyrate	n/a	6/18/2008	Treatment of beta thalassemia	HemaQuest Pharmaceuticals, Inc.
76	2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-C]pyridine-3,6(2H,5H)-dione	n/a	9/21/2010	Treatment of idiopathic pulmonary fibrosis.	GenKyoTex S.A.
77	2-(2-phenylvinyl)-4-[4-methylpiperazin-1-yl]-6-(5-methyl-2H-pyrazol-3-ylamino)-pyrimidine L(+) tartrate salt	n/a	3/18/2009	Treatment of ovarian carcinoma	EntreMed, Inc.
78	2-(2-phenylvinyl)-4-[4-methylpiperazin-1-yl]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt	n/a	12/22/2008	Treatment of multiple myeloma.	EntreMed, Inc.
79	2-(2-phenylvinyl)-4-[-methylpiperazin-1-yl]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt	n/a	1/29/2010	Treatment of acute myeloid leukemia.	EntreMed, Inc.
80	2-(3-diethylaminopropyl)-8,8-dipropyl-2-azaspiro [4,5] decan dimaleate	Atiprimod	12/2/2003	Treatment of mulitple myeloma and associated bone resorption	Callisto Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
81	2-(3-Diethylaminopropyl)-8,8-dipropyl-2-azaspiro[4,5] decane dimaleate	Atiprimod	9/18/2006	Treatment of carcinoid tumors	Callisto Pharmaceuticals, Inc.
82	2,2'-(2-[1R]-1-(((2,5-dichlorobenzoyl)amino)acetyl)amino)-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diyl}diacetic acid (ixazomib citrate)	n/a	3/9/2012	Treatment of systemic light chain (AL) amyloidosis.	Millennium Pharmaceuticals, Inc.
83	2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol	Epidiolex	11/14/2013	Treatment of Dravet syndrome.	GW Pharma Ltd.
84	2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol	Epidiolex	2/27/2014	Treatment of Lennox-Gastaut syndrome	GW Pharma Ltd.
85	2-[(3-methyl-4-(2,2,2-trifluoroethoxy) pyridin-2-yl)methylsulfinyl] -1H-benzoimidazole	Prevonco (Tm)	8/27/2008	Treatment of hepatocellular carcinoma.	BioQuant, Inc.
86	2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide	n/a	12/18/2007	Treatment of malignant melanoma stages IIb through IV.	AbbVie, Inc.
87	2-[(R)-2methylpyrrolidin-2-yl]-1h-benzimidazole-4-carboxamide	n/a	9/3/2009	Treatment of epithelial ovarian cancer in combination with DNA-damaging agents	AbbVie, Inc.
88	2-[[3-({4-[(5-{2-[(3-Fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}propyl)(ethyl)amino)ethyl dihydrogen phosphate trihydrate	n/a	1/19/2010	Treatment of acute myeloid leukemia	AstraZeneca Pharmaceuticals LP
89	2-[4-Methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indian-2-carboxylic acid	n/a	5/14/2013	Treatment of patients with systemic sclerosis	Sanofi U. S., Inc.
90	2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide	n/a	4/30/2010	Treatment of pulmonary arterial hypertension	Actelion Ltd
91	2-O-Butyryl-1-O-octyl-myo-inositol 3,4,5,6-tetrakisphosphate	n/a	8/15/2003	Treatment of cystic fibrosis	Inologic, Inc.
92	2-O-desulfated heparin	Aeropin	9/17/1993	Treatment of cystic fibrosis.	Kennedy & Hoidal, M.D.'s

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
93	20-mer complementary to Akt mRNA	n/a	12/10/2004	Treatment of stomach cancer	Rexahn Corporation
94	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/8/2004	Treatment of pancreatic cancer	Rexahn Corporation
95	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/8/2004	Treatment of glioblastoma	Rexahn Corporation
96	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/1/2004	Treatment of ovarian cancer	Rexahn Corporation
97	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/1/2004	Treatment of renal cell carcinoma	Rexahn Corporation
98	24,25 dihydroxycholecalciferol	n/a	2/27/1987	Treatment of uremic osteodystrophy.	Lemmon Company
99	2-Chloro-4-[1-(4-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridinium sulfate	n/a	3/9/2012	Treatment of Fragile X Syndrome	Hoffmann-La Roche, Inc.
100	2-chloroethyl-3-sarcosinamide-1-nitrosoarea	Sarmustine	11/15/2001	Treatment for malignant glioma	Pangene Corporation
101	2-chloroethyl-3-sarcosinamide-1-nitrosoarea	n/a	8/3/2001	Treatment for malignant gliomas	Lawrence Panasci, MD
102	2-Chloro-N6--(3-iodobenzyl)adenosine-5'-N-methyluronamide	n/a	2/17/2012	Treatment of hepatocellular carcinoma	Can-Fite BioPharma Ltd.
103	2'-deoxycytidine	n/a	9/9/1996	As a host-protective agent in the treatment of acute myelogenous leukemia.	Grant, Steven M.D.
104	2-hydroxypropyl-B-cyclodextrin	Kleptose	2/18/2013	Treatment of Niemann-Pick disease type C	National Institutes of Health
105	2-iminobiotin	n/a	2/24/2009	Treatment of perinatal asphyxia.	Neurophyxia B.V.
106	2-methoxyestradiol	Pulmolar	4/11/2005	Treatment of pulmonary arterial hypertension	PR Pharmaceuticals, Inc.
107	2'-O-methyl phosphorothioate 5'-GCUAGGUUUACGGGACCUCU-3'	n/a	10/31/2012	Treatment of amyotrophic lateral sclerosis	LifeSplice Pharma LLC
108	2S,4R ketoconazole	n/a	3/9/2012	Treatment of endogenous Cushing's syndrome	Cortendo AB (HQ address)
109	3-(3,5-Dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one	n/a	3/23/2000	Treatment of von Hippel-Lindau disease.	Sugen, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
110	3-(3,5-dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one	n/a	9/11/1998	Treatment of Kaposi's sarcoma.	Sugen, Inc.
111	3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxyl-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid	n/a	3/2/2010	Treatment of cystic fibrosis	Vertex Pharmaceuticals Inc.
112	3,4 diaminopyridine and choline bitartrate	n/a	4/30/2010	Treatment of Lambert-Eaton myasthenic syndrome	MS Therapeutics Limited
113	3,4-diaminopyridine	n/a	12/18/1990	Treatment of Lambert-Eaton myasthenic syndrome.	Jacobus Pharmaceutical Company
114	3,4-Diaminopyridine phosphate	n/a	11/12/2009	Treatment of Lambert-Eaton Myasthenic Syndrome	Catalyst Pharmaceutical Partners, Inc.
115	3,5,3'-triiodothyroacetate	n/a	9/20/2000	Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid gland.	Elliot Danforth, Jr., M.D.
116	3,5-diiodothyropropionic acid	n/a	5/14/2013	Treatment of Allan-Herndon-Dudley syndrome	Zarion Pharmaceuticals P/L
117	3-bromopyruvate	n/a	3/5/2013	Treatment of liver and intrahepatic bile duct cancer	Primocure Pharma, Inc.
118	3-bromopyruvate	n/a	4/29/2014	Treatment of pancreatic cancer	PreScience Labs, LLC
119	3-chloro-4-fluorophenyl-[4-fluoro-4-[[5-methylpyrimidin-2-ylmethyl)amino]methyl]piperidin-1yl]methanone	n/a	10/25/2013	Treatment of Rett syndrome	Neurolaxis, Inc.
120	3-fluoro-5-[5-(2-menthyl-thiazol-4-ylethynyl)-pyridin-2-yl]-benzonitrile dihydrochloride	n/a	7/28/2008	Treatment of behavioral abnormalities associated with fragile X syndrome.	Seaside Therapeutics

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
121	4-(2-fluorophenyl)-6-methyl-2-(1-piperziny)	n/a	10/11/2006	Treatment of Chronic Functional Vomiting to include functional vomiting and cyclic vomiting syndrome.	Dynogen Pharmaceuticals, Inc.
122	4-(3-Methanesulfonyl-phenyl)-1-propylpiperidine HCl	n/a	12/12/2005	Treatment of Huntington's disease.	Teva Branded Pharmaceutical Products R&D
123	4-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl)sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide	n/a	3/27/2014	Treatment of diffuse large B-cell lymphoma.	AbbVie
124	4-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl)sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide	n/a	9/20/2012	Treatment of chronic lymphocytic leukemia	AbbVie, Inc.
125	4-(6-(4-(piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline hydrochloride	n/a	4/15/2013	Treatment of fibrodysplasia ossificans progressiva	La Jolla Pharmaceutical Company, Inc.
126	4, 5 dibromorhodamine methyl ester	Theralux Photodynamic Therapy	10/30/2008	Treatment of follicular lymphoma	Kiadis Pharma Canada, Inc.
127	4, 5 dibromorhodamine methyl ester	Theralux Photodynamic Therapy	10/30/2008	Treatment of diffuse large B-cell lymphoma	Kiadis Pharma Canada, Inc.
128	4,5 dibromorhodamine methyl ester	Theralux Photodynamic Therapy	10/23/2007	For immune reconstitution and prevention of graft versus host disease following allogeneic hematopoietic stem cell transplantation.	Kiadis Pharma Canada, Inc.
129	4,5,6,7-tetrachloro-2',4',5',7'-tetraiodofluorescein disodium salt	n/a	4/18/2011	Treatment of hepatocellular carcinoma.	Provectus Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
130	4-[(5R)-6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile	n/a	9/13/2013	Treatment of Cushing's disease	Novartis Pharmaceuticals corporation
131	4-[[9-(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-trans-cyclohexanol	n/a	9/23/2011	Treatment of idiopathic pulmonary fibrosis	Celgene Corporation
132	4-[1]benzofuro[3,2-d]pyrimidin-4-yl-N-(1,3-benzodioxol-5-ylmethyl)piperazine-1-carbothioamide	n/a	7/30/2008	Treatment, in combination with radiotherapy and temozolomide chemotherapy, of patients with glioblastoma multiforme.	SuperGen, Inc.
133	4-[131I]iodo-L-phenylalanine	n/a	1/4/2011	Treatment of glioma.	Therapeia GmbH & Co KG
134	4-[2-(3-Propyl-[1,2,4]Oxadiazol-5-yl)-vinyl]-benzene-1,2-diol	n/a	10/4/2011	Treatment of chronic myeloid leukemia	Piramal Enterprises Limited
135	4-[4-[[[3-(1,1-dimethylethyl)-1-(6-quinolinyl)-1H-pyrazol-5-yl]amino]carbonyl]-amino]-3-fluorophenoxy]-N-methyl-2-pyridinecarboxamide, p-toluenesulfonate salt	n/a	9/3/2009	Treatment of Philadelphia chromosome positive chronic myeloid leukemia	Deciphera Pharmaceuticals, LLC
136	4-[[[(2R,3S,4R,5S)-4-(4-Chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino]-3-methoxy-benzoic acid	n/a	5/19/2014	Treatment of Acute Myeloid Leukemia	Roche Genentech
137	40K PEGylated recombinant factor IX	n/a	3/18/2013	Routine prophylactic administration for prevention of bleeding in patients with hemophilia B (Christmas disease).	Novo Nordisk, Inc.
138	4-Amino-1-[5-O-[(2R, 4S)-2-oxido-4-(4-pyridinyl)-1, 3, 2-dioxaphosphorinan-2-yl]-b-D-arabinofuranosyl]-2(1H)-pyrimidinone	n/a	8/22/2007	Treatment of hepatocellular carcinoma.	Ligand Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
139	4-Aminopyridine	n/a	12/14/2005	Treatment chronic functional motor and sensory deficits from Guillain-Barre syndrome	Acorda Therapeutics, Inc.
140	4-aminosalicylic acid	Pamisyl (P-D), Rezipas (Squibb)	12/13/1989	Treatment of mild to moderate ulcerative colitis in patients intolerant to sulfasalazine.	Beeken, Warren M.D.
141	4-aminosalicylic acid	Paser Granules	4/26/2006	Treatment of acute flares in pediatric patients with ileo-cecal Crohn's disease	Jacobus Pharmaceutical Co., Inc.
142	4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide monohydrochloride	n/a	7/20/2006	Treatment of acute myeloid leukemia	Johnson & Johnson Pharmaceutical Research & Dev,
143	4-pyridinylmethyl 3(4-chlorophenyl)adamantine carboxamide	n/a	11/2/2010	Treatment of pancreatic cancer.	Apogee Biotechnology Corporation
144	5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine hydrochloride	n/a	4/18/2011	Treatment of progressive supranuclear palsy.	Mithridion, Inc.
145	5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzop[d]oxazole	n/a	11/22/2011	Treatment of Duchenne Muscular Dystrophy	Summit Corporation plc
146	5(S)-(2'-hydroxy ethoxy)-20(S)-Camptothecin	n/a	6/15/2007	Treatment of osteosarcoma (bone cancer)	Dr. Reddy's Laboratories, Inc.
147	5,5',5''-[Phosphinothiolyldiene-tris(imino-2,1-ethanediyl)]tris[5-methylchelidoninium]trihydroide hexahydrochloride	n/a	8/20/2003	Treatment of pancreatic cancer	Now Pharm AG
148	5,6-dihydro-5-azacytidine	n/a	5/11/1992	Treatment of malignant mesothelioma.	ILEX Oncology, Inc.
149	5,7-dihydroxy-3-(4-hydroxyphenyl)-chromen-4-one	n/a	6/18/2007	Prevention of acute radiation syndrome	Humanetics Corporation
150	5-[(E)-2-(4-hydroxyphenyl)-ethenyl] benzene-1,3 diol	Resveratrol	3/13/2008	Treatment of MELAS syndrome	Sirtis Pharmaceuticals, Inc.
151	5-[1-(2,6-Dichlorobenzyl)-piperidin-4-yl]methoxyquinazoline-2,4-diamine	n/a	8/25/2009	Treatment of spinal muscular atrophy	Pfizer Incorporated

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
152	5'fA ₂ Ã,ÃfÃ,ÃcÃfA ₂ ÃfÃ,Ã-"-GAATATTAACAIACTGACAAGTC-3ÃfA ₂ Ã,ÃfÃ,ÃcÃfA ₂ ÃfÃ,Ã-"	n/a	10/31/2012	Prophylaxis following documented or suspected exposure to marburg virus	Sarepta Therapeutics, Inc.
153	5-aminolevulinic acid	Gliolan	1/15/2013	Visualization of malignant tissue during surgery for malignant glioma (WHO grade III and IV)	NX Development Corporation
154	5-aza-2'-deoxycytidine	n/a	8/3/1987	Treatment of acute leukemia.	SuperGen, Inc.
155	5'-GCCATGGTTTTTCTCAGG-3'	n/a	10/31/2012	Prophylaxis for patients following documented or suspected exposure to ebolavirus	Sarepta Therapeutics, Inc.
156	5-hydroxymethyl-2-furfuraldehyde	n/a	5/26/2006	Treatment of sickle cell disease	AesRx, LLC
157	5-iodo-2-pyrimidinone-2'-deoxyribose	n/a	5/26/2006	Treatment of malignant glioma	Hana Biosciences, Inc.
158	5-methyl-1-phenyl-2-(1H)-pyridone(CAS 53179-13-8)	Pirfenidone	3/5/2004	Treatment of idiopathic pulmonary fibrosis	InterMune, Inc.
159	6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo-[1,2-alpha]pyrazin-8-amine bis-methanesulfonate	n/a	4/14/2014	Treatment of chronic lymphocytic leukemia	Gilead Sciences, Inc.
160	6,8-bis-benzylsulfanyl-octanoic acid	n/a	2/6/2006	Treatment of pancreatic cancer	Cornerstone Pharmaceuticals, Inc.
161	6,8-bis-benzylsulfanyl-octanoic acid	n/a	8/22/2011	Treatment of acute myeloid leukemia.	Cornerstone Pharmaceuticals, Inc.
162	6,8-bis-benzylsulfanyl-octanoic acid	n/a	9/26/2013	Treatment of myelodysplastic syndrome	Cornerstone Pharmaceuticals, Inc.
163	6-alpha-ethylchenodeoxycholic acid	n/a	4/9/2008	Treatment of primary sclerosing cholangitis	Intercept Pharmaceuticals, Inc.
164	6-amino-5-chloro-N-[1R)-1-[5-[[[5-chloro-4-(trifluoromethyl)-2pyridinyl]amino]carbonyl]-2-thiazoyl]ethyl]-4-pyrimidinecarboxamide	n/a	10/15/2013	Treatment of stage IIb-IV melanoma	Millennium Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
165	6-mercaptopurine oral liquid	n/a	12/7/2009	Treatment of acute lymphoblastic leukemia in the pediatric population	Orbona Pharma Ltd
166	7-B-Hydroxy Cholesteryl-3-B-Oleate-Ester	n/a	6/15/2011	Treatment of gliomas.	Intsel Chimos SA
167	8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naph-thyrin-3(2H)-one mono-hydrochloride	n/a	9/3/2009	Treatment of ovarian cancer.	Merck Sharp & Dohme Corp.
168	8-methoxsalen	Uvadex	6/22/1993	For use in conjunction with the UVAR photopheresis to treat diffuse systemic sclerosis.	Therakos, Inc.
169	8-methoxsalen	Uvadex	5/12/1994	For the prevention of acute rejection of cardiac allografts.	Therakos, Inc.
170	90Y-hPAMA4	Pan-Cide	1/29/2004	Treatment of pancreatic cancer	Immunomedics, Inc.
171	9-nitro-20-(S)-camptothecin	Camvirex	5/15/2001	Treatment of pediatric HIV infection/AIDS	NovoMed Pharmaceuticals, Inc.
172	9-nitro-20-(S)-camptothecin	n/a	9/16/1996	Treatment of pancreatic cancer.	SuperGen, Inc.
173	a live attenuated bioengineered Listeria monocytogenes cancer immunotherapy	n/a	4/29/2014	Treatment of Stage II to IV invasive cervical carcinoma	Advaxis, Inc.
174	A10 & AS2-1 Antineoplaston	n/a	9/3/2004	Treatment for patients with brain stem glioma	Burzynski Research Institute, Inc.
175	aadeno-associated viral vector, serotype 2, containing the human choroideremia gene encoding human Rab escort protein 1	n/a	9/12/2013	Treatment of choroideremia due to mutations in the human choroideremia gene (CHM)	Ctr for Cellular & Molecular Therapeutics
176	AAV-G6Pase vector	n/a	3/11/2013	Treatment of glycogen storage disease type Ia	GlyGenix Therapeutics, Inc.
177	abatacept	Orencia	5/30/2013	Treatment of type 1 diabetes mellitus patients with residual beta cell function	Orban Biotech LLC
178	abeotaxane inhibitor of microtubules	n/a	10/7/2011	Treatment of gliomas	Cortice Biosciences
179	abeotaxane inhibitor of microtubules	n/a	4/18/2011	Treatment of pediatric neuroblastoma.	Cortice Biosciences

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
180	Abetimus	n/a	7/28/2000	Treatment of lupus nephritis.	La Jolla Pharmaceutical Co.
181	acadesine	n/a	5/4/2011	Treatment of multiple myeloma	Advancell-Advanced In Vitro Cell Technologies S.A.
182	acadesine	n/a	3/3/2011	Treatment of chronic lymphocytic leukemia	Avanced In Vitro Cell Technologies, S.L.
183	acamprostate	n/a	3/25/2013	Treatment of fragile X syndrome	Confluence Pharmaceuticals, LLC
184	Acetylcysteine	Mucomyst/Mucomyst 10 Iv	8/13/1987	Intravenous treatment of patients presenting with moderate to severe acetaminophen overdose.	Bristol-Myers Squibb Company
185	acetylcysteine	Acetadote	10/19/2001	For the intravenous treatment of moderate to severe acetaminophen overdose	Cumberland Pharmaceuticals, Inc.
186	acetyl-L-carnitine	n/a	7/24/2012	Treatment of Fragile X syndrome	Sigma-Tau Pharmaceuticals, Inc.
187	acetyl-L-carnitine (ALC)	n/a	3/18/2011	Treatment of Rett syndrome	sigma-tau Pharmaceuticals, Inc.
188	acid sphingomyelinase	n/a	8/3/2000	Treatment of acid sphingomyelinase deficiency (Niemann-Pick disease)	Genzyme Corporation
189	ActRIIB-IgG1)	n/a	8/16/2010	Treatment of Duchenne muscular dystrophy	Acceleron Pharma, Inc.
190	acyclovir	n/a	9/16/2010	Treatment of herpetic keratitis	GlaxoSmithKline
191	acyclovir	n/a	12/13/2010	Treatment of acute herpetic keratitis caused by Herpes Simplex Virus type 1 and 2.	Fera Pharmaceuticals
192	Ad5/3-D24-granulocyte-macrophage colony stimulating factor (GM-CSF)-encoding oncolytic adenovirus	n/a	3/17/2014	Treatment of ovarian cancer	Oncos Therapeutics Ltd

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
193	adalimumab	Humira	5/11/2011	Treatment of pediatric patients with ulcerative colitis	AbbVie, Inc.
194	adalimumab	Humira	10/19/2006	Treatment of pediatric Crohn's disease.	AbbVie, Inc.
195	adalimumab	Humira	5/13/2014	Treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis	AbbVie, Inc.
196	Adalimumab	Humira	3/21/2005	Treatment of juvenile rheumatoid arthritis	AbbVie, Inc.
197	adeno associated viral vector containing human ARSB gene	n/a	3/17/2011	Treatment of mucopolysaccharidosis type VI (MPS VI; Maroteaux-Lamy syndrome)	Fondazione Telethon
198	adeno associated viral vector serotype rh.10 carrying the human SGSH and SUMF1 cDNAs	n/a	5/6/2013	Treatment of mucopolysaccharidosis type IIIA (Sanfilippo type A syndrome)	Lysogene
199	adeno associated virus with modified transthyretin and sequence encoding factor IX variant gene	n/a	3/14/2014	Treatment of hemophilia B	Chatham Therapeutics LLC
200	Adeno-associated vector expressing the human lipoprotein lipase protein	n/a	5/21/2007	Treatment of lipoprotein lipase deficiency	uniQure B.V.
201	adeno-associated viral vector containing DNA encoding an RNAi targeting rhodopsin in combination with an adeno-associated viral vector containing DNA encoding a rhodopsin gene	n/a	12/13/2012	treatment of retinitis pigmentosa	Genable Technologies Limited
202	adeno-associated viral vector containing modified U11 snRNA	n/a	9/15/2010	Treatment of Duchenne muscular dystrophy.	uniQure B.V.
203	Adeno-associated viral vector containing the gene for human coagulation factor IX	Coagulin-B	6/13/2001	Intrahepatic treatment of patients with moderate to severe hemophilia	Avigen, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
204	Adeno-associated viral vector containing the gene for human coagulation factor IX	Coagulin-B	6/13/2001	Intramuscular treatment of patients with moderate to severe hemophilia	Avigen, Inc.
205	adeno-associated viral vector containing the human NADH Dehydrogenase 4 Gene	n/a	11/20/2013	Treatment of Leber Hereditary Optic Neuropathy	Gen Sight Biologics
206	Adeno-associated viral vector expressing human acid alpha glucosidase gene	n/a	3/20/2007	Treatment of Pompe disease	Applied Genetic Technologies Corporation
207	adeno-associated viral vector expressing human retinoschisin-1 gene	n/a	5/21/2007	Treatment of X-linked juvenile retinoschisis (XLRS).	Applied Genetic Technologies Corporation
208	Adeno-Associated Viral Vector Expressing Low-Density Lipoprotein Receptor	n/a	1/31/2012	Treatment of homozygous familial hypercholesterolemia	ReGenX Biosciences LLC
209	adeno-associated viral vector serotype 9 containing human N-acetylglucosaminidase alpha gene	n/a	12/27/2012	Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome)	Laboratorios del Dr. Esteve, S.A.
210	adeno-associated virus transgene of follistatin	n/a	11/19/2012	Treatment of Duchennes and Becker's muscular dystrophy	Milo Biotechnology
211	adeno-associated virus vector serotype 9 expressing human sulfamidase	n/a	6/1/2011	Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A Syndrome).	Laboratorios del Dr. Esteve, S.A.
212	Adenosine triphosphate type 1 competitive inhibitor of JAK2 V617F tyrosine kinase	n/a	3/3/2011	Treatment of myeloproliferative disorders (polycythemia vera, essential thrombocythemia, and myelofibrosis)	Eli Lilly and Company
213	Adenoviral vector expressing Herpes simplex virus thymidine kinase gene	n/a	6/17/2005	Treatment of malignant brain tumors	Advantagene, Inc.
214	adenovirus containing a human FAS-c gene	n/a	4/2/2012	Treatment of malignant glioma	Vascular Biogenics Ltd
215	Adenovirus-based vector Factor VIII complementary DNA to somatic cells	Miniadviii	12/15/1999	Treatment of hemophilia A.	GenStar Therapeutics Corporation
216	ADF-APO-CCN-GUC-K67-MET-MMP-MUC-RGS; HLA class I/II binding tumor associated peptides	n/a	9/28/2012	Treatment of renal cell carcinoma in HLA-A*2 positive patients	Immatics Biotechnologies GmbH

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
217	adult adherent bone marrow-derived multipotent stem cells	Multistem	7/6/2012	Treatment of MPS-1, including Hurler syndrome	Athersys, Inc.
218	ADXS11-001	n/a	8/12/2013	Treatment of HPV-positive associated anal cancer	Advaxis, Inc.
219	aerosolized beractant	n/a	3/11/2013	Treatment of respiratory distress syndrome	Beena G. Sood, MD, MS
220	AEZS-108 (LHRH-agonist linked to doxorubicin)	n/a	4/30/2010	Treatment of ovarian cancer	Aeterna Zentaris
221	afamelanotide	n/a	12/11/2009	Treatment of solar urticaria	Clinuvel, Inc.
222	afamelanotide	n/a	5/14/2014	Treatment of familial benign chronic pemphigus (Hailey-Hailey disease)	Clinuvel, Inc.
223	afatinib	Gilotrif	12/3/2012	Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).	Boehringer Ingelheim Pharmaceuticals, Inc.
224	a-Galactosidase A	Plant-Produced Human A-Galactosidase A	1/21/2003	Treatment of Fabry's disease	iBio, Inc.
225	Albendazole	Albenza	1/18/1996	Treatment of neurocysticercosis due to Taenia solium as: 1) chemotherapy of parenchymal, subarachnoidal and racemose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2) prophylaxis of epilepsy and other sequelae in asymptomatic neurocysticercosis.	SmithKline Beecham Pharmaceuticals
226	Albendazole	Albenza	1/17/1996	Treatment of hydatid disease (cystic echinococcosis due to E. granulosus larvae or alveolar echinococcosis due to E. multilocularis larvae).	SmithKline Beecham Pharmaceuticals

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
227	Albuterol	n/a	3/12/2002	Prevention of paralysis due to spinal cord injury	MotoGen, Inc.
228	Aldesleukin	Proleukin	3/22/1989	Treatment of primary immunodeficiency disease associated with T-cell defects.	Prometheus Laboratories, Inc.
229	Aldesleukin	Proleukin	11/24/1998	For the treatment non-Hodgkin's lymphoma.	Prometheus Laboratories, Inc.
230	Aldesleukin	Proleukin	9/14/1988	Treatment of metastatic renal cell carcinoma.	Chiron Corporation
231	Aldesleukin	Proleukin	9/10/1996	Treatment of metastatic melanoma.	Chiron Corporation
232	alemtuzumab	Campath	10/20/1997	Treatment of chronic lymphocytic leukemia.	Genzyme Corporation
233	Alendronate disodium	Fosamax	2/13/2001	Treatment of the bone manifestations of Gaucher disease	Richard J. Wenstrup, M.D.
234	Alfentanil	n/a	7/8/2005	Management of postherpetic neuralgia	Cinergen, LLC
235	Alfentanil	n/a	8/9/2005	Treatment of painful HIV-associated neuropathy	Cinergen, LLC
236	alfimeprase	n/a	9/20/2012	Treatment of ST-elevation myocardial infarcted patients who are undergoing primary percutaneous coronary intervention	Niche Therapeutics, LLC
237	algenpantucel-L	Hyperacute(R)-Pancreatic Cance	10/21/2010	Treatment of pancreatic cancer.	NewLink Genetics Corporation
238	Alglucerase injection	Ceredase	7/21/1995	Replacement therapy in patients with Type II and III Gaucher's disease.	Genzyme Corporation
239	Alglucerase injection	Ceredase	3/11/1985	For replacement therapy in patients with Gaucher's disease type I.	Genzyme Corporation
240	alicaforsen	n/a	6/24/2008	Treatment of pouchitis.	Atlantic Healthcare Limited

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
241	alisertib	n/a	5/14/2012	Treatment of peripheral T-cell lymphoma	Millennium Pharmaceuticals, Inc.
242	alisertib	n/a	7/12/2013	Treatment of small cell lung cancer	Millennium Pharmaceuticals, Inc.
243	Alitretinoin	Panretin	4/10/1992	Treatment of acute promyelocytic leukemia	Ligand Pharmaceuticals, Inc.
244	Alitretinoin	Panretin	3/24/1998	Treatment of AIDS-related Kaposi's sarcoma.	Eisai, Inc
245	allantoin	Alwextin	11/21/2002	Treatment of skin blistering and erosions associated with inherited epidermolysis bullosa	Scioderm, Inc.
246	all-cis-docosa-4,7,10,13,16,19-hexaenoic acid	Retriacyl	5/21/2014	Treatment of retinitis pigmentosa	Natac Pharma, S.L.
247	allogeneic cord blood cells, ex vivo modulated with 16,16 dimethyl prostaglandin E2 (dmPGE2)	n/a	12/2/2010	Enhancement of stem cell engraftment through ex vivo treatment of human allogeneic hematopoietic stem cells (treatment of neutropenia, thrombocytopenia, lymphopenia, and anemia).	Fate Therapeutics, Inc.
248	allogeneic ex vivo expanded umbilical cord blood cells	Stemex	2/1/2010	For use as hematopoietic support in patients with chronic myeloid leukemia	Gamida Cell - Teva Joint Venture
249	allogeneic ex vivo expanded umbilical cord blood cells	Stemex	2/1/2010	For use as hematopoietic support in patients with myelodysplastic syndromes	Gamida Cell - Teva Joint Venture
250	allogeneic ex-vivo expanded placental adherent stromal cells	n/a	8/22/2011	Treatment of thromboangiitis obliterans (Buerger's disease)	Pluristem Therapeutics, Inc.
251	allogeneic ex-vivo expanded placental adherent stromal cells	n/a	2/18/2013	Treatment of Aplastic Anemia	Pluristem Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
252	allogeneic hematopoietic stem cell	Atir(Tm)	2/2/2010	Prevention (reduction) of transplant related mortality (TRM, which is caused by graft versus host disease and/or infections) following mismatched (haploidentical) allogeneic hematopoietic stem cell transplantation.	Kiadis Pharma Netherlands B.V.
253	Allogeneic human aortic endothelial cells cultured in a porcine gelatin matrix	Vascugel (R)	4/3/2009	Prevention of arteriovenous fistula or arteriovenous graft failure in patients with end stage renal disease receiving hemodialysis or preparing for hemodialysis	Shire Regenerative Medicine, Inc.
254	allogeneic mesenchymal precursor cells derived from ex vivo healthy donors harvested from iliac crest.	n/a	9/12/2008	Treatment of insufficient hematopoietic stem cell production in patients with hematologic malignancies who have failed treatment with conventional chemotherapy.	Mesoblast, Inc.
255	Allogeneic motor neuron progenitor cells derived from human embryonic stem cells	Motorgraft (Tm)	1/17/2014	Treatment of Amyotrophic Lateral Sclerosis	California Stem Cell Inc.
256	Allogeneic peripheral blood mononuclear cells sensitized against patient alloantigens by mixed lymphocyte culture	Cytoimplant	6/13/1997	Treatment of pancreatic cancer	Applied Immunotherapeutics, LLC
257	Allogeneic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor	n/a	9/1/2004	Treatment of retinitis pigmentosa	Neurotech USA, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
258	Allogeneic T-cells cultured with anti-CD3 and IL-2; transduced with retroviral vector (SFCMM-3), expressing herpes simplex 1 virus-thymidine kinase (HSV-TK) and truncated low affinity nerve growth factor receptor; selected with anti-low affinity nerve gro	n/a	1/28/2005	Immunotherapy for acceleration of T-cell reconstitution in patients undergoing allogeneic hematopoietic stem cell transplantation	MolMed S.p.A.
259	allogenic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor	n/a	7/24/2012	Treatment of macular telangiectasia type 2 (MacTel)	Neurotech USA, Inc.
260	allopregnanolone	n/a	4/20/2014	Treatment of status epilepticus	Sage Therapeutics
261	allopregnanolone	n/a	7/12/2013	Treatment of Neimann-Pick disease, type C	LaJolla Pharmaceutical company, Inc.
262	Allopurinol sodium	Aloprim For Injection	10/16/1992	Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.	Catalytica Pharmaceuticals, Inc
263	alpha melanotropin	n/a	9/2/2010	Treatment of chronic beryllium disease	mondoBIOTECH Laboratories AG
264	alpha1 proteinase inhibitor (human)	n/a	1/29/2010	Treatment of emphysema secondary to congenital alpha1-antitrypsin deficiency.	Grifols Therapeutics, Inc.
265	alpha-1 proteinase inhibitor (human)	Glassia	7/28/2011	Treatment of patients with recent onset (Kamada, Ltd.
266	Alpha1-antitrypsin(human)	n/a	4/3/2008	Treatment of bronchiectasis	Kamada, Ltd.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
267	Alpha1-Proteinase Inhibitor (Human)	n/a	12/22/2004	Inhalation therapy for the the treatment of congenital deficiency of alpha1-proteinase inhibitor.	Kamada Ltd.
268	Alpha1-Proteinase Inhibitor (Human)	Arc-Api	9/1/2004	Treatment of cystic fibrosis	Kamada Ltd.
269	alpha1-proteinase inhibitor (human)	n/a	2/20/2009	Treatment of cystic fibrosis	CSL Behring LLC
270	alpha1-proteinase inhibitor (human)	n/a	4/6/2012	Treatment of cystic fibrosis	Grifols Therapeutics, Inc.
271	Alpha1-proteinase inhibitor (human)	Prolastin	12/7/1984	For replacement therapy in the alpha-1-proteinase inhibitor congenital deficiency state.	Bayer Corporation
272	Alpha-galactosidase A	Replagal	6/22/1998	Long-term enzyme replacement therapy for the treatment of Fabry disease	Shire Human Genetic Therapies, Inc.
273	Alpha-galactosidase A	Cc-Galactosidase	6/17/1991	Treatment of alpha-galactosidase A deficiency (Fabry's disease).	David Calhoun, Ph.D.
274	Alpha-galactosidase A	Fabrase	7/20/1990	Treatment of Fabry's disease.	Desnick, Robert J. M.D.
275	Alpha-melanocyte stimulating hormone	n/a	8/19/1997	Prevention and treatment of intrinsic acute renal failure due to ischemia.	National Institute of Diabetes, and Digestive and Kidney Diseases
276	Alpha-tocopherol quinone	n/a	3/28/2006	Treatment of inherited mitochondrial respiratory chain diseases	Penwest Pharmaceuticals Company
277	alpha-tocotrienol quinone	n/a	10/21/2010	Treatment of inherited mitochondrial respiratory chain diseases.	Edison pharmaceuticals, Inc.
278	alteplase	Activase	1/27/2003	Treatment of intraventricular hemorrhage associated with intracerebral hemmorrhage	Daniel F. Hanley, MD
279	Altretamine	Hexalen	2/9/1984	Treatment of advanced adenocarcinoma of the ovary.	Medimmune Oncology, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
280	Alvocidib	n/a	4/13/2007	Treatment of B-cell chronic lymphocytic leukemia (B-CLL) or prolymphocytic leukemia arising from CLL.	Tolero Pharmaceuticals, Inc.
281	ALX-0081 nanobody, directed towards the human A1 domain of von Willebrand factor	n/a	4/14/2009	Treatment of thrombotic thrombocytopenic purpura	Ablynx NV
282	amatuximab	n/a	9/28/2012	Treatment of mesothelioma	Morphotek, Inc.
283	ambrisentan	Letairis	7/16/2004	Treatment of pulmonary arterial hypertension	Gilead Colorado
284	ambroxol	n/a	6/29/2011	Treatment of Gaucher disease	ZYWIE, LLC
285	Amifostine	Ethyol	5/30/1990	For use as a chemoprotective agent for cyclophosphamide in the treatment of advanced ovarian carcinoma.	Medimmune, LLC
286	Amifostine	Ethyol	5/30/1990	For use as a chemoprotective agent for cisplatin in the treatment of metastatic melanoma.	Medimmune LLC
287	Amifostine	Ethyol	10/4/1999	Treatment of myelodysplastic syndromes.	Medimmune Oncology, Inc.
288	Amifostine	Ethyol	11/24/1998	For the reduction of the incidence and severity of toxicities associated with cisplatin administration.	Medimmune LLC
289	Amifostine	Ethyol	5/30/1990	For use as a chemoprotective agent for cisplatin in the treatment of advanced ovarian carcinoma.	Medimmune Oncology, Inc.
290	Amifostine	Ethyol	5/12/1998	Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.	Medimmune Oncology, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
291	Amikacin	Arikace	3/9/2006	Treatment of bronchopulmonary Pseudomonas aeruginosa infections in cystic fibrosis patients	Insmed, Inc.
292	Aminocaproic acid	Caprogel	1/6/1995	For the topical treatment of traumatic hyphema of the eye.	Eastern Virginia Medical School
293	aminolevulinic acid hydrochloride	Levulan	3/20/2007	Treatment of esophageal dysplasia	DUSA Pharmaceuticals, Inc.
294	Aminosaliclic acid	Paser Granules	2/19/1992	Treatment of tuberculosis infections	Jacobus Pharmaceutical Company
295	Aminosidine	Paromomycin	9/9/1994	Treatment of visceral leishmaniasis (kala-azar).	Kanyok, Thomas P. Pharm.D.
296	Aminosidine	Gabbromicina	5/14/1993	Treatment of tuberculosis.	Kanyok, Thomas P. Pharm.D.
297	Aminosidine	Gabbromicina	11/15/1993	Treatment of Mycobacterium avium complex.	Kanyok, Thomas P. Pharm.D.
298	aminosidine	Paromomycin	3/29/2005	Treatment of visceral leishmaniasis	The Institute for One World Health
299	Amiodarone	Amio-Aqueous	8/17/1993	Treatment of incessant ventricular tachycardia.	Academic Pharmaceuticals, Inc.
300	Amiodarone HCl	Cordarone	3/16/1994	For the acute treatment and prophylaxis of life-threatening ventricular tachycardia or ventricular fibrillation.	Wyeth-Ayerst Laboratories
301	amitriptyline and ketamine	Epicept(Tm) Np-1	1/19/2010	Treatment of postherpetic neuralgia	EpiCept Corporation
302	Ammonium tetrathiomolybdate	Coprex	1/31/1994	Treatment of Wilson's disease.	Pipex Pharmaceuticals, Inc.
303	ammonium tetrathiomolybdate	n/a	5/5/2008	Treatment of idiopathic pulmonary fibrosis	Pipex Pharmaceuticals, Inc.
304	amphotericin B	n/a	9/15/2010	Treatment of visceral leishmaniasis.	iCo Therapeutics Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
305	Amphotericin B inhalation powder	n/a	12/15/2005	Prevention of pulmonary fungal infections in patients at risk for aspergillosis due to immunosuppressive therapy including those receiving organ or stem cell transplants, or treated with chemotherapy or radiation for hematologic malignancies	Novartis Pharmaceuticals Corporation
306	Amphotericin B lipid complex	Abelcet	12/5/1991	Treatment of invasive fungal infections.	Liposome Company, Inc.
307	amrubicin	n/a	3/10/2008	Treatment of small cell lung cancer	Celgene Corporation
308	Amyl nitrite, sodium nitrite, sodium thiosulfate	Cyanide Antidote Kit	12/18/2006	Treatment of cyanide poisoning	Akorn, Inc.
309	an adeno-associated viral vector containing a codon-optimised human factor IX gene (AAV5-hFIXco)	n/a	12/22/2011	Treatment of hemophilia B	uniQure, B.V.
310	Anagrelide	Agrylin	7/14/1986	Treatment of thrombocytosis in chronic myelogenous leukemia.	Roberts Pharmaceutical Corp.
311	Anagrelide	Agrylin	6/11/1985	Treatment of polycythemia vera.	Roberts Pharmaceutical Corp.
312	Anagrelide	Agrylin	1/27/1988	Treatment of essential thrombocythemia.	Roberts Pharmaceutical Corp.
313	anakinra	Kineret	8/19/2010	Treatment of cryopyrin-associated periodic syndromes	Swedish Orphan Biovitrum AB (publ)
314	Ananain, comosain	Vianain	1/21/1992	For the enzymatic debridement of severe burns.	Genzyme Corporation

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
315	Anatibant	n/a	4/15/2005	Treatment of patients having experienced a severe traumatic brain injury (Glasgow Coma Scale 3 to 8) in order to decrease early mortality and improve long-term functional and neurological outcome	Xytis, Inc.
316	Ancrod	Viprinex	10/20/1989	To establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.	Knoll Pharmaceutical Company
317	Angiotensin (1-7)	n/a	11/26/2013	Treatment of limb-girdle muscular dystrophy	US Biotest, Inc.
318	angiotensin (1-7)	n/a	8/30/2013	Treatment of patients requiring stem cell transplantation to accelerate the mobilization of hematopoietic stem cells (CD34+) from the bone marrow to the peripheral blood when combined with a granulocyte colony-stimulating factor	US Biotest, Inc.
319	angiotensin (1-7)[A(1-7)]	n/a	7/25/2013	Treatment of Duchenne muscular dystrophy	US Biotest, Inc.
320	Angiotensin 1-7	Marstem	8/3/2001	Treatment of myelodysplastic syndrome	Maret Pharmaceutical Corporation
321	Angiotensin 1-7	n/a	2/16/2000	Treatment of neutropenia associated with autologous bone marrow transplantation.	Maret Pharmaceuticals

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
322	angiotensin 1-7	n/a	6/17/2010	To accelerate engraftment of hematopoietic cells (treatment of neutropenia, thrombocytopenia, lymphoma, and anemia) in hematopoietic stem cell transplants.	US Biotest, Inc.
323	angiotensin 1-7	n/a	1/29/2010	Treatment of sarcoma.	W. Jeffrey Petty, MD
324	Angiotensin-(1-7)	n/a	9/13/2011	Treatment of pulmonary arterial hypertension.	US Biotest, Inc.
325	anthrax immune globulin	n/a	9/3/2009	Treatment of inhalation anthrax disease	Emergent Biosolutions, Inc.
326	anthrax immune globulin (human)	n/a	7/29/2008	Treatment of toxemia associated with inhalational anthrax.	Cangene Corporation
327	anti human Nogo-A human monoclonal antibody	n/a	10/20/2008	Treatment of acute spinal cord injury	Novartis Pharmaceuticals Corporation
328	antiangiogenic components extracted from marine cartilage	Neovastat (Ae-941)	10/16/2002	Treatment of renal cell carcinoma	AEterna Zentaris, Inc.
329	anti-CD3 mAb (SPV-T3a)-ricin A chain fusion protein and anti-CD7 mAb (WT1)-ricin A chain fusion protein	n/a	9/13/2013	Treatment of graft versus host disease	Xenikos BV
330	anti-CD30 Fc engineered humanized monoclonal antibody	n/a	12/2/2008	Treatment of Hodgkin lymphoma	Xencor, Inc.
331	Antiepilepsirine	n/a	3/23/1989	Treatment of drug resistant generalized tonic-clonic epilepsy in children and adults.	Children's Hospital
332	Antihemophilic factor (human)	Alphanate	1/5/1996	Treatment of von Willebrand's disease	Grifols Biologicals Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
333	Antihemophilic factor (recombinant)	Refacto	2/8/1996	For the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).	Wyeth Pharmaceuticals, Inc.
334	Antihemophilic factor (recombinant)	Kogenate	9/25/1989	Prophylaxis and treatment of bleeding in individuals with hemophilia A or for prophylaxis when surgery is required in individuals with hemophilia A.	Bayer Corporation
335	Antihemophilic factor (recombinant) formulated with sucrose reconstituted with liposome diluent	Kogenate Fs/Liposomal Diluent	4/29/2009	Treatment of hemophilia A	Bayer HealthCare LLC
336	Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized	Humate-P	10/16/1992	Treatment of patients with von Willebrand's disease	CSL Behring
337	anti-inhibitor coagulant complex	Feiba	4/12/2013	Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors	Baxter Healthcare Corporation
338	anti-insulin-like type 1 receptor immunoglobulin 1	n/a	11/23/2010	Treatment of pancreatic cancer.	Amgen
339	anti-interferon-gamma Fab from goats	n/a	11/18/2003	For the treatment of immunologic corneal allograft rejection	Advanced Biotherapy, Inc.
340	anti-Lewis Y humanized monoclonal antibody	n/a	3/9/2012	Treatment of ovarian cancer	Recepta Biopharma S.A.
341	antimesothelin-ADC (antibody drug conjugate)	n/a	7/5/2012	Treatment of mesothelioma	Bayer HealthCare Pharmaceuticals, Inc.
342	antineoplaston A10, antineoplaston AS2-1	n/a	10/30/2008	Treatment of gliomas	Burzynski Research Institute, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
343	anti-nogo-A monoclonal antibody	n/a	7/7/2009	Treatment of amyotrophic lateral sclerosis	GlaxoSmithKline
344	Antisense 20-mer oligonucleotide complementary to R2 component of ribonucleotide reductase mRNA	n/a	4/15/2005	Treatment of acute myeloid leukemia	Lorus Therapeutics, Inc.
345	antisense 20-mer phosphorothioate oligonucleotide [complementary to the coding region of R2 component of the human ribonucleotide reductase mRNA]	Gti-2040	3/12/2003	Treatment for renal cell carcinoma	Lorus Therapeutics, Inc.
346	anti-sense oligonucleotide consisting of 2'â€O-methyl RNA with a phosphorothioate backbone	n/a	9/23/2013	Treatment of cystic fibrosis	ProQR therapeutics B.V.
347	Antisense oligonucleotide directed against connexin43	Nexagon	4/27/2009	Treatment of persistent corneal epithelial defects	CoDa Therapeutics, Inc.
348	antisense oligonucleotide targeted to human transthyretin (TTR) mRNA	n/a	7/24/2012	Treatment of familial amyloid polyneuropathy	Isis Pharmaceuticals, Inc.
349	Anti-T cell receptor murine monoclonal antibody	n/a	4/3/2009	Prophylaxis of acute rejection of solid organ transplantation	Tolera Therapeutics, Inc.
350	anti-TCR murine monoclonal antibody (MAB, type IgM)	n/a	1/12/2011	Treatment of pediatric multiple sclerosis in patients less than or equal to 16 years of age	Tolera Therapeutics, Inc.
351	anti-TCR murine monoclonal antibody (MAb, type IgM)	n/a	6/7/2010	Treatment of patients 16 years of age and younger with immune-mediated T1DM and preserved pancreatic beta cell function	Tolera Therapeutics, Inc.
352	Anti-tenascin 81C6 monoclonal antibody labeled w/ I 131	Neuradiab	10/4/2005	Treatment of primary malignant brain tumors	Bradmer Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
353	Antithrombin III (human)	Atnativ	2/8/1985	For the treatment of patients with hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.	Pharmacia & Upjohn AB
354	Antithrombin III (human)	Thrombate Iii	11/26/1984	For replacement therapy in congenital deficiency of AT-III for prevention and treatment of thrombosis and pulmonary emboli.	Bayer Corporation
355	Antithrombin III human	Antithrombin Iii Human	1/2/1986	Preventing or arresting episodes of thrombosis in patients with congenital AT-III deficiency and/or to prevent the occurrence of thrombosis in patients with AT-III deficiency who have undergone trauma or who are about to undergo surgery or parturition.	American National Red Cross
356	anti-thymocyte globulin [rabbit]	Thymoglobulin	5/25/2010	Prophylaxis of acute organ rejection in patients receiving renal transplants	Genzyme Corporation
357	Anti-thymocyte serum	Nashville Rabbit Anti-Thymocyte Serum	6/2/1993	Treatment of allograft rejection, including solid organ (kidney, liver, heart, lung, and pancreas) and bone marrow transplantation.	Applied Medical Research
358	anti-T-lymphocyte immune globulin, rabbit	Atg-Fresenius(R)	3/26/2010	Prevention of graft versus host disease (GVHD)	Neovii Biotech NA, Inc.
359	anti-T-lymphocyte immune globulin, rabbit	n/a	9/12/2008	Prophylaxis of acute allograft rejection in adult recipients in solid organ transplantation	Neovii Biotech NA, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
360	Antivenin crotaline (pit-viper) equine immune F(ab)2	Antivipmyn	1/29/2004	Treatment of envenomation by Crotaline snakes	Instituto Bioclon, S.A de C.V.
361	Antivenin, crotalidae polyvalent immune Fab (ovine)	Crofab	1/12/1994	Treatment of envenomations inflicted by North American crotalid snakes.	Protherics, Inc.
362	Antivenom (crotalidae) purified (avian)	n/a	2/12/1991	Treatment of envenomation by poisonous snakes belonging to the Crotalidae family.	Ophidian Pharmaceuticals, Inc.
363	Anti-von Willebrand Aptamer	n/a	4/9/2008	Treatment of thrombotic thrombocytopenic purpura	Archemix Corporation
364	apolipoprotein E mimetic peptide	n/a	12/3/2012	Treatment of homozygous familial hypercholesterolemia	LipimetiX Development, LLC
365	Apomorphine	n/a	7/17/1995	Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.	Pentech Pharmaceuticals, Inc.
366	Apomorphine HCl	Apokyn	4/22/1993	Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.	US WorldMeds, LLC
367	Apomorphine hydrochloride	n/a	5/23/2006	For the treatment of patients in a vegetative state or minimally conscious state for up to 12 months following a severe traumatic brain injury (traumatic or spontaneous)	NeuroHealing Pharmaceuticals, Inc.
368	apremilast	n/a	1/17/2013	Treatment of Behcet's disease	Celgene Corporation

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
369	Aprotinin	Trasylol	11/17/1993	For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary coronary artery bypass graft surgery where the risk of bleeding is especially high (impaired hemostasis) or where transfusion is unavailable or unacceptable.	Bayer Corporation
370	AQ-13 (4-aminoquinoline analog)	n/a	9/12/2008	Treatment of malaria	Immtech Pharmaceuticals, Inc.
371	Arenegyr	n/a	8/22/2008	Treatment of malignant pleural mesothelioma	MolMed S.p.A.
372	Arginine butyrate	n/a	4/7/1992	Treatment of beta-hemoglobinopathies and beta-thalassemia.	Perrine, Susan P., M.D.
373	arimoclomol	n/a	3/29/2005	Treatment of amyotrophic lateral sclerosis	CytRx Corporation
374	aripiprazole	Abilify	1/25/2006	Treatment of Tourette's syndrome	Otsuka Pharmaceutical Development & Commercializat
375	arsenic	Trisenox	11/2/2001	Treatment of acute myelocytic leukemia subtypes M0, M1, M2, M4, M5, M6 and M7	Teva Branded Pharmaceutical Products R&D, Inc.
376	Arsenic trioxide	Trisenox	3/4/2005	Treatment of malignant glioma	Teva Branded Pharmaceutical Products R&D, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
377	Arsenic trioxide	Trisenox	4/28/2000	Treatment of multiple myeloma.	TEVA Branded Pharmaceutical Products R & D, Inc.
378	Arsenic trioxide	Trisenox	5/13/2003	Treatment of chronic lymphocytic leukemia	Teva Branded Pharmaceutical Products R&D, Inc.
379	arsenic trioxide	Trisenox	7/17/2000	Treatment of myelodysplastic syndrome.	Teva Branded Pharmaceutical Products R&D, Inc.
380	arsenic trioxide	Trisenox	10/18/2001	Treatment of chronic myeloid leukemia	Teva Branded Pharmaceutical Products R*D, Inc.
381	arsenic trioxide	Trisenox	6/13/2003	Treatment of liver cancer	Teva Branded Pharmaceutical Products R&D, Inc.
382	Arsenic trioxide	Trisenox	3/3/1998	Treatment of acute promyelocytic leukemia.	Cephalon
383	artemether/lumefantrine	Coartem	8/31/2007	For the treatment of infections due to Plasmodium falciparum or mixed infections including P. falciparum.	Novartis Pharmaceuticals
384	Artesunate	n/a	7/19/1999	Treatment of malaria.	World Health Organization
385	Artesunate	n/a	3/28/2006	Immediate treatment of malaria	US Army Medical Materiel Development Activity
386	arylsulfatase A (rhASA)	n/a	2/27/2008	Treatment of metachromatic leukodystrophy	Shire Human Genetic Therapies, Inc.
387	ascorbic acid	n/a	5/11/2009	Treatment of Charcot-Marie-Tooth disease type 1A.	Murigenetics SAS
388	Ascorbic acid	Ascor L 500	8/31/2007	Treatment of scurvy	McGuff Pharmaceuticals Inc.
389	Asfotase alfa	n/a	9/12/2008	Treatment of hypophosphatasia	Alexion Pharma International

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
390	astuprotimut-R	n/a	5/29/2009	Treatment of MAGE-A3 positive non-small cell lung cancer	GlaxoSmithKline Biologicals, S.A.
391	astuprotimut-R	n/a	5/29/2009	Treatment of MAGE-A3 positive stages IIb to IV malignant melanoma	GlaxoSmithKline Biologicals, S.A.
392	ataluren	n/a	1/10/2005	Treatment of Muscular Dystrophy resulting from premature stop mutations in the dystrohin gene	PTC Therapeutics, Inc.
393	ataluren	n/a	9/1/2004	For use in the treatment of cystic fibrosis resulting from a nonsense (premature stopcodon) mutation in the cystic fibrosis transmembrane conductance regulatory gene	PTC Therapeutics, Inc.
394	ataluren	n/a	3/10/2008	Treatment of spinal muscular atrophy	PTC Therapeutics, Inc.
395	Atovaquone	Mepron	9/10/1990	Treatment of AIDS associated Pneumocystis Carinii Pneumonia.	Glaxo Wellcome Inc.
396	Atovaquone	Mepron	8/14/1991	Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm3.	Glaxo Wellcome Research and Development
397	Attenuated autologous cancer cells and granulocyte macrophage colony stimulating factor in combination with activated autologous blood derived T-cells	n/a	4/27/2007	Treatment of primary central nervous system malignancies	TVAX Biomedical, LLC

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
398	auranofin	Ridaura	4/30/2010	Treatment of amebiasis	Ctr for Discovery & Innovation in Parasitic Diseases
399	Autologous CD34+ cells transfected with lentiviral vector containing the human WAS cDNA (Telethon 003)	n/a	4/30/2010	Treatment of Wiskott Aldrich syndrome	Fondazione Telethon
400	autologous CD34+ hematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ABCD1 cDNA	n/a	4/19/2012	Treatment of adrenoleukodystrophy	bluebird bio, Inc.
401	autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human BA-T87Q-globin gene	n/a	3/18/2013	Treatment of B-thalassemia major and intermedia	bluebird bio, Inc.
402	autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human BA-T87Q-globin gene	n/a	2/26/2014	For the treatment of Sickle Cell Disease	bluebird bio Inc.
403	autologous CD4+CD25hiFoxP3+regulatory T cells	n/a	11/19/2013	Prevention of graft rejection following solid organ transplantation	iREG Medical AB
404	Autologous cultured endothelial cells on a donor human corneal disk	n/a	6/1/2007	Treatment of Fuch's dystrophy, pseudophakic bullous keratopathy, and bullous keratopathy	Cellular Bioengineering, Inc.
405	autologous dendritic cells pulsed with allogeneic tumor cell lysate	n/a	5/6/2014	Treatment of malignant mesothelioma	Amphera BV
406	Autologous dendritic cells pulsed with autologous antigens from primay malignant brain tumor cells	Dcvax-Brain	11/29/2002	Treatment of primary brain malignant cancer	Northwest Biotherapeutics, Inc.
407	Autologous dendritic cells pulsed with recombinant human fusion protein (mucin1-glutathione S transferase) coupled to oxidized polymannose	Cvac(Tm)	9/13/2010	Treatment of ovarian cancer.	Prima Biomed Ltd.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
408	Autologous DNP-conjugated tumor vaccine	M-Vax	2/23/1999	For adjuvant therapy in melanoma patients with surgically resectable lymph node metastasis (Stage III and limited Stage IV disease).	Avax Technologies, Inc.
409	Autologous Engineered Skin Substitute	Permaderm	6/1/2012	Treatment of hospitalized patients with deep partial and full thickness burns requiring grafting.	Lonza
410	autologous ex vivo expanded CD4+-enriched leukocytes treated with the de-methylating agent 5-aza-2'-deoxycytidine	Alecsat	9/13/2013	Treatment of glioblastoma multiforme	CytoVac A/S
411	Autologous incubated macrophage	n/a	9/3/2004	Therapy to improve the motor and sensory neurological outcome in acute cases of spinal cord injury	Proneuron Biotechnologies, Inc.
412	autologous lymphocytes depleted ex vivo of immunoreactive T cells using 4,5	Theralux Photodynamic Therapy	4/3/2008	Treatment of chronic graft versus host disease	Kiadis Pharma Canada, Inc.
413	Autologous lymphoma-derived immunoglobulin idiotype antigen vaccine conjugated to keyhole limpet hemocyanin	Biovaxid	10/18/2011	Treatment of Waldenstrom's macroglobulinemia	Biovest International, Inc.
414	autologous neo-uninary conduit	n/a	6/7/2011	Treatment of bladder dysfunction requiring incontinent urinary diversion.	Tengion, Inc.
415	Autologous olfactory neural progenitors	Rhinocytes	2/1/2008	Treatment of spinal cord injury patients with ASIA Impairment grades A, B, or C	RhinoCyte, Inc.
416	autologous olfactory neural progenitors	Rhinocytes	12/31/2008	Treatment of amyotrophic lateral sclerosis	RhinoCyte, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
417	Autologous or allogeneic limbal epithelial stem cells expanded ex vivo on human amniotic membrane	n/a	7/14/2005	Treatment of ocular surface diseases that are characterized by total limbal stem cell deficiency	TissueTech, Inc.
418	autologous peripheral blood T lymphocytes transduced with retroviral vector containing anti CD19 CD28/CD3 zeta chimeric antigen receptor	n/a	3/27/2014	Treatment of diffuse large B-cell lymphoma.	Kite Pharma, Inc.
419	Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19	n/a	1/31/2014	For the treatment of Acute Lymphoblastic Leukemia	Novartis Pharmaceuticals Corporation
420	autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19	n/a	3/14/2014	Treatment of chronic lymphocytic leukemia	Novartis Pharmaceuticals Corporation
421	autologous tumor-derived gp96 heat shock protein-peptide complex	Oncophage	5/10/2002	Treatment of renal cell carcinoma	Agenus, Inc.
422	autologous tumor-derived gp96 heat shock protein-peptide complex	Oncophage	7/11/2002	Treatment of metastatic melanoma	Agenus, Inc.
423	autologous umbilical cord blood	n/a	7/24/2012	Treatment of pediatric (0-16 yrs old inclusive) cerebral palsy due to acquired brain injury	Duke University
424	autologous CD34+ cells transfected with retroviral vector containing adenosine deaminase gene	n/a	8/26/2009	Treatment of severe combined immunodeficiency due to adenosine deaminase deficiency.	Glaxo Group Limited
425	Autolymphocyte therapy	n/a	7/12/1994	Treatment of renal cell carcinoma.	Cytogen Corporation
426	aviptadil	n/a	2/22/2005	Treatment of pulmonary arterial hypertension	Mondobiotec Laboratories AG
427	Azacitidine	Vidaza	6/18/2008	Treatment of acute myeloid leukemia	Celgene Corporation
428	azacitidine	Vidaza	12/3/2001	Treatment of myelodysplastic syndromes	Celgene Corporation

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
429	Azathioprine	Imuran	9/14/1999	Treatment of oral manifestations of graft-versus-host disease.	Oral Solutions, Inc.
430	aztreonam	n/a	5/15/2009	Improvement of respiratory symptoms in patients with bronchiectasis and gram-negative bacteria in the airways.	Gilead Sciences, Inc.
431	aztreonam	Cayston	3/12/2002	Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis	Gilead Sciences (formerly Corus Pharma)
432	Bacillus Calmette-Guerin vaccine	n/a	8/9/2006	Treatment of stage IIb through IV metastatic melanoma	OncoVac Corporation
433	Bacitracin	Altracin	3/13/1984	Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.	A. L. Laboratories, Inc.
434	Baclofen	Lioresal Intrathecal	9/26/1994	Treatment of spasticity associated with cerebral palsy.	Medtronic, Inc.
435	baclofen	n/a	12/16/1991	Treatment of intractable spasticity due to multiple sclerosis or spinal cord injury.	Infusaid, Inc.
436	baclofen	n/a	12/2/2003	Treatment of dystonia	Medtronic Neurological

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
437	baclofen	Lioresal Intrathecal	11/10/1987	Treatment of intractable spasticity caused by spinal cord injury, multiple sclerosis, and other spinal diseases (including spinal ischemia, spinal tumor, transverse myelitis, cervical spondylosis, and degenerative myelopathy).	Medtronic, Inc.
438	bacterium Bacteroides thetaiotaomicron	n/a	9/26/2013	Treatment of active Crohn's disease in the pediatric population	GT Biologics Ltd
439	Balsalazide disodium	Colazal	8/12/2005	Treatment of pediatric patients with ulcerative colitis	Salix Pharmaceuticals, Inc.
440	Bardoxolone	n/a	8/6/2008	Treatment of pancreatic cancer	Reata Pharmaceuticals, Inc.
441	Basiliximab	Simulect	12/12/1997	Prophylaxis of solid organ rejection.	Novartis Pharmaceuticals Corporation
442	beclomethasone	n/a	3/4/2009	Treatment of pediatric patients with ulcerative colitis	Aptalis Pharma US, Inc.
443	beclomethasone 17,21-dipropionate	Orbec(R)	7/24/2009	Treatment of gastrointestinal symptoms with chronic grafted host disease in patients undergoing allogeneic hematopoietic cell transplantation	Soligenix, Inc.
444	beclomethasone 17,21-dipropionate	n/a	11/19/2012	Prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster	Soligenix, Inc

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
445	beclomethasone 17,21-dipropionate	Bec	8/28/2001	Prevention of gastrointestinal graft-versus-host disease	Soligenix, Inc.
446	beclomethasone 17,21-dipropionate	n/a	12/18/2007	Treatment of pediatric patients with Crohn disease.	Soligenix, Inc.
447	Beclomethasone dipropionate	n/a	3/27/1998	For oral administration in the treatment of intestinal graft-versus-host disease.	Soligenix, Inc.
448	bedaquiline; (1R,2S) 6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-(1-naphthyl)-beta-phenyl-3-quinolineethanol	Sirturo	1/10/2005	Treatment of active tuberculosis	Janssen Research & Development, LLC
449	belatacept	Nulojix	2/20/2008	Prophylaxis of organ rejection in renal allograft recipients	Bristol-Myers Squibb Company
450	Belinostat	Beleodaq	9/3/2009	Treatment of peripheral T-cell lymphoma	Spectrum Pharmaceuticals, Inc.
451	beloranib	n/a	1/15/2013	Treatment of Prader-Willi syndrome	Zafgen, Inc.
452	Bendamustine hydrochloride	Treanda	8/17/2007	Treatment of chronic lymphocytic leukemia	Cephalon, Inc.
453	bendamustine hydrochloride	Treanda	11/26/2013	Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)	Cephalon, Inc.
454	bendamustine hydrochloride with betadex sulfobutyl ether sodium	n/a	9/10/2013	Treatment of chronic lymphocytic leukemia	Supratek Pharma, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
455	benznidazole	n/a	4/14/2014	Treatment of Chagas disease	Chemo Research, S.L.
456	benzoate	n/a	7/6/2012	Treatment of pediatric schizophrenia	SyneuRx International (Taiwan) Corp.
457	Benzoate and phenylacetate	Ucephan	1/21/1986	For adjunctive therapy in the prevention and treatment of hyperammonemia in patients with urea cycle enzymopathy due to carbamylphosphate synthetase, ornithine, transcarbamylase, or argininosuccinate synthetase deficiency.	ImmunexImmunex
458	benzoate/phenylacetate	Ammonul	11/22/1993	Treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.	Medicis Pharmaceutical Corp.
459	Benzophenone-3, octylmethoxycinnamate, avobenzone, titanium dioxide, zinc oxide	Total Block VI Spf 75	8/13/2001	For the prevention of visible light induced skin photosensitivity as a result of porfimer sodium photodynamic therapy	Fallien Cosmeceuticals Ltd.
460	Benzydamine hydrochloride	Tantum	5/18/1998	Prophylactic treatment of oral mucositis resulting from radiation therapy for head and neck cancer.	Angelini Pharmaceuticals, Inc.
461	Benzympenicillin, benzympenicilloic, benzympenilloic acid	Pre-Pen/Mdm	9/28/1987	Assessing the risk of administering penicillin when it is the preferred drug of choice in adult patients who have previously received penicillin and have a history of clinical sensitivity.	AllerQuest LLC

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
462	Beractant	Survanta Intratracheal Suspension	12/20/1993	Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis.	Ross Laboratories
463	Beractant	Survanta Intratracheal Suspension	2/5/1986	Treatment of neonatal respiratory distress syndrome.	Ross Laboratories
464	Beractant	Survanta Intratracheal Suspension	2/5/1986	Prevention of neonatal respiratory distress syndrome.	Ross Laboratories
465	Beraprost	n/a	4/29/1999	Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV).	LungRx, Inc.
466	beraprost sodium 314d	n/a	12/22/2011	Treatment of pulmonary arterial hypertension	Lung Rx, Inc.
467	Beta alethine	Betathine	3/24/1997	Treatment of metastatic melanoma.	Dovetail Technologies, Inc.
468	Beta alethine	Betathine	3/24/1997	Treatment of multiple myeloma.	Dovetail Technologies, Inc.
469	Betahistine dihydrochloride	n/a	11/8/2007	Treatment of obesity associated with Prader Willi syndrome	Floyd R. Sallee, M.D., Ph.D.
470	Betaine	Cystadane	5/16/1994	Treatment of homocystinuria.	Jazz Pharmaceuticals
471	Betulinic acid	n/a	8/9/2007	Topical treatment of metastatic melanoma	Advanced Life Sciences, Inc. (ALS)
472	bevacizumab	Avastin	10/20/2004	Treatment of pancreatic cancer	Genentech, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
473	bevacizumab	Avastin	10/13/2009	Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen	Genentech, Inc.
474	bevacizumab	Avastin	2/9/2006	Therapeutic treatment of patients with ovarian cancer	Genentech, Inc.
475	bevacizumab	Avastin	11/20/2009	In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.	Genentech, Inc.
476	bevacizumab	Avastin	11/23/2010	Treatment of fallopian tube carcinoma.	Genentech, Inc.
477	bevacizumab	Avastin	11/2/2010	Treatment of primary peritoneal carcinoma.	Genentech, Inc.
478	bevacizumab	n/a	10/21/2010	Treatment of hereditary hemorrhagic telangiectasia	Terence M. Davidson, MD
479	bevacizumab	Avastin	11/6/2003	Treatment of renal cell carcinoma	Genentech, Inc.
480	bevacizumab	Avastin	5/26/2006	Treatment of malignant glioma	Genentech, Inc.
481	Bexarotene	Targretin	6/18/1999	Treatment of cutaneous T-cell lymphoma.	Eisai, Inc.
482	bezafibrate	Bezalip	7/24/2013	For therapeutic treatment of Barth syndrome	Barth Syndrome Foundation, Inc.
483	BF2.649 (Pitolisant)	n/a	5/17/2010	Treatment of narcolepsy	Bioprojet Pharma
484	bifidobacterium infantis 35624	n/a	3/24/2008	Treatment of pediatric ulcerative colitis	Alimentary Health Limited
485	bifidobacterium longum infantis 35624	n/a	1/16/2003	Treatment of pediatric Crohn's disease	Alimentary Health Limited
486	Bindarit	n/a	2/3/1998	Treatment of lupus nephritis.	Angelini Pharmaceuticals, Inc.
487	binimetinib	n/a	11/19/2013	Treatment Stage IIB-IV melanoma.	Novartis Pharmaceuticals Corporation

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
488	Bioartificial liver system utilizing xenogenic hepatocytes in a hollow fiber bioreactor cartridge (BAL)	n/a	2/11/2002	Treatment of patients with acute liver failure presenting with encephalopathy deteriorating beyond Parson's grade 2	Excorp Medical, Inc.
489	biocarbonate infusate	Normocarb Hf	8/9/2005	Use in the management of patients undergoing continuous renal replacement therapy with hemofiltration	Dialysis Solutions, Inc.
490	Bio-engineered oral mucosal tissue	n/a	4/27/2006	For use as a graft for restoring a cornea-like epithelial phenotype to substitute for the normal corneal epithelium that is lost in patients due to total limbal stem cell deficiency	TissueTech, Inc.
491	Bis(4-fluorophenyl)phenylacetamide	n/a	3/2/2000	Treatment of sickle cell disease.	ICAgen Inc.
492	bisantrene HCl	n/a	2/14/2014	Treatment of acute myeloid leukemia	Update Pharma, Inc.
493	bi-shRNAfurin and granulocyte macrophage colony stimulating factor augmented autologus tumor cell vaccine	Fang	2/17/2012	Treatment of stage IIB to IV melanoma	Gradalis, Inc.
494	bi-shRNAfurin and granulocyte macrophage colony stimulating factor augmented autologus tumor cell vaccine	Fang	4/18/2011	Treatment of ovarian cancer	Gradalis, Inc.
495	bispecific antibody (monoclonal antibody)	n/a	8/8/2013	Treatment of HER2-expressing advanced adenocarcinoma of the stomach and gastroesophageal junction	Merrimack Pharmaceuticals, inc.
496	bispecific antibody (monoclonmal antibody)	n/a	8/8/2013	Treatment of HER2-expressing adenocarcinoma of the esophagus	Merrimack Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
497	bispecific antibody targeting interleukin 4 (IL-4) and interleukin 13 (IL-13)	n/a	9/14/2011	Treatment of idiopathic pulmonary fibrosis.	Sanofi-Aventis US, Inc.
498	bivalirudin	Angiomax	11/2/2005	For use as an anticoagulant in patients with or at risk of heparin-induced thrombocytopenia/heparin-induced thrombocytopenia thrombosis syndrome	The Medicines Company
499	Bleomycin	Blenoxane	2/9/1999	Treatment of pancreatic cancer.	Genetronics, Inc.
500	Bleomycin	n/a	12/20/2010	Treatment of pancreatic cancer.	CIRJ Company Ltd.
501	Bleomycin sulfate	Blenoxane	9/17/1993	Treatment of malignant pleural effusion.	Bristol-Myers Squibb Pharmaceutical Research Institute
502	Blinatumomab	n/a	2/6/2006	Treatment of indolent B-cell lymphoma, excluding CLL and NHL with CNS involvement	Amgen Rockville, Inc.
503	Blinatumomab	n/a	5/16/2008	Treatment of chronic lymphocytic leukemia	Amgen Rockville, Inc.
504	blinatumomab	n/a	5/16/2008	Treatment of acute lymphocytic leukemia	Amgen Rockville, Inc.
505	blinatumomab	n/a	5/16/2008	Treatment for hairy cell leukemia.	Amgen Rockville, Inc.
506	blinatumomab	n/a	5/16/2008	Treatment of prolymphocytic leukemia	Amgen Rockville, Inc.
507	Bone marrow-derived mononuclear cells	n/a	5/17/2010	Treatment of thromboangiitis obliterans (Buerger's disease)	t2cure GmbH
508	bortezomib	Velcade	1/4/2011	Treatment of follicular non-Hodgkin lymphoma	Millennium Pharmaceuticals, Inc.
509	bortezomib	Velcade For Injection	4/18/2011	Treatment of mantle cell lymphoma (MCL).	Millennium Pharmaceuticals, Inc.
510	bortezomib	Velcade	1/15/2003	Treatment of multiple myeloma	Millennium Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
511	bosentan	Tracleer(R)	6/7/2010	Reduction of the number (treatment) of new digital ulcers in patients with systemic sclerosis	Actelion Ltd.
512	Bosentan	Tracleer	10/6/2000	Treatment of pulmonary arterial hypertension.	Actelion Life Sciences Ltd.
513	bosutinib	Bosulif	2/24/2009	Treatment of chronic myelogenous leukemia	Wyeth Pharmaceuticals, Inc.
514	Botulinum toxin type A	Dysport	10/20/1999	Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.	Ipsen Limited
515	Botulinum toxin type A	Dysport	3/23/1989	Treatment of essential blepharospasm.	Porton International, Inc.
516	Botulinum toxin type A	n/a	9/15/1992	Treatment of synkinetic closure of the eyelid associated with VII cranial nerve aberrant regeneration.	Botulinum Toxin Research Associates, Inc.
517	Botulinum toxin type A	Botox	12/6/1991	Treatment of dynamic muscle contracture in pediatric cerebral palsy patients.	Allergan, Inc.
518	Botulinum toxin type A	Dysport	8/12/1998	Treatment of spasmodic torticollis (cervical dystonia).	Ipsen Biopharm Limited
519	Botulinum toxin type A	Botox	8/20/1986	Treatment of cervical dystonia.	Allergan, Inc.
520	Botulinum toxin type A	Botox	3/22/1984	Treatment of strabismus and blepharospasms	Allergan, Inc.
521	Botulinum toxin type B	Myobloc	1/16/1992	Treatment of cervical dystonia.	Soltice Neurosciences, LLC
522	Botulinum toxin type F	n/a	10/24/1991	Treatment of spasmodic torticollis (cervical dystonia).	Ipsen Limited
523	botulism antitoxin heptavalent (A, B, C, D, E, F, G) (Equine)	n/a	6/29/2011	Treatment of botulism.	Cangene Corporation
524	Botulism immune globulin	Babybig	1/31/1989	Treatment of infant botulism.	California Department of Health Services

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
525	Bovine colostrum	n/a	11/19/1990	Treatment of AIDS-related diarrhea.	Hastings, Donald DVM
526	Bovine immunoglobulin concentrate, Cryptosporidium parvum	Sporidin-G	3/1/1994	Treatment and symptomatic relief of Cryptosporidium parvum infection of the gastrointestinal tract in immunocompromised patients.	GalaGen, Inc.
527	Bovine whey protein concentrate	Immuno-C	9/30/1993	Treatment of cryptosporidiosis caused by the presence of Cryptosporidium parvum in the gastrointestinal tract of patients who are immunodeficient/immunocompromised or immunocompetent.	Biomune Systems, Inc.
528	Branched chain amino acids	n/a	12/23/1988	Treatment of amyotrophic lateral sclerosis.	Mount Sinai Medical Center
529	brentuximab vedotin	Adcetris(R)	1/31/2014	Treatment of patients with diffuse large B-cell lymphoma.	Seattle Genetics, Inc.
530	brentuximab vedotin	Adcetris	11/19/2012	Treatment of mycosis fungoides	Seattle Genetics, Inc.
531	brentuximab vedotin	Adcetris	9/13/2013	Treatment of patients with angioimmunoblastic T-cell lymphoma	SeattleGenetics, Inc.
532	brentuximab vedotin	Adcetris	4/15/2013	Treatment of patients with peripheral T-cell lymphoma, not otherwise specified	Seattle Genetics, Inc.
533	brentuximab vedotin	Adcetris	10/23/2008	Treatment of anaplastic large cell lymphoma	Seattle Genetics, Inc.
534	brentuximab vedotin	Adcetris	1/30/2007	Treatment of Hodgkin's lymphoma	Seattle Genetics, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
535	Brilliant Blue G	Dorc IIm-Blue	7/31/2012	To selectively stain the thickened internal limiting membrane, which has formed onto the inner side of the retina in vitreo-retinal disorders	Dutch Ophthalmic Research Center
536	brilliant blue G	Brilliant Peel	12/16/2009	For use in ophthalmic surgery to aid in the removal of the inner limiting membrane of the eye.	Fluron GmbH - Subsidiary of Geuder AG
537	Brimonidine	Alphagan	2/7/2000	Treatment of anterior ischemic optic neuropathy.	Allergan, Inc.
538	brivanib alaninate	n/a	3/21/2011	Treatment of hepatocellular carcinoma	Bristol-Myers Squibb
539	Brivaracetam	n/a	10/5/2005	Treatment of symptomatic myoclonus	UCB Pharma, Inc.
540	Broxuridine	Broxine/Neomark	9/18/1995	Radiation sensitizer in the treatment of primary brain tumors.	NeoPharm, Inc.
541	Bruton's tyrosine kinase inhibitor	n/a	2/10/2014	Treatment of chronic lymphocytic leukemia	Celgene Corporation
542	bryostatin-1	n/a	12/3/2001	For use in combination with paclitaxel in the treatment of esophageal cancer	GPC Biotech, Inc.
543	budesonide	n/a	12/20/2006	Treatment of patients with eosinophilic esophagitis.	Meritage Pharma, Inc.
544	budesonide	Uceris	5/6/2013	Treat of ulcerative colitis in pediatric patients aged 0 through 16 years.	Santarus, Inc.
545	budesonide	Nefecon	5/17/2010	To slow the progression of immunoglobulin A nephropathy & delay kidney failure in patients affected by the disease.	Pharmalink AB

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
546	Buffered intrathecal electrolyte/dextrose injection	Elliotts B Solution	8/24/1994	For use as a diluent in the intrathecal administration of methotrexate and cytarabine for the prevention or treatment of meningeal leukemia and lymphocytic lymphoma	Lukare Medical, LLC
547	Buffered Ursodeoxycholic Acid	Ursocarb	9/3/2004	Treatment of pruritus in patients with Alagille Syndrome	Digestive Care, Inc.
548	bupivacaine	Transdur	6/18/2008	Relief of persistent pain associated with postherpetic neuralgia	Impax Laboratories, Inc.
549	Buprenorphine hydrochloride	Subutex	6/15/1994	Treatment of opiate addiction in opiate users.	Reckitt Benckiser Pharmaceuticals, Inc.
550	buprenorphine in combination with naloxone	Suboxone	10/27/1994	Treatment of opiate addiction in opiate users	Reckitt Benckiser Pharmaceuticals, Inc.
551	Busulfan	Spartaject	7/7/1997	Treatment of primary brain malignancies.	SuperGen, Inc.
552	Busulfan	Spartaject	4/21/1994	For use as preparative therapy for malignancies treated with bone marrow transplantation.	Sparta Pharmaceuticals, Inc.
553	busulfan	Partaject	11/25/2002	Preparative therapy for pediatric patients undergoing bone marrow transplantation	SuperGen, Inc.
554	Busulfan	Busulfex	7/28/1994	As preparative therapy in the treatment of malignancies with bone marrow transplantation.	Otsuka Pharmaceutical Company
555	Buthionine sulfoxamine	n/a	10/5/2005	Use as a modulator of chemotherapy for the treatment of pediatric patients with primary malignant brain tumors	USC-CHLA Institute for Pediatric Clinical Research

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
556	Buthionine sulfoxamine	n/a	10/5/2005	For use in children as a modulator of chemotherapy for the treatment of pediatric patients with neuroblastoma	USC-CHLA Institute for Pediatric Clinical Research
557	Butyrylcholinesterase	n/a	3/25/1992	For the reduction and clearance of toxic blood levels of cocaine encountered during a drug overdose.	Shire Laboratories Inc.
558	Butyrylcholinesterase	n/a	9/30/1992	Treatment of post-surgical apnea.	Shire Laboratories Inc.
559	C1 esterase inhibitor (human)	n/a	8/21/1996	Treatment and prevention of angioedema caused by C1-esterase inhibitor deficiency.	Alpha Therapeutic Corporation
560	C1 esterase inhibitor (human)	Cinryze(R)	7/16/2004	Treatment of angioedema	ViroPharma Biologics Incorporated
561	C1-esterase-inhibitor, human, pasteurized	Beriner (R)	10/16/1992	Prevention and/or treatment of acute attacks of hereditary angioedema.	CSL Behring LLC
562	C20-D3-retinyl acetate	n/a	9/16/2010	Treatment of Stargardt's disease	Alkeus pharmaceuticals, Inc.
563	C66H100N6O27	n/a	3/11/2013	Treatment of of hepatocellular carcinoma	GenSpera, Inc.
564	cabozantinib	Cometriq	11/29/2010	Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer.	Exelixis, Inc.
565	Caffeine	Cafcit	9/20/1988	Treatment of apnea of prematurity.	O.P.R. Development, L.P.
566	caffeine and sodium benzoate	n/a	8/22/2012	Treatment of seizure prolongation in patients undergoing electroconvulsive therapy	Luitpold Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
567	Calcitonin-human for injection	Cibacalcin	1/20/1987	Treatment of symptomatic Paget's disease (osteitis deformans).	Novartis Pharmaceutical Corporation
568	Calcium acetate	n/a	6/27/1989	Treatment of hyperphosphatemia in end stage renal disease.	Pharmedic Company
569	Calcium acetate	Phos-Lo	12/22/1988	Treatment of hyperphosphatemia in end stage renal failure.	Fresenius Medical Care North America
570	calcium benzoate and risperidone	n/a	12/20/2010	Treatment of pediatric patients with schizophrenia	University of California, Los Angeles
571	Calcium carbonate	R & D Calcium Carbonate/600	6/6/1990	Treatment of hyperphosphatemia in patients with end stage renal disease.	R & D Laboratories, Inc.
572	Calcium gluconate	Calgonate	11/20/1997	For use as a wash for hydrofluoric acid spills on human skin.	Calgonate Corp.
573	Calcium gluconate gel	H-F Gel	5/21/1991	For use in the emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.	Calgonate Corporation
574	Calcium gluconate gel 2.5%	n/a	9/10/1990	Emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.	Paddock Laboratories, Inc.
575	Calfactant	Infasurf	9/5/2000	Acute respiratory distress syndrome (ARDS)	ONY, Inc.
576	camostat	n/a	5/18/2011	Treatment of chronic pancreatitis	NIXS Corporation
577	canakinumab	n/a	9/4/2012	Treatment of TNF-receptor associated periodic syndrome (TRAPS)	Novartis Pharmaceuticals Corporation
578	canakinumab	Ilaris	12/5/2013	Treatment of familial mediterranean fever	Novartis Pharmaceuticals Corporation

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
579	canakinumab	Ilaris	12/5/2013	Treatment of hyperimmunoglobulinemia D and periodic fever syndrome	Novartis Pharmaceuticals Corporation
580	canakinumab	Ilaris	9/30/2008	Treatment of pediatric (age 16 and under) juvenile rheumatoid arthritis.	Novartis Pharmaceuticals Corporation
581	canakinumab	Ilaris	12/18/2007	Treatment of cryopyrin-associated periodic syndromes	Novartis Pharmaceuticals Corporation
582	cantharidin	n/a	7/24/2012	Treatment of perforating diseases, including Kyrle's disease, reactive perforating collangenosis, perforating folliculitis and elastosis perforans serpiginosa	Orenova Group, LLC
583	caprine hyperimmune serum against HIV lysate	n/a	10/28/2009	Treatment of amyotrophic lateral sclerosis	Daval International Limited
584	caprine hyperimmune serum against HIV lysate	n/a	2/14/2014	Treatment of systemic sclerosis	Daval International Limited
585	Capsaicin	n/a	8/3/2005	Treatment of postherpetic neuralgia.	TheraQuest Biosciences, LLC
586	Capsaicin	n/a	9/29/2006	Treatment of intermetatarsal neuroma (Morton's Neuroma) that does not respond to conservative treatment and requires either neurectomy or neurolysis	Centrexion Corporation
587	capsaicin	n/a	10/23/2002	Treatment of erythromelalgia	Acorda Therapeutics, Inc.
588	capsaicin	Qutenza	5/2/2003	Treatment of painful HIV-associated neuropathy	Acorda Therapeutics, Inc.
589	capsaicin	Qutenza	5/22/2009	Management of neuropathic pain in patients with postherpetic neuralgia	Acorda Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
590	carbetocin	n/a	4/10/2014	Treatment of Prader Willi syndrome	Ferring Pharmaceuticals, Inc.
591	carbon monoxide	n/a	9/28/2012	Treatment of sickle cell disease	Hillhurst Biopharmaceuticals, Inc.
592	cardiotrophin-1	n/a	6/24/2008	To protect the liver from ischemia-reperfusion injury inherent to the procedure of transplantation.	Digna Biotech, S.L.
593	cardiotrophin-1	n/a	9/13/2011	Treatment of acute liver failure.	Digna Biotech S.L.
594	carfilzomib	Kyprolis	1/18/2008	Treatment of multiple myeloma	Onyx Therapeutics, Inc.
595	carglumic acid	Carbaglu	1/20/1998	Treatment of N-acetylglutamate synthetase deficiency.	Orphan Europe SARL
596	carisbamate	n/a	3/16/2012	Management of patients with infantile spasms	SK Life Science, Inc.
597	carlumab	n/a	10/24/2006	Treatment of pancreatic cancer	Centocor, Inc.
598	Carmustine	n/a	7/3/2000	Treatment of intracranial malignancies.	Direct Therapeutics, Inc.
599	Cascara sagrada fluid extract	n/a	3/21/1989	Treatment of oral drug overdosage to speed lower bowel evacuation.	Intramed Corporation
600	Catumaxomab	Removab	6/9/2006	Treatment of ovarian cancer	Neoviibiotech North America, Inc.
601	catumaxomab	n/a	7/1/2009	Treatment of gastric cancer	Neoviibiotech North America, Inc.
602	CD40/CD80/CD86 modified autologous dendritic cell therapy	n/a	12/20/2013	Treatment Type 1 diabetes mellitus patients with residual beta cell function	DiaVacs, Inc.
603	cediranib	n/a	12/13/2010	Treatment of glioblastoma	AstraZeneca
604	Ceftriaxone sodium	Rocephin	3/28/2006	Treatment of amyotrophic lateral sclerosis	Mass General Hospital

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
605	cell based therapeutic composed of allogeneic donor apoptotic cells	Apocell	3/18/2013	Prevention of graft versus host disease	Enlivex Therapeutics Ltd.
606	Cells produced using the AastromReplicelle System and SC-I Therapy Kit	n/a	7/10/2002	For use in patients receiving high dose chemotherapy who are unable to generate an acceptable dose of peripheral blood stem cells and who have a sufficient bone marrow aspirate without morphological evidence of tumor	Aastrom Biosciences Incorporated
607	cenersen	Aezea	6/18/2008	Treatment of stage IIB through IV melanoma	Eleos, Inc.
608	cenersen	Aezea	2/27/2008	Treatment of chronic lymphocytic leukemia	Eleos, Inc.
609	cenersen	n/a	5/8/2006	Treatment of acute myeloid leukemia	Eleos, Inc.
610	Centruroides immune F(ab)2	Anascorp	6/12/2000	Treatment of scorpion envenomations requiring medical attention.	Rare Disease Therapeutics, Inc.
611	Ceramide trihexosidase/alpha-galactosidase A	Fabrazyme	1/19/1988	Treatment of Fabry's disease.	Genzyme Corporation
612	ceritinib	Zykadia	9/27/2013	Treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase(ALK)-positive	Novartis Pharmaceuticals Corp.
613	cethromycin	Restanza(Tm)	9/9/2009	Prophylactic treatment of plague due to Yersinia pestis	Advanced Life Sciences, Inc.
614	cethromycin	Restanza(Tm)	9/9/2009	Prophylactic treatment of tularemia due to Francisella tularensis.	Advanced Life Sciences, Inc.
615	cethromycin	n/a	2/28/2007	Prophylactic treatment of patients exposed to inhalation anthrax.	Advanced Life Sciences, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
616	cetuximab	Erbitux	7/3/2000	Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor	ImClone Systems Incorporated
617	Chelating agent delivering Holmium-166	n/a	2/10/1999	Treatment of multiple myeloma.	NeoRx Corporation
618	chelmab-y or chelamusab-Y	Oncorad Ov103	4/24/1990	Treatment of ovarian cancer.	Cytogen Corporation
619	Chenodeoxycholic acid	Chenofalk	1/29/2004	Treatment of cerebrotendinous xanthomatosis	Dr. Falk Pharma GmbH
620	chenodeoxycholic acid	n/a	2/12/2007	Treatment of cerebrotendinous xanthomatosis	Sigma-Tau Pharmaceuticals, Inc.
621	chenodiol	Chenadal	3/22/2010	Treatment of cerebrotendinous xanthomatosis	Manchester Pharmaceuticals, Inc.
622	Chenodiol	Chenix	9/21/1984	For patients with radiolucent stones in well opacifying gallbladders, in whom elective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age.	Solvay
623	Chimeric monoclonal antibodies, c-alphaStx2	n/a	10/4/2005	For treatment of shiga-toxin producing bacterial infection	Thallion Pharmaceuticals, Inc.
624	chimeric monoclonal antibody 14.18 (ch14.18)	n/a	12/20/2010	Treatment of neuroblastoma	United Therapeutics Corporation
625	chimeric monoclonal antibody against Claudin 6	n/a	3/18/2013	Treatment of ovarian cancer	Ganymed Pharmaceuticals AG
626	chimeric monoclonal antibody against claudin-18 splice variant 2	n/a	9/26/2013	Treatment of pancreatic cancer	GANYMED Pharmaceuticals AG
627	chimeric monoclonal antibody to claudin 18 splice variant 2	n/a	11/20/2012	Treatment of gastric cancer	GANYMED Pharmaceuticals AG

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
628	Chimeric monoclonal antibody to mesothelin	n/a	10/31/2006	Treatment of pancreatic cancer	Morphotek, Inc.
629	Chimeric, humanized monoclonal antibody to staphylococcus	n/a	8/3/2000	Prophylaxis of Staphylococcus epidermidis sepsis in low birth weight (1500 grams or less) infants.	Biosynexus, Inc.
630	Chlorhexidine gluconate mouthrinse	Peridex	8/18/1986	For use in the amelioration of oral mucositis associated with cytoreductive therapy used in conditioning patients for bone marrow transplantation therapy.	Procter & Gamble Company
631	chlorobutanol/propylene glycol/hydrochloric acid	Patul-End	2/18/1997	Treatment of patulous eustachian tube	Ear Foundation
632	chloropyramine	n/a	10/22/2010	Treatment of pancreatic cancer	CurFAKtor Pharmaceuticals, LLC
633	Chlorotoxin	n/a	12/18/2007	Treatment of malignant glioma	Morphotek, Inc.
634	chlorotoxin	n/a	12/2/2008	Treatment of stage IIb, IIc, III & IV melanoma	Morphotek, Inc.
635	cholest-4-en-3-one, oxime	n/a	2/17/2009	Treatment of spinal muscular atrophy.	Trophos SA
636	cholic acid (3 alpha, 7 alpha, 12 alpha trihydroxy 5-beta cholanoic acid)	Falkochol	7/18/2003	Treatment of inborn errors of cholesterol and bile acid synthesis and metabolism	Asklepion Pharmaceuticals LLC
637	Choline chloride	Intrachol	2/10/1994	Treatment of choline deficiency, specifically the choline deficiency, hepatic steatosis, and cholestasis, associated with long-term parenteral nutrition.	Alan L. Buchman, MD, MSPH
638	Choline chloride	Intrachol	7/20/2006	Prevention and/or treatment of choline deficiency in patients on long-term parenteral nutrition	Alan L. Buchman, M.D., M.S.P.H.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
639	choline tetrathiomolybdate	n/a	8/25/2011	Treatment of Wilson's disease.	Wilson Therapeutics AB
640	Chondrocyte-alginate gel suspension	n/a	12/1/1997	For use in correcting vesicoureteral reflux in the pediatric population.	Curis, Inc.
641	Ciliary neurotrophic factor	n/a	1/30/1992	Treatment of amyotrophic lateral sclerosis.	Regeneron Pharmaceuticals Inc
642	cinacalcet	Sensipar	5/12/2003	Treatment of hypercalcemia in patients with parathyroid carcinoma	Amgen, Inc.
643	cinacalcet	Sensipar	4/30/2010	Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery	Amgen, Inc.
644	Cintredekin Besudotox	n/a	4/30/2010	Treatment of idiopathic pulmonary fibrosis	Insys Therapeutics, Inc.
645	ciprofloxacin	n/a	6/1/2011	The management of bronchiectasis	Aradigm Corporation
646	ciprofloxacin DPI	Ciprofloxacin Pulmosphere(R)	2/2/2010	Management of pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis patients	Bayer HealthCare Pharmaceuticals, Inc.
647	ciprofloxacin dry powder inhaler	n/a	4/17/2014	Treatment of non-cystic fibrosis bronchiectasis	Bayer HealthCare Pharmaceuticals, Inc.
648	cis-adamantane-2-spiro-3'-8'-[4'-[2'-(4'-morpholinyl)ethoxy]phenyl]-1',2',4'-trioxaspiro[4.5] decane mesylate	n/a	1/19/2010	Treatment of malaria caused by Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, or Plasmodium malariae	Medicines for Malaria Venture (MMV)
649	Cisplatin in liposomal formulation	Slit Cisplatin For Inhalation	3/20/2007	Treatment of osteosarcoma	Eleison Pharmaceuticals, LLC

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
650	Cisplatin/epinephrine	Intradose	9/7/2000	Treatment of metastatic malignant melanoma.	Matrix Pharmaceutical, Inc.
651	Cisplatin/epinephrine	Intradose	4/3/2000	Treatment of squamous cell carcinoma of the head and neck.	Matrix Pharmaceutical, Inc.
652	Citric acid, glucono-delta-lactone and magnesium carbonate	Renacidin Irrigation	8/28/1989	Treatment of renal and bladder calculi of the apatite or struvite variety.	United-Guardian, Inc.
653	civamide	Zucapsaicin	12/9/2002	Treatment of postherpetic neuralgia of the trigeminal nerve	Winston Laboratories, Inc.
654	civamide	n/a	2/17/2009	Treatment of postherpetic neuralgia.	Winston Laboratories, Inc.
655	Cladribine	Mylinax	4/19/1994	Treatment of the chronic progressive form of multiple sclerosis.	Johnson & Johnson Pharmaceutical R & D, LLC
656	Cladribine	Leustatin Injection	4/19/1993	Treatment of non-Hodgkin's lymphoma.	Janssen Research & Development, LLC
657	Cladribine	Leustatin Injection	12/31/1990	Treatment of chronic lymphocytic leukemia.	Janssen Research & Development, LLC
658	Cladribine	Leustatin	7/20/1990	Treatment of acute myeloid leukemia.	Janssen Research & Development, LLC
659	Cladribine	Leustatin Injection	11/15/1990	Treatment of hairy cell leukemia.	R. W. Johnson Pharmaceutical Research Institute
660	clarithromycin, rifabutin, clofazimine	n/a	4/26/2011	Treatment of pediatric Crohn's disease.	RedHill Biopharma Ltd.
661	Clazosentan	Erajel	2/16/2006	Treatment of cerebral vasospasm following subarachnoid hemorrhage	Actelion Pharmaceuticals Ltd.
662	Clindamycin	Cleocin	10/28/1988	Prevention of Pneumocystis carinii pneumonia in AIDS patients.	Pfizer Inc.
663	Clindamycin	Cleocin	10/28/1988	Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.	Pharmacia & Upjohn

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
664	Clindamycin hydrochloride	n/a	8/9/2006	Treatment of sarcoidosis	Autoimmunity Research Foundation
665	clobazam	Onfi	12/18/2007	Treatment of Lennox-Gastaut Syndrome	Lundbeck, Inc.
666	clofarabine	Clofarex	3/14/2002	Treatment of acute myelogenous leukemia	Genzyme Corp (Ilex Products, Inc.)
667	clofarabine	Clolar	2/7/2002	Treatment of acute lymphoblastic leukemia	Genzyme Corporation
668	Clofazimine	Lamprene	6/11/1984	Treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum.	Novartis Pharmaceutical Corporation
669	Clonazepam	Klonopin	8/4/1994	Treatment of hyperekplexia (startle disease).	Hoffmann-La Roche, Inc.
670	Clonazepam Intranasal Spray	n/a	12/19/2007	Treatment of recurrent acute repetitive seizures	Jazz Pharmaceuticals, Inc.
671	Clonidine	Duraclon	1/24/1989	For continous epidural administration as adjunctive therapy with intraspinal opiates for the treatment of pain in cancer patients tolerant to, or unresponsive to, intraspinal opiates.	Roxane Laboratories, Inc.
672	Clotrimazole	n/a	3/13/2006	Treatment of Huntington's disease	EnVivo Pharmaceuticals, Inc.
673	Clotrimazole	n/a	6/14/2005	Topical treatment of children and adults with pouchitis	AesRx, LLC
674	Clotrimazole	n/a	4/24/1995	Treatment of sickle cell disease.	Brugnara, Carlo M.D.
675	CNDO-109-activated allogeneic natural killer cells	n/a	6/18/2012	Treatment of acute myeloid leukemia	Coronado Biosciences, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
676	Coagulation factor IX	Mononine	6/27/1989	Replacement treatment and prophylaxis of the hemorrhagic complications of hemophilia B.	Armour Pharmaceutical Company
677	Coagulation Factor IX (human)	Alphanine	7/5/1990	For use as replacement therapy in patients with hemophilia B for the prevention and control of bleeding episodes, and during surgery to correct defective hemostasis.	Alpha Therapeutic Corporation
678	Coagulation Factor IX (recombinant)	Benefix	10/3/1994	Treatment of hemophilia B.	Genetics Institute, Inc.
679	coagulation factor IX (recombinant)	Rixubis	10/31/2012	Prophylactic use to prevent or reduce the frequency of bleeding episodes in patients with hemophilia B (routine prophylaxis in patients where there is no evidence or suspicion of bleeding)	Baxter Healthcare Corporation
680	Coagulation factor IX (recombinant), Fc fusion protein	Alprolix	10/30/2008	Control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency or Christmas disease)	Biogen Idec Inc.
681	Coagulation factor VIIa (Recombinant)	Novoseven	6/18/2004	Treatment of bleeding episodes in Glanzmann's thrombasthenia	Novo Nordisk, Inc.
682	Coagulation factor VIIa (recombinant)	Novoseven	6/18/2004	Prevention of bleeding episodes in Glanzmann's thrombasthenia	Novo Nordisk, Inc.
683	Coagulation Factor VIIa (Recombinant)	Novoseven	7/16/2004	Treatment of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX	Novo Nordisk, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
684	Coagulation factor VIIa (recombinant)	Novoseven	9/10/2004	Treatment of bleeding episodes in patients with congenital factor VII deficiency	Novo Nordisk, Inc.
685	Coagulation factor VIIa (recombinant)	Novoseven	9/10/2004	Prevention of bleeding episodes in patients with congenital Factor VII deficiency	Novo Nordisk, Inc.
686	Coagulation factor VIIa (recombinant)	Novoseven	7/21/2004	Prevention of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX	Novo Nordisk, Inc.
687	Coagulation factor VIIa (recombinant)	Novoseven	6/18/2004	Prevention of bleeding episodes in patients with hemophilia A or B, with or without inhibitors	Novo Nordisk, Inc.
688	Coagulation factor VIIa (recombinant)	Novoseven	6/6/1988	Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.	Novo Nordisk, Inc.
689	coagulation factor XIII A-subunit (recombinant)	Tretten	11/6/2003	Prophylaxis of bleeding associated with congenital factor XIII deficiency	Novo Nordisk, Inc.
690	cobimetinib	n/a	1/31/2014	Treatment of stage IIb, IIc, III, and IV melanoma with BRAFV600E mutation.	Genentech, Inc.
691	cobiprostone	n/a	11/14/2002	Treatment of cystic fibrosis	Sucampo Pharma Americas, LLC.
692	coccidioidin SD Skin Test Antigen	n/a	12/19/2007	For the diagnosis of Coccidioidomycosis	Allermed Laboratories, Inc.
693	Coenzyme Q10	n/a	3/5/2001	Treatment of Huntington's disease	Integrative Therapeutics, Inc.
694	coenzyme Q10 and d-alpha-tocopherol	n/a	3/14/2011	Treatment of Friedreich's Ataxia.	NBI Pharmaceuticals, Inc.
695	Colchicine	n/a	9/25/2007	Treatment of Behcet's Syndrome	AR Scientific, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
696	colchicine	Colcrys	9/25/2007	Treatment of familial Mediterranean fever	AR Holding Company, Inc.
697	Colfosceril palmitate, cetyl alcohol, tyloxapol	Exosurf Neonatal For Intratracheal Suspension	10/20/1989	Prevention of hyaline membrane disease, also known as respiratory distress syndrome, in infants born at 32 weeks gestation or less.	Glaxo Wellcome Inc.
698	Colfosceril palmitate, cetyl alcohol, tyloxapol	Exosurf Neonatal For Intratracheal Suspension	10/20/1989	Treatment of established hyaline membrane disease at all gestational ages.	Glaxo Wellcome Inc.
699	collagenase clostridium histolyticum	Xiaflex	5/23/1996	Treatment of advanced (involutional or residual stage) Dupuytren's disease.	Auxilium Pharmaceuticals, Inc.
700	collagenase clostridium histolyticum	Xiaflex	3/12/1996	Treatment of Peyronie's disease.	Auxilium Pharmaceuticals, Inc.
701	combretastatin A 1 diphosphate	n/a	11/19/2012	Treatment of acute myelogenous leukemia	OxiGene, Inc.
702	Combretastatin A4 Phosphate	n/a	7/23/2003	Treatment of anaplastic thyroid cancer, medullary thyroid cancer, and stage IV papillary or follicular thyroid cancer	OxiGENE, Inc
703	Combretastatin A4 phosphate	n/a	5/8/2006	Treatment of ovarian cancer	OxiGENE, Inc.
704	Conjugate of a dengue virus specific small chemical ligand and an amphiphilic PEG based polymer	n/a	8/6/2013	Treatment of dengue fever (includes dengue hemorrhagic fever and dengue shock syndrome)	NanoViricides Incorporated
705	conjugate of human transferrin and a mutant diphtheria toxin (CRM 107)	Transmid	12/3/2001	Treatment of malignant tumors of the central nervous system	Xenova Biomedix Limited
706	conjugated bile acids	Cobartin	7/18/2003	Treatment of steatorrhea in patients with short bowel syndrome	Jarrow Formulas, Inc.
707	Contulakin-G	n/a	7/7/2005	Intrathecal treatment of neuropathic pain associated with spinal cord injury	Cognetix, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
708	copper histidine	n/a	5/14/2012	Treatment of Menkes disease	Stephen G. Kaler, M.D.
709	Cordycepin	n/a	7/5/2007	Treatment of TdT-positive acute lymphocytic leukemia	OncoVista, Inc.
710	corifungin	n/a	7/6/2011	Treatment of visceral leishmaniasis	Sandler Center for Drug Discovery
711	corifungin	n/a	8/22/2011	Treatment of amebic meningoencephalitis.	Ctr for Discovery & Innovation in Parasitic Diseases
712	Corticotropin ovine triflutate	Acthrel	11/24/1989	For use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing's syndrome.	Ferring Laboratories, Inc.
713	Corticotropin-releasing factor, human	Xerecept	4/6/1998	Treatment of peritumoral brain edema.	Neurobiological Technologies, Inc.
714	Coumarin	Onkolox	12/22/1994	Treatment of renal cell carcinoma.	Drossapharm LTD
715	Coxsackievirus A21	Cavatak	12/15/2005	Treatment of stage II (T4), stage III, and stage IV melanoma	Viralytics Limited
716	Creatine	Creapure	10/11/2005	Treatment of Huntington's disease	Avicena Group, Inc.
717	creatine	Creapure	2/12/2002	Treatment of amyotrophic lateral sclerosis	Avicena Group, Inc.
718	crenolanib	n/a	12/20/2010	Treatment of malignant glioma	AROG Pharmaceuticals, LLC
719	crenolanib	n/a	10/31/2012	Treatment of acute myelogenous leukemia	AROG Pharmaceuticals, LLC
720	crenolanib	n/a	3/11/2011	Treatment of soft tissue sarcoma	AROG Pharmaceuticals, LLC

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
721	cridanimod	n/a	1/12/2011	Treatment of progesterone receptor negative endometrial cancer in conjunction with progesterone therapy.	Kevelt Ltd.
722	crizotinib	Xalkori	9/28/2012	Treatment of anaplastic large cell lymphoma	Pfizer, Inc.
723	crizotinib	Xalkori	10/31/2012	Treatment of neuroblastoma	Pfizer
724	crizotinib	Xalkori	9/13/2010	Treatment of ALK-positive, MET-positive, or ROS-positive non-small cell lung cancer	Pfizer, Inc.
725	Cromolyn sodium	Gastrocrom	3/8/1984	Treatment of mastocytosis.	Fisons Corporation
726	Cromolyn sodium 4% ophthalmic solution	Opticrom 4% Ophthalmic Solution	7/24/1985	Treatment of vernal keratoconjunctivitis.	Fisons Corporation
727	Cryptosporidium hyperimmune bovine colostrum IgG concentrate	n/a	12/30/1991	Treatment of diarrhea in AIDS patients caused by infection with Cryptosporidium parvum.	ImmuCell Corporation
728	cultured, partially T-Cell depleted, allogenic thymic tissue for transplantation	n/a	8/15/2003	As a therapy for primary immune deficiency resulting from athymia associated with complete DiGeorge Syndrome	Duke University Medical Center
729	cyclic pyranopterin monophosphate (cPMP)	n/a	11/5/2009	Treatment of molybdenum cofactor deficiency type A (MoCD)	Alexion Pharmaceuticals, Inc.
730	Cyclo {(E,Z)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)nona-6,8-dienoyl}-L-2-aminobutyl-N-methyl-glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl}	n/a	12/20/2006	Treatment and chronic control of non-infectious posterior, intermediate and pan-uveitis	Lux Biosciences, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
731	cyclo(-γ-aminobutyryl-L-phenylalanyl-L-tryptophanyl-D-tryptophanyl-L-lysyl-L-threonyl-L-phenylalanyl-N-3-carboxypropyl)-glycine amide, acetate salt	n/a	6/24/2013	Treatment of acromegaly	Aspireo Pharmaceuticals Limited
732	cyclocreatine	n/a	6/18/2012	Treatment of creatine transporter deficiency	Lumos Pharma
733	cyclophosphamide	Cyrevia(Tm)	6/17/2011	Prevention of graft versus host disease following allogeneic hematopoietic stem cell transplant	Accentia Biopharmaceuticals, Inc.
734	cyclophosphamide	Cyrevia(Tm)	6/7/2011	Treatment of systemic sclerosis.	Accentia Biopharmaceuticals, Inc.
735	Cyclosporin A	Mitogard	10/29/2004	Treatment of amyotrophic lateral sclerosis and its variants	Maas Biolab, LLC
736	Cyclosporine	Pluminiq	11/25/2003	Treatment of acute rejection in patients requiring allogeneic lung transplants	APT Pharmaceuticals, Inc.
737	Cyclosporine	n/a	11/25/2003	Prophylaxis of organ rejection in patients receiving allogeneic lung transplant	APT Pharmaceuticals, Inc.
738	cyclosporine	n/a	2/17/2009	Treatment of graft-versus-host disease	Sigmoid Pharma Limited
739	cyclosporine	n/a	2/17/2009	Prophylaxis of graft-versus-host disease	Sigmoid Pharma Limited
740	cyclosporine	n/a	11/23/2010	Treatment of moderate to severe traumatic brain injury.	NeuroVive Pharmaceutical AB
741	Cyclosporine 2% ophthalmic ointment	n/a	8/1/1991	Treatment of patients at high risk of graft rejection following penetrating keratoplasty.	Allergan, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
742	Cyclosporine 2% ophthalmic ointment	n/a	8/1/1991	For use in corneal melting syndromes of known or presumed immunologic etiopathogenesis, including Mooren's ulcer.	Allergan, Inc.
743	Cyclosporine A	n/a	5/4/2007	Treatment of vernal keratoconjunctivitis	NOVAGALI Pharma SA
744	cyclosporine A	Nova22007	4/9/2008	Treatment of herpes simplex virus stromal keratitis	Novagali Pharma S.A.
745	cyclosporine A	n/a	9/30/2008	Prevention of corneal graft rejection	Novagali Pharma S.A.
746	Cyclosporine in combination with omega-3 polyunsaturated fatty acids	n/a	12/6/2000	Prevention of solid organ graft rejection.	RTP Pharma Corporation
747	Cyclosporine ophthalmic	Optimmune	11/9/1988	Treatment of severe keratoconjunctivitis sicca associated with Sjogren's syndrome.	University Of Georgia
748	Cys-His-Ala-Val-Cys	n/a	2/14/2008	For use in conjunction with melphalen for the treatment of malignant melanoma, AJCC stages IIB, IIC, III and IV	Adherex Technologies, Inc.
749	Cysteamine	n/a	5/1/1986	Treatment of nephropathic cystinosis.	Thoene, Jess G., M.D.
750	cysteamine	n/a	5/9/2008	Treatment of Huntington's disease	Raptor Therapeutics
751	cysteamine	n/a	8/6/2008	Treatment of neuronal ceroid lipofuscinoses (Batten disease)	Raptor Pharmaceuticals, Inc.
752	cysteamine	n/a	9/11/2013	Treatment of pancreatic cancer	Raptor Pharmaceuticals, Inc.
753	Cysteamine	Cystagon	1/25/1991	Treatment of nephropathic cystinosis.	Mylan Laboratories, Inc.
754	cysteamine enteric coated	Procysbi	10/24/2006	Treatment of cystinosis	Raptor Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
755	Cysteamine hydrochloride	Cystaran	8/19/1997	Treatment of corneal cystine crystal accumulation in cystinosis patients.	Sigma-Tau Pharmaceuticals, Inc.
756	Cystic fibrosis Tr gene therapy (recombinant adenovirus)	Adgvcfr.10	3/9/1995	Treatment of cystic fibrosis.	GenVec, Inc.
757	Cystic fibrosis transmembrane conductance regulator gene	n/a	1/8/1993	Treatment of cystic fibrosis.	Genetic Therapy, Inc.
758	Cytarabine liposomal	Depocyt	6/2/1993	Treatment of neoplastic meningitis.	Pacira Pharmaceuticals, Inc.
759	cytarabine liposome	Depocyt	1/30/2007	Treatment of gliomas	Bruce Frankel, MD
760	Cytarabine:daunorubicin liposome injection	n/a	8/22/2008	Treatment of acute myeloid leukemia	Celator Pharmaceuticals, Inc.
761	cytochrome C, flavin mononucleotide and thiamin diphosphate	n/a	6/17/2011	Treatment of mitochondrial disorders	NBI Pharmaceuticals, Inc
762	Cytomegalovirus DNA Vaccine w/Copolymer/Benzalkonium Chloride	n/a	9/23/2006	For use in prevention of clinically significant CMV viremia, CMV disease and associated complications in at-risk hematopoietic cell transplant and solid organ transplant populations	Vical Inc.
763	Cytomegalovirus DNA vaccine with plasmids expressing pp65 and gB genes	n/a	6/3/2005	Prevention of clinically significant cytomegalovirus (CMV) viremia, CMV disease and associated complications in at-risk hematopoietic cell transplant and solid transplant populations	Astellas Pharma Global Development, Inc.
764	Cytomegalovirus immune globulin (human)	Cytogam	8/3/1987	Prevention or attenuation of primary cytomegalovirus disease in immunosuppressed recipients of organ transplants.	CSL Behring LLC

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
765	Cytomegalovirus immune globulin intravenous (human)	n/a	1/28/1991	For use in conjunction with ganciclovir sodium for the treatment of cytomegalovirus pneumonia in bone marrow transplant patients.	Bayer Corporation
766	dabrafenib	Tafinlar	1/12/2011	Treatment BRAF V600 mutation positive Stage IIB through IV melanoma	GlaxoSmithKline, LLC
767	dacetuzumab	n/a	8/13/2004	Treatment of multiple myeloma.	Seattle Genetics, Inc.
768	dacetuzumab	n/a	10/6/2005	Treatment of chronic lymphocytic leukemia	Seattle Genetics, Inc.
769	Daclizumab	Zenapax	3/5/1993	Prevention of acute renal allograft rejection.	Hoffmann-La Roche, Inc.
770	dalfampridine	Ampyra	6/2/1987	Relief of symptoms of multiple sclerosis	Acorda Therapeutics
771	dantrolene sodium	n/a	9/25/2012	Treatment of heat stroke	Eagle Pharmaceuticals, Inc.
772	dantrolene sodium suspension for injection	n/a	8/16/2013	Treatment of malignant hyperthermia syndrome	Eagle Pharmaceuticals, Inc.
773	Dapsone	n/a	11/7/1994	Prophylaxis of toxoplasmosis in severely immunocompromised patients with CD4 counts below 100.	Jacobus Pharmaceutical Company, Inc.
774	Dapsone USP	Dapsone	1/8/1992	For the combination treatment of Pneumocystis carinii pneumonia in conjunction with trimethoprim.	Jacobus Pharmaceutical Company
775	Dapsone USP	Dapsone	12/24/1991	Prophylaxis for Pneumocystis carinii pneumonia.	Jacobus Pharmaceutical Company
776	daratumumab	Humax(R)-Cd38	5/6/2013	Treatment of multiple myeloma.	Janssen Research & Development, LLC

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
777	Darinaparsin	n/a	9/13/2010	Treatment of peripheral T-cell lymphoma.	Ziopharm Oncology, Inc.
778	Dasatinib	Sprycel	11/28/2005	Treatment of chronic myelogenous leukemia	Bristol-Myers Squibb Company
779	Dasatinib	Sprycel	11/18/2005	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Bristol-Myers Squibb Company
780	dasiprotimut-T	Biovaxid	10/28/2009	Treatment of follicular lymphoma	Biovest International, Inc.
781	dasiprotimut-T	Biovax Id	6/17/2010	Treatment of mantle cell lymphoma	Biovest International, Inc.
782	daunorubicin citrate liposome	Daunoxome	4/15/2013	Treatment of acute myeloid leukemia	Galen Limited
783	Daunorubicin citrate liposome injection	Daunoxome	5/14/1993	Treatment of patients with advanced HIV-associated Kaposi's sarcoma.	NeXstar Pharmaceuticals, Inc.
784	Daunorubicin liposomal	n/a	9/5/2008	Treatment of acute myeloid leukemia	Diatos USA, LLC
785	davunetide	n/a	12/7/2009	Treatment of progressive supranuclear palsy.	Allon Therapeutics, Inc.
786	DCVAC OvCa	n/a	5/14/2013	Treatment of ovarian cancer	SOTIOS a.s.
787	DEAE-rebeccamycin	n/a	3/1/2004	Treatment of bile duct tumors	Helsinn Healthcare SA
788	debrase	Debridase	8/20/2003	Debridement of acute, deep dermal burns in hospitalized patients	MediWound, Ltd.
789	Decitabine	Dacogen	8/4/2006	Treatment of acute myeloid leukemia	Eisai, Inc.
790	Decitabine	n/a	3/8/1999	Treatment of chronic myelogenous leukemia.	Eisai, Inc.
791	decitabine	n/a	9/9/2002	Treatment of sickle cell anemia	Eisai, Inc.
792	Decitabine	Dacogen	3/8/1999	Treatment of myelodysplastic syndromes.	Eisai, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
793	Deferasirox	Exjade	11/21/2002	Treatment of chronic iron overload in patients with transfusion-dependent anemias	Novartis Pharmaceuticals Corporation
794	deferiprone	n/a	9/1/2011	Treatment of superficial siderosis	ApoPharma, Inc.
795	deferiprone	n/a	7/31/2008	Treatment of Friedreich's ataxia.	ApoPharma, Inc.
796	deferiprone	Ferriprox	12/12/2001	Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy	ApoPharma, Inc. A Division of
797	deferoxamine starch conjugate	n/a	1/28/2005	Treatment of acute iron poisoning	Biomedical Frontiers, Inc.
798	deferoxamine starch conjugate	n/a	12/21/1998	Treatment of chronic iron overload resulting from conventional transfusional treatment of beta-thalassemia major and sickle cell anemia.	Biomedical Frontiers, Inc.
799	Defibrotide	n/a	7/5/1985	Treatment of thrombotic thrombocytopenic purpura.	Crinos International
800	defibrotide	n/a	1/8/2007	For the prevention of hepatic veno-occlusive disease.	Gentium SpA
801	defibrotide	n/a	5/21/2003	For the treatment of hepatic veno-occlusive disease	Gentium SpA
802	deflazacort	n/a	8/16/2013	Treatment of Duchenne muscular dystrophy	Marathon Pharmaceuticals, LLC
803	deflazacort	Calcort	9/16/2010	Treatment of Duchenne muscular dystrophy	University of Rochester Medical Center
804	dehydrated alcohol	n/a	3/16/2012	Treatment of trigeminal neuralgia	Luitpold Pharmaceuticals, Inc.
805	dehydrated alcohol	Ablysinol	9/11/2013	Treatment of hypertrophic obstructive cardiomyopathy	Belcher Pharmaceuticals, LLC

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
806	Dehydroepiandrosterone (DHEA)	Fidelin	8/19/2003	Replacement therapy in individuals with adrenal insufficiency	Paladin Labs, Inc.
807	Dehydroepiandrosterone sulfate sodium	n/a	1/28/1997	To accelerate the re-epithelialization of donor sites in those hospitalized burn patients who must undergo autologous skin grafting.	Pharmadigm, Inc.
808	Dehydroepiandrosterone sulfate sodium	n/a	1/29/1997	Treatment of serious burns requiring hospitalization.	Pharmadigm, Inc.
809	delta-1,4,9(11)-pregnatriene-17-alpha,21-dihydroxy-16-alpha-methyl-3,20-dione	n/a	12/2/2011	Treatment of Duchenne muscular dystrophy.	ReveraGen Biopharma
810	demcizumab	n/a	4/30/2014	Treatment of pancreatic cancer	OncoMed Pharmaceuticals, Inc.
811	dendritic cells pulsed with synthetic peptides derived from antigens MAGE1, HER-2, AIM-2, TRP-2, gp100 and interleukin-13 receptor alpha	n/a	6/7/2010	Treatment of glioblastoma or brain stem glioma	ImmunoCellular Therapeutics Ltd.
812	dendritic hybrid cell vaccine	Neuroblaxin	9/23/2011	Treatment of neuroblastoma	Orbis Health Solutions, LLC
813	denileukin diftitox	n/a	7/12/2013	Treatment of cutaneous T-cell lymphoma	Eisai Inc.
814	denileukin diftitox	Ontak	4/30/2010	Treatment of peripheral T-cell lymphoma	Eisai, Inc.
815	denileukin diftitox	n/a	6/29/2011	Treatment of peripheral T-cell lymphoma (PTCL)	Eisai, Inc.
816	denileukin diftitox	Ontak	8/21/1996	Treatment of patients with cutaneous T-cell lymphoma	Eisai, Inc.
817	denosumab	Xgeva	9/11/2013	Treatment of hypercalcemia of malignancy	Amgen, Inc.
818	denosumab	Xgeva	12/20/2010	Treatment of patients with giant cell tumor of bone	Amgen, Inc.
819	Dermagraft	n/a	12/13/2010	Treatment of epidermolysis bullosa	Shire Regenerative Medicine, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
820	Deslorelin	Somagard	11/5/1987		Roberts Pharmaceutical Corp.
821	Desmoglein 3 synthetic peptide (PI-0824)	n/a	10/26/2004	Treatment of pemphigus vulgaris	Peptimmune, Inc.
822	Desmopressin acetate	n/a	1/22/1991	Treatment of mild hemophilia A and von Willebrand's disease.	Aventis Behring L.L.C.
823	dexamethasone intravitreal implant	Ozurdex	9/11/1998	Treatment of non-infectious ocular inflammation of the posterior segment in patients with intermediate, posterior, and panuveitis	Allergan
824	dexamethasone phosphate	n/a	12/2/2008	Treatment of corneal graft rejection.	EyeGate Pharmaceuticals, Inc.
825	dexamethasone sodium phosphate encapsulated in autologous erythrocytes	n/a	7/24/2012	Treatment of ataxia-telangiectasia	EryDel S.p.A.
826	dexanabinol	n/a	8/11/2004	For the attenuation or amelioration of the long-term neurological sequelae associated with moderate and severe traumatic brain injury	Pharmos Corporation
827	dexpramipexole	n/a	10/11/2007	Treatment of amyotrophic lateral sclerosis	Biogen Idec, Inc.
828	Dexrazoxane	Zinecard	12/17/1991	For the prevention of cardiomyopathy associated with doxorubicin administration.	Pharmacia & Upjohn
829	dexrazoxane	Totect(R)	3/25/2004	Treatment of anthracycline extravasation during chemotherapy	Biocodex
830	dextran 1	n/a	3/21/2003	Treatment of cystic fibrosis	BCY LifeSciences Inc.
831	Dextran 70	Dehydrex	3/5/1990	Treatment of recurrent corneal erosion unresponsive to conventional therapy.	Holles Laboratories, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
832	Dextran and deferoxamine	Bio-Rescue	3/8/1991	Treatment of acute iron poisoning.	Biomedical Frontiers, Inc.
833	Dextran sulfate (inhaled, aerosolized)	Uendex	10/5/1990	For use as an adjunct to the treatment of cystic fibrosis.	Kennedy & Hoidal, M.D.'s
834	Dextran sulfate sodium	n/a	11/19/1987	Treatment of acquired immunodeficiency syndrome.	Ueno Fine Chemicals Industry, Ltd.
835	DHA-paclitaxel	Taxoprexin	9/25/2001	Treatment of pancreatic cancer	Luitpold Pharmaceuticals, Inc..
836	DHA-paclitaxel	Taxoprexin	5/1/2003	Treatment of adenocarcinoma of the stomach or lower esophagus	Luitpold Pharmaceuticals, Inc.
837	DHA-paclitaxel	Taxoprexin	10/10/2002	Treatment of metastatic malignant melanoma	Luitpold Pharmaceuticals, Inc.
838	Dianeal peritoneal dialysis solution with 1.1% amino acids	Nutrineal (Peritoneal Dialysis Solution With 1.1% Amino Acid	6/11/1992	For use as a nutritional supplement for the treatment of malnourishment in patients undergoing continuous ambulatory peritoneal dialysis.	Baxter Healthcare Corporation
839	diannexin	n/a	10/28/2009	Prevention of ischemia-reperfusion injury in solid organ transplants	Astellas Pharma Global Development, Inc.
840	diazepam (intranasal)	n/a	7/31/2012	Management of patients with acute repetitive seizures	Acorda Therapeutics, Inc.
841	diazepam auto-injector	n/a	5/30/2013	Management of selected, refractory patients with epilepsy on stable regimens of antiepileptic drugs, who require intermittent use of diazepam to control bouts of increased seizure activity	Meridian Medical Technologies-a Pfizer subsidiary

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
842	Diazepam viscous solution for rectal administration	n/a	2/25/1992	For the management of selected, refractory, patients with epilepsy, on stable regimens of antiepileptic drugs (AEDs), who require intermittent use of diazepam to control bouts of increased seizure activity.	Valeant Pharmaceuticals
843	diazoxide	n/a	12/3/2012	Treatment of Prader Willi Syndrome	Sedogen, LLC
844	diazoxide choline	n/a	5/13/2014	Treatment of Prader-Willi Syndrome	Essentialis, Inc.
845	dichlorphenamide	n/a	9/2/2010	Treatment of primary periodic paralyses	Taro Pharmaceuticals
846	Diethyldithiocarbamate	Imuthiol	4/3/1986	Treatment of AIDS.	Connaught Laboratories
847	diethylenetriaminepentaacetate (DPTA)	n/a	4/14/2004	For treatment of patients with known or suspected internal contamination with plutonium, americium or curium to increase the rates of elimination.	CIS-US
848	Diethylenetriaminepentaacetic acid (DTPA)	n/a	4/28/2004	Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination.	HamelN Pharmaceuticals gmbh
849	diferuloylmethane	n/a	6/13/2003	Treatment of cystic fibrosis	Allertein Therapeutics, LLC
850	difluprednate	Durezol	9/30/2008	Treatment of endogenous and traumatic anterior uveitis and panuveitis.	Alcon Pharmaceuticals. Ltd.
851	digitoxin	n/a	5/27/2005	Treatment of cystic fibrosis	Bette S. Pollard, LLC
852	digitoxin	n/a	11/2/2001	Treatment of ovarian cancer	PrimeCyte, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
853	digitoxin	n/a	10/18/2001	Treatment of soft tissue sarcomas	PrimeCyte, Inc.
854	digoxin immune fab (ovine)	n/a	2/3/2012	Treatment of severe preeclampsia and eclampsia	Glenveigh Medical, LLC
855	Digoxin immune FAB (Ovine)	Digibind	11/1/1984	Treatment of potentially life threatening digitalis intoxication in patients who are refractory to management by conventional therapy.	Glaxo Wellcome Inc.
856	Digoxin immune fab(ovine)	Digidote	3/11/1985	Treatment of life-threatening acute cardiac glycoside intoxication manifested by conduction disorders, ectopic ventricular activity and (in some cases) hyperkalemia.	Boehringer Mannheim Corp.
857	dihydroartemisinin and piperaquine	Eurartesim	1/8/2007	Treatment of uncomplicated malaria caused by "Plasmodium falciparum," Plasmodium vivax," Plasmodium malariae," or "Plasmodium ovale."	Sigma-Tau Pharmaceuticals, Inc.
858	Dihydrotestosterone	Androgel -Dht	2/5/1996	Treatment of weight loss in AIDS patients with HIV-associated wasting.	Besins Internaitonal, US Inc.
859	dimebon	n/a	5/12/2009	Treatment of Huntington's Disease.	Medivation, Inc.
860	Dimerizing drug that binds to mutated Fas protein/drug-binding domain fusion protein (FKBP)	n/a	11/24/1999	Treatment of acute graft-versus-host disease in patients undergoing bone marrow transplantation.	Bellicum Pharmaceuticals, Inc.
861	dimethyl fumarate	n/a	9/11/2013	Treatment of Friedreich's Ataxia	Gino Cortopassi

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
862	Dimethyl sulfoxide	n/a	11/22/1994	Treatment of increased intracranial pressure in patients with severe, closed-head injury, also known as traumatic brain coma, for whom no other effective treatment is available.	Abela Pharmaceuticals, Inc.
863	dimethyl sulfoxide	n/a	5/9/2008	For use in combination with antimicrobial drugs for the treatment of drug resistant tuberculosis	Abela Pharmaceuticals, Inc.
864	Dimethylsulfoxide	n/a	4/15/1997	Topical treatment for the prevention of soft tissue injury following extravasion of cytotoxic drugs.	Cancer Technologies, Inc.
865	Dimethylsulfoxide	n/a	4/6/1998	Treatment of palmar-plantar erythrodysethesia syndrome.	Cancer Technologies, Inc.
866	dinaciclib	n/a	8/25/2011	Treatment of chronic lymphocytic leukemia.	Merck Sharp & Dohme Ltd.
867	Dipalmitoylphosphatidylcholine /phosphatidylglycerol	Alec	7/28/1988	Prevention and treatment of neonatal respiratory distress syndrome.	Forum Products, Inc.
868	diphenylcyclopnone	n/a	6/13/2003	Treatment of chronic severe forms of alopecia areata (Alopecia Totalis [AT]/Alopecia Universalis [AU])	Lloyd E. King, Jr.
869	Disaccharide tripeptide glycerol dipalmitoyl	Immther	3/1/1990	Treatment of pulmonary and hepatic metastases in patients with colorectal adenocarcinoma.	ImmunoTherapeutics, Inc.
870	Disodium clodronate	n/a	6/16/1993	Treatment of hypercalcemia of malignancy.	Discovery Experimental & Development, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
871	Disodium clodronate tetrahydrate	Bonefos	3/5/1990	Treatment of increased bone resorption due to malignancy.	Anthra Pharmaceuticals, Inc.
872	D-mannitol and L-proline	Prodarsan	4/20/2009	Treatment of Cockayne syndrome	DNage B.V.
873	DNA plasmid expressing diphtheria toxin triggered by the presence of oncofetal gen H19	n/a	8/20/2009	Treatment of ovarian cancer	BioCancell Therapeutics Ltd.
874	DNA plasmid vector (pCK-HGFX7) expressing human hepatocyte growth factor	n/a	2/6/2014	Treatment of amyotrophic lateral sclerosis	ViroMed Co., Ltd.
875	DNA plasmid vector expressing eIF5Ak50	n/a	12/13/2010	Treatment of multiple myeloma.	Senesco Technologies, Inc.
876	DNA plasmid vector expressing eIF5Ak50R protein, siRNA directed against the native eIF5A mRNA, and PEI (polyethyleneimine)	n/a	7/24/2012	Treatment of diffuse large B cell lymphoma	Senesco Technologies, Inc.
877	DNA plasmid vector expressing eIF5Ak50R protein, siRNA directed against the native eIF5A mRNA, and PEI (polyethyleneimine)	n/a	7/24/2012	Treatment of mantle cell lymphoma	Senesco Technologies, Inc.
878	DNA plasmid vector expressing human IL-12 gene	n/a	4/4/2005	Treatment of ovarian cancer.	Expression Genetics, Inc.
879	DNA-lipid complex (DMRIE/DOPE)/plasmid vector (VCL-1102, Vical) expressing human interleukin-2	Leuvectin	4/28/2000	Treatment of renal cell carcinoma.	Vical Incorporated
880	DNP-Modified autologous tumor vaccine	O-Vax	9/21/2000	Adjuvant therapy for the treatment of ovarian cancer	AVAX Technologies, Inc.
881	docosahexanoic acid-paclitaxel	Taxoprexin	3/5/2001	Treatment of hormone-refractory prostate cancer.	Luitpold Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
882	domperidone	n/a	9/2/2011	Treatment of hypoprolactinemia in breastfeeding mothers, and in some hypoprolactinemic conditions following the use of cabergoline or bromocriptine in mothers who wish to initiate or return to breastfeeding	Thomas W. Hale, RPh, PhD
883	Doripenem	n/a	7/16/2004	Treatment of bronchopulmonary infection in patients with cystic fibrosis who are colonized with Pseudomonas aeruginosa or Burkholderia cepacia.	Shionogi, Inc.
884	Dornase alfa	Pulmozyme	1/16/1991	To reduce mucous viscosity and enable the clearance of airway secretions in patients with cystic fibrosis.	Genentech, Inc.
885	Double-stranded DNA plasmid carrying the gene for the diphtheria toxin A (DT-A) chain	n/a	8/6/2010	Treatment of pancreatic cancer	BioCancell Therapeutics Israel Ltd.
886	dovitinib	n/a	9/26/2013	Treatment of adenoid cystic carcinoma	Novartis Pharmaceuticals Corporation
887	DOXO-EMCH	n/a	4/18/2011	Treatment of adenocarcinoma of the pancreas.	CytRx Corp.
888	doxofylline	n/a	2/14/2014	Treatment of bronchiectasis	Alitair Pharmaceuticals, Inc.
889	doxorubicin	n/a	8/25/2009	Treatment of hepatocellular carcinoma.	Delcath Systems, Inc.
890	doxorubicin HCL liposome injection	Doxil	12/29/2004	Treatment of multiple myeloma	Johnson & Johnson Pharmaceutical Research & Dev.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
891	Doxorubicin HCl with pluronic L-61 and pluronic F-127	n/a	10/7/2005	Treatment of esophageal carcinoma	Supratek Pharma Inc.
892	Doxorubicin liposome	Doxil	11/4/1998	Treatment of ovarian cancer.	Alza Corporation
893	doxorubicin PIHCA nanoparticles	Doxorubicin Transdrug	3/14/2005	Treatment of hepatocellular carcinoma	BioAlliance Pharma
894	doxorubicin with pluronics F-127 and L-61	n/a	2/20/2008	Treatment of gastric cancer	Supratek Pharma, Inc.
895	D-peptide	Nerofe	2/4/2011	Treatment of acute myelogenous leukemia	Immune System Key, Ltd
896	D-peptide of the sequence AKRHHGYKRKFH - NH2	Pulmadex	10/23/2002	Treatment of cystic fibrosis	Demegen, Inc.
897	Dronabinol	Marinol	1/15/1991	For the stimulation of appetite and prevention of weight loss in patients with a confirmed diagnosis of AIDS.	Unimed Pharmaceuticals, Inc.
898	droxidopa	Northera	1/17/2007	Treatment of neurogenic symptomatic orthostatic hypotension in patients with primary autonomic failure, dopamine-beta-hydroxylase deficiency, and nondiabetic autonomic neuropathy.	Chelsea Therapeutics, Inc.
899	Duramycin	n/a	12/11/1997	Treatment of cystic fibrosis.	Lantibio, Inc.
900	duvoglustat hydrochloride	n/a	6/18/2007	Treatment of Pompe disease	Amicus Therapeutics, Inc
901	Dynamine	n/a	2/5/1990	Treatment of Lambert Eaton myasthenic syndrome.	Mayo Foundation
902	Dynamine	n/a	10/16/1991	Treatment of hereditary motor and sensory neuropathy type I (Charcot-Marie-Tooth disease).	Mayo Foundation
903	ecallantide	Kalbitor	2/4/2003	Treatment of angioedema	Dyax Corp.
904	ecopipam hydrochloride	n/a	7/21/2009	Symptomatic treatment of self injurious behaviors in patients with Lesch-Nyhan disease.	Psyadon Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
905	ecopipam hydrochloride	n/a	9/29/2010	Treatment of Tourette's syndrome in children 0-16 years old.	Psyadon Pharmaceuticals, Inc.
906	Eculizumab	n/a	9/21/2000	Treatment of dermatomyositis	Alexion Pharmaceuticals, Inc.
907	eculizumab	Soliris	10/18/2011	Treatment of Shiga-Toxin producing escherichia coli hemolytic uremic syndrome	Alexion Pharmaceuticals, Inc.
908	eculizumab	n/a	3/5/2001	Treatment of idiopathic membranous glomerular nephropathy	Alexion Pharmaceuticals, Inc.
909	eculizumab	Soliris	1/10/2014	Prevention of delayed graft function after renal transplantation	Alexion Pharmaceuticals, Inc.
910	eculizumab	Soliris	6/24/2013	Treatment of neuromyelitis optica	Alexion Pharmaceuticals, Inc.
911	eculizumab	Soliris	4/29/2009	Treatment of atypical hemolytic uremic syndrome	Alexion Pharmaceuticals, Inc.
912	eculizumab	Soliris	8/20/2003	Treatment of paroxysmal nocturnal hemoglobinuria	Alexion Pharmaceuticals, Inc.
913	Edotreotide	Onalta(Tm)	7/28/2005	Treatment of somatostatin receptor-positive neuroendocrine gastroenteropancreatic tumors	ITG Isotope Technologies Garchig GmbH
914	efaproxiral	n/a	7/28/2004	Adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with breast cancer	Allos Therapeutics, Inc.
915	Efdispo (tm)	Efdispo (Tm)	1/15/2013	Treatment of Ewings Sarcoma.	TDP Biotherapeutics, Inc.
916	Eflornithine	n/a	9/29/2006	Treatment of anaplastic glioma	Orbus Therapeutics, Inc.
917	eflornithine	n/a	2/4/2011	Treatment of Familial Adenomatous Polyposis	Cancer Prevention Pharmaceuticals

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
918	eflornithine	n/a	11/23/2010	Treatment of neuroblastoma	Cancer Prevention Pharmaceutical, Inc.
919	Eflornithine HCl	Ornidyl	4/23/1986	Treatment of Trypanosoma brucei gambiense infection (sleeping sickness).	Hoechst Marion Roussel
920	eflornithine plus sulindac	n/a	1/22/2013	Treatment of familial adenomatous polyposis	Cancer Prevention Pharmaceuticals, Inc.
921	eicosapentaenoic acid	n/a	3/8/2011	Treatment of familial adenomatous polyposis	S.L.A. Pharma Ltd. (UK)
922	elacytarabine	n/a	6/18/2008	Treatment of acute myeloid leukemia (AML)	Clavis Pharma ASA
923	elafin	n/a	12/28/2012	Treatment of pulmonary arterial hypertension	Proteo Biotech AG
924	Elcatonin	n/a	9/25/1995	Intrathecal treatment of intractable pain.	Innapharma, Inc.
925	Elesclomol	n/a	12/18/2007	Treatment of metastatic melanoma in combination with paclitaxel	Synta Pharmaceuticals Corporation
926	eliglustat	Cerdelga	9/17/2008	Treatment of Gaucher disease	Genzyme Corporation
927	elosulfase alfa	Vimizim	5/15/2009	Use in the treatment of mucopolysaccharidosis (MPS) Type IV A (Morquio A syndrome)	BioMarin Pharmaceutical Inc.
928	elotuzumab	n/a	9/1/2011	Treatment of multiple myeloma	Bristol-Myers Squibb Company
929	eltrombopag	Promacta	11/8/2013	Treatment of aplastic anemia	GlaxoSmithKline LLC
930	eltrombopag	Promacta	5/5/2008	Treatment of idiopathic thrombocytopenia purpura	GlaxoSmithKline
931	emricasan	n/a	11/20/2013	Treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end stage liver disease	Conatus Pharmaceuticals Inc.
932	Enadoline hydrochloride	n/a	1/28/1997	Treatment of severe head injury.	Warner-Lambert Company

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
933	enalapril maleate (powder for oral solution)	Epaned	1/30/2013	Treatment of hypertension in pediatric patients	Silvergate Pharmaceuticals, Inc.
934	Encapsulated porcine islet preparation	Betarx	7/5/1995	Treatment of type I diabetic patients who are already on immunosuppression.	VivoRx
935	enchochleate amphotericin B	n/a	1/10/2014	Treatment of visceral leishmaniasis	Aquarius Biotechnologies, Inc.
936	encorafenib	n/a	11/19/2013	Treatment of Stage IIB-IV melanoma positive for BRAF mutation	Novartis Pharmaceuticals Corporation
937	encorafenib + binimetinib	n/a	11/19/2013	Treatment in Stage IIB-IV melanoma positive for the BRAF mutation.	Novartis Pharmaceuticalues Corporation
938	Engineered variant of recombinant human fibroblast growth factor 19	n/a	2/6/2014	Treatment of primary biliary cirrhosis	NGM Biopharmaceuticals, Inc.
939	eniluracil	n/a	12/15/2005	Treatment of hepatocellular carcinoma.	Adherex Technologies, Inc.
940	ensituximab	n/a	10/21/2010	Treatment of pancreatic cancer.	Neogenix Oncology, Inc.
941	Enzastaurin	n/a	9/19/2005	Treatment of glioblastoma multiforme	Eli Lilly and Company
942	enzastaurin	n/a	3/4/2009	Treatment of diffuse large B-cell lymphoma	Eli Lilly and Company
943	Epidermal growth factor (human)	n/a	10/5/1987	For acceleration of corneal epithelial regeneration and the healing of stromal tissue in the condition of non-healing corneal defects.	Chiron Vision
944	Epirubicin	Ellence	9/14/1999	Treatment of breast cancer.	Pharmacia & Upjohn Company
945	Epitalon	n/a	9/2/2010	Treatment of retinitis pigmentosa	BioDiem Ltd
946	Epoetin alfa	n/a	12/20/1993	Treatment of myelodysplastic syndrome.	Johnson & Johnson Pharmaceutical Research & Dev.,

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
947	Epoetin alfa	Epogen	4/10/1986	Treatment of anemia associated with end stage renal disease.	Amgen, Inc.
948	Epoetin alfa	Epogen	7/1/1991	Treatment of anemia associated with HIV infection or HIV treatment.	Amgen, Inc.
949	Epoetin alpha	Procrit	8/27/1987	Treatment of anemia associated with end stage renal disease.	R. W. Johnson Pharmaceutical Research Institute
950	Epoetin alpha	Procrit	3/7/1989	Treatment of HIV associated anemia related to HIV infection or HIV treatment.	R. W. Johnson Pharmaceutical Research Institute
951	Epoetin beta	Marogen	10/22/1987	Treatment of anemia associated with end stage renal disease.	Chugai-USA, Inc.
952	Epoprostenol	Flolan	9/25/1985	Treatment of primary pulmonary hypertension.	Glaxo Wellcome Inc.
953	epoprostenol	Flolan	3/22/1999	Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.	GlaxoSmithKline
954	epratuzumab	Lymphocide	7/13/1998	Treatment of non-Hodgkin's lymphoma	Immunomedics, Inc.
955	epratuzumab	n/a	9/30/2008	Treatment of acute lymphoblastic leukemia	Immunomedics, Inc.
956	Eprodisate	Kiacta(Tm)	4/6/1999	Treatment of secondary amyloidosis	C. T. Development America, Inc.
957	Epstein Barr Virus specific cytotoxic T lymphocytes	n/a	12/27/2006	Prevention and treatment of EBV-post transplant lymphoproliferative disease after hematopoietic stem cell transplant or solid organ transplant.	Center for Cell and Gene Therapy
958	eptifibatide and iloprost	n/a	4/20/2012	Treatment of purpura fulminans	Thrombologic

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
959	erdosteine	n/a	12/20/2013	Treatment bronchiectasis	Alitair Pharmaceuticals, Inc.
960	eribulin mesylate	Halaven(R)	5/14/2012	Treatment of advanced soft tissue sarcoma	Eisai, Inc.
961	Erlotinib Hydrochloride	Tarceva	7/18/2003	Treatment of malignant gliomas	Genentech, Inc
962	Erwinia L-asparaginase	Erwinase	7/30/1986	Treatment of acute lymphocytic leukemia.	Jazz Pharmaceuticals, Inc.
963	Erythropoietin (recombinant human)	n/a	8/19/1987	Treatment of anemia associated with end stage renal disease.	McDonnell Douglas Corp
964	Estradiol Gel	Estrogel (R)	10/31/2006	Estrogen replacement therapy in females with Turner syndrome	Ascend Therapeutics US, LLC
965	etanercept	Enbrel	10/27/1998	Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.	Immunex Corporation
966	etarfolatide	n/a	2/16/2000	For the identification of ovarian carcinomas	Endocyte, Inc.
967	eteplirsen	n/a	10/23/2007	Treatment of Duchenne Muscular Dystrophy.	Sarepta Therapeutics, Inc.
968	Ethanol gel	n/a	3/29/2006	Treatment of congenital venous malformations	Orfagen
969	Ethanol gel	n/a	3/13/2006	Treatment of congenital lymphatic malformations	Orfagen

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
970	ethanolamine	Ethamolin	1/17/2014	Prophylactic use in pediatric patients (age 0 through 16 years) with esophageal varices that are at risk of bleeding to obliterate varices and to prevent bleeding	QOL Medical, LLC
971	Ethanolamine oleate	Ethamolin	3/22/1984	Treatment of patients with esophageal varices that have recently bled, to prevent rebleeding.	QOL Medical
972	ethiodized oil injection	Lipiodol	9/26/2013	Management of patients with known hepatocellular carcinoma (HCC)	Guerbet LLC
973	Ethyl eicosapentaenoate	n/a	4/6/2000	Treatment of Huntington's disease.	Laxdale Ltd.
974	Etidronate disodium	Didronel	3/21/1986	Treatment of hypercalcemia of malignancy inadequately managed by dietary modification and/or oral hydration.	MGI Pharma, Inc.
975	Etiocholanedione	n/a	5/7/1996	Treatment of Prader-Willi syndrome.	SuperGen, Inc.
976	Etiocholanedione	n/a	11/3/1995	Treatment of aplastic anemia.	SuperGen, Inc.
977	etirinotecan pegol	n/a	4/18/2011	Treatment of ovarian cancer.	Nektar Therapeutics
978	everolimus	Afinitor(R)	7/23/2012	Treatment of hepatocellular carcinoma	Novartis Pharmaceuticals Corporation
979	everolimus	Afinitor	9/16/2010	Treatment of Waldenstrom macroglobulinemia (also known as lymphoplasmacytic lymphoma)	Novartis Pharmaceuticals Corporation
980	everolimus	Afinitor	5/24/2011	Treatment of gastric cancer	Novartis Pharmaceuticals Corporation

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
981	everolimus	Afinitor	2/14/2008	Treatment of neuroendocrine tumors	Novartis Pharmaceuticals Corporation
982	everolimus	Afinitor	6/8/2009	Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)	Novartis Pharmaceuticals Corporation
983	Ex vivo cultured adult human mesenchymal stem cells	Prochymal(R)	12/14/2005	Treatment of acute graft versus host disease	Mesoblast, Inc.
984	ex vivo cultured human mesenchymal stromal cells	n/a	5/8/2014	Prevention of graft rejection following solid organ transplantation	iCell Science AB
985	Exemestane	Aromasin	9/19/1991	Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.	Pharmacia & Upjohn
986	exendin-(9-39)	n/a	6/1/2011	Treatment of congenital hyperinsulinemic hypoglycemia and other causes of hyperinsulinemic hypoglycemia in adults and children.	The Children's Hospital of Philadelphia
987	Exisulind	n/a	2/14/1994	For the suppression and control of colonic adenomatous polyps in the inherited disease adenomatous polyposis coli.	OSI Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
988	Exon 44 specific phosphorothioate oligonucleotide	n/a	11/5/2009	Treatment of Duchenne Muscular Dystrophy in patients who have a mutation correctable by skipping of exon 44of the dystrophin gene.	Prosensa Therapeutics B.V.
989	Exon 45 specific phosphorothioate oligonucleotide	n/a	1/23/2013	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 45	Prosensa Therapeutics B V
990	Exon 51 specific phosphorothioate oligonucleotide	n/a	8/25/2009	Treatment of Duchenne Muscular Dystrophy.	Prosensa Therapeutics BV
991	Exon 52 specific phosphorothiate oligonucleotide	n/a	1/23/2013	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 52	Prosensa Therapeutics B V
992	exon 53 specific phosphorothioate oligonucleotide	n/a	1/23/2013	treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 53	Prosensa Therapeutics B.V.
993	Exon 55 specific phosphorothioate oligonucleotide	n/a	1/23/2013	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 55	Prosensa Therapeutics B.V.
994	expanded allogeneic human dermal fibroblasts in hypothermosol(r)-FRS	n/a	8/20/2009	Treatment of Dystrophic Epidermolysis Bullosa.	Intercytex Ltd.
995	expanded human allogeneic neural retinal progenitor cells extracted from neural retina	n/a	8/22/2013	Treatment of retinitis pigmentosa	ReNeuron Ltd
996	Extract of sea cucumber, sea sponge, shark fin, sea urchin, and sargassum grass	n/a	5/14/2012	Treatment of multiple myeloma	Unicorn Pacific Corporation

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
997	extract of sorghum bicolor extract	n/a	11/19/2012	Treatment of sickle cell disease	Invenux, LLC
998	ex-vivo cultered adult human mesenchymal stem cells	Prochymal(R)	4/30/2010	Treatment of Type 1 diabetes patients with residual beta cell function	Mesoblast, Inc.
999	ex-vivo expanded autologous bone marrow-derived mesenchymal stem cells	n/a	12/20/2010	Treatment of Amyotrophic Lateral Sclerosis	TCA Cellular Therapy, LLC
1000	ezatiostat hydrochloride	Telintra	1/9/2013	Treatment of myelodysplastic syndrome	Telik, Inc.
1001	Facilitated DNA Plasmid Vaccine	n/a	3/8/1995	Treatment of cutaneous T cell lymphoma.	Wyeth-Lederle Vaccines and Pediatrics
1002	factor VIII mimetic bispecific antibody	n/a	1/10/2014	Treatment of hemophilia A	Chugai Pharma USA, LLC
1003	Factor XIII [A2] homodimer, recombinant DNA origin	n/a	5/21/2003	Treatment of congenital FXIII deficiency	Novo Nordisk Pharmaceuticals, INC.
1004	factor XIII concentrate (human)	Corifact	1/16/1985	Treatment of congenital factor XIII deficiency	CSL Behring LLC
1005	Fampridine	Neurelan	6/2/1997	Treatment of chronic, incomplete spinal cord injury.	Acorda Therapeutics, Inc.
1006	farletuzumab	n/a	6/16/2006	Treatment of ovarian cancer	Morphotek, Inc.
1007	Fast skeletal muscle troponin activator	n/a	3/2/2010	Treatment of amyotrophic lateral sclerosis (ALS)	Cytokinetics Inc.
1008	fecal microbiota	n/a	3/10/2014	Treatment of recurrent Clostridium difficile infection (Clostridium difficile gastrointestinal disease)	Rebiotx, Inc.
1009	Felbamate	Felbatol	1/24/1989	Treatment of Lennox-Gastaut syndrome.	Wallace Laboratories
1010	fenfluramine HCl	Brabafen	12/20/2013	For the Treatment of Dravet Syndrome	Brabant Pharma Limited
1011	Fenobam hydrochloride	n/a	11/20/2006	Treatment of fragile X syndrome	Neuropharm, Ltd.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1012	Fenretinide	n/a	4/7/2010	Treatment of Pseudomonas aeruginosa lung infections in cystic fibrosis patients	McGill University
1013	Fenretinide	n/a	10/5/2005	Treatment of neuroblastoma	USC-CHLA Institute for Pediatric Clinical Research
1014	fenretinide	n/a	9/4/2013	Treatment of cutaneous T-cell lymphoma	CerRx, Inc.
1015	fenretinide	n/a	2/1/2007	Treatment of Ewing's sarcoma family of tumors.	Cancer Research UK
1016	fenretinide	n/a	9/4/2013	Treatment of peripheral T-cell lymphoma	CerRx, Inc.
1017	ferric hexacyanoferrate (II) "Prussian Blue"	n/a	6/26/2003	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	Degussa AG
1018	ferumoxytol	n/a	10/7/2011	For use in magnetic resonance imaging in brain metastases	Oregon Health & Science University
1019	ferumoxytol	Feraheme	4/29/2011	For use in MR imaging for the mangement of brain tumors	Edward A. Neuwelt, MD
1020	ferumoxytol	n/a	4/6/2012	For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)	ArsNova Partners, LLC
1021	fialuridine	n/a	7/24/1992	Adjunctive treatment of chronic active hepatitis B.	Oclassen Pharmaceuticals, Inc.
1022	Fibrin-based agent containing a N-terminally modified parathyroid hormone fragment TGplPTH1-34	n/a	2/1/2007	Treatment of solitary (unicameral) bone cysts	Kuros Biosurgery AG

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1023	Fibrinogen (human)	n/a	8/23/1995	For the control of bleeding and prophylactic treatment of patients deficient in fibrinogen.	Alpha Therapeutic Corporation
1024	Fibronectin (human plasma derived)	n/a	9/5/1988	Treatment of non-healing corneal ulcers or epithelial defects which have been unresponsive to conventional therapy and the underlying cause has been eliminated.	Melville Biologics, Inc.
1025	Fibronectin Peptide	n/a	6/29/2011	Prevention of burn injury progression of acute, deep dermal burns in hospitalized patients.	NeoMatrix Formulations, Inc.
1026	fidaxomicin	Dificid	12/13/2010	Treatment of pediatric Clostridium difficile infection	Optimer Pharmaceuticals, Inc.
1027	filanesib	n/a	5/6/2014	Treatment of multiple myeloma.	Array BioPharma, Inc.
1028	Filgrastim	Neupogen	11/20/2013	Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident	Amgen, Inc.
1029	Filgrastim	Neupogen	11/7/1990	Treatment of patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm3).	Amgen, Inc.
1030	Filgrastim	Neupogen	11/7/1996	Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.	Amgen, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1031	Filgrastim	Neupogen	7/17/1995	For use in the mobilization of peripheral blood progenitor cells for collection in patients who will receive myeloablative or myelosuppressive chemotherapy.	Amgen, Inc.
1032	Filgrastim	Neupogen	10/1/1990	Treatment of neutropenia associated with bone marrow transplants.	Amgen, Inc.
1033	fingolimod	n/a	4/30/2010	Treatment of chronic inflammatory demyelinating polyneuropathy	Novartis Pharmaceutical Corporation
1034	firtecane pegol	n/a	4/18/2011	Treatment of neuroblastoma.	Enzon Pharmaceuticals, Inc.
1035	FlC Flagellin Deletion Variant TLR5 Agonist	n/a	11/23/2010	Prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster	Cleveland BioLabs, Inc.
1036	Floxuridine, FUDR	n/a	12/22/2004	Intraperitoneal treatment of gastric cancer.	Franco Muggia, M.D.
1037	flubendazole	n/a	1/23/2014	Treatment of lymphatic filariasis caused by nematodes of the family Filarioididea, in children and adults.	Janssen Research and Development, LLC
1038	flubendazole	n/a	10/25/2013	Treatment of onchocerciasis caused by Onchocerca volvulus	Janssen Research & Development, LLC
1039	Fludarabine phosphate	Fludara	4/18/1989	Treatment and management of patients with non-Hodgkins lymphoma.	Berlex Laboratories, Inc.
1040	Fludarabine phosphate	Fludara	4/18/1989	Treatment of chronic lymphocytic leukemia (CLL), including refractory CLL.	Berlex Laboratories, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1041	Fludarabine phosphate oral tablets	n/a	12/18/2007	Treatment of B-cell chronic lymphocytic leukemia	Sanofi-Aventis U.S., Inc.
1042	Flunarizine	Sibelium	1/6/1986	Treatment of alternating hemiplegia.	Janssen Research Foundation
1043	flunarizine hydrochloride	n/a	6/24/2013	Treatment of alternating hemiplegia	Marathon Pharmaceuticals, LLC
1044	Fluocinolone	Retisert	7/31/2000	Treatment uveitis involving the posterior segment of the eye.	Bausch & Lomb Pharmaceuticals, Inc.
1045	Fluorouracil	n/a	4/18/1990	For use in combination with interferon alpha-2a, recombinant, for the treatment of advanced colorectal carcinoma.	Hoffmann-La Roche, Inc.
1046	Fluorouracil	n/a	6/29/2000	Treatment of glioblastoma multiforme.	Ethypharm SA
1047	Fluorouracil	n/a	10/27/1989	For use in combination with interferon alpha-2a, recombinant, for the treatment of esophageal carcinoma.	Hoffmann-La Roche, Inc.
1048	Fluoxetine	Prozac	4/30/1999	Treatment of autism.	Neuropharm, Ltd.
1049	Fluoxetine	Prozac	4/14/2004	Treatment of body dysmorphic disorder in children and adolescents	Hollander, Eric MD
1050	fluticasone propionate	n/a	1/19/2011	Treatment of pediatric and adult eosinophilic esophagitis	Forest Laboratories, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1051	Follitropin alfa, recombinant	Gonal-F	12/21/1998	For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism. AMENDED indication 6/27/00: For the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure.	EMD Serono, Inc.
1052	Fomepizole	Antizole	12/22/1988	Treatment of methanol or ethylene glycol poisoning.	Jazz Pharmaceuticals
1053	fosfomycin/tobramycin	n/a	11/28/2008	Treatment of pulmonary infections associated with cystic fibrosis	Gilead Sciences, Inc.
1054	Fosphenytoin	Cerebyx	6/4/1991	For the acute treatment of patients with status epilepticus of the grand mal type.	Warner-Lambert Company
1055	fresolimumab	n/a	10/21/2010	Treatment of primary focal segmental glomerulosclerosis	Genzyme
1056	FTV1+GDP-fucose	n/a	3/18/2011	To improve homing to bone (treatment of myeloablation) in patients receiving hematopoietic stem cell transplantation.	America Stem Cell, Inc.
1057	Full Phosphorothioate Antisense Oligonucleotide against EWS-Fli-1 nanoparticles	n/a	9/22/2008	Treatment of Ewing's sarcoma	The Cure Our Children Foundation

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1058	Fully human anti-interferon gamma monoclonal antibody	Ni-0501	3/26/2010	Treatment of hemophagocytic lymphohistiocytosis	NovImmune S.A.
1059	fusion protein analog with recombinant human growth hormone (rhGH) at once-a-month dosing	n/a	10/16/2013	Treatment of growth hormone deficiency	Versartis, Inc.
1060	Fusion protein consisting of human immunoglobulin G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1	n/a	1/11/2006	Treatment of X-linked hypohidrotic ectodermal dysplasia	Edimer Pharmaceuticals, Inc.
1061	G17DT Immunogen	Gastrimmune(Tm)	7/10/2002	Treatment of adenocarcinoma of the pancreas	Cancer Advances, Inc.
1062	G17DT Immunogen	Gastrimmune(Tm)	7/18/2002	Treatment of gastric cancer.	Cancer Advances, Inc.
1063	gabapentin	Neurontin	7/5/1995	Treatment of amyotrophic lateral sclerosis	Warner-Lambert Company
1064	gabapentin	Gralise	11/8/2010	Management of postherpetic neuralgia	Depomed, Inc.
1065	gabapentin enacarbil	Horizant	6/7/2011	Treatment of postherpetic neuralgia	XenoPort, Inc.
1066	Gallium [Ga-68]-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-L-cysteinyl-L-threonine-cyclic(2-7)disulfide	n/a	12/31/2013	Diagnostic for the Management of Gastro-Entero-Pancreatic Neuroendocrine Tumors	Advanced Accelerator Applications
1067	Gallium-68 (DOTA0-Phe1-Tyr3)octreotide	n/a	10/23/2013	The management of neuroendocrine tumors	Society of Nuclear Medicine & Molecular Imaging
1068	Gamma hydroxybutyrate	n/a	12/3/1987	Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations and automatic behavior.	Biocraft Laboratories, Inc.
1069	Gammalinolenic acid	n/a	7/27/1994	Treatment of juvenile rheumatoid arthritis.	Zurier, Robert B. M.D.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1070	Ganaxolone	n/a	5/25/1994	Treatment of infantile spasms.	Marinus Pharmaceuticals, Inc.
1071	ganciclovir	Zirgan	3/22/2007	Treatment of acute herpetic keratitis (dendritic and geographic ulcers)	Sirion Therapeutics, Inc.
1072	Ganciclovir intravitreal implant	Vitrasert Implant	6/7/1995	Treatment of cytomegalovirus retinitis.	Bausch & Lomb Surgical, Chiron Vision Products
1073	Gastrin 17C Diphtheria Toxoid Immunogen	n/a	7/7/2009	Treatment of pancreatic cancer	Astrimmune Ltd.
1074	gemcabene	n/a	2/6/2014	Treatment of homozygous familial hypercholesterolemia	Michigan Life Therapeutics, LLC
1075	Gemtuzumab zogamicin	Mylotarg	11/24/1999	Treatment of CD33-positive acute myeloid leukemia.	Wyeth-Ayerst Laboratories
1076	gene encoding chimeric CD40 ligand	n/a	2/4/2009	Treatment of chronic lymphocytic leukemia	Memgen, LLC
1077	genetically engineered herpes simplex virus (G207)	n/a	4/29/2002	Treatment of malignant glioma	MediGene, Inc.
1078	Genetically engineered human recombinant IgG4 monoclonal antibody directed against human TNF alpha	n/a	12/11/1997	Treatment of Crohn's disease.	Celltech Chiroscience Limited
1079	Geneticin	n/a	6/6/2005	Treatment of amoebiasis.	ProcesScience, Inc (PSI)
1080	Gentamicin impregnated PMMA beads on surgical wire	Septopal	1/31/1991	Treatment of chronic osteomyelitis of post-traumatic, postoperative, or hematogenous origin.	Lipha Pharmaceuticals, Inc.
1081	Gentamicin liposome injection	Maitec	7/10/1990	Treatment of disseminated Mycobacterium avium-intracellulare infection.	Liposome Company, Inc.
1082	gevokizumab	n/a	2/21/2014	Treatment of pyoderma gangrenosum	XOMA (US) LLC
1083	gevokizumab	n/a	7/27/2010	Treatment of Behcet's disease	XOMA (US) LLC

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1084	gevokizumab	n/a	8/20/2012	Treatment of non-infectious intermediate, posterior or pan uveitis, or chronic non-infectious anterior uveitis	XOMA (US) LLC
1085	givinostat	n/a	4/12/2013	Treatment of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy	Italfarmaco SpA
1086	glatiramer acetate	Copaxone	11/14/2007	Treatment of amyotrophic lateral sclerosis (ALS).	Teva Neurosciences, Inc.
1087	Glatiramer acetate	Copaxone	11/9/1987	Treatment of multiple sclerosis.	Teva Pharmaceuticals USA
1088	Glatiramer acetate for injection	Copaxone	6/5/2001	Treatment of primary-progressive multiple sclerosis	TEVA Pharmaceuticals, USA
1089	glioma derived cell lysates and irradiated cells	n/a	1/12/2011	Treatment of glioma.	Epitopoietic Research Corp.
1090	glucagon	n/a	12/5/2012	Prevention of hypoglycemia in the congenital hyperinsulinism population	Biodel, Inc.
1091	glucarpidase	Voraxaze	8/19/2003	Treatment of patients at risk of methotrexate toxicity	BTG International Inc.
1092	glufosfamide	n/a	9/18/2006	For treatment of pancreatic cancer.	Eleison Pharmaceuticals LLC
1093	Glutamine	Nutrestore	3/6/1995	For use with human growth hormone in the treatment of short bowel syndrome (nutrient malabsorption from the gastrointestinal tract resulting from an inadequate absorptive surface).	Emmaus Medical, Inc.
1094	Glutathione pegylated liposomal doxorubicin hydrochloride	n/a	8/16/2010	Treatment of glioma	to-BBB technologies BV
1095	glycafilin	n/a	8/22/2008	Prevention of delayed graft function after solid organ transplantation	ProtAffin Biotechnologie AG

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1096	glycerol phenylbutyrate	Ravicti	4/27/2009	Maintenance treatment of patients with deficiencies in enzymes of the urea cycle	Hyperion Therapeutics, Inc.
1097	Glyceryl tri (4-phenylbutyrate)	n/a	5/24/2005	Treatment of spinal muscular atrophy	Ucyclyd Pharma, Inc
1098	Glyceryl trioleate and glyceryl trierucate	n/a	2/14/1995	Treatment of adrenoleukodystrophy.	Moser, Hugo W. M.D.
1099	glycopyrrolate	Cuvposa	6/9/2006	Treatment of pathologic (chronic moderate to severe) drooling in pediatric patients	Shionogi, Inc.
1100	glycopyrrolate 2%	n/a	6/17/2010	Treatment of Frey's syndrome	Wellesley Therapeutics, Inc.
1101	glycosylated recombinant human interleukin-7	n/a	9/27/2012	Treatment of progressive multifocal leukoencephalopathy	Cytheris, Inc.
1102	glycyl-L-2-methylprolyl-L-glutamic Acid	n/a	10/23/2013	Treatment of Fragile X Syndrome	Neuren Pharmaceuticals, Ltd.
1103	Glyeraldehyde-3-phosphate dehydrogenase	Proenzy	4/30/2010	Treatment of pediatric multiple sclerosis	BPT Pharmaceuticals, Inc.
1104	GNE Lipoplex	n/a	11/13/2008	Treatment of hereditary inclusion body myopathy-2	Gradalis, Inc.
1105	GNE plasmid(H001)	n/a	3/26/2010	Treatment of hereditary inclusion body myopathy type 2	HIBM Research Group
1106	golimumab	Simponi	3/16/2012	Treatment of pediatric ulcerative colitis	Janssen Biotech, Inc.
1107	golnerminogene pradenovec	Tnferade(Tm) Biologic	10/28/2009	Treatment of pancreatic cancer.	GenVec, Inc.
1108	Gonadorelin acetate	Lutrepulse	4/22/1987	For induction of ovulation in women with hypothalamic amenorrhea due to a deficiency or absence in the quantity or pulse pattern of endogenous GnRH secretion.	Ferring Laboratories, Inc.
1109	Gossypol	n/a	10/22/1990	Treatment of cancer of the adrenal cortex.	Reidenberg, Marcus M. M.D.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1110	Gp100 adenoviral gene therapy	n/a	3/25/1997	Treatment of metastatic melanoma.	Genzyme Corporation
1111	granulocyte macrophage colony stimulating factor	n/a	8/27/2008	Treatment of cystic fibrosis	DrugRecure Aps
1112	granulocyte-macrophage colony stimulating factor-coding oncolytic adenovirus, Ad5/3-D24-GMCSF	n/a	7/24/2013	Treatment of soft tissue sarcoma	Oncos Therapeutics Ltd
1113	Growth hormone releasing factor	n/a	8/7/1989	For the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Valeant Pharmaceuticals North America
1114	guanfacine	Tenex	8/5/1999	Treatment of fragile X syndrome.	Watson Laboratories, Inc.
1115	gusperimus trihydrochloride	n/a	6/29/2011	Treatment of Wegener's granulomatosis	Nordic Group B.V.
1116	GVAX melanoma	n/a	12/23/2010	Treatment of stage IIb to IV melanoma	Aduro BioTech, Inc.
1117	glyceryl tri (4-pheynlybutyrate)	n/a	9/3/2009	For intermittent or chronic treatment of patients with cirrhosis and any grade hepatic encephalopathy.	Hyperion Therapeutics, Inc.
1118	H-(D)p-Benzoylphenylalanyl-(D)seryl-(D)tryptophanyl-(D)seryl-(D)pentafluorophenylalanyl-(D)cyclohexylalanyl-(D)arginyl-(D)arginyl-(D)arginyl-(D)glutaminy-(D)arginyl-(D)arginine acetate salt	n/a	12/22/2011	For use in combination with cisplatin and pemetrexed for the treatment of patients with mesothelioma	CanBas Company, Ltd.
1119	Halofantrine	Halfan	11/4/1991	Treatment of mild to moderate acute malaria caused by susceptible strains of P. falciparum and P. vivax.	SmithKline Beecham Pharmaceuticals
1120	Halofuginone	Stenorol	2/7/2000	Treatment of systemic sclerosis.	Collgard Biopharmaceuticals Ltd.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1121	halofuginone hydrobromide	n/a	10/13/2011	Treatment of Duchenne Muscular Dystrophy	Halo Theraeputics, LLC
1122	Hanferon	Hanferon	3/9/2012	Treatment of Behcet's disease	HanAll BioPharma Co., Ltd.
1123	Hantaan virus and Puumala virus DNA vaccines	n/a	11/13/2012	Prevention of hemorrhagic fever with renal syndrome caused by Hantaan virus and Puumala virus.	Surgeon General of the U. S. Army
1124	heat killed Mycobacterium w immunomodulator	Cadi Mw	9/3/2004	Active tuberculosis	Cadila Pharmaceuticals Limited, Inc.
1125	heat killed mycobacterium w immunomodulator	Cadi Mw	11/21/2002	Adjuvant to multi-drug therapy in the management of multibacillary leprosy	CPL, Inc.
1126	heat killed mycobacterium w immunomodulator	Cadi-Mw	7/31/2012	Treatment of non-small cell lung cancers that express desmocollin-3	Cadila Pharmaceuticals Limited
1127	Heat Shock Protein (hsp60) antigen	Diapep277	5/21/2012	For use in type 1 diabetic mellitus patients with residual beta-cell function	Andromeda Biotech, LTD
1128	Heat Shock Protein 70	n/a	3/18/2011	Treatment of amyotrophic lateral sclerosis	ALS Biopharma, LLC
1129	Heme arginate	Normosang	3/10/1988	Treatment of symptomatic stage of acute porphyria.	Orphan Europe SARL
1130	Heme arginate	Normosang	3/1/1994	Treatment of myelodysplastic syndromes.	Orphan Europe
1131	Hemin	Panhematin	3/16/1984	Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.	Abbott Laboratories
1132	Hemin and zinc mesoporphyrin	Hemex	12/20/1993	Treatment of acute porphyric syndromes.	Bonkovsky, Herbert L. M.D.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1133	Hemoximer (pyridoxalated hemoglobin polyoxyethylene)	n/a	12/18/2007	Treatment of cardiogenic shock	Apex Bioscience, Inc.
1134	heparin activated recombinant human fibroblast growth factor 1 (FGF1)in combination with a surgically implanted biodegradable device	n/a	10/24/2011	Treatment of patients with a confirmed traumatic complete spinal cord injury where no motor or sensory function is preserved below the injury(Scale A)	BioArctic Neuroscience AB
1135	Heparin sodium	n/a	6/29/2006	Treatment of cystic fibrosis	Ockham Biotech Limited
1136	Heparin-binding epidermal growth factor-like growth factor	n/a	9/18/2006	Prevention and treatment of necrotizing enterocolitis (NEC) in preterm infants with birth weight less than 1,500 grams	Trillium Therapeutics, Inc.
1137	hepatitis B immune globulin (human)	Hepagam	3/24/2008	Prevention of hepatitis B recurrence following orthotopic liver transplant	Cangene Corporation
1138	Hepatitis B immune globulin intravenous (human)	Nabi-Hb	3/8/1995	Prophylaxis against hepatitis B virus reinfection in liver transplant patients.	Biotest Pharmaceuticals Corporation
1139	hepatitis B virus neutralizing human monoclonal antibody	Hepabig Gene	5/6/2013	Prevention of hepatitis B recurrence following liver transplantation	Green Cross Corp.
1140	Hepatitis C virus immune globulin (human)	Civacir(Tm)	11/14/2002	Prophylaxis of hepatitis C infection in liver transplant recipients.	Biotest Pharmaceuticals Corporation
1141	Heptadecasodium salt of an 18-base residue phosphorothioate oligonucleotide	n/a	4/18/2011	Treatment of spinal muscular atrophy	Isis Pharmaceuticals, Inc.
1142	herpes simplex Type-1 virus encoded with human granulocyte-	Oncovexgm-Csf	3/14/2011	Treatment of stage IIb-stage IV melanoma	BioVex, Inc.
1143	Herpes simplex virus gene	n/a	10/16/1992	Treatment of primary and metastatic brain tumors.	Genetic Therapy, Inc.
1144	heterologous human adult liver derived progenitor cells (HHALPC)	n/a	1/13/2012	Treatment of urea cycle disorders	Promethera Biosciences

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1145	heterologous human liver derived progenitor cells	n/a	3/9/2012	Treatment of Crigler-Najjar syndrome	Promethera Biosciences
1146	hexasodium phytate	n/a	12/2/2012	Treatment of calciphylaxis	Laboratoris Sanifit, S.L.
1147	HIRMAb-IDS	n/a	5/15/2013	Treatment of mucopolysaccharidosis Type II (Hunter Syndrome)	ArmaGen Technologies, Inc.
1148	His-His-Ile-Tyr-Leu-Gly-Ala-Val-Asn-Tyr-Ile-Tyr	n/a	3/11/2013	Treatment of retinal detachment	ONL Therapeutics, LLC
1149	Histamine	Maxamine	2/1/2000	For use as an adjunct to cytokine therapy in the treatment of malignant melanoma.	EpiCept Corporation
1150	Histamine	Ceplene	12/15/1999	Adjunct to cytokine therapy in the treatment of acute myeloid leukemia.	EpiCept Corporation
1151	Histrelin	n/a	5/3/1991	Treatment of acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria.	Anderson, Karl E., M.D.
1152	Histrelin	Supprelin La	11/18/2005	Treatment of central precocious puberty	Endo Pharmaceuticals Solutions, Inc.
1153	Histrelin acetate	Supprelin Injection	8/10/1988	Treatment of central precocious puberty.	Roberts Pharmaceutical Corp.
1154	HLA-B7/Beta2M DNA Lipid (DMRIE/DOPE) Complex	Allovectin-7	9/30/1999	Treatment of invasive and metastatic melanoma (Stages II, III, and IV).	Vical Incorporated
1155	H-Leu-Pro-Pro-Ser-Arg-OH	n/a	9/20/2012	Treatment of Kaposi sarcoma	Immuno Tech, Inc.
1156	homoharringtonine	n/a	2/8/2002	Treatment for chronic myelogenous leukemia	American BioScience, Inc.
1157	HPV-16 cancer therapeutic trojan peptide vaccine	n/a	1/12/2009	Treatment of HPV-16 expressing head and neck squamous cell carcinoma.	Gliknik, Inc.
1158	HPV16 E6/E7 synthetic long peptides vaccine	n/a	9/1/2011	Treatment of epithelial neoplasias of the vulva positive for human papilloma virus type 16.	ISA Therapeutics BV

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1159	hRS7-SN-38 IgG Conjugate	n/a	11/27/2013	Treatment of small cell lung cancer	Immunomedics, INC.
1160	H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg- alys-aleu-Ser-Ser-Ile-Glu-Ser-Asp-Val-OH	n/a	5/14/2013	Treatment of subarachnoid hemorrhage	NoNO, Inc.
1161	H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg- Lys-Leu-Ser-Ser-Ile-Glu- Ser-Asp-Val-OH	n/a	4/11/2014	Treatment of acute ischemic stroke patients presenting within 3 hours of symptom onset	NoNO, Inc.
1162	Hu1D10, humanized monoclonal antibody	Remitogen	11/28/2001	For use in the treatment of 1D10+ B cell non-Hodgkin's lymphoma	PDL BioPharma, Inc.
1163	human allogeneic bone marrow derived osteoblastic cells	Allob	1/10/2014	Treatment of osteonecrosis	Bone Therapeutics SA
1164	Human alpha 2,6 sialyltransferase adenoviral gene therapy	n/a	4/4/2005	Treatment of patients with invasive (malignant) brain and central nervous system tumors lacking alpha 2,6 sialyltransferase.	Falk Center for Molecular Therapeutics
1165	Human anti-CD30 monoclonal antibody	n/a	9/27/2004	Treatment of Hodgkin's disease	Bristol-Myers Squibb, Inc.
1166	human anti-CD4 monoclonal antibody	Humax-Cd4	8/13/2004	Treatment of mycosis fungoides	Emergent Product Development Seattle, LLC
1167	human anti-cellular adhesion molecule-1 monoclonal antibody	n/a	7/29/2008	Treatment of multiple myeloma	BioInvent International AB
1168	Human anti-integrin receptor av monoclonal antibody	n/a	5/5/2005	Treatment of patients with angiosarcoma	Janssen Research & Development, LLC
1169	human anti-integrin receptor avb3/avb5 monoclonal antibody	n/a	12/1/2004	Treatment of patients with high-risk stage II, stage III, and stage IV malignant melanoma	Janssen Research & Development, LLC
1170	human anti-transforming growth factor-B1,2,3	n/a	7/9/2004	Treatment of idiopathic pulmonary fibrosis	Genzyme Corporation
1171	Human autologous bone-forming cell derived from bone marrow stem cells	n/a	3/24/2008	Treatment of osteonecrosis	Bone Therapeutics S.A.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1172	human coagulation factor VIII	Octanate	12/3/2012	Immune tolerance induction in hemophilia A patients with inhibitors	OCTAPHARMA USA, Inc.
1173	human coagulation factor XI	Hemoleven	11/8/2007	Treatment of severe congenital Factor XI deficiency.	Laboratoire francais du Fractionnement et des Biot
1174	Human cytomegalovirus immunoglobulin	n/a	12/20/2006	Prevention of congenital cytomegalovirus (CMV) infection following primary CMV infection in pregnant women	Biotest Pharmaceuticals Corporation
1175	Human factor X	n/a	11/8/2007	Treatment of hereditary factor X deficiency	Bio Products Laboratory
1176	human fibrinogen concentrate, pasteurized	Riastap	3/13/2008	Treatment of fibrinogen deficient patients	CSL Behring, LLC
1177	human gammaglobulin	Oralgam	9/16/2002	Treatment of gastrointestinal disturbances (to include constipation, diarrhea, and abdominal pain) associated with regression-onset autism in pediatric patients.	Latona Life Sciences, Inc.
1178	human gammaglobulin	Oralgam	5/25/2001	Treatment for juvenile rheumatoid arthritis	Latona Life Sciences, Inc.
1179	human gammaglobulin	Oralgam	11/14/2003	Treatment of idiopathic inflammatory myopathies	Latona Life Sciences, Inc.
1180	human glial restricted progenitor cells and their progeny	Q-Cells(R)	9/11/2013	Treatment of amyotrophic lateral sclerosis	Q Therapeutics, Inc.
1181	human haptoglobin	n/a	11/19/2013	Treatment of sickle cell disease	BioProducts Laboratory Limited
1182	Human Hemin	n/a	8/6/2013	Prevention of ischemia reperfusion injury in patients undergoing solid organ transplantation	Borders Technology Management Ltd
1183	human Hepatocarcinoma-Intestine-pancreas/pancreatitis associated protein	n/a	5/11/2011	Treatment of acute liver failure	Alfact Innovation SAS

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1184	human heterologous liver cells	n/a	2/14/2011	Treatment of urea cycle disorders	Cytonet GmbH & Co. KG
1185	human IgG1k monoclonal antibody	n/a	10/16/2013	Treatment of systemic sclerosis	MedImmune
1186	Human immune globulin	Xepol(Tm)	3/29/2006	Treatment of post-polio syndrome	Instituto Grifols, S.A.
1187	Human immunoglobulin anti-CD30 monoclonal antibody	n/a	1/10/2006	Treatment of CD30+ T-cell lymphoma	Bristol-Myers Squibb
1188	human insulin beta chain peptide with incomplete Freund's adjuvant vaccine	n/a	2/11/2013	Treatment of Type 1 diabetes patients with residual beta cell function	Orban Biotech, LLC
1189	human interleukin-3 genetically conjugated to diphtheria toxin protein	n/a	2/18/2011	Treatment of acute myeloid leukemia.	Stemline Therapeutics, Inc.
1190	human interleukin-3 genetically conjugated to diphtheria toxin protein	n/a	6/6/2013	Treatment of blastic plasmacytoid dendritic cell neoplasm	Stemline Therapeutics, Inc.
1191	human laminin-111	n/a	9/23/2011	Treatment of merosin (laminin-alpha2) deficient congenital muscular dystrophy type 1A.	Prothelia, Inc.
1192	human leukocyte-derived cytokine mixture	n/a	7/7/2005	Neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck	IRX Therapeutics, Inc.
1193	human lysosomal acid lipase, recombinant, transgenic gallus	n/a	7/1/2010	Treatment of lysosomal acid lipase deficiency	Synageva BioPharma Corp.
1194	human MHC non-restricted cytotoxic T-cell line	n/a	7/6/2012	Treatment of ovarian cancer	Galileo Research srl
1195	Human monoclonal antibody against platelet-derived growth factor D	n/a	11/2/2004	To slow the progression of IgA nephropathy and delay kidney failure in patients affected by the disease.	CuraGen Corporation
1196	human monoclonal antibody against human interleukin 13 (IL-13)	n/a	10/15/2013	Treatment of eosinophilic esophagitis	Novartis Pharmaceuticals Corporaton

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1197	human monoclonal antibody directed against active plasma kallikrein	n/a	11/16/2013	Treatment of hereditary angioedema (HAE)	Dyax Corporation
1198	Human monoclonal antibody directed against serotype O11 Pseudomonas aeruginosa	Aerumab 11	9/18/2006	Treatment of hospital acquired pneumonia caused by serotype O11 positive Pseudomonas aeruginosa	Kenta Biotech Limited
1199	human monoclonal antibody directed against serotype O1 Pseudomonas aeruginosa	n/a	1/6/2010	Treatment of pneumonia caused by serotype O1 positive Pseudomonas aeruginosa	Kenta Biotech Limited
1200	Human monoclonal antibody inhibitor of mannan-binding lectin-associated serine protease-2 (MASP-2)	n/a	12/16/2013	Prevention (inhibition) of complement-mediated thrombotic microangiopathy	Omeros Corporation
1201	Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)	n/a	4/30/2010	Treatment of ovarian cancer	Ortho Biotech
1202	human monoclonal anti-PA antibody	n/a	10/21/2010	For post-exposure prophylaxis and treatment of inhalation anthrax.	Emergent Product Development Gaithersburg, Inc.
1203	human monoclonal IgG2 to human proprotein convertase subtilisin/kexin type 9	n/a	9/12/2013	Treatment of homozygous familial hypercholesterolemia	Amgen Inc.
1204	Human plasma coagulation Factor VIII and human plasma von Willebrand Factor	Wilate	4/18/2007	Treatment of von Willebrand disease except for surgical and/or invasive procedures in patients with von Willebrand disease in whom desmopressin is either ineffective or contraindicated	Octapharma USA, Inc.
1205	Human plasma derived conagulation protein-Factor XI	n/a	4/30/2014	For the treatment of congenital Factor XI deficiency	Cambryn Biologics
1206	human plasminogen	n/a	6/7/2010	Treatment of ligneous conjunctivitis	Kedrion, S.p.A.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1207	human platelet antigen-1a immunoglobulin (anti-HPA-1a)	Tromplate	6/27/2013	Prevention of fetal and neonatal alloimmune thrombocytopenia	Prophylix Pharma AS
1208	Human prothrombin complex concentrate	Octaplex	2/1/2008	Reversal of anticoagulation therapy in patients needing treatment of serious or life threatening bleeding and/or needing urgent surgery or invasive procedures	Octapharma USA, Inc.
1209	human recombinant DNA-derived, IgG1 kappa monoclonal anti-body to connective growth factor	n/a	7/6/2012	Treatment of idiopathic pulmonary fibrosis	FibroGen, Inc.
1210	human retinal progenitor cells	n/a	7/23/2012	Treatment of retinitis pigmentosa	jCyte, Inc.
1211	human spinal cord derived neural stem cells	n/a	2/4/2011	Treatment of amyotrophic lateral sclerosis.	Neuralstem, Inc.
1212	Human telomerase reverse transcriptase peptide vaccine	n/a	7/20/2006	Treatment of pancreatic cancer	GemVax A/S
1213	Human T-lymphotropic virus type III Gp160 antigens	Vaxsyn Hiv-1	11/20/1989	Treatment of AIDS.	MicroGeneSys, Inc.
1214	human tumor necrosis factor coupled to the C terminus of CNGRCG peptide	n/a	10/1/2009	Treatment of liver cancer	Molecular Medicine S.p.A. (Molmed)
1215	human umbilical cord blood-derived mesenchymal stem cells	Pneumostem	11/26/2013	Prevention of bronchopulmonary dysplasia	MEDIPOST America, Inc.
1216	Humanized 3F8-IgG1 monoclonal antibody	n/a	6/24/2013	Treatment of neuroblastoma	Memorial Sloan-Kettering Cancer Center
1217	humanized anti programmed cell death 1 monoclonal IgG4 antibody	n/a	11/19/2012	Treatment of Stage IIB through IV malignant melanoma	Merck, Sharp & Dohme Corp.
1218	Humanized anti-CD3 monoclonal antibody	n/a	9/29/2006	Treatment of recent-onset Type I diabetes	MacroGenics, Inc.
1219	Humanized anti-tac	Zenapax	3/5/1993	Prevention of acute graft-vs-host disease following bone marrow transplantation.	Hoffmann-La Roche, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1220	humanized Fc engineered monoclonal antibody against CD19	n/a	4/29/2014	Treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma	MorphoSys AG
1221	humanized IgG1 anti-serum amyloid A monoclonal antibody	n/a	2/17/2012	Treatment of AA amyloidosis and AL amyloidosis	Onclave Theraeputics Limited
1222	humanized IgG1 monoclonal anti-CD20 antibody	n/a	5/26/2011	Treatment of follicular lymphoma	MENTRIK Biotech, LLC
1223	humanized IgG2 antibody	n/a	7/22/2008	Treatment of vaso-occlusive crisis in patients with sickle cell disease.	Selexys Pharmaceuticals Corp.
1224	humanized IgG4 monoclonal antibody	n/a	12/12/2011	Prevention of ischemia/reperfusion injury associated with solid organ transplantation	Opsona Theraeputics
1225	humanized immunoglobulin monoclonal antibody against CD38	n/a	5/22/2014	Treatment of multiple myeloma.	Sanofi-Aventis U.S., LLC
1226	humanized monoclonal antibody against human integrin alphaVbeta6	n/a	8/5/2010	Treatment of idiopathic pulmonary fibrosis	Biogen Idec, Inc.
1227	humanized monoclonal antibody to tissue factor	n/a	4/26/2011	Treatment of pancreatic cancer.	Morphotek, Inc.
1228	Humanized monoclonal antibody to TumorEndothelial Marker-1	n/a	4/29/2011	Treatment of soft tissue sarcoma	Morphotek
1229	humanized monoclonal antibody against human integrin alphaVbeta6	n/a	6/18/2008	Treatment of fibrosis-associated chronic allograft nephropathy in kidney transplant patients.	Stromedix, Inc.
1230	humanized single chain monoclonal antibody(scFV: IgG1 hinge: IgG1 CH2 and CH3 domains)	n/a	11/17/2011	Treatment of chronic lymphocytic leukemia	Emergent Product Development Seattle, LLC
1231	humanized, afucosylated IgG1 kappa monoclonal antibody	n/a	12/3/2009	Treatment of scleroderma	MedImmune
1232	hyaluronic acid	n/a	3/19/2002	Treatment of emphysema in patients due to alpha-1 antitrypsin deficiency	CoTherix

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1233	Hydralazine	n/a	4/9/2004	Treatment of severe intrapartum hypertension (diastolic blood pressure greater than or equal to 110 or systolic blood pressure greater than or equal to 160) associated with severe preeclampsia/eclampsia of pregnancy	Bioniche Pharma USA LLC
1234	hydralazine - magnesium valproate	Transkrip(R)	3/17/2011	Treatment of myelodysplastic syndrome	Neolpharma S.A. de C.V.
1235	hydralazine - magnesium valproate	Transkrip(R)	3/17/2011	Treatment of cutaneous T-cell lymphoma.	Neolpharma S.A.DE C.V.
1236	hydrocortisone modified release tabs	Duocort	6/18/2008	Treatment of adrenal insufficiency	Shire ViroPharma, Inc.
1237	Hydroxocobalamin	n/a	9/22/2000	Treatment of acute cyanide poisoning	Jazz Pharmaceuticals
1238	Hydroxocobalamin	Cyanokit	11/25/2003	Treatment of acute cyanide poisoning	Merck Sante, s.a.a.
1239	hydroxycarbamide (hydroxyurea)	Siklos	7/24/2013	Treatment of sickle cell disease in patients under 18 years of age	addmedica Laboratories
1240	hydroxyprogesterone caproate	Makena	1/25/2007	Prevention of preterm birth in singleton pregnancies	KV Pharmaceutical Company
1241	Hydroxy-Propyl-Beta-Cyclodextrin	Trappsol	5/17/2010	Treatment of Niemann Pick Disease, Type C	Childrens Hospital & Research Center Oakland
1242	hydroxyurea	n/a	4/15/2005	Treatment of pediatric patients with sickle cell anemia.	UPM Pharmaceuticals, Inc.
1243	Hydroxyurea	Droxia	10/1/1990	Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S.	Bristol-Myers Squibb Pharmaceutical Research Institute
1244	Hypericin	n/a	8/3/2000	Treatment of glioblastoma multiforme.	HyBiopharma, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1245	Hypericin	n/a	2/7/2000	Treatment of cutaneous T-cell lymphoma.	HyBiopharma, Inc.
1246	Hypothiocyanite and lactoferrin	Meveol	11/5/2009	Treatment of cystic fibrosis	Alaxia Biotechnologies Sante
1247	I(131)-TM-601 (chlorotoxin)	n/a	2/14/2002	Treatment of malignant glioma	Morphotek, Inc.
1248	ibritumomab tiuxetan	Zevalin	9/6/1994	Treatment of B-cell non-Hodgkin's lymphoma.	Spectrum Pharmaceuticals, Inc.
1249	ibrutinib	n/a	5/16/2013	Treatment of multiple myeloma	Pharmacyclics, Inc.
1250	ibrutinib	n/a	10/15/2013	Treatment of Waldenstrom's macroglobulinemia	Pharmacyclics, Inc.
1251	ibrutinib	n/a	5/30/2013	Treatment of small lymphocytic lymphoma	Pharmacyclics, Inc.
1252	ibrutinib	n/a	10/23/2013	Treatment of diffuse large B-cell lymphoma	Pharmacyclics, Inc.
1253	ibrutinib	Imbruvica	4/6/2012	Treatment of chronic lymphocytic leukemia (CLL)	Pharmacyclics, Inc.
1254	ibrutinib	Imbruvica	12/3/2012	Treatment of mantle cell lymphoma.	Pharmacyclics, Inc.
1255	Ibuprofen i.v. solution	Salprofen	10/29/1996	Prevention of patent ductus arteriosus.	Farmacon-IL, LLC
1256	Ibuprofen lysine	Neoprofen	10/29/1996	Treatment of patent ductus arteriosus	Lundbeck, Inc.
1257	icatibant	Firazyr	11/25/2003	Treatment of angioedema	Shire Orphan Therapies
1258	Icodextrin 7.5% with Electrolytes Peritoneal Dialysis Solution	Extraneal (With 7.5% Icodextrin) Peritoneal Dialysis Solutio	7/18/1997	Treatment of those patients having end stage renal disease and requiring peritoneal dialysis treatment.	Baxter Healthcare Corporation
1259	Idarubicin HCl for injection	Idamycin	7/25/1988	Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.	Adria Laboratories, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1260	idebenone	n/a	3/25/2004	Treatment of Friedreich's ataxia	Santhera Pharmaceuticals LLC
1261	idebenone	n/a	10/31/2006	Treatment of Leber's hereditary optic neuropathy.	Santhera Pharmaceuticals Limited
1262	idebenone	n/a	2/16/2007	Treatment of Duchenne muscular dystrophy	Santhera Pharmaceuticals Limited
1263	idebenone	n/a	5/22/2009	Treatment of mitochondrial myopathy, encephalopathy, lactic acidosis with stroke-like episodes syndrome (MELAS)	Santhera Pharmaceuticals Limited
1264	idelalisib	n/a	10/15/2013	Treatment of splenic marginal zone lymphoma	Gilead Sciences, Inc.
1265	idelalisib	n/a	10/15/2013	Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma	Gilead Sciences, Inc.
1266	idelalisib	n/a	10/15/2013	Treatment of extranodal marginal zone lymphoma	Gilead Sciences, Inc.
1267	idelalisib	n/a	10/15/2013	Treatment of nodal marginal zone lymphoma.	Gilead Sciences, Inc.
1268	idelalisib	n/a	9/26/2013	Treatment of follicular lymphoma	Gilead Sciences, Inc.
1269	idelalisib	n/a	9/26/2013	Treatment of lymphoplasmacytic lymphoma with or without Waldenström's macroglobulinemia	Gilead Sciences, Inc.
1270	idelalisib	n/a	8/25/2011	Treatment of chronic lymphocytic leukemia	Gilead Sciences, Inc.
1271	Idoxuridine	n/a	4/8/1996	Treatment of nonparenchymatous sarcomas.	NeoPharm, Inc.
1272	IDUA-HIRMAb fusion protein	Agt-181	1/10/2008	Treatment of mucopolysaccharidosis Type 1 (MPS)	ArmaGen Technologies, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1273	idursulfase	Elaprase	11/28/2001	Long term enzyme replacement therapy for patients with mucopolysaccharidosis II (Hunter Syndrome)	Shire Human Genetic Therapies, Inc.
1274	idursulfase beta	n/a	2/11/2013	Treatment of Hunter Syndrome (mucopolysaccharidoses)	Green Cross Corp.
1275	idursulfase IT	n/a	9/3/2009	For treatment of neurocognitive symptoms associated with Hunter Syndrome	Shire Human Genetic Therapies
1276	iduvec	n/a	1/21/2011	Treatment of Mucopolysaccharidosis Type I	Zebraic Corporation
1277	iferanserin (S-MPEC)	n/a	12/13/2010	For use in pulmonary arterial hypertension.	Sam Amer & Company, Inc.
1278	Ifosfamide	Ifex	8/7/1985	Treatment of soft tissue sarcomas.	Bristol-Myers Squibb Pharmaceutical Research Institute
1279	Ifosfamide	Ifex	8/7/1985	Treatment of bone sarcomas	Bristol-Myers Squibb Company
1280	Ifosfamide	Ifex	1/20/1987	Treatment of testicular cancer.	Bristol-Myers Squibb Pharmaceutical Research Institute
1281	IgG1 chimeric monoclonal antibody	n/a	6/22/2011	Treatment of multiple myeloma.	Immune System Therapeutics Ltd
1282	IL-12 secreting dendritic cells loaded with autologous tumor lysate	n/a	6/24/2013	Treatment of malignant glioma	Activartis Biotech GmbH
1283	IL13-PE38QQR	n/a	11/2/2001	Treatment of malignant glioma	Insys Therapeutics, Inc.
1284	IL-4 Pseudomonas Toxin Fusion Protein (IL-4(38-37)-PE38KDEL)	n/a	4/6/2000	Treatment of astrocytic glioma.	Medicenna Therapeutics, Inc.
1285	iloprost	n/a	4/6/2012	Treatment of pulmonary arterial hypertension	Algorithm Sciences, LLC

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1286	iloprost inhalation solution	Ventavis	8/17/2004	Treatment of pulmonary arterial hypertension	CoTherix, Inc.
1287	ilorasertib	n/a	3/16/2012	Treatment of ovarian cancer	AbbVie, Inc.
1288	Imatinib	Gleevec	1/31/2001	Treatment of chronic myelogenous leukemia	Novartis Pharmaceuticals Corporation
1289	imatinib	Gleevec	10/11/2005	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Novartis Pharmaceuticals Corporation
1290	Imatinib mesylate	Gleevec	9/9/2005	Treatment of systemic mastocytosis without the D816V c-kit mutation	Novartis Pharmaceuticals Corporation
1291	Imatinib mesylate	Gleevec	10/5/2005	Treatment of myeloproliferative disorders/myelodysplastic syndromes associated with platelet-derived growth factor gene re-arrangements	Novartis Pharmaceuticals Corporation
1292	Imatinib mesylate	Gleevec	8/25/2005	Treatment of idiopathic hypereosinophilic syndrome including acute and chronic eosinophilic leukemia	Novartis Pharmaceuticals Corporation
1293	imatinib mesylate	Gleevec	12/19/2005	Treatment of dermatofibrosarcoma protuberans	Novartis Pharmaceuticals Corporation
1294	imatinib mesylate	Gleevec	11/1/2001	Treatment of gastrointestinal stromal tumors	Novartis Pharmaceuticals Corp.
1295	Imciromab pentetate	Myoscint	1/25/1989	Detecting early necrosis as an indication of rejection of orthotopic cardiac transplants.	Centocor, Inc.
1296	Imexon	n/a	11/8/1996	Treatment of multiple myeloma.	AmpliMed Corporation
1297	imexon	Amplimexon	8/12/2005	Treatment of ovarian cancer.	AmpliMed Corporation

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1298	Imiglucerase	Cerezyme	11/5/1991	Replacement therapy in patients with types I, II, and III Gaucher's disease.	Genzyme Corporation
1299	Immortalized human liver cells found in the extracorporeal liver assist device	Elad	7/16/2004	Treatment of fulminant hepatic failure (acute liver failure)	Vital Therapies, Inc.
1300	immune globulin (human)	n/a	3/2/2010	Treatment of Guillain-Barre syndrome	Octapharma USA, Inc.
1301	Immune Globulin (Human)	Gamunex(R)-C	7/27/2004	Treatment of chronic inflammatory demyelinating polyneuropathy	Grifols Therapeutics, Inc.
1302	Immune Globulin (Human) containing high titers of West Nile virus antibodies	Omr-Igg-Am (Tm) 5% (Wnv)	3/17/2004	Treatment of the West Nile virus infection	OMRIX Biopharmaceuticals, Ltd.
1303	immune globulin infusion (human)	Gammagard Liquid	7/20/2006	Treatment of multifocal motor neuropathy	Baxter Healthcare Corporation
1304	Immune Globulin Intravenous (human)	Carimune Nf	5/4/2004	Treatment for Guillain Barre Syndrome	ZLB Bioplasma AG
1305	Immune globulin intravenous, human	Gamimune N	2/18/1993	Infection prophylaxis in pediatric patients affected with the human immunodeficiency virus.	Bayer Corporation
1306	immune globulin intravenous (human)	Gammaplex	4/29/2011	Treatment of idiopathic thrombocytopenic purpura (also known as primary immune thrombocytopenia)	Bio Products Laboratory
1307	Immunotherapeutic vaccine consisting of (PAM)2-Lys-Ser-Ser-Gln-Tyr-Ile-Lys-Ala-Asn-Ser-Lys-Phe-Ile-Gly-Ile-Thr-Glu-Ala-Ala-Ala-Phe-Leu-Pro-Ser-Asp-Phe-Phe-Pro-Ser-Val	n/a	3/16/1994	Treatment of chronic active hepatitis B infection in HLA-A2 positive patients.	Cytel Corporation

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1308	Imported fire ant venom, allergenic extract	n/a	5/12/1992	For skin testing of victims of fire ant stings to confirm fire ant sensitivity and if positive, for use as immunotherapy for the prevention of IgE-mediated anaphylactic reactions.	ALK Laboratories, Inc.
1309	Inalimarev and falimarev	n/a	1/10/2006	Treatment of adenocarcinoma of the pancreas	Therion Biologics Corporation
1310	Indium-111 pentetreotide	Neuroendomedix	6/16/2006	Treatment of neuroendocrine tumors	Radiolotope Therapy of America (RITA) Foundation
1311	Inecalcitol	n/a	5/14/2014	Treatment of chronic lymphocytic leukemia	Hybrigenics, S.A.
1312	Infliximab	Remicade	5/21/2003	Treatment of chronic sarcoidosis	Centocor, Inc.
1313	infliximab	Remicade	10/23/2002	Treatment of juvenile rheumatoid arthritis	Centocor, Inc.
1314	Infliximab	Remicade	11/12/2003	Treatment of pediatric (0 to 16 years of age) Crohn's Disease	Centocor, Inc.
1315	infliximab	Remicade	11/12/2003	Treatment of pediatric (0 to 16 years of age) ulcerative colitis	Janssen Biotech Inc.
1316	infliximab	Remicade	11/14/1995	Treatment of Crohn's disease	Centocor, Inc.
1317	inhibitor of microRNA-451	n/a	2/4/2011	Treatment of polycythemia vera	miRagen Therapeutics, Inc.
1318	Inhibitor of Tissue Factor Pathway Inhibitor (TFPI)	n/a	1/29/2010	Treatment of hemophilia A and hemophilia B.	Baxter Healthcare Corporation, Baxter BioScience
1319	inolimomab	Leukotac	10/23/2002	Treatment of graft versus host disease	Jazz Pharmaceuticals
1320	Inosine pranobex	Isoprinosine	9/20/1988	Treatment of subacute sclerosing panencephalitis.	Newport Pharmaceuticals

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1321	inotuzumab ozogamicin	n/a	3/25/2013	Treatment of B-cell acute lymphoblastic leukemia	Pfizer, Inc.
1322	insecticidal toxin derived from <i>Bacillus thuringiensis</i>	n/a	9/5/2008	Treatment of soil transmitted helminth infection strongyloidiasis	University of California, San Diego
1323	Interferon alfa-2a	Roferon A	6/6/1989	Treatment of chronic myelogenous leukemia.	Hoffmann-La Roche, Inc.
1324	Interferon alfa-2a (recombinant)	Roferon-A	4/18/1988	Treatment of renal cell carcinoma.	Hoffmann-La Roche, Inc.
1325	Interferon alfa-2a (recombinant)	Roferon-A	5/11/1990	For the treatment of metastatic malignant melanoma in combination with Teceleukin.	Hoffmann-La Roche, Inc.
1326	Interferon alfa-2a (recombinant)	Roferon-A	5/14/1990	For the concomitant administration with fluorouracil for the treatment of advanced colorectal cancer.	Hoffmann-La Roche, Inc.
1327	Interferon alfa-2a (recombinant)	Roferon-A	5/2/1990	For the concomitant administration with Teceleukin for the treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc.
1328	Interferon alfa-2a (recombinant)	Roferon-A	10/27/1989	For use in combination with fluorouracil for the treatment of esophageal carcinoma.	Hoffmann-La Roche, Inc.
1329	Interferon alfa-2a (recombinant)	Roferon-A	12/14/1987	Treatment of AIDS related Kaposi's sarcoma.	Hoffmann-La Roche, Inc.
1330	Interferon alfa-2b (recombinant)	Intron A	6/24/1987	Treatment of AIDS-related Kaposi's sarcoma.	Schering Corporation
1331	Interferon beta-1a	Rebif	3/11/1996	Treatment of patients with secondary progressive multiple sclerosis.	EMD Serono, Inc.
1332	Interferon beta-1a	Avonex	12/16/1991	Treatment of multiple sclerosis.	Biogen, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1333	Interferon beta-1a (recombinant human)	n/a	7/24/1992	Treatment of acute non-A, non-B hepatitis.	Biogen, Inc.
1334	Interferon beta-1a (recombinant)	Rebif	12/2/1992	Treatment of symptomatic patients with AIDS including all patients with CD4 T-cell counts less than 200 cells per mm3.	EMD Serono, Inc.
1335	Interferon beta-1b	Betaseron	11/17/1988	Treatment of multiple sclerosis.	Chiron Corp. & Berlex Laboratories
1336	Interferon gamma	n/a	10/11/2007	Treatment of idiopathic pulmonary fibrosis	mondoBIOTECH Laboratories AG
1337	interferon gamma	n/a	11/4/2011	Treatment of Friedreich's ataxia	Roberto Testi, MD
1338	Interferon gamma 1-b	Actimmune	9/30/1988	Treatment of chronic granulomatous disease.	Vidara Therapeutics Research Limited
1339	Interferon gamma-1b	Actimmune	12/4/1995	Treatment of renal cell carcinoma.	Vidara Therapeutics Research Limited
1340	Interferon gamma-1b	Actimmune	9/30/1996	Delaying time to disease progression in patients with severe, malignant osteopetrosis.	Vidara Therapeutics Research Limited
1341	Interferon-alfa-1b	n/a	4/17/2001	Treatment of multiple myeloma	Ernest C.Borden
1342	interferon-alpha secreting autologous micro-organ tissue converting into a biopump	Infradure Biopump	6/14/2012	Treatment of chronic hepatitis D	Medgenics, Inc.
1343	Interleukin-1 receptor antagonist, human recombinant	Antril	9/23/1991	Treatment of juvenile rheumatoid arthritis.	Swedish Orphan Biovitrum AB (publ) (SOBI)
1344	Interleukin-1 receptor antagonist, human recombinant	Antril	10/16/1992	Prevention and treatment of graft versus host disease in transplant recipients.	Swedish Orphan Biovitrum AB (publ) (SOBI)
1345	Interleukin-1 Trap	n/a	4/4/2005	Treatment of Still's disease including juvenile rheumatoid arthritis and adult-onset Still's disease	Regeneron Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1346	Interleukin-2	Teceleukin	2/5/1990	Treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc.
1347	Interleukin-2	Teleleukin	2/6/1990	Treatment of metastatic malignant melanoma.	Hoffmann-La Roche, Inc.
1348	Interleukin-2	Teceleukin	5/3/1990	In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc.
1349	Interleukin-2	Teceleukin	5/11/1990	In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.	Hoffmann-La Roche, Inc.
1350	Intraoral fluoride releasing system	lfrs	7/31/2001	Prevention of dental caries due to radiation-induced xerostomia in patients with head and neck cancer	Digestive Care, Inc.
1351	intravenous carbamazepine	n/a	6/27/2013	Treatment of epilepsy patients who cannot take anything by mouth (NPO)	Lundbeck, LLC
1352	Intravenous immune globulin	Vitigam	7/26/2007	Treatment of Stage IIB to IV malignant melanoma	GammaCan Ltd.
1353	Intravenous immune globulin (human) 10%	Octagam(R)	7/31/2008	Treatment of stiff-person syndrome	Octapharma USA, Inc.
1354	Iobenguane I 123	Adreview	12/1/2006	For the diagnosis of pheochromocytomas	GE Healthcare, Inc.
1355	Iobenguane I 123	Adreview	12/1/2006	For the diagnosis of neuroblastomas	GE Healthcare, Inc.
1356	Iobenguane I 131	Azedra Ultratrace	1/18/2006	Treatment of neuroendocrine tumors	Molecular Insight Pharmaceuticals
1357	Iobenguane I 131	n/a	7/5/2007	Treatment of neuroendocrine tumors	Jubilant DraxImage, Inc.
1358	Iobenguane Sulfate I-123	Omaclear	10/17/2005	For scintigraphic detection, localization and staging of neuroblastoma.	Brogan Pharmaceuticals, LLC

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1359	iobenguane sulfate I-123	Omaclear	10/21/2005	For the detection, localization, and staging of pheochromocytomas.	Brogan Pharmaceuticals, Inc.
1360	Iodine 131 6B-iodomethyl-19-norcholesterol	n/a	8/1/1984	For use in adrenal cortical imaging.	David E. Kuhl, M.D.
1361	Iodine I 123 murine monoclonal antibody to hCG	n/a	11/7/1988	Detection of hCG producing tumors such as germ cell and trophoblastic cell tumors.	Immunomedics, Inc.
1362	Iodine I 131 bis(indium-diethylenetriaminepentaacetic acid)tyrosyllysine/hMN-14 x m734 F(ab') ₂ bispecific monoclonal antibody	Pentacea	2/22/2000	Treatment of small-cell lung cancer.	IBC Pharmaceuticals, L.L.C.
1363	Iodine I-131 radiolabeled chimeric MAb tumor necrosis treatment (TNT-1B)	131ichtnt-1	2/12/1999	Treatment of glioblastoma multiforme and anaplastic astrocytoma.	Peregrine Pharmaceuticals, Inc.
1364	Ipatasertib	n/a	4/30/2014	For the treatment of gastric cancer including cancer of the gastro-esophageal junction.	Genentech, Inc.
1365	ipilimumab	Yervoy	6/3/2004	Treatment of high risk Stage II, Stage III, and Stage IV melanoma	Bristol-Myers Squibb Pharmaceutical Research Insti
1366	iron(III)-hexacyanoferrate(II)	Radiogardase	5/1/2003	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	Heyl Chemisch-Pharmzeutische Fabrik GMBH & Co, KG
1367	isavuconazonium sulfate	n/a	5/6/2013	Treatment of invasive aspergillosis.	Astellas
1368	isavuconazonium sulfate	n/a	10/25/2013	Treatment of zygomycosis	Astellas
1369	Isobutyramide	n/a	5/25/1994	Treatment of sickle cell disease and beta thalassemia.	Alpha Therapeutic Corporation

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1370	Isobutyramide	Isobutyramide Oral Solution	12/18/1992	Treatment of beta-hemoglobinopathies and beta-thalassemia syndromes.	Perrine, Susan P., M.D.
1371	isofagomine tartrate	n/a	1/10/2006	Treatment of Gaucher disease	Amicus Therapeutics, Inc.
1372	isotretinoin	n/a	4/10/2014	Treatment of congenital ichthyosis	Patagonia Pharmaceuticals, LLC
1373	Itraconazole suspension	n/a	10/30/2008	Topical treatment of fungal otitis externa (otomycosis)	Fairfield Clinical Trials, LLC
1374	ivacaftor	Kalydeco	12/20/2006	Treatment of patients with cystic fibrosis	Vertex Pharmaceuticals, Inc.
1375	ixazomib citrate	n/a	2/18/2011	Treatment of multiple myeloma	Millennium Pharmaceuticals
1376	Japanese encephalitis vaccine (live, attenuated)	n/a	5/19/1999	Prevention of Japanese encephalitis.	Glovax Co., Ltd.
1377	Japanese encephalitis vaccine, inactivated, adsorbed	Ixiaro	9/25/2012	Prevention of Japanese encephalitis virus in pediatric patients.	Intercell AG
1378	Kre-Celazine	n/a	4/1/2013	Treatment of juvenile rheumatoid arthritis joint and related tissue inflammation in the pediatric population	All American Pharmaceutical & Natural Foods Corpor
1379	L. reuteri	n/a	8/1/2013	Prevention of necrotizing enterocolitis in preterm infants with birth weight less than or equal to 1,500 grams	Infant Bacterial Therapeutics
1380	L-2-oxothiazolidine-4-carboxylic acid	Procysteine	6/14/1994	Treatment of adult respiratory distress syndrome.	Transcend Therapeutics, Inc.
1381	L-2-oxothiazolidine-4-carboxylic acid	Procysteine	7/30/1996	Treatment of amyotrophic lateral sclerosis.	Transcend Therapeutics, Inc.
1382	L-5 Hydroxytryptophan	n/a	11/1/1984	Treatment of postanoxic intention myoclonus.	Watson Laboratories, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1383	L-5-hydroxytryptophan	n/a	1/20/1999	Treatment of tetrahydrobiopterin deficiency.	Watson Laboratories, Inc.
1384	Lactic acid	Aphthaid	6/29/1999	Treatment of severe aphthous stomatitis in severely, terminally immunocompromised patients.	Frontier Pharmaceutical, Inc.
1385	lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococci)	n/a	1/15/2002	Treatment of active chronic pouchitis	VSL Pharmaceuticals, Inc.
1386	lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococcus species)	n/a	1/15/2002	Prevention of disease relapse in patients with chronic pouchitis	VSL Pharmaceuticals, Inc.
1387	lactobacillus brevis CD2	n/a	10/4/2011	Treatment Behcet's disease	VSL Pharmaceuticals, Inc.
1388	laminin-111 (human)	n/a	7/21/2011	Treatment of Duchenne Muscular Dystrophy	Prothelia, Inc.
1389	L-amino acids, vitamins and minerals combined with omega-3 fatty acids	n/a	1/12/2011	Treatment of patients with pediatric Crohn's disease	Immunopath Profile, Inc.
1390	L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal	n/a	1/18/2006	Treatment of Duchenne and Becker muscular dystrophy	CepTor Corporation
1391	Lamotrigine	Lamictal	8/23/1995	Treatment of Lennox-Gastaut syndrome.	Glaxo Wellcome Research and Development
1392	Lanreotide	Somatuline Depot	9/11/2000	Treatment for acromegly	IPSEN, Inc.
1393	lanreotide acetate	n/a	9/8/2011	Treatment of symptoms associated with carcinoid syndrome	Ipsen Biopharmaceuticals, Inc.
1394	lanreotide acetate	n/a	8/25/2011	Treatment of neuroendocrine tumors.	Ipsen Biopharmaceuticals, Inc.
1395	lapatinib	Tykerb	5/29/2009	Treatment of ErbB2 positive gastric cancer	GlaxoSmithKline
1396	lapatinib ditosylate hydrochloride	Tykerb	5/29/2009	Treatment of ErbB2 positive esophageal cancer	GlaxoSmithKline

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1397	L-arginyl-L-isoleucyl-L-valyl-L-prolyl-L-alanine-amide	n/a	9/11/2013	Treatment of acute radiation syndrome	Soligenix, Inc.
1398	Laromustine	Cloretazine	3/27/2014	Treatment of acute myelogenous leukemia	Nanotherapeutics, Inc.
1399	laromustine	Onrigin	10/21/2004	Treatment of acute myelogenous leukemia	Vion Pharmaceuticals, Inc.
1400	laronidase	Aldurazyme	9/24/1997	Treatment of patients with mucopolysaccharidosis-I.	BioMarin Pharmaceutical, Inc.
1401	L-asparaginase	n/a	3/27/2014	Treatment of acute myeloid leukemia	ERYTECH Pharma S.A.
1402	L-asparaginase encapsulated in red blood cells	Graspa	1/6/2010	Treatment of acute lymphoblastic leukemia	Erytech Pharma
1403	L-asparaginase encapsulated in red blood cells	Graspa	7/6/2012	Treatment of pancreatic cancer.	ERYTECH Pharma
1404	late stage human motor neuron progenitors	Motorgraft(Tm)	11/25/2009	Treatment of spinal muscular atrophy	California Stem Cell, Inc.
1405	Latrodectus immune F(ab)2	Analatro	6/18/2001	Treatment of black widow spider envenomations	Instituto Bioclon, S.A. de C.V.
1406	L-baclofen	Neuralgon	12/17/1991	Treatment of spasticity associated with spinal cord injury or multiple sclerosis.	Osmotica Pharmaceutical Corp.
1407	L-baclofen	n/a	7/13/1990	Treatment of trigeminal neuralgia.	Fromm, Gerhard M.D.
1408	L-baclofen	n/a	1/6/1998	Treatment of trigeminal neuralgia	Osmotica Pharmaceutical Corp.
1409	L-baclofen	Neuralgon	1/30/1992	Treatment of intractable spasticity in children with cerebral palsy.	Osmotica Pharmaceutical Corp.
1410	L-cycloserine	n/a	8/1/1989	Treatment of Gaucher's disease.	Lev, Meir M.D.
1411	L-cysteine	n/a	5/16/1994	For the prevention and lessening of photosensitivity in erythropoietic protoporphyria.	Brigham and Women's Hospital

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1412	Leflunomide	n/a	10/18/1996	Prevention of acute and chronic rejection in patients who have received solid organ transplants.	Williams, MD, James W.
1413	lenalidomide	Revlimid	9/13/2013	Treatment of follicular lymphoma	Celgene Corporation
1414	lenalidomide	Revlimid	1/17/2007	Treatment of chronic lymphocytic leukemia	Celgene Corporation
1415	lenalidomide	Revlimid	3/28/2011	Treatment of diffuse large B-cell lymphoma	Celgene Corporation
1416	lenalidomide	Revlimid	9/20/2001	Treatment for multiple myeloma	Celgene Corporation
1417	lenalidomide	Revlimid	4/27/2009	Treatment of mantle cell lymphoma	Celgene Corporation
1418	lenalidomide	Revlimid	1/29/2004	Treatment of myelodysplastic syndromes	Celgene Corporation
1419	Lentiviral vector containing the human ABCA4 gene	Stargen (Tm)	4/30/2010	Treatment of Stargardt disease	Sanofi US Services, Inc.
1420	Lentiviral vector containing the human MYO7A gene	Ushstat(Tm)	5/17/2010	Treatment of retinitis pigmentosa associated with Usher syndrome 1B gene defect.	Sanofi US Services, Inc.
1421	Lentiviral vector encoded with a human beta-globin gene plasmid	Thalagen	1/11/2006	Treatment of beta-thalassemia major and beta-thalassemia intermedia	Memorial Sloan-Kettering Cancer Center
1422	lenvatinib	n/a	3/26/2014	Treatment of stage IIB to Stage IV melanoma	Eisai, Inc.
1423	lenvatinib	n/a	3/27/2014	Treatment of hepatocellular carcinoma	Eisai, Inc.
1424	lenvatinib	n/a	12/27/2012	Treatment of follicular, medullary, anaplastic, and metastatic or locally advanced papillary thyroid cancer	Eisai, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1425	Lepirudin	Refluden	2/13/1997	Treatment of heparin-associated thrombocytopenia type II.	Hoechst Marion Roussel
1426	Lestaurtinib	n/a	3/24/2006	Treatment of acute myeloid leukemia	Teva Branded Pharmaceutical Products R&D, Inc.
1427	lestaurtinib	n/a	9/3/2009	Treatment of Philadelphia-negative classic myeloproliferative disorders	Teva Branded Pharmaceutical Products R&D, Inc.
1428	letermovir	n/a	12/12/2011	Prevention of human cytomegalovirus viremia and disease in at risk populations	Merck Sharpe & Dhome Corporation
1429	Leucovorin	Leucovorin Calcium	12/8/1986	For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.	Immunex Corporation
1430	Leucovorin	Leucovorin Calcium	8/17/1988	For rescue use after high dose methotrexate therapy in the treatment of osteosarcoma.	Immunex Corporation
1431	leukocyte interleukin	Multikine	5/4/2007	Neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck	CEL-SCI Corporation
1432	Leupeptin	n/a	9/18/1990	For use as an adjunct to microsurgical peripheral nerve repair.	Neuromuscular Adjuncts, Inc.
1433	Leuprolide acetate	Lupron Injection	7/25/1988	Treatment of central precocious puberty	Tap Pharmaceuticals, Inc.
1434	levetiracetam	Keppra	4/30/2010	Treatment of neonatal seizures	University of California
1435	Levocarnitine	Carnitor	11/15/1989	For the prevention of secondary carnitine deficiency in valproic acid toxicity.	Sigma-Tau Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1436	Levocarnitine	Carnitor	11/15/1989	For the treatment of secondary carnitine deficiency in valproic acid toxicity.	Sigma-Tau Pharmaceuticals, Inc.
1437	Levocarnitine	Carnitor	4/7/1997	Treatment of zidovudine-induced mitochondrial myopathy.	Sigma-Tau Pharmaceuticals, Inc.
1438	Levocarnitine	Carnitor	11/22/1993	Treatment of pediatric cardiomyopathy.	Sigma-Tau Pharmaceuticals, Inc.
1439	Levocarnitine	Carnitor	7/26/1984	Treatment of primary and secondary carnitine deficiency of genetic origin.	Sigma-Tau Pharmaceuticals, Inc.
1440	Levocarnitine	Carnitor	2/28/1984	Treatment of genetic carnitine deficiency.	Sigma-Tau Pharmaceuticals, Inc.
1441	Levocarnitine	Carnitor	9/6/1988	Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.	Sigma-Tau Pharmaceuticals, Inc.
1442	Levodopa and carbidopa	Duodopa	1/18/2000	Treatment of late stage Parkinson's disease	AbbVie, Inc.
1443	Levofloxacin	n/a	2/27/2008	Treatment of pulmonary infections due to Pseudomonas aeruginosa and other bacteria in patients with cystic fibrosis	Forest Research Institute, Inc.
1444	Levoleucovorin	Fusilev	8/1/1991	For use in conjunction with high-dose methotrexate in the treatment of osteosarcoma.	Spectrum Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1445	levoleucovorin	Fusilev	12/18/1990	For use in combination chemotherapy with the approved agent 5-fluorouracil in the palliative treatment of metastatic adenocarcinoma of the colon and rectum	Spectrum Pharmaceuticals, Inc.
1446	Levomethadyl acetate hydrochloride	Orlaam	1/24/1985	Treatment of heroin addicts suitable for maintenance on opiate agonists.	Biodevelopment Corporation
1447	levothyroxine sodium	n/a	4/26/2011	The preservation of organ function in brain-dead organ donors.	Fera Pharmaceuticals, LLC
1448	L-glutamine	n/a	8/1/2001	Treatment of sickle cell disease	Emmaus Medical, Inc.
1449	L-glutamyl-L-tryptophan	n/a	10/20/1999	Treatment of AIDS-related Kaposi's sarcoma.	Implicit Bioscience Pty Ltd
1450	liarozole	n/a	6/18/2004	Treatment of congenital ichthyosis	Stiefel Laboratories, Inc.
1451	Lidocaine patch 5%	Lidoderm Patch	10/24/1995	For relief of allodynia (painful hypersensitivity), and chronic pain in postherpetic neuralgia.	Teikoku Pharma USA, Inc.
1452	Liothyronine sodium injection	Triostat	7/30/1990	Treatment of myxedema coma/precoma.	SmithKline Beecham Pharmaceuticals
1453	Lipid/DNA human cystic fibrosis gene	n/a	4/8/1996	Treatment of cystic fibrosis.	Genzyme Corporation
1454	liposomal α -galactosylceramide	Lip. Alpha Galactosylceramide	9/28/2012	Prevention of graft-versus-host disease	REGiMMUNE Corporation
1455	liposomal amikacin	Arikace	8/25/2009	Treatment of bronchiectasis in patients with Pseudomonas aeruginosa or other susceptible microbial pathogens	Insmed, Inc.
1456	liposomal amikacin	Arikace	3/25/2013	Treatment infections caused by non-tuberculous mycobacteria	Insmed Incorporated

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1457	Liposomal amphotericin B	Ambisome	12/10/1996	Treatment of histoplasmosis.	Fujisawa USA, Inc.
1458	Liposomal amphotericin B	Ambisome	12/10/1996	Treatment of cryptococcal meningitis.	Fujisawa USA, Inc.
1459	Liposomal amphotericin B	Ambisome	12/6/1996	Treatment of visceral leishmaniasis.	Fujisawa USA, Inc.
1460	Liposomal annamycin	n/a	6/17/2005	Treatment of acute lymphoblastic leukemia	Callisto Pharmaceuticals, Inc.
1461	Liposomal annamycin	n/a	6/17/2005	Treatment of acute myeloid leukemia	Callisto Pharmaceuticals, Inc.
1462	liposomal busulfan	Busulipo	6/24/2013	For use as a conditioning regimen for patients with malignancies undergoing autologous or allogeneic hematopoietic stem cell transplantation	Pharmalink AB
1463	Liposomal ciprofloxacin for inhalation	n/a	4/19/2006	Management of cystic fibrosis	Aradigm Corporation
1464	Liposomal ciprofloxacin for inhalation	n/a	12/27/2006	Management of bronchiectasis	Aradigm Corporation
1465	liposomal ciprofloxacin plus ciprofloxacin	n/a	6/1/2012	For the management of cystic fibrosis	Aradigm Corporation
1466	Liposomal cisplatin	Lipova-Pt	5/23/2006	Treatment of ovarian cancer	Eleison Pharmaceuticals, LLC
1467	Liposomal cyclosporin A	Cyclospire	4/30/1998	For aerosolized administration in the prevention and treatment of lung allograft rejection and pulmonary rejection events associated with bone marrow transplantation.	Vernon Knight, M.D.
1468	liposomal cyclosporine	n/a	5/11/2009	Treatment of bronchiolitis obliterans	PARI Pharma GmbH
1469	liposomal cyclosporine for inhalation	n/a	6/24/2008	Prevention of bronchiolitis obliterans.	PARI Pharma GmbH
1470	Liposomal doxorubicin hydrochloride	Sarcodoxome	12/27/2006	Treatment of soft tissue sarcomas	GP-Pharm SA

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1471	liposomal gadodiamide	n/a	11/12/2008	Treatment of glioma.	MedGenesis Therapeutix, Inc.
1472	Liposomal Glutathione	n/a	4/30/2010	Support of glutathione deficiency in individuals with inborn errors of metabolism of glutathione (IEMG)	Your Energy Systems, LLC
1473	liposomal irinotecan	n/a	7/21/2011	Treatment of pancreatic cancer	Merrimack Pharmaceuticals, Inc.
1474	Liposomal N-Acetylglucosminyl-N-Acetylmuramyl-L-Ala-D-isoGln-L-Ala - glycerolidpalmitoyl	Immther	6/10/1998	Treatment of Ewing's sarcoma.	Endorex Corp.
1475	Liposomal N-Acetylglucosminyl-N-Acetylmuramyl-L-Ala-D-isoGln-L-Ala - glycerolidpalmitoyl	Immther	6/10/1998	Treatment of osteosarcoma.	Endorex Corp.
1476	Liposomal nystatin	Nyotran	6/13/2000	Treatment of invasive fungal infections.	The University of Texas
1477	liposomal p-ethoxy growth receptor bound protein-2 antisense product	n/a	12/5/2003	Treatment of chronic myelogenous leukemia	Bio-Path, Inc.
1478	liposomal topotecan hydrochloride	n/a	10/30/2008	Treatment of gliomas	MedGenesis Therapeutix, Inc.
1479	Liposome encapsulated recombinant interleukin-2	n/a	6/20/1994	Treatment of cancers of the kidney and renal pelvis	Oncothyreon Canada, Inc.
1480	Liposome encapsulated recombinant interleukin-2	n/a	11/25/1991	Treatment of brain and CNS tumors.	Oncothyreon Canada, Inc.
1481	Lisofylline	n/a	6/10/1999	Treatment of patients undergoing induction therapy for acute myeloid leukemia.	Cell Therapeutics, Inc.
1482	listeria monocytogenes	n/a	9/5/2013	Treatment of pancreatic cancer	Aduro BioTech, Inc.
1483	lisuride	n/a	1/17/2013	Treatment of pulmonary arterial hypertension	Sinova Pharma
1484	lithium citrate tetrahydrate (in reverse micelle formulation)	n/a	12/13/2010	Treatment of Huntington's disease.	Medesis Pharma
1485	live attenuated bioengineered Listeria monocytogenes immunotherapy	n/a	5/21/2014	Treatment of osteosarcoma.	Advaxis, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1486	live attenuated bioengineered Listeria monocytogenes immunotherapy	n/a	11/4/2013	Treatment of human papilloma virus-associated head and neck cancer	Advaxis, Inc.
1487	live attenuated E. Coli expressing Beta catenin shRNA	n/a	12/20/2010	Treatment of Familial Adenomatous Polyposis	Marina Biotech
1488	Lodoxamide tromethamine	Alomide Ophthalmic Solution	10/16/1991	Treatment of vernal keratoconjunctivitis.	Alcon Laboratories, Inc.
1489	lomitapide	n/a	3/3/2011	Treatment of Familial Chylomicronemia	Aegerion Pharmaceuticals, Inc.
1490	lomitapide	Juxtapid	10/23/2007	Treatment of homozygous familial hypercholesterolemia	Aegerion Pharmaceuticals, Inc.
1491	Lonafarnib	n/a	11/19/2013	Treatment of Hepatitis Delta Virus (HDV)infection	Eiger Biopharmaceuticals, Inc.
1492	lonafarnib	n/a	4/18/2011	Treatment of Hutchinson-Gilford progeria syndrome	The Progeria Research Foundation, Inc.
1493	long acting recombinantFactor VIIa-CTP3	n/a	2/27/2014	Treatment and prophylaxis of bleeding episodes in patietns with hemophilia A or B with inhibitors to factor VIII or factor IX	PROLOR Biotech, Ltd
1494	L-ornithine phenylacetate	n/a	4/7/2010	Treatment of hyperammonemia and resultant hepatic encephalopathy (HE) in patients with acute liver failure or acute on chronic liver disease	Ocera Therapeutics, Inc.
1495	losartan	n/a	12/12/2011	Treatment of Marfan Syndrome	National Marfan Foundation
1496	low molecular weight dextran sulfate	lbsolvmir(R)	7/6/2011	Treatment to mobilze progenitor cells prior to stem cell transplantation	TikoMed AB

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1497	low molecular weight dextran sulfate	Ibsolvmir	10/20/2009	Prevention of graft rejection during pancreatic islet transplantation	TikoMed AB
1498	L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser	n/a	9/13/2011	Treatment of neuropathic pain in patients with sarcoidosis.	Araim Pharmaceuticals, Inc.
1499	L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser	n/a	9/18/2009	Prevention of delayed graft function following renal transplant	Araim Pharmaceuticals, Inc.
1500	L-threonyl-L-prolyl-L-prolyl-L-threonine	n/a	4/26/2005	Treatment of neuropathic pain associated with spinal cord injury	Nyxis Neurotherapies, Inc.
1501	L-tyrosine-L-serine-L-leucine	Cms-024	9/10/2004	Treatment of hepatocellular carcinoma.	CMS Peptides Patent Holding Company Limited
1502	Lucinactant	Surfaxin(R), Aerosurf(R)	10/21/2010	Treatment of cystic fibrosis.	Discovery Laboratories, Inc.
1503	Lucinactant	Surfaxin	7/17/1995	Treatment of acute respiratory distress syndrome in adults.	Discovery Laboratories, Inc.
1504	Lucinactant	Surfaxin	10/18/1995	Treatment of respiratory distress syndrome in premature infants.	Discovery Laboratories, Inc.
1505	Lucinactant	Surfaxin	10/21/2005	Treatment of bronchopulmonary dysplasia in premature infants.	Discovery Laboratories, Inc.
1506	Lucinactant	Surfaxin	5/23/2006	Prevention of bronchopulmonary dysplasia in premature infants	Discovery Laboratories, Inc.
1507	Iurbinectedin	n/a	8/20/2012	Treatment of ovarian cancer	Pharma Mar USA Inc.
1508	lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase	n/a	9/10/2008	Treatment of mucopolysaccharidosis Type IVA (Morquio Syndrome)	Vivendy Therapeutics LTD
1509	lyso-thermosensitive liposomal doxorubicin	Thermodox (R)	3/17/2009	Treatment of hepatocellular carcinoma	Celsion Corporation

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1510	MA09-hRPE cells	n/a	2/2/2010	Treatment of Stargardt's macular dystrophy.	Advanced Cell Technology, Inc.
1511	macitentan	Opsumit	9/3/2009	Treatment of pulmonary arterial hypertension	Actelion Pharmaceuticals Ltd
1512	Mafenide acetate solution	Sulfamylon Solution	7/18/1990	For use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.	Mylan Laboratories, Inc.
1513	Mafosfamide	n/a	1/21/2003	Treatment of neoplastic meningitis	Baxter Healthcare Corporation
1514	MAGE-A3 cancer therapeutic Trojan peptide vaccine	n/a	11/24/2008	Treatment of MAGE-A3 expressing head and neck squamous cell carcinoma	Gliknik, Inc.
1515	manganese (II) chloride tetrahydrate (with L-alanine and vitamin D3 as promoters of absorption)	n/a	9/26/2013	Use as a targeted contrast agent for diagnostic MRI for the detection and localization of focal liver lesions in patients where gadolinium based contrast agents are contraindicated or cannot be administered	CMC Contrast AB
1516	Manganese superoxide dismutase mimetic	n/a	2/27/2008	Prevention of radiation- or chemotherapy-induced oral mucositis in cancer patients	Galera Therapeutics, LLC
1517	Mannitol	Bronchitol	2/11/2005	For use to facilitate clearance of mucus in patients with bronchiectasis and in patients with cystic fibrosis at risk for bronchiectasis	Pharmaxis Ltd.
1518	mannopentaose phosphate sulfate	n/a	4/27/2004	Treatment of high-risk Stage II, Stage III, and Stage IV melanoma	Medigen Biotechnology Corp.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1519	maribavir	n/a	2/1/2007	Prevention of cytomegalovirus viremia and disease in the populations at risk.	Shire ViroPharma, Inc.
1520	maribavir	n/a	6/7/2011	Treatment of clinically significant cytomegalovirus viremia and disease in at-risk patients.	ViroPharma, Inc.
1521	Marijuana	n/a	5/25/1999	Treatment of HIV-associated wasting syndrome.	Multidisciplinary Association for Psychedelic Studies, Inc.
1522	Marizomib	n/a	12/13/2013	Treatment of multiple myeloma	Triphase Research and Development I Corp.
1523	masitinib	n/a	7/21/2009	Treatment of patients with pancreatic cancer	AB Science
1524	masitinib	n/a	4/20/2005	Treatment of malignant gastrointestinal stromal tumors	AB Science
1525	Matrix metalloproteinase inhibitor	Galardin	12/5/1991	Treatment of corneal ulcers.	Glycomed, Inc
1526	MaxAdFVIII	n/a	3/3/2003	Treatment of Hemophilia A	GenStar Therapeutics Corporation
1527	Maytansinoid DM-1 Conjugated Humanized Monoclonal Antibody N901	n/a	8/17/2010	Treatment of small cell lung cancer.	ImmunoGen, Inc.
1528	maytansinoid DM1-conjugated humanized monoclonal antibody N901	n/a	3/2/2010	Treatment of Merkel cell carcinoma	ImmunoGen, Inc.
1529	maytansinoid DM1-conjugated humanized monoclonal antibody N901	n/a	11/29/2010	Treatment of multiple myeloma.	ImmunoGen, Inc.
1530	Mazindol	Sanorex	12/8/1986	Treatment of Duchenne muscular dystrophy.	Collipp, Platon J. M.D.
1531	MCMV5322A/MCMV3068A	n/a	11/22/2011	Prevention of maternal-fetal transmission of congenital CMV in pregnant women who acquire CMV infection during pregnancy	Genentech

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1532	Mecamylamine	Inversine	10/14/1998	Treatment of Tourette's syndrome.	Targacept, Inc.
1533	mecasermin	Iplex	12/3/2007	Treatment of myotonic dystrophy	Insmed, Inc.
1534	Mecasermin	Increlex	12/12/1995	Treatment of growth hormone insensitivity syndrome.	Ipsen Biopharmaceuticals, Inc.
1535	mecasermin rinfabate	Iplex	7/23/2012	Treatment of amyotrophic lateral sclerosis	PCUT BioPartners, Inc.
1536	mecasermin rinfabate	n/a	9/20/2012	Prevention of retinopathy of prematurity in premature infants born at risk for the disease	Premacure AB
1537	mecasermin rinfabate	Iplex	5/17/2002	Treatment of growth hormone insensitivity syndrome (GHIS)	Insmed, Inc.
1538	meclorethamine	Valchlor	8/17/2004	Treatment of mycosis fungoides	Actelion Pharmaceuticals Ltd.
1539	Medroxyprogesterone acetate	Hematrol	2/22/2001	Treatment of immune thrombocytopenic purpura.	ZaBeCor Pharmaceutical Company, LLC
1540	Mefloquine HCl	Mephaquin	7/22/1987	Prevention of chloroquine-resistant Falciparum malaria.	Mepha AG
1541	Mefloquine HCl	Mephaquin	7/22/1987	Treatment of chloroquine-resistant Falciparummalaria.	Mepha AG
1542	mefloquine HCL	Lariam	4/13/1988	For use in the treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax, and for the prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs	Hoffmann-La Roche, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1543	Megestrol acetate	Megace	4/13/1988	Treatment of patients with anorexia, cachexia, or significant weight loss (\geq 10% of baseline body weight) and confirmed diagnosis of AIDS.	Bristol-Myers Squibb Pharmaceutical Research Institute
1544	Melanoma autologous dendritic cell vaccine	n/a	9/6/2006	Treatment of stage IIIb through IV metastatic melanoma	California Stem Cell, Inc.
1545	Melanoma cell vaccine	Canvaxin	10/13/1994	Treatment of invasive melanoma.	CancerVax Corporation
1546	Melanoma peptide vaccine	n/a	3/29/2005	Treatment of HLA-A2+ patients with stage IIB, IIC, III, and IV malignant melanoma	Bristol-Myers Squibb Research Inst
1547	Melanoma vaccine	Melacine	12/20/1989	Treatment of stage III - IV melanoma.	Ribi ImmunoChem Research, Inc.
1548	melarsoprol-hydroxypropylbetadex	n/a	9/13/2013	Treatment of human African trypanosomiasis (sleeping sickness)	Peter Kennedy, CBE, MD, PhD, DSc, FRCP FMedSci,
1549	Melatonin	Circadin	7/9/2004	Treatment of non-24-hour sleep-wake disorder in blind individuals without light perception	Neurim Pharmaceuticals, Ltd.
1550	Melatonin	n/a	11/15/1993	Treatment of circadian rhythm sleep disorders in blind people with no light perception.	Sack, Robert, M.D.
1551	melatonin	n/a	4/12/2013	Treatment of neonatal hypoxic ischemic encephalopathy	Scharper S.p.A.
1552	meloxicam	Mobic	11/22/2002	Treatment of juvenile rheumatoid arthritis	Boehringer Ingelheim Pharmaceuticals, Inc.
1553	melphalan	n/a	11/19/2012	Treatment of retinoblastoma	Icon Bioscience, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1554	melphalan	n/a	11/24/2008	High dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation	Spectrum Pharmaceuticals, INC.
1555	melphalan	n/a	11/19/2012	Treatment of Stage IIB through IV melanoma	OncoTx, LLC
1556	Melphalan	Alkeran For Injection	2/24/1992	Treatment of patients with multiple myeloma for whom oral therapy is inappropriate.	Glaxo Wellcome Inc.
1557	melphalan hydrochloride	n/a	5/22/2009	Treatment of neuroendocrine tumors	Delcath Systems, Inc.
1558	melphalan hydrochloride	n/a	11/12/2008	Treatment of patients with ocular (uveal) melanoma.	Delcath Systems, Inc.
1559	melphalan hydrochloride	n/a	11/12/2008	Treatment of patients with cutaneous melanoma.	Delcath Systems, Inc.
1560	melphalan hydrochloride	n/a	9/26/2013	Treatment of patients with hepatocellular carcinoma	Delcath Systems, Inc.
1561	Menadione Sodium Bisulfite	n/a	5/14/2014	For the treatment of autosomal dominant polycystic kidney disease	IC-MedTech Corporation
1562	menadione sodium bisulfite	n/a	5/14/2014	Treatment of autosomal dominant polycystic liver disease	IC-MedTech Corporation
1563	menaquinone	Menaquinonegold	9/4/2012	Treatment of calciphylaxis	Nu Science Trading, LLC
1564	menatetrenone	Mk4(R)	11/2/2010	Treatment of hepatocellular carcinoma (HCC).	NBI Pharmaceuticals, Inc.
1565	menatetrenone	Mk4(R)	11/2/2010	Treatment of acute promyelocytic leukemia.	NBI Pharmaceuticals, Inc.
1566	menatetrenone	Mk4(R)	2/4/2011	Treatment of myelodysplastic syndrome.	NBI Pharmaceuticals, Inc.
1567	menatetrenone	Mk4	3/17/2011	Treatment of acute myeloid leukemia	NBI Pharmaceuticals, Inc.
1568	menatetrenone and Vitamin D3	n/a	8/22/2011	Treatment of myelodysplastic syndrome	NBI Pharmaceuticals, Inc.
1569	Mepivacaine	n/a	10/18/2006	Treatment of painful HIV-associated neuropathy	Cinergen

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1570	mepivacaine	n/a	1/8/2007	Treatment of postherpetic neuralgia	Cinergen, LLC
1571	mepolizumab	n/a	7/14/2011	Treatment of Churg-Strauss Syndrome.	GlaxoSmithKline LLC
1572	mepolizumab	n/a	5/28/2004	For first-line treatment in patients with hypereosinophilic syndrome	GlaxoSmithKline LLC
1573	mercaptopurine oral solution	Purixan	8/20/2012	Treatment of acute lymphoblastic leukemia in pediatric patients	Nova Laboratories Limited
1574	mesalamine	Canasa	1/19/2010	Treatment of pediatric ulcerative colitis	Aptalis Pharma US, Inc.
1575	mesalamine and N-acetylcysteine	n/a	9/10/2009	Treatment of pediatric patients with ulcerative colitis (inclusive through age 16 years)	Altheus Therapeutics, Inc.
1576	mesalamine; 5-aminosalicylic acid	Lialda	2/27/2008	Treatment of ulcerative colitis in pediatric patients (revised indication 10/21/2010).	Shire
1577	mesenchymal stromal cells secreting neurotrophic factors	Nurown	2/4/2011	Treatment of Amyotrophic Lateral Sclerosis	BrainStorm Cell Therapeutics Ltd.
1578	Mesna	Mesnex	11/14/1985	For use as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.	Degussa Corporation
1579	metadoxine	n/a	12/16/2013	Treatment of Fragile X Syndrome	Alcobra, Inc.
1580	met-enkephalin; Met-N	n/a	2/18/2011	Treatment of pancreatic cancer.	NBI Pharmaceuticals, Inc.
1581	Methionine/L-methionine	n/a	8/21/1996	Treatment of AIDS myelopathy.	Genopia USA, Inc.
1582	methotrexate	n/a	8/20/2009	Treatment of acute lymphoblastic leukemia	Orbona Pharma Ltd
1583	Methotrexate sodium	Methotrexate	10/21/1985	Treatment of osteogenic sarcoma.	Lederle Laboratories

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1584	Methotrexate with laurocapram	Methotrexate/Azone	10/15/1990	Topical treatment of mycosis fungoides.	Echo Therapeutics, Ltd.
1585	Methoxsalen	Uvadex(R)	10/14/1998	For use in conjunction with the UVAR photopheresis system to treat graft versus host disease.	Therakos, Inc.
1586	Methyl O-4-O-[2-[2-[2-[N-[(1R)-1-[[4-(aminoiminomethyl)phenyl]methyl]-2-oxo-2-(1-piperidinyl)ethyl]-N2-[[4-methoxy-2,3,6-trimethylphenyl)sulfonyl]-L-Asparaginyl-4-aminobutanoyl-N6-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[n/a	4/18/2011	Prevention of ischemia reperfusion injury associated with solid organ transplantation	Endotis Pharma
1587	methylene blue	n/a	7/24/2012	Treatment of methemoglobinemia	Fera Pharmaceuticals, LLC
1588	methylene blue injection	n/a	8/11/2012	Treatment of congenital and acquired methemoglobinemia	Luitpold Pharmaceuticals, Inc.
1589	methylene blue 0.5%	n/a	12/18/2012	Treatment of hereditary and acquired methemoglobinemia	Provepharm SAS
1590	methylparaben suberohydroxamic acid phenyl ester	n/a	4/15/2013	Treatment of cutaneous T-cell lymphoma	Shape Pharmaceuticals, Inc.
1591	metreleptin	n/a	8/22/2001	Treatment of leptin deficiency secondary to generalized lipodystrophy and partial familial lipodystrophy	Amylin Pharmaceuticals LLC
1592	metreleptin	Myalept	8/22/2001	Treatment of metabolic disorders secondary to lipodystrophy	Amylin Pharmaceuticals, LLC
1593	Metronidazole	Metrogel	10/24/1991	Treatment of perioral dermatitis.	Galderma Laboratories, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1594	metronidazole	n/a	4/26/2011	Treatment of pouchitis.	S.L.A. Pharma Limited (UK)
1595	metronidazole	n/a	9/17/2008	Treatment of pouchitis	Formac Pharmaceuticals, NV
1596	Metronidazole (topical)	Metrogel	10/22/1987	Treatment of acne rosacea.	Galderma Laboratories, Inc.
1597	Metronidazole 10% ointment	n/a	11/8/2007	Topical treatment of active perianal Crohn's disease	SLA Pharma (UK) Ltd
1598	metyrapone	n/a	9/25/2012	Treatment of Cushing's syndrome	Laboratoire HRA Pharma
1599	metyrosine	Demser	7/25/2008	Treatment of velocardiofacial syndrome associated psychosis.	Cerberus Princeton, LLC
1600	mexiletine	n/a	9/2/2010	Treatment of nondystrophic myotonia	University of Rochester Medical Center
1601	mibefradil	n/a	8/25/2009	Treatment of glioblastoma multiforme.	Tau Therapeutics, LLC
1602	mibefradil	n/a	10/16/2008	Treatment of pancreatic cancer.	Tau Therapeutics, LLC
1603	mibefradil	n/a	6/15/2007	Treatment of ovarian cancer	Tau Therapeutics, LLC
1604	Microbubble contrast agent	Filmix Neurosonographic Contrast Agent	11/16/1990	Intraoperative aid in the identification and localization of intracranial tumors.	Cav-Con, Inc.
1605	Microvesiculated modified glycosylated tissue factor	n/a	1/25/2007	Treatment of non-life threatening, mild to severe bleeding episodes due to cutaneous injuries or dental procedures in hemophiliac patients	Thrombotargets Corp.
1606	Microvesiculated modified glycosylated tissue factor	n/a	10/11/2007	Treatment of non-life threatening, mild to severe bleeding episodes due to cutaneous injuries or dental procedures in patients with von Willebrand disease.	Thrombotargets Corp.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1607	midazolam	n/a	10/20/2009	Rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity (e.g. acute repetitive seizures, seizure clusters)	Upsher-Smith Laboratories, Inc.
1608	midazolam	n/a	7/24/2012	Treatment of nerve agent-induced seizures	Meridian Medical Technologies, Inc.
1609	midazolam	n/a	5/8/2006	Treatment of bouts of increased seizure activity in selected refractory patients with epilepsy who are on stable regimens of anti-epileptic drugs and who require intermittent use of midazolam	UCB, Inc
1610	Midodrine HCl	Amatine	6/21/1985	Treatment of patients with symptomatic orthostatic hypotension.	Schier Ridgewood F.K.A. (Roberts Pharmaceutical Corp.)
1611	Midostaurin	Rydapt	4/30/2010	Treatment of mastocytosis	Novartis Oncology
1612	Midostaurin	n/a	7/7/2009	Treatment of acute myeloid leukemia	Novartis Pharmaceuticals Corporation
1613	mifamuritide	Junovan	6/5/2001	Treatment of osteosarcoma	Millennium Pharmaceuticals, Inc.
1614	Mifepristone	n/a	2/7/2005	Treatment of Cushing's syndrome secondary to ectopic ACTH secretion	HRA Pharma
1615	mifepristone	Korlym	7/5/2007	Treatment of the clinical manifestations of endogenous Cushing's syndrome	Corcept Therapeutics, Inc.
1616	migalastat hydrochloride	n/a	2/25/2004	Treatment of Fabry Disease	Amicus Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1617	miglustat	Zavesca (R)	11/12/2008	Treatment of the neurological manifestations of Niemann-Pick disease, type C.	Actelion Pharmaceuticals Ltd
1618	miglustat	Zavesca	5/29/1998	Treatment of Gaucher disease.	Actelion Pharmaceuticals Ltd
1619	milatuzumab	n/a	3/10/2008	Treatment of multiple myeloma	Immunomedics, Inc.
1620	milatuzumab	n/a	6/24/2008	Treatment of chronic lymphocytic leukemia.	Immunomedics, Inc.
1621	milciclib maleate	n/a	9/20/2012	Treatment of thymic epithelial tumors.	Nerviano Medical Sciences S.r.l.
1622	miltefosine	Miltex/Impavido	3/18/2009	Topical treatment of cutaneous lymphoma encompassing cutaneous manifestations of T-cell lymphoma and B-cell lymphoma	ExperGen Drug Development GmbH
1623	miltefosine	Impavido	10/10/2006	Treatment of leishmaniasis.	Paladin Therapeutics, Inc.
1624	Minnelide	Minnelide (Tm)	2/18/2013	Treatment of pancreatic cancer	Minneamrita Therapeutics, LLC
1625	Minocycline hydrochloride	n/a	3/28/2006	Treatment of sarcoidosis	Autoimmunity Research Foundation
1626	mipomersen	Kynamro	5/23/2006	Treatment of homozygous familial hypercholesterolemia	Genzyme Corporation
1627	misoprostol	Gymiso	1/10/2005	Treatment of intrauterine fetal death not accompanied by complete expulsion of the products of conception in the second and third trimesters of pregnancy.	Gynuity Health Projects, LLC

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1628	Mitoguazone	Apep	3/18/1994	Treatment of diffuse non-Hodgkin's lymphoma, including AIDS-related diffuse non-Hodgkin's lymphoma.	ILEX Oncology, Inc.
1629	Mitolactol	n/a	1/23/1989	Treatment of invasive carcinoma of the uterine cervix	Targent, Inc..
1630	Mitolactol	n/a	7/12/1995	As adjuvant therapy in the treatment of primary brain tumors.	Targent, INC.
1631	mitomycin	n/a	6/1/2011	Prevention of corneal sub-epithelial haze formation following surface ablation laser keratectomy	Mobius Therapeutics, LLC
1632	mitomycin	n/a	1/13/2011	Prevention of recurrence of pterygium after its surgical excision.	Mobius Therapeutics, LLC
1633	Mitomycin-C	n/a	8/20/1993	Treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.	IOP Inc.
1634	mitomycin-C	Mitosol	1/8/2008	Treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.	Mobius Therapeutics, LLC
1635	Mitoxantrone	Novantrone	8/21/1996	Treatment of hormone refractory prostate cancer.	Serono
1636	Mitoxantrone	Novantrone	8/13/1999	Treatment of secondary-progressive multiple sclerosis.	Serono, Inc.
1637	Mitoxantrone	Novantrone	8/13/1999	Treatment of progressive-relapsing multiple sclerosis.	Serono, Inc.
1638	Mitoxantrone HCl	Novantrone	7/13/1987	Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.	Lederle Laboratories

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1639	MLN4924-Inhibitor of Nedd8-activating enzyme (NAE)	n/a	2/4/2011	Treatment of acute myelogenous leukemia.	Millennium Pharmaceuticals
1640	MLN4924-Inhibitor of Nedd8-activating enzyme (NAE)	n/a	2/4/2011	Treatment of Myelodysplastic syndrome	Millennium Pharmaceuticals, Inc.
1641	MN14 monoclonal antibody to carcinoembryonic antigen	Cea-Cide	9/18/1998	Treatment of small cell lung cancer	Immunomedics, Inc.
1642	MN14 monoclonal antibody to carcinoembryonic antigen	Cea-Cide	11/24/1998	Treatment of pancreatic cancer.	Immunomedics, Inc.
1643	MOD-423 hGH analogue	n/a	9/29/2010	Treatment of growth hormone deficiency.	PROLOR-Biotech, Ltd.
1644	Modafinil	Provigil	3/15/1993	Treatment of excessive daytime sleepiness in narcolepsy.	Cephalon, Inc.
1645	modified recombinant human C-type natriuretic peptide (CNP)	n/a	1/17/2013	Treatment of achondroplasia	BioMarin Pharmaceutical, Inc.
1646	modified recombinant human Factor VIIa (rFVIIa) molecule	n/a	5/30/2013	Treatment of bleeding episodes in hemophilia A or B subjects with inhibitors	Bayer HealthCare Pharmaceuticals, Inc.
1647	modified recombinant mitochondrial transcription factor A (TFAM) containing the mitochondrial transduction domain	n/a	8/20/2012	Treatment of inherited mitochondrial respiratory chain disease	Gencia Corporation
1648	mogamulizumab	n/a	11/2/2010	Treatment of patients with cutaneous T-cell lymphoma.	Kyowa Kakko Kirin Pharma, Inc.
1649	mogamulizumab	n/a	11/2/2010	Treatment of peripheral T-cell lymphoma.	Kyowa Hakko Kirin Pharma, Inc.
1650	mogamulizumab	n/a	7/14/2011	Treatment of adult T-cell leukemia/lymphoma (ATLL).	Kyowa Hakko Kirin Pharma, Inc.
1651	monarsen	n/a	11/14/2003	Treatment of myasthenia gravis	Bioline Rx, Ltd.
1652	monoclonal antibody	n/a	1/21/2011	Prevention of congenital cytomegalovirus (CMV)infection following primary CMV infection in pregnant women.	Theraclone Sciences
1653	monoclonal antibody 11-1F4	n/a	12/7/2009	For use as a radioimaging agent in amyloidosis	Alan Solomon, M.D.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1654	monoclonal antibody 11-1F4	n/a	12/11/2009	For use as a therapeutic agent for patients AL amyloidosis.	Alan Solomon, M.D.
1655	monoclonal antibody 3F8	n/a	10/16/2008	Treatment of neuroblastoma	United Therapeutics Corporation
1656	monoclonal antibody directed at hepatitis C virus E2 glycoprotein	n/a	11/4/2013	Prevention of Hepatitis C recurrence in patients receiving liver transplantation	MassBiologics-University of MA Medical School
1657	Monoclonal antibody for immunization against lupus nephritis	n/a	1/7/1993	Treatment of lupus nephritis.	VivoRx Autoimmune, Inc.
1658	monoclonal antibody Hu3F8	n/a	1/10/2014	Treatment of osteosarcoma	Memorial Sloan-Kettering Cancer Center
1659	Monoclonal antibody-B43.13	Ovarex Mab-B43.13	11/25/1996	Treatment of epithelial ovarian cancer.	Quest PharmaTech, Inc.
1660	Monolaurin	Glylorin	4/29/1993	Treatment of congenital primary ichthyosis.	Glaxo Wellcome Inc.
1661	Monooctanoin	Moctanin	5/30/1984	For dissolution of cholesterol gallstones retained in the common bile duct.	Ethitek Pharmaceuticals, Inc.
1662	Morphine sulfate concentrate (preservative free)	Infumorph	7/12/1990	For use in microinfusion devices for intraspinal administration in the treatment of intractable chronic pain.	Elkins-Sinn, Inc.
1663	motexafin gadolinium	Xcytrin	1/27/2003	For use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors	Pharmacyclics, Inc.
1664	mouse-human chimeric monoclonal anti-GD2 IgG1 antibody	n/a	9/20/2012	Treatment of neuroblastoma.	APEIRON Biologics AG
1665	moxetumomab pasudotox	n/a	11/15/2007	Treatment of hairy cell leukemia	MedImmune, LLC

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1666	moxetumomab pasudotox	n/a	6/28/2013	Treatment of acute lymphoblastic leukemia	MedImmune, LLC
1667	moxetumomab pasudotox	n/a	11/15/2007	Treatment of CD22-positive chronic lymphocytic leukemia	MedImmune, LLC
1668	moxidectin	n/a	9/29/2010	Treatment of onchocerciasis volvulus in children and adults.	World Health Organization (WHO)
1669	mPEG-r-crisantaspase	Asparec(Tm)	2/1/2010	Treatment of acute lymphoblastic leukemia.	Jazz Pharmaceuticals, Inc.
1670	MTC-DOX for Injection	n/a	1/3/2001	Treatment of hepatocellular carcinoma	FeRx Incorporated
1671	mTOR kinase inhibitor (CC-223)	n/a	10/16/2013	Treatment of hepatocellular carcinoma	Celgene Corporation
1672	Multi-ligand somatostatin analog	n/a	7/27/2004	Treatment of patients with functional gastroenteropancreatic (GEP) neuroendocrine tumors (specifically, carcinoid, insulinoma, gastrinoma, somastatinoma, GRFoma, VIPoma and glucagonoma.	Novartis Pharmaceuticals Corporation
1673	Multi-peptide cancer vaccine	n/a	6/23/2013	Treatment of multiple myeloma	OncoPep, Inc.
1674	Multistem(r)	n/a	9/15/2010	Prophylaxis of graft vs host disease	Athersys, Inc.
1675	Multi-vitamin infusion (neonatal formula)	n/a	12/12/1989	For establishment and maintenance of total parenteral nutrition in very low birth weight infants.	Astra Pharmaceuticals, L.P.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1676	multi-vitiam infusion without vitamin K	M.V.I.-12	3/8/2004	Prevention of vitamin deficiency and thromboembolic complications in people receiving home parenteral nutrition and warfarin-type anticoagulant therapy	Mayne Pharma (USA) Inc.
1677	Murine MAb (Lym-1) and Iodine 131-I radiolabeled murine MAb (Lym-1) to human B-cell lymphoma	Oncolym	11/27/1998	Treatment of B-cell non-Hodgkin's lymphoma.	Peregrine Pharmaceuticals, Inc.
1678	Murine MAb to polymorphic epithelial mucin, human milk fat globule 1	Theragyn	3/22/1999	Adjuvant treatment of ovarian cancer.	Antisoma plc
1679	murine monoclonal antibody against CD26	Begedina	2/18/2011	Treatment of graft versus host disease	Adienne S.r.l.
1680	Mx-dnG1	Rexin-G(R)	6/24/2008	Treatment of soft tissue sarcoma	Epeius Biotechnologies Corporation
1681	Mx-dnG1	Rexin-G	6/24/2008	Treatment of osteosarcoma.	Epeius Biotechnologies Corporation
1682	Mx-dnG1 or Rexin-G retroviral vector	Rexin-G	8/15/2003	Treatment of pancreatic cancer	Epeius Biotechnologies Corporation
1683	Mycobacterium avium sensitin RS-10	n/a	10/11/1995	For use in the diagnosis of invasive Mycobacterium avium disease in immunocompetent individuals.	Statens Seruminstitut
1684	mycobacterium vaccae	n/a	8/20/2010	Treatment of tuberculosis	Immodulon Therapeutics Ltd
1685	mycobacterium vaccae	n/a	8/6/2010	Treatment of pancreatic cancer	Immodulon Therapeutics Ltd.
1686	myo-inositol	n/a	4/7/2005	Prevention of retinopathy of prematurity in preterm infants at risk for developing retinopathy of prematurity	Abbott Nutrition
1687	N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide dihydrobromide	n/a	8/8/2007	Treatment of Hodgkin's lymphoma	MethylGene, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1688	N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide dihydrobromide	n/a	2/1/2008	Treatment of acute myeloid leukemia	MethylGene
1689	N-(3-fluorobenzyl)-2-(5-(4-morpholinophenyl)pyridin-2-yl) Acetamide Besylate	n/a	11/26/2013	Treatment of gliomas	Kinex Pharmaceuticals, Inc.
1690	N-(4-Fluoro-benzoyl)-L-arginyl-L-arginyl-[L-3-(naphthyl-alanyl)-L-cysteinyl-L-tyrosyl-L-citrullinyl-L-lysyl-D-lysyl-L-prolyl-L-trosyl-L-arginyl-L-citrullinyl-L-cysteinyl-L-arginine amide, cyclic (4-13)-disulfide	n/a	7/6/2012	For use in combination with G-CSF to mobilize HSCs from the marrow to peripheral blood for collection for autologous or allogeneic transplantation	BioLineRx, Ltd.
1691	N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-(morpholin-4-yl)ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride salt	n/a	3/18/2009	Treatment of acute myeloid leukemia	Ambit Biosciences Corporation
1692	N-(cyanomethyl)-4-(2-[[4-(morpholin-4-yl(phenyl)amino}pyrimidin-4-yl)benzamide	n/a	8/5/2010	Treatment of myelofibrosis	Gilead Sciences, Inc.
1693	N-(methyl-diazacyclohexyl-methylbenzamide)-azaphenyl-aminothiopyrrole) mesylate	n/a	10/17/2005	Treatment of multiple myeloma.	AB Science
1694	N,N'-bis(2-mercaptoethyl)isophthalamide (NBMI)	n/a	4/6/2012	Treatment of mercury toxicity	CTI Science, Inc.
1695	N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino] isonicotinamide hydrochloride	n/a	1/12/2011	Treatment of acute myeloid leukemia (AML).	EMD Serono, Inc.
1696	N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino] isonicotinamide hydrochloride	n/a	1/29/2010	Treatment of pancreatic cancer	EMD Serono, Inc.
1697	N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide	n/a	9/30/2004	Treatment of neuroblastoma	AbbVie, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1698	N-[3-(4',5'-bipyrimidin-2-ylamino)-4-methylphenyl]-4-[[[(3S)-3-(dimethylamino)pyrrolidin-1-yl]methyl]-3-(trifluoromethyl)benzamide	n/a	12/27/2006	Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia.	CytRx Corporation
1699	N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-methylphenyl) urea	n/a	10/23/2007	Treatment of acute myelogenous leukemia	AbbVie, Inc.
1700	N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-methylphenyl)urea	n/a	5/23/2007	Treatment of hepatocellular carcinoma	AbbVie, Inc.
1701	N-[4-(trifluoromethyl)phenyl] 5 methylisoxazole-4-carboxamide	n/a	5/25/1995	Treatment of malignant glioma.	Sugen, Inc.
1702	N-[4-(trifluoromethyl)phenyl]-5-methylisoxazole-4-carboxamide	n/a	3/12/1996	Treatment of ovarian cancer.	Sugen, Inc.
1703	N-[[[(5S)-3-(3-fluoro-4-thiomorpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide	n/a	2/4/2011	Treatment of tuberculosis.	Sequella, Inc.
1704	N-{3-[(2-{[4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl]amino}-5-(trifluoromethyl)pyrimidin-4-yl)amino]phenyl}prop-2-enamide	n/a	5/14/2013	Treatment of non-small cell lung cancer and mutations in the epidermal growth factor receptor	Clovis Oncology, Inc.
1705	N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-Maytansine-Conjugated Humanized C242 Monoclonal Antibody	n/a	12/7/2000	For pancreatic cancer	SmithKline Beecham Pharmaceuticals
1706	N2'-Deacetyl-N2'-[4-methyl-4-(oxobuthyldithio)-1-oxopentyl]-maytansine-chimerized anti-CD138 IgG4 Monoclonal Antibody	n/a	2/27/2008	Treatment of multiple myeloma	Biotest Pharmaceuticals Corporation
1707	nabumetone	n/a	5/5/2008	Treatment of pediatric juvenile rheumatoid arthritis	Cook Pharma
1708	N-acetyl cysteine amide	n/a	12/31/2013	Treatment of retinitis pigmentosa	Brighton Biotech, Inc.
1709	N-acetylcysteinate Lysine	Nacystelyn Dry Powder Inhaler	12/27/2000	For the management of cystic fibrosis	Galephar Pharmaceutical Research, Inc.
1710	N-acetylcysteine	n/a	9/9/2002	Treatment of acute liver failure	Cumberland Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1711	N-acetylcysteine	n/a	7/19/2012	Prevention of ototoxicity caused by platinum-based chemotherapeutic agents used to treat pediatric cancers	Edward A. Neuwelt, MD
1712	N-acetylgalactosamine-4-sulfatase, recombinant human	Naglazyme	2/17/1999	Treatment of mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome).	BioMarin Pharmaceutical, Inc.
1713	N-acetyl-glucosamine thiazoline	n/a	2/6/2006	Treatment of adult Tay-Sachs disease	ExSAR Corporation
1714	N-Acetylmannosamine (ManNAc)	n/a	4/5/2010	Treatment of hereditary inclusion body myopathy type 2	New Zealand Pharmaceuticals Ltd
1715	N-acetyl-procainamide	n/a	12/10/1996	Prevention of life-threatening ventricular arrhythmias in patients with documented procainamide-induced lupus.	NAPA of the Bahamas
1716	N-adamantanyl-N'-Geranyl-ethylenediamine	n/a	10/16/2007	Treatment of tuberculosis.	Sequella, Inc.
1717	Nafarelin acetate	Synarel Nasal Solution	7/20/1988	Treatment of central precocious puberty.	Syntex (USA), Inc.
1718	naloxone	n/a	11/23/2010	Topical treatment of pruritus associated with mycosis fungoides	Elorac, Inc.
1719	naltrexone	n/a	1/19/2010	Treatment of Crohn's disease in pediatric patients	TNI BioTech, Inc.
1720	Naltrexone HCl	Trexan	3/11/1985	For blockade of the pharmacological effects of exogenously administered opioids as an adjunct to the maintenance of the opioid-free state in detoxified formerly opioid-dependent individuals.	DuPont Pharmaceuticals

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1721	naltrexone/clonidine combination	n/a	4/14/2014	Treatment of postherpetic neuralgia	Allodynic Therapeutics LLC
1722	NanoDTPA(tm)	n/a	6/17/2011	Treatment of known or suspected cases of internal contamination with plutonium, americium, or curium	Nanotherapeutics, Inc.
1723	Natural human lymphoblastoid interferon-alpha	n/a	1/18/2000	Treatment of Behcet's disease	Amarillo Biosciences, Inc.
1724	Natural human lymphoblastoid interferon-alpha	n/a	8/10/2000	Treatment of papillomavirus warts in the oral cavity of HIV positive patients.	Amarillo Biosciences, Inc.
1725	natural human lymphoblastoid interferon-alpha	n/a	11/18/2002	Treatment of polycythemia vera	Amarillo Biosciences, Inc.
1726	NDX-peptides	n/a	12/14/2010	Treatment of amyotrophic lateral sclerosis	NeoDiagnostic Research Ltd
1727	Nebacumab	Centoxin	10/1/1986	Treatment of patients with gram-negative bacteremia which has progressed to endotoxin shock.	Centocor, Inc.
1728	nelarabine	n/a	9/2/1999	Treatment of chronic lymphocytic leukemia.	GlaxoSmithKline LLC
1729	nelarabine	Arranon	8/10/2004	Treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma	GlaxoSmithKline LLC
1730	neostigmine	n/a	3/18/2013	Treatment of acute colonic pseudo-obstruction	Luitpold Pharmaceuticals, Inc.
1731	neostigmine methylsulfate	n/a	2/17/2012	Treatment of Myasthenia Gravis	Luitpold Pharmaceuticals, Inc.
1732	neridronate	n/a	3/25/2013	Treatment of complex regional pain syndrome (CRPS-1, CRPS-II, CRPS-NOS)	Grunenthal USA, Inc.
1733	Neurotrophin-1	n/a	9/13/1994	Treatment of motor neuron disease/amyotrophic lateral sclerosis.	Ericsson, Arthur Dale, M.D.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1734	Neutrophil-endothelial interaction inhibitor	Cylexin	12/22/1993	Treatment of post-ischemic pulmonary reperfusion edema following surgical treatment for chronic thromboembolic pulmonary hypertension.	Cytel Corporation
1735	nevirapine	n/a	11/25/2009	Prevention of HIV infection in pediatric patients under the age of 16 years	Auritec Pharmaceuticals
1736	N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide	n/a	1/13/2012	Treatment of meningioma	Arno Therapeutics, Inc.
1737	N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide	n/a	1/13/2012	Treatment of Schwannoma of the central nervous system	Arno Therapeutics, Inc.
1738	Nifedipine	n/a	6/13/1991	Treatment of interstitial cystitis.	Fleischmann, Jonathan M.D.
1739	nifurtimox	Lampit	8/5/2010	Treatment of Chagas disease (American Trypanosomiasis) caused by T. cruzi	Bayer HealthCare Pharmaceuticals, Inc.
1740	nifurtimox	n/a	12/31/2013	Treatment of Chagas disease	MetronomX Therapeutics, LLC
1741	Nikkomycin Z	n/a	2/14/2006	Treatment of coccidioidomycosis	Valley Fever Center for Excellence (1-111 INF)
1742	nilotinib	Tasigna	4/27/2006	Treatment of chronic myelogenous leukemia	Novartis Pharmaceutical Corporation
1743	nimodipine	Nymalize	9/16/2011	Treatment of subarachnoid hemorrhage.	Arbor Pharmaceuticals, Inc.
1744	Nimotuzumab	n/a	11/17/2004	Treatment of glioma	InnoKeys PTE Ltd.
1745	Nine amino acid polypeptide derived from proteinase 3	n/a	9/3/2004	Treatment of chronic myelogenous leukemia.	The Vaccine Company
1746	Nine amino acid polypeptide derived from proteinase 3	n/a	9/3/2004	Treatment of myelodysplastic syndromes requiring therapy	The Vaccine Company

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1747	Nine amino acid polypeptide derived from proteinase 3	n/a	9/3/2004	Treatment of acute myelogenous leukemia	The Vaccine Company
1748	nintedanib	n/a	6/29/2011	Treatment of patients with idiopathic pulmonary fibrosis.	Boehringer Ingelheim
1749	niprisan	Hemoxin	8/15/2003	Treatment of sickle cell disease	Xechem International, Inc.
1750	nitazoxanide	Cryptaz	10/23/2001	Treatment for intestinal amebiasis	Romark Laboratories, L.C.
1751	Nitazoxanide	Alinia	12/12/1996	Treatment of cryptosporidiosis.	Romark Laboratories, L.C.
1752	nitazoxanide	Alinia	2/14/2002	Treatment of intestinal giardiasis	Romark Laboratories, L.C.
1753	Nitisinone	Orfadin	10/19/2001	Treatment of alkaptonuria	Swedish Orphan AB
1754	Nitisinone	Orfadin	5/16/1995	Treatment of tyrosinemia type 1.	Swedish Orphan Biovitrum AB (PUBL)
1755	Nitric oxide	n/a	7/10/1995	Treatment of acute respiratory distress syndrome in adults.	INO Therapeutics, Inc.
1756	Nitric oxide	n/a	9/11/2013	Treatment of cystic fibrosis	Novoteris, LLC
1757	Nitric oxide	n/a	2/16/2005	Diagnosis of sarcoidosis	SensorMedics Corporation
1758	Nitric oxide	Inomax	9/27/2004	To reduce the risk of chronic lung disease in premature neonates	INO Therapeutics
1759	nitric oxide	Inomax	12/28/2011	Treatment of pulmonary arterial hypertension	Bellerophon Therapeutics
1760	nitric oxide	Inomax (R)	9/5/2008	Use in combination with a drug delivery device for acute treatment of sickle cell vaso-occlusive crisis (pain crises)	INO Therapeutics
1761	nitric oxide	n/a	6/18/2012	Treatment of persistent pulmonary hypertension in newborns	GeNO, LLC

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1762	Nitric oxide	Inomax	6/22/1993	Treatment of persistent pulmonary hypertension in the newborn.	INO Therapeutics, Inc.
1763	Nitroprusside	n/a	2/21/2001	Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.	Thomas, MD, Jeffrey Evan
1764	nivolumab	n/a	1/23/2013	Treatment of Stage IIb to IV melanoma	Bristol-Myers Squibb Co.
1765	N-methyl-4-({4-[(3-methyl(methylsulfonyl)amino)pyrazin-2-yl)methyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzamide hydrochloride	n/a	7/18/2013	Treatment of mesothelioma	Verastem, Inc.
1766	NorLeu3-Angiotensin(1-7) [NorLeu3-A(1-7)]	n/a	12/31/2013	Treatment of leakage from the surgical site following penetrating keratoplasty	US Biotest, Inc.
1767	NorLeu3-Angiotensin(1-7) [NorLeu3-A(1-7)]	n/a	1/31/2014	Treatment of dermal injury due to nuclear/radiation incident	US Biotest, Inc.
1768	N-tert-butyl-3-[(5-methyl-2-[[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino]pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate	n/a	3/21/2013	Treatment of polycythemia vera	sanofi-aventis U.S. LLC
1769	N-tert-butyl-3-[5-methyl-2-[[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino]pyrimidin-4-yl-amino] benzenesulfonamide dihydrochloride monohydrate	n/a	5/18/2009	Treatment of secondary and primary myelofibrosis	Sanofi-Aventis US, LLC a Sanofi company
1770	Nucleic acid aptamer binding to tumor cell nucleolin	n/a	9/10/2009	Treatment of acute myeloid leukemia	Antisoma, Inc.
1771	Nucleic acid aptamer binding to tumor cell nucleolin	n/a	8/17/2004	Treatment of pancreatic cancer	Antisoma Research Ltd.
1772	Nucleic acid aptamer binding to tumor cell nucleon	n/a	7/28/2005	Treatment of renal cell carcinoma	Antisoma Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1773	O-(3-piperidino-2-hydroxyl-1-propyl)-nicotinic acid amidoxime hydrochloride	n/a	1/15/2013	Treatment of Duchenne Muscular Dystrophy	N-Gene Research Laboratories, Inc.
1774	O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate	n/a	12/13/2013	Treatment of multiple myeloma	JSK Therapeutics, Inc.
1775	O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate	n/a	3/16/2012	Treatment of acute myeloid leukemia	JSK Therapeutics, Inc.
1776	obeticholic acid	n/a	4/9/2008	Treatment of primary biliary cirrhosis	Intercept Pharmaceuticals, Inc.
1777	obinutuzumab	n/a	2/17/2012	Treatment of diffuse large B cell lymphoma	Genentech, Inc.
1778	obinutuzumab	Gazyva	2/17/2012	Treatment of chronic lymphocytic leukemia	Genentech, Inc.
1779	oblimersen	Genasense	7/31/2000	Treatment of advanced malignant melanoma (Stages II,III, IV).	Genta, Inc.
1780	oblimersen	Genasense	8/28/2001	Treatment of chronic lymphocytic leukemia	Genta, Inc,
1781	oblimersen	Genasense	8/28/2001	Treatment of multiple myeloma	Genta, Inc.
1782	oblimersen	Genasense	8/28/2001	Treatment of acute myelocytic leukemia	Genta Inc.
1783	octreotide	Sandostatin Lar	8/5/2010	Treatment of neuroendocrine tumors	Novartis Pharmaceuticals Corporation
1784	Octreotide	Sandostatin Lar	8/24/1998	Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).	Novartis Pharmaceuticals Corporation
1785	Octreotide	Sandostatin Lar	8/24/1998	Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.	Novartis Pharmaceuticals Corporation
1786	Octreotide	Sandostatin Lar	8/24/1998	Treatment of acromegaly.	Novartis Pharmaceuticals Corporation

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1787	octreotide (oral)	Octreolin(Tm)	6/17/2010	For the oral treatment of acromegaly	Genentech, Inc.
1788	octreotide acetate subcutaneous implant	n/a	12/7/2009	Treatment of acromegaly	Endo Pharmaceuticals Solutions, Inc.
1789	ofatumumab	Arzerra	3/10/2009	Treatment of chronic lymphocytic leukemia	Glaxo Group Limited d/b/a GlaxoSmithKline
1790	Ofloxacin	Ocuflox Ophthalmic Solution	4/18/1991	Treatment of bacterial corneal ulcers.	Allergan, Inc.
1791	ogluflanide disodium	n/a	9/24/2001	Treatment of ovarian cancer	Implicit Bioscience Pty Ltd
1792	olaparib	n/a	10/16/2013	Treatment of ovarian cancer	AstraZeneca Pharmaceuticals LP
1793	oleylphosphocholine	n/a	10/25/2013	Treatment of leishmaniasis	Dafra Pharma International nv
1794	oligopeptide containing 6 amino acids (H-Phe-Ser-Arg-Tyr-Ala-Arg-OH)	n/a	2/27/2014	Treatment of amyotrophic lateral sclerosis	Genervon Biopharmaceuticals, LLC
1795	omacetaine mepesuccinate	n/a	1/12/2009	Treatment of myelodysplastic syndromes	IVAX International GmbH
1796	omacetaxine mepesuccinate	Synribo	3/10/2006	Treatment of chronic myelogenous leukemia	IVAX International GmbH
1797	ombrabulin; N-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]phenyl}-L-serinamide hydrochloride	n/a	3/3/2011	Treatment of soft tissue sarcoma	Sanofi-Aventis U.S., Inc.
1798	Omega-3 (n-3) polyunsaturated fatty acid with all double bonds in the cis configuration	n/a	11/22/1995	Prevention of organ graft rejection.	Research Triangle Pharmaceuticals
1799	Omega-3 (n-3) polyunsaturated fatty acids	Omacor	5/4/2000	Treatment of IgA nephropathy.	Pronova Biocare, AS
1800	Omegaven emulsion	Omegaven	2/27/2008	Treatment of parenteral nutrition-associated liver disease	Fresenius Kabi Deutschland GmbH
1801	omigapil	n/a	6/24/2008	Treatment of congenital muscular dystrophy.	Santhera Pharmaceuticals Limited

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1802	onartuzumab	n/a	1/23/2013	Treatment of gastric cancer including gastroesophageal cancer	Genentech, Inc.
1803	onartuzumab (MetMab)	n/a	12/16/2013	Treatment of hepatocellular carcinoma	Genentech, Inc.
1804	oncophage	n/a	4/14/2009	Treatment of glioma	Agenus, Inc.
1805	opioid growth factor	n/a	4/16/2013	Treatment of liver and intrahepatic bile duct cancer	Primocure Pharma, Inc.
1806	opium tincture	n/a	12/2/2011	Treatment of chronic diarrhea in short bowel syndrome patients with an inadequate response to anti-diarrheal treatment	Marathon Pharmaceuticals, LLC
1807	Oprelvekin	Neumega	12/17/1996	Prevention of severe chemotherapy-induced thrombocytopenia.	Genetics Institute, Inc.
1808	optically pure phenylalanine derivative	n/a	8/20/2012	Treatment of narcolepsy	Jazz Pharmaceuticals International III Limited
1809	oral unfractionated heparin	n/a	1/29/2004	Treatment of sickle cell disease	TRF Technologies, Inc.
1810	otelixizumab	n/a	2/6/2006	Treatment of new-onset type I diabetes mellitus	GlaxoSmithKline
1811	Oxaliplatin	n/a	10/6/1992	Treatment of ovarian cancer.	Debio Pharm S.A.
1812	oxaloacetate	n/a	7/24/2012	Treatment of gliomas	Terra Biological LLC
1813	Oxalobacter formigenes	n/a	3/29/2006	Treatment of primary hyperoxaluria	OxThera, Inc.
1814	Oxandrolone	Oxandrin	4/22/1997	Treatment of patients with Duchenne's muscular dystrophy and Becker's muscular dystrophy.	Savient Pharmaceuticals, Inc.
1815	Oxandrolone	Oxandrin	9/6/1991	Adjunctive therapy for AIDS patients suffering from HIV-wasting syndrome.	Bio-Technology General Corp.
1816	oxybate	Xyrem	11/7/1994	Treatment of narcolepsy.	Jazz Pharmaceuticals

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1817	Oxymorphone	Numorphan H.P.	3/19/1985	For relief of severe intractable pain in narcotic-tolerant patients.	DuPont Merck Pharmaceutical Company
1818	Oxypurinol	n/a	11/9/1998	Treatment of hyperuricemia in patients intolerant to allopurinol.	Cardiome Pharma Corp.
1819	p1-(uridine 5'-)-p4-(2'-deoxycytidine 5'-) tetraphosphate, tetrasodium salt	n/a	3/7/2001	For the treatment of cystic fibrosis	Inspire Pharmaceuticals, Inc.
1820	P140K MGMT transduced human CD34 cells	n/a	1/9/2013	For bone marrow protection in the treatment of glioblastoma multiforme	Lentigen Corporation
1821	Paclitaxel	Paxene	4/15/1997	Treatment of AIDS-related Kaposi's sarcoma.	Baker Norton Pharmaceuticals, Inc.
1822	paclitaxel	n/a	5/1/2009	Treatment of pancreatic cancer	MediGene AG
1823	Paclitaxel	Taxol	3/25/1997	Treatment of AIDS-related Kaposi's sarcoma.	Bristol-Myers Squibb Pharmaceutical Research Institute
1824	paclitaxel aqueous gel	Oncogel (Tm)	12/23/2008	Treatment of brain cancer.	BTG International, Inc
1825	paclitaxel aqueous gel	Oncogel(Tm)	2/1/2008	Treatment of esophageal cancer	BTG International, Inc.
1826	paclitaxel nanoparticles	n/a	1/3/2013	Treatment of pancreatic cancer	CIRJ Co., Ltd.
1827	paclitaxel poliglumex	Opaxio	9/20/2012	Treatment of glioblastoma multiforme	Cell Therapeutics, Inc.
1828	paclitaxel protein-bound particles	Abraxane	9/3/2009	Treatment of pancreatic cancer.	Abraxis BioScience, LLC
1829	Paclitaxel protein-bound particles for injection suspension	Abraxane	10/1/2009	Treatment of stage IIb to IV melanoma	Abraxis BioScience, LLC
1830	paclitaxel, micellar	Paclical	4/3/2009	Treatment of ovarian cancer	Oasmia Pharmaceutical AB
1831	pacritinib	n/a	3/13/2008	Treatment of myeloproliferative disorders with the JAK2 V617F mutation	Cell Therapeutics, Inc..

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1832	Pafuramidine maleate	n/a	8/31/2007	Treatment of human African trypanosomiasis (sleeping sickness)	Immtech Pharmaceuticals, Inc.
1833	Pafuramidine maleate	n/a	5/14/2007	Treatment of malaria	Immtech Pharmaceuticals, Inc.
1834	pafuramidine maleate	n/a	11/17/2006	Treatment of pneumocystis jiroveci pneumonia	Immtech Pharmaceuticals, Inc.
1835	Palifosfamide	n/a	5/5/2008	Treatment of soft tissue sarcomas	ZIOPHARM Oncology, Inc.
1836	panobinostat	Farydak	8/20/2012	Treatment of multiple myeloma	Novartis Pharmaceuticals Corporation
1837	Papain, trypsin, and chymotrypsin	Wobe-Mugos	12/21/1998	Treatment of multiple myeloma.	Marlyn Nutraceuticals, Inc.
1838	paquinimod	n/a	1/17/2014	Treatment of systemic sclerosis	Active Biotech AB
1839	parathyroid hormone	n/a	8/31/2007	Treatment of hypoparathyroidism	NPS Pharmaceuticals, Inc.
1840	paromomycin sulfate/gentamicin sulfate	n/a	1/18/2008	Treatment of all uncomplicated cutaneous leishmaniasis (both New World and Old World)	Office of the Surgeon General
1841	Parvovirus B19 (recombinant VP1 and VP2; S.frugiperda cells) vaccine	Medi-491	5/7/1999	Prevention of transient aplastic crisis in patients with sickle cell anemia.	MedImmune, Inc.
1842	pasireotide	n/a	8/25/2009	Treatment of acromegaly	Novartis Pharmaceuticals Corporation
1843	pasireotide	Signifor	7/24/2009	Treatment of Cushing's disease	Novartis Pharmaceuticals Corporation
1844	pazopanib	n/a	5/6/2013	Treatment of ovarian cancer.	Glaxo Wellcome Mfg Pte Ltd
1845	pazopanib	Votrient	10/20/2009	Treatment of soft tissue sarcomas	GlaxoSmithKline

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1846	Pegademase bovine	Adagen	5/29/1984	For enzyme replacement therapy for ADA deficiency in patients with severe combined immunodeficiency.	Sigma-tau Pharmaceuticals, Inc.
1847	Pegaspargase	Oncaspar	10/20/1989	Treatment of acute lymphocytic leukemia.	Sigma-tau Pharmaceuticals, Inc.
1848	Pegfilgrastim	Neulasta	11/20/2013	Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident	Amgen, Inc.
1849	PEG-glucocerebrosidase	Lysodase	12/9/1992	For use as chronic enzyme replacement therapy in patients with Gaucher's disease who are deficient in glucocerebrosidase.	National Institute of Mental Health, NIH
1850	Peginterferon alfa-2a	Pegasys	9/30/1999	Treatment of chronic myelogenous leukemia.	Hoffman-La Roche Inc.
1851	Peginterferon alfa-2a	Pegasys	7/13/1998	Treatment of renal cell carcinoma.	Hoffman-La Roche Inc.
1852	peginterferon alfa-2b	Sylatron	4/9/2008	Treatment of malignant melanoma stages IIb through IV.	Schering-Plough Corporation
1853	PEG-interleukin-2	n/a	2/1/1990	Treatment of primary immunodeficiencies associated with T-cell defects.	Chiron Corporation
1854	pegloticase	Krystexxa	2/21/2001	To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.	Savient Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1855	pegsitacase	Uricase-Peg 20	12/3/2009	Treatment of Lesch-Nyhan syndrome.	EnzymeRx, LLC
1856	Pegvisomant	Somavert	6/24/1997	Treatment of acromegaly.	Sensus Corporation
1857	Pegylated arginine deiminase	Melanocid	4/12/1999	Treatment of invasive malignant melanoma.	Polaris Pharmaceuticals, Inc.
1858	pegylated arginine deiminase	Hepacid	3/26/1999	Treatment of hepatocellular carcinoma	Polaris Pharmaceuticals, Inc.
1859	pegylated carboxyhemoglobin	n/a	10/21/2010	Treatment of acute painful sickling crises in patients with sickle cell disease	Sangart, Inc.
1860	pegylated granulocyte colony stimulating factor	n/a	4/30/2014	Treatment of patients at risk of developing myelosuppression following a radiological or nuclear incident	PharmaEssentia
1861	pegylated proline interferon alpha-2b	n/a	4/10/2014	Treatment of myelofibrosis	PharmaEssentia, Corporation
1862	pegylated proline interferon alpha-2b	n/a	4/11/2014	Treatment of thrombocythemia	PharmaEssentia, Corporation
1863	pegylated proline-interferon alpha-2b; PEG-P-IFNa-2b	n/a	4/2/2012	Treatment of polycythemia vera	PharmaEssentia Corporation
1864	PEGylated recombinant anti-Pseudomonas aeruginosa PcrV Fab' antibody	n/a	10/25/2013	Treatment of cystic fibrosis patients with Pseudomonas aeruginosa lung infections	KaloBios Pharmaceuticals, Inc.
1865	Pegylated recombinant human megakaryocyte growth and development factor	Megagen	10/20/1997	For reducing the period of thrombocytopenia in patients undergoing hematopoietic stem cell transplantation.	Amgen, Inc.
1866	Peldesine	n/a	10/5/1993	Treatment of cutaneous T-cell lymphoma.	BioCryst Pharmaceuticals, Inc.
1867	pemetrexed disodium	Alimta	8/28/2001	Treatment of malignant pleural mesothelioma	Eli Lilly and Company
1868	pentagastrin	n/a	5/29/2009	To aid in the diagnosis of medullary thyroid carcinoma	Medical Defense Technologies, LLC

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1869	pentamidine	n/a	8/12/2013	Treatment of liver and intrahepatic bile duct cancer	Oncozyme Pharma, Inc.
1870	pentamidine	n/a	8/12/2013	Treatment of ovarian cancer	Oncozyme Pharma, Inc.
1871	pentamidine	n/a	9/13/2010	Treatment of pancreatic cancer.	Oncozyme Pharma, Inc.
1872	Pentamidine isethionate	n/a	10/29/1984	Treatment of Pneumocystis carinii pneumonia.	Aventis Behring L.L.C.
1873	Pentamidine isethionate	Nebupent	1/12/1988	Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.	Fujisawa USA, Inc.
1874	Pentamidine isethionate	Pentam 300	2/28/1984	Treatment of Pneumocystis carinii pneumonia.	Fujisawa USA, Inc.
1875	Pentamidine isethionate (inhalation)	Pneumopent	10/5/1987	Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.	Fisons Corporation
1876	Pentasaccharide ethyl glycoside consisting of one alpha-D-sialylosyl residue as a sodium salt, two beta-D-galactopyranosyl residues, one 2-acetamido-beta-D-glucopyranosyl unit, and one alpha-L-fucopyranosyl unit	Cylexin	7/18/1997	Treatment of neonates and infants undergoing cardiopulmonary bypass during surgical repair of congenital heart lesions.	Cytel Corporation
1877	Pentastarch	Pentaspan	8/28/1985	As an adjunct in leukapheresis to improve the harvesting and increase the yield of leukocytes by centrifugal means.	Du Pont Pharmaceuticals
1878	pentetate trisodium	Diethylenetriaminepentaacetate	4/12/2004	Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium.	Heyl Chemisch-Pharmazeutische Fabrik GMBH & Co. KG
1879	pentosan polysulfate sodium	n/a	9/16/2011	Treatment of sickle cell disease.	Vanguard Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1880	pentosan polysulfate sodium	n/a	11/21/2008	Treatment of sickle cell disease.	TRF Pharma, Inc.
1881	Pentosan polysulfate sodium	Elmiron	8/7/1985	Treatment of interstitial cystitis.	Alza Corporation
1882	Pentostatin	Nipent	11/24/1999	Treatment of peripheral T-cell lymphomas.	SuperGen, Inc.
1883	Pentostatin	Nipent	3/27/1998	Treatment of cutaneous T-cell lymphoma.	SuperGen, Inc.
1884	Pentostatin	Nipent	1/29/1991	Treatment of patients with chronic lymphocytic leukemia.	SuperGen, Inc.
1885	Pentostatin for injection	Nipent	9/10/1987	Treatment of hairy cell leukemia.	SuperGen, Inc.
1886	pentoxifylline	n/a	6/14/2012	Treatment of Behcet's disease	Keck Graduate Institute of Applied Life Sciences
1887	Peptide 144 TGF beta-1 inhibitor	n/a	4/27/2006	Treatment of systemic sclerosis	Digna Biotech, S.L.
1888	Peptide 144 TGF beta-1-inhibitor	n/a	4/26/2006	Treatment of localized scleroderma	Digna Biotech, S.L.
1889	Peptide that inhibits mechanosensitive ion channel (MSC) activity	n/a	9/15/2010	Treatment of Duchenne Muscular Dystrophy (DMD.)	Rose Pharmaceuticals
1890	peptide YY	n/a	4/18/2011	Treatment of hepatocellular carcinoma.	mondoBIOTECH Laboratories AG
1891	peptide-based vaccine targeting telomerase reverse transcriptase	n/a	2/20/2009	Treatment of telomerase reverse transcriptase (TERT) positive non-small cell lung cancer in HLA-A*0201 positive patients	VAXON-Biotech

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1892	peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO)	n/a	9/3/2009	Treatment of Duchenne muscular dystrophy in patients with a deletion, duplication or frame shift mutation correctable by skipping of exon 50 of the dystrophin gene to allow restoration of the reading frame (including mutations within exons 51, 51-53, or 51-55).	Sarepta Therapeutics, Inc.
1893	peptides mimicking antigen receptors on autoimmune B cells and autoimmune T cells associated with myasthenia gravis	n/a	2/4/2011	Treatment of myasthenia gravis	CuraVac Europe SPRL
1894	Peptidomimetic analog of hexarelin	n/a	5/14/2007	Diagnosis of growth hormone deficiency	Aeterna Zentaris GmbH
1895	perampanel	Fycompa	12/7/2012	Treatment of Lennox-Gastaut Syndrome	Eisai, Inc.
1896	peretinoin	n/a	9/23/2011	Treatment of hepatocellular carcinoma.	Kowa Pharmaceutical Europe Co. Ltd.
1897	Perflubron	Liquivent	4/26/2001	Treatment of acute respiratory distress disease (ARDS) in adults	Alliance Pharmaceutical Corp.
1898	perhexiline maleate	n/a	6/14/2012	Treatment of moderate to severe symptomatic (NYHA class III or IV) hypertrophic cardiomyopathy	Heart Metabolics, Limited.
1899	perifosine	n/a	7/9/2010	Treatment of neuroblastoma	Aeterna Zentaris GmbH
1900	perillyl alcohol	n/a	4/18/2011	Treatment of glioma.	NeOnc Technologies, Inc.
1901	pertuzumab	n/a	6/8/2009	Treatment of ovarian cancer	Genentech, Inc.
1902	pertuzumab	n/a	7/12/2013	Treatment of gastric cancer	Genentech, Inc.
1903	pexastimogene devacirepvec	n/a	5/6/2013	Treatment of hepatocellular carcinoma	Jennerex, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1904	PG2 (Astragalus polysaccharides extracted and purified from the dry root of Astragalus membranaceus)	n/a	7/5/2012	Treatment of idiopathic thrombocytopenic purpura	EcoPharm Corporation
1905	PGC-C12E-terlipressin	n/a	12/27/2012	Treatment of refractory ascites due to all etiologies except for cancer	PharmaIN Corporation
1906	phenobarbital sodium injection	n/a	10/23/2013	Treatment of hypoxic-ischemic encephalopathy to prevent seizures in neonates	Fera Pharmaceuticals, LLC
1907	Phenylacetate	n/a	3/6/1998	For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Elan Drug Delivery, Inc.
1908	Phenylalanine ammonia-lyase	Phenylase. Ravpal-Peg	3/8/1995	Treatment of hyperphenylalaninemia	BioMarin Pharmaceutical
1909	Phenylbutyrate	n/a	1/19/2000	Treatment of acute promyelocytic leukemia.	Elan Drug Delivery, Inc.
1910	phenylephrine	n/a	2/14/2002	Treatment of ileal pouch anal anastomosis related fecal incontinence	S.L.A. Pharma
1911	phenylephrine	n/a	1/31/2012	Treatment of Tetralogy of Fallot	Luitpold Pharmaceuticals, Inc.
1912	Phosphatidylinositol 3-Kinase "PI3K" Inhibitor	n/a	11/2/2010	Treatment of chronic lymphocytic leukemia (CLL)	Semafore Pharmaceuticals
1913	phosphorothioate antisense oligonucleotide against EWS-Fli-1	n/a	9/22/2008	Treatment of Ewing's sarcoma	The Cure Our Children Foundation
1914	phoxilium	n/a	2/14/2014	For use as a replacement solution in patients undergoing continuous renal replacement therapy	Gambro Renal Products, Inc.
1915	picibanil	n/a	5/15/2009	Treatment of patients with lymphatic malformations	Royds Pharmaceuticals, Inc.
1916	picibanil	n/a	3/17/2011	Treatment of lymphatic malformations	Richard Smith, M.D.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1917	Picoplatin	n/a	11/2/2005	Treatment of small cell lung cancer	Poniard Pharmaceuticals
1918	Pilocarpine	Salagen	9/24/1990	Treatment of xerostomia induced by radiation therapy for head and neck cancer.	MGI Pharma, Inc.
1919	Pilocarpine HCl	Salagen	2/28/1992	Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.	MGI Pharma, Inc.
1920	pirfenidone	n/a	11/19/2013	Treatment of systemic sclerosis (including the associated interstitial lung disease)	InterMune, Inc.
1921	Plasmid DNA vector expressing cystic fibrosis transmembrane gene	n/a	3/29/2005	Treatment of cystic fibrosis	Copernicus Therapeutics, Inc.
1922	plasmin (human)	n/a	3/30/2009	Treatment of acute peripheral arterial occlusion	Grifols Therapeutics, Inc.
1923	plasminogen (human)	n/a	3/5/2013	Treatment of hypoplasminogenemia, or type I plasminogen deficiency	ProMetic Biotherapeutics, Inc.
1924	plerixafor	Mozobil (R)	7/10/2003	For use to improve the yield of progenitor cells in the apheresis product for subsequent stem cell transplantation following myelosuppressive or myeloablative chemotherapy	Genzyme Corporation
1925	Plitidepsin	Aplidin	9/30/2004	Treatment of multiple myeloma	PharmaMar USA, Inc.
1926	polifeprosan 20 with carmustine	Gliadel	12/13/1989	Treatment of malignant glioma.	Guilford Pharmaceuticals, Inc.
1927	polifeprosan 20 with carmustine	Gliadel	12/13/1989	Treatment of malignant glioma	Guilford Pharmaceuticals, Inc.
1928	Poloxamer 188	Florcor	2/22/1990	Treatment of severe burns requiring hospitalization.	CytRx Corporation

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1929	Poloxamer 188	n/a	11/8/2013	Treatment of Acute Limb Ischemia	Mast Therapeutics, Inc
1930	Poloxamer 188	n/a	8/5/1997	Treatment of vasospasm in subarachnoid hemorrhage patients following surgical repair of a ruptured cerebral aneurysm.	CytRx Corporation
1931	poloxamer 188 (purified)	n/a	6/27/1989	Treatment of sickle cell disease (this includes the treatment and prevention of complications of sickle cell disease)	Mast Therapeutics Inc.
1932	Poloxamer 331	Protox	3/21/1991	Initial therapy of toxoplasmosis in patients with AIDS.	CytRx Corporation
1933	poloxamer-188 NF	n/a	1/19/2010	Treatment of Duchenne muscular dystrophy	Phrixus Pharmaceuticals, Inc.
1934	Poly I: poly C12U	Ampligen	12/9/1993	Treatment of chronic fatigue syndrome.	Hemispherx Biopharma, Inc.
1935	Poly I: poly C12U	Ampligen	12/9/1993	Treatment of invasive metastatic melanoma (stage IIb, III, IV).	Hemispherx Biopharma, Inc.
1936	Poly I: poly C12U	Ampligen	5/20/1991	Treatment of renal cell carcinoma.	Hemispherx Biopharma, Inc.
1937	poly(lactide-co-glycolide) carboxylated microparticle	n/a	10/25/2013	Treatment of acute encephalitis syndrome	Cour Pharmaceutical Development Company, Inc.
1938	Polyethylene glycol-modified uricase	n/a	6/6/2005	Treatment of hyperuricemia in patients with gout refractory to conventional therapy or in whom conventional therapy is contraindicated	EnzymeRx, LLC
1939	Polyethylene glycol-modified uricase	Zurase	12/21/1998	Treatment of tumor lysis syndrome in cancer patients undergoing chemotherapy.	EnzymeRx, LLC

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1940	Polyethylene glycol-modified uricase	Zurase	9/14/1999	Prophylaxis of hyperuricemia in cancer patients prone to develop tumor lysis syndrome during chemotherapy.	EnzymeRx, LLC
1941	Poly-ICLC	Hiltonol	3/17/1997	Treatment of primary brain tumors.	Oncovir
1942	polyinosinic-polycytidilic acid	Poly-Iclc	8/2/2002	As an adjuvant to smallpox vaccination	Oncovir
1943	polyinosinic-polycytidilic acid	Poly-Iclc	3/3/2003	Treatment of flavivirus infections including those due to West Nile, Japanese encephalitis, dengue, St. Louis encephalitis, yellow fever, Murray valley, and Banzai viruses	Oncovir
1944	polyinosinic-polycytidilic acid (Poly-ICLC)	Hiltonol	11/19/2002	Treatment for orthopox virus infections	Oncovir
1945	Polymeric oxygen	n/a	3/25/1992	Treatment of sickle cell anemia.	Capmed USA
1946	polyphenon E	n/a	7/17/2008	Treatment of chronic lymphocytic leukemia	Mitsui Norin Co., Ltd
1947	Polyribonucleotide; Polyribo-inosinic/-cyclidylic/-uridylic acid	Ampligen	7/19/1988	Treatment of AIDS.	Hemispherx Biopharma, Inc.
1948	Polyvalent, shed-antigen melanoma vaccine	n/a	6/9/2006	Treatment of stage IIb to stage IV melanoma	Polynoma LLC
1949	pomalidomide	n/a	8/22/2013	Treatment of systemic sclerosis	Celgene Corporation
1950	pomalidomide	n/a	9/21/2010	Treatment of persons with myeloproliferative neoplasm-associated myelofibrosis and anemia who are red blood cell transfusion dependent.	Celgene Corporation
1951	pomalidomide	Pomalyst	1/15/2003	Treatment of multiple myeloma	Celgene Corporation

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1952	ponatinib	Iclusig	11/20/2009	Treatment of chronic myeloid leukemia	ARIAD Pharmaceuticals Inc.
1953	ponatinib	Iclusig	11/20/2009	Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)	ARIAD Pharmaceuticals Inc.
1954	Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation	Neurocell-Pd	12/17/1996	Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.	Diacrin/Genzyme LLC
1955	Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared for intracerebral implantation.	Neurocell-Pd	12/17/1996	Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.	Diacrin/Genzyme LLC
1956	Porcine fetal neural gabaergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation	Neurocell-Hd	12/10/1996	Treatment of Huntington's disease.	Diacrin/Genzyme LLC
1957	Porcine fetal neural gabaergic cells and/or precursors aseptically prepared for intracerebral implantation for Huntington's disease.	Neurocell-Hd	12/10/1996	Treatment of Huntington's disease.	Diacrin/Genzyme LLC
1958	porcine GM1 ganglioside	n/a	12/3/2012	Treatment of acute spinal cord injury	TRB Chemedica International S.A.
1959	Porcine Sertoli cells aseptically prepared for intracerebral co-implantation with fetal neural tissue	N-Graft	6/24/1997	Treatment of Hoehn and Yahr stage four and five Parkinson's disease.	Titan Pharmaceuticals, Inc.
1960	porfimer	Photofrin	10/19/2001	For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy	Axcan Scandipharm Inc.
1961	Porfimer sodium	Photofrin	11/18/2004	Treatment of cholangiocarcinoma	Pinnacle Biologics, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1962	Porfimer sodium	Photofrin	11/15/1989	For the photodynamic therapy of patients with transitional cell carcinoma in situ of the urinary bladder.	QLT Phototherapeutics, Inc.
1963	Porfimer sodium	Photofrin	6/6/1989	For the photodynamic therapy of patients with primary or recurrent obstructing (either partially or completely) esophageal carcinoma.	QLT Phototherapeutics, Inc.
1964	Porfiromycin	Promycin	9/19/1995	Treatment of head and neck cancer.	Boehringer Ingelheim Pharmaceuticals, Inc.
1965	Porfiromycin	Promycin	3/13/1997	Treatment of cervical cancer.	Boehringer Ingelheim Pharmaceuticals, Inc.
1966	Posaconazole	Posoril	7/16/2004	Treatment of zygomycosis	Schering-Plough Corporation
1967	Potassium citrate	Urocit-K	11/1/1984	Prevention of calcium renal stones in patients with hypocitraturia.	University of Texas Health Science Center at Dallas
1968	Potassium citrate	Urocit-K	11/1/1984	Prevention of uric acid nephrolithiasis.	University of Texas Health Science Center at Dallas
1969	Potassium citrate	Urocit-K	11/1/1984	For avoidance of the complication of calcium stone formation in patients with uric lithiasis.	University of Texas Health Science Center at Dallas
1970	Potassium Iodide Oral Solution	Thyroshield	11/17/2004	For use as a thyroid blocking agent in pediatric patients exposed to radioactive iodine	Fleming & Company, Pharmaceuticals
1971	potassium sodium aluminosilicate	n/a	1/8/2007	For treatment of poisoning by or exposure to cesium.	Framework Therapeutics, LLC
1972	pracinostat	n/a	2/27/2014	Treatment of acute myeloid leukemia	MEI Pharma Inc.
1973	pralatrexate	n/a	10/20/2008	Treatment of follicular lymphoma	Allos Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1974	pralatrexate	n/a	5/3/2010	Treatment of advanced or metastatic transitional cell carcinoma of the urinary bladder	Allos Therapeutics, Inc.
1975	pralatrexate	n/a	10/20/2008	Treatment of diffuse large B-cell lymphoma	Allos Therapeutics, Inc.
1976	pralatrexate	Folotyn	7/20/2006	Treatment of T-cell lymphoma	Allos Therapeutics, Inc.
1977	pralmorelin hydrochloride	n/a	10/18/2012	As a diagnostic agent for the detection of growth hormone deficiency	Sella Pharmaceuticals, Inc.
1978	pramipexole	Mirapex	1/31/2008	Treatment of Tourette's syndrome in pediatric patients	Boehringer-Ingelheim Pharmaceuticals, Inc.
1979	Primaquine phosphate	n/a	7/23/1993	For use in combination with clindamycin hydrochloride in the treatment of Pneumocystis carinii pneumonia associated with AIDS.	Sanofi Winthrop, Inc.
1980	Procarbazine HCl	Matulane	8/8/2006	Treatment of malignant glioma	Sigma-Tau Pharmaceuticals, Inc.
1981	profimer sodium	Photofrin	12/2/2011	Treatment of malignant mesothelioma	Pinnacle Biologics, Inc.
1982	progesterone	n/a	12/22/1994	Establishment and maintenance of pregnancy in women undergoing in vitro fertilization or embryo transfer procedures.	Watson Laboratories, Inc.
1983	progesterone	n/a	9/3/2009	For early intervention in the treatment of moderate to severe closed-head traumatic brain injury	BHR Pharma, LLC
1984	prolactin receptor antagonist	Prolanta	4/15/2013	Treatment of ovarian cancer	Oncolix, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1985	propranolol	Hemangeol	9/5/2008	Treatment of proliferating infantile hemangiomas requiring systemic therapy	Pierre Fabre Dermatologie
1986	Prostaglandin E1 enol ester (AS-013)	Circulase	6/12/1998	Treatment of Fontaine Stage IV chronic critical limb ischemia.	LTT Baio-Pharma Co., Ltd
1987	Protaxel	n/a	5/21/2003	Treatment of ovarian cancer	Biophysica, Inc.
1988	Protein C concentrate	Protein C Concentrate (Human) Vapor Heated, Immuno	6/19/1992	For replacement therapy in patients with congenital or acquired protein C deficiency for the prevention and treatment of warfarin-induced skin necrosis during oral anticoagulation.	Immuno Clinical Research Corp.
1989	Protein C concentrate	Ceprothin	6/23/1992	For replacement therapy in congenital protein C deficiency for the prevention and treatment of thrombosis, pulmonary emboli, and purpura fulminans.	Baxter Healthcare Corporation
1990	prothrombin complex concentrate (human)	Kcentra	12/27/2012	Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures	CSL Behring
1991	Pulmonary surfactant replacement, porcine	Curosurf	8/2/1993	For the treatment and prevention of respiratory distress syndrome in premature infants.	Dey Laboratories
1992	purified bovine type collagen	n/a	4/27/2009	Treatment of idiopathic pulmonary fibrosis	ImmuneWorks, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1993	Purified extract of Pseudomonas aeruginosa	Immudyn	9/22/1997	Treatment of immune thrombocytopenia purpura where it is required to increase platelet counts.	Able Laboratories, Inc.
1994	Purified type II collagen	Colloral	2/9/1995	Treatment of juvenile rheumatoid arthritis.	AutoImmune, Inc.
1995	pyridoxine; vitamin B6	n/a	3/3/2011	Treatment of pyridoxine dependent seizures.	NBI Pharmaceuticals, Inc.
1996	pyrimethamine	n/a	8/16/2011	Treatment of GM-2 gangliosidosis (Tay-Sachs disease and Sandhoff disease).	ExSAR Corporation
1997	Pyruvate	n/a	2/21/2001	Treatment of interstitial lung disease.	Cellular Sciences, Inc
1998	quinacrine	n/a	9/28/2012	Treatment of hepatocellular carcinoma	Cleveland BioLabs, Inc & Incuron, LLC Joint Ventur
1999	quinine sulfate	n/a	12/2/2008	Treatment of malaria excluding Plasmodium faliparum	Zydus Pharmaceuticals, Inc.
2000	quinine Sulfate	n/a	6/3/2004	Treatment of malaria	AR Holding Company, Inc.
2001	R-(-)-gossypol	n/a	10/24/2006	Treatment of chronic lymphocytic leukemia.	Ascenta Therapeutics, Inc.
2002	R-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1 H -1,4-benzodiazepine -3-yl]-3-(3-methylaminophenyl)urea	n/a	9/10/2009	Treatment of gastric carcinoids	Trio Medicines Ltd.
2003	R-4-amino-3-(4-chlorophenyl)butanoic acid	n/a	11/28/2008	Treatment of the behavioral abnormalities associated with fragile X syndrome	Seaside Therapeutics, Inc.
2004	rAAV2-CB-hRPE65	n/a	2/11/2005	Treatment of type II Leber's Congenital Amaurosis	Applied Genetic Technologies Corp.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2005	Rabbit anti-human thymocyte globulin (rATG)	Thymoglobulin	9/26/2006	Induction treatment to prevent rejection and to minimize maintenance immunosuppression in pediatric liver transplant recipients	Children's Hospital of Pittsburgh
2006	radiolabeled somastatin analog	Galiomedix(Tm)	12/31/2013	Diagnostic for the management of neuroendocrine tumors	RadioMedix, Inc.
2007	Raloxifene	Evista	7/14/2005	Reduction of the risk of breast cancer in postmenopausal women	Eli Lilly and Company
2008	raloxifene hydrochloride	Evista	8/20/2010	Treatment of hereditary hemorrhagic telangiectasia	Consejo Superior de Investigaciones Cientificas
2009	ramucirumab	Cyramza	2/16/2012	Treatment of gastric cancer	Eli Lilly and Company
2010	Ramucirumab; rHuman MAb to VEGFR-2	n/a	11/4/2011	Treatment of hepatocellular carcinoma.	ImClone Systems LLC
2011	ranagengliotucel-L	Glionix(Tm)	5/29/2009	Treatment of astrocytic tumors	NovaRx Corporation
2012	ranprinase	Onconase	1/25/2007	Treatment of malignant mesothelioma	Alfacell Corporation
2013	Rapamycin	n/a	3/20/2007	Treatment of tuberous sclerosis complex	Oncolmmune, Inc.
2014	rasburicase	Elitek	10/11/2000	Treatment of malignancy-associated or chemotherapy-induced hyperuricemia.	Sanofi-Synthelabo Research
2015	raxibacumab	Abthraxtm	11/12/2003	Treatment of anthrax	Human Genome Sciences, Inc.
2016	Re188 P2045 somatostatin analog	n/a	2/6/2014	Treatment of small cell lung cancer	Andarix Pharmaceuticals
2017	Recombinant AAV9 expressing human alpha-N-acetylglucosaminidase	n/a	4/30/2014	Mucopolysaccharidosis III-B (Sanfilippo Syndrome Type B)	Abeona Therapeutics LLC

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2018	recombinant AAV9 expressing human sulfoglucosamine sulfohydrolase	n/a	4/29/2014	Treatment of mucopolysaccharidosis type III-A (Sanfilippo Syndrome Type A)	Abeona Therapeutics
2019	recombinant adeno- associated virus vector AAV2/rh8 expressing human B-hexosaminidase A and B subunits	n/a	3/25/2013	For the treatment of Sandhoff disease	Nat'l Tay-Sachs & Allied Diseases Association
2020	Recombinant adeno-associated virus (serotype 2) (rAAV2) gene transfer agent expressing RPE65	n/a	5/11/2009	Treatment of Leber's congenital amaurosis	AmpliPhi Biosciences Corporation
2021	recombinant adeno-associated virus alpha 1-antitrypsin vector	Raav-Aat	1/27/2003	Treatment of alpha1-antitrypsin deficiency	Applied Genetic Technologies Corp.
2022	recombinant adeno-associated virus encoded gene for X-linked mammalian inhibitor of apoptosis protein (XIAP)	n/a	8/25/2009	Treatment of Huntington's disease.	Neurologix, Inc.
2023	Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2	n/a	6/24/2008	Treatment of Leber congenital amaurosis due to RPE65 mutations.	Spark Therapeutics, LLC
2024	recombinant adeno-associated virus vector expressing the cyclic nucleotide gated channel beta subunit (rAAV-CNGB3)	n/a	2/4/2011	Treatment of achromatopsia caused by mutations in the CNGB3 gene.	Applied Genetic Technologies Corporation
2025	recombinant adenovirus vector AAV2/rh8 expressing human B-hexosaminidase A & B subunits	n/a	3/25/2013	Treatment of Tay-Sachs disease	Na't Tay-Sachs & Allied Diseases Association
2026	Recombinant antibody construct against human CD30 and CD16A	n/a	8/20/2009	Treatment of Hodgkin lymphoma	Affimed Therapeutics AG
2027	recombinant chimeric monoclonal antibody to anthrax	Anthim	6/9/2006	Treatment of exposure to B. anthracis spores	Elusys Therapeutics, Inc.
2028	Recombinant coagulation factor VIIa	Novoseven	4/26/2006	Treatment of diffuse alveolar hemorrhage	PharmaOrigin ApS
2029	Recombinant deriative of C3 transferase	Cethrin(Tm)	11/18/2005	Treatment of acute spinal cord injury.	BioAxone BioSciences, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2030	Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs	n/a	7/29/2008	Prevention of thrombotic thrombocytopenic purpura including its congenital, acquired idiopathic and secondary forms.	Baxter Healthcare Corporation
2031	Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs	n/a	7/29/2008	Treatment of thrombotic thrombocytopenic purpura including its congenital, acquired idiopathic, and secondary forms.	Baxter Healthcare Corporation
2032	recombinant DNA plasmid	n/a	1/31/2014	Treatment of stage IIb, IIc, III and IV melanoma.	Scancell Ltd.
2033	recombinant elafin	n/a	3/18/2013	Prevention of inflammatory complications of transthoracic esophagectomy	Proteo Biotech AG
2034	Recombinant Epstein-Barr virus gp350 glycoprotein vaccine	n/a	8/18/2005	Prevention of post-transplantation lymphoproliferative disorders in pediatric recipients of solid-organ transplantation	Henogen S.A.
2035	Recombinant fully human monoclonal antibody to anthrax protective antigen	Valortim	2/16/2006	Treatment of anthrax infection	PharmAthene, Inc.
2036	Recombinant Fusion Protein	n/a	7/24/2012	Treatment of Myelodysplastic Syndrome	Apogenix GmbH
2037	recombinant fusion protein consisting of a modified form of extracellular domain of human Activin receptor IIB	n/a	3/18/2013	Treatment of myelodysplastic syndrome	Acceleron Pharma, Inc
2038	recombinant fusion protein consisting of a modified form of the extracellular domain of human activin receptor IIB (ActRIIB) linked to a human IgG1 Fc domain	n/a	3/11/2013	Treatment of B-thalassemia	Acceleron Pharma, Inc.
2039	recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP)	n/a	4/27/2012	Treatment of patients with congenital factor IX deficiency (hemophilia B).	CSL Behring, LLC

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2040	recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)	n/a	5/6/2013	Treatment of congenital factor VII deficiency which includes treatment and prophylaxis of bleeding episodes in patients with congenital factor VII deficiency	CSL Behring
2041	Recombinant fusion protein of Mycobacterium bovis BCG Hsp65 and HPV16 E7	n/a	3/19/2001	Treatment of recurrent respiratory papillomatosis (RRP)	StressGen Biotechnologies, Inc. is now Nventa
2042	recombinant fusion protein with a truncated form of the cytotoxic protein Pseudomonas exotoxin	Proxinium	1/28/2005	Treatment of Ep-CAM-positive squamous cell carcinoma of the head and neck	Viventia Biotech, Inc.
2043	Recombinant fusion protein-extracellular portion of CD95 fused to the Fc part of human IgG1	n/a	10/13/2009	Treatment of glioblastoma multiforme	Apogenix GmbH
2044	recombinant glycosylated independent lysosomal targeting (GILT) tagged human acid alpha glucosidase	n/a	8/20/2010	Treatment of Pompe disease.	BioMarin Pharmaceutical, Inc.
2045	Recombinant human acid alpha-glucosidase	1. Myozyme 2.Lumizyme	8/19/1997	Treatment of glycogen storage disease type II.	Genzyme Corporation
2046	recombinant human acid ceramidase	Plexcerase(Tm)	12/24/2013	Treatment of Farber disease	Plexcera Therapeutics, LLC
2047	Recombinant human alpha 1-antitrypsin	n/a	4/28/2005	Prevention of bronchopulmonary dysplasia	Arriva Pharmaceuticals, Inc.
2048	recombinant human alpha 1-antitrypsin (rAAT)	n/a	11/20/2001	Treatment of cystic fibrosis	AiroMedica LLC
2049	recombinant human alpha-1 antitrypsin	n/a	3/6/1998	Treatment of cystic fibrosis.	PPL Therapeutics (Scotland) Limited
2050	recombinant human alpha-1 antitrypsin (rAAT)	n/a	8/28/2001	To delay progression of chronic obstructive pulmonary disease resulting from AAT deficiency-mediated emphysema and bronchiectasis	AiroMedica LLC

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2051	Recombinant Human Alpha-Fetoprotein (rhAFP)	n/a	2/22/2001	Treatment of myasthenia gravis	Merrimack Pharmaceuticals, Inc.
2052	recombinant human alpha-glucosidase conjugated with synthetic bis-mannose-6-phosphate-Man6 glycan	n/a	11/19/2013	Treatment of Pompe Disease	Genzyme, a Sanofi Company
2053	Recombinant human alpha-mannosidase	n/a	2/2/2006	Treatment of alpha-mannosidosis	Zymenex A/S
2054	recombinant human alpha-N-acetylglucosaminidase	n/a	4/15/2013	Treatment of mucopolysaccharidosis IIIB (Sanfilippo B syndrome)	Synageva BioPharma Corp.
2055	recombinant human anti-GDF-8 monoclonal antibody	n/a	7/24/2012	Treatment of Duchenne Muscular Dystrophy.	Pfizer, Inc.
2056	recombinant human antithrombin	Atryn	12/7/2007	Treatment of congenital antithrombin deficiency to prevent the occurrence of serious, potentially life-threatening venous thromboembolisms which may develop as a result of surgical or obstetrical procedures	GTC Biotherapeutics, Inc.
2057	Recombinant human antithrombin III	n/a	4/6/2000	Treatment of antithrombin III dependent heparin resistance requiring anticoagulation.	AT III LLC
2058	recombinant human beta-glucuronidase	n/a	2/16/2012	Treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome)	Ultragenyx Pharmaceutical, Inc.
2059	Recombinant human C1 inhibitor	n/a	6/9/2006	Prevention and/or treatment of delayed graft function after solid organ transplantation	Pharming Group N.V.
2060	Recombinant human C1 inhibitor	n/a	6/9/2006	Treatment of capillary leakage syndrome	Pharming Technologies B.V.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2061	Recombinant human C1-esterase inhibitor	n/a	2/23/1999	Treatment of (acute attacks of) angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming N.V.
2062	Recombinant human C1-esterase inhibitor	n/a	2/23/1999	Prophylactic treatment of angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming N.V.
2063	Recombinant human CD4 immunoglobulin G	n/a	8/30/1990	Treatment of AIDS resulting from infection with HIV-1.	Genentech, Inc.
2064	Recombinant human Clara Cell 10kDa protein	n/a	7/13/1998	Prevention of neonatal bronchopulmonary dysplasia in premature neonates with respiratory distress syndrome.	Clarassance, Inc.
2065	recombinant human coagulation factor VIII Fc fusion protein	n/a	11/23/2010	Treatment of hemophilia A	Biogen Idec Hemophilia, Inc.
2066	recombinant human collagen alpha-1 (VII) chain homo-trimer (rC7)	n/a	3/17/2014	Treatment of dystrophic epidermolysis bullosa	Shire Human Genetic Therapies, Inc.
2067	Recombinant human endostatin protein	n/a	8/13/2001	Treatment of neuroendocrine tumors	EntreMed, Inc.
2068	recombinant human endostatin protein	n/a	2/21/2002	Treatment of metastatic melanoma	EntreMed, Inc.
2069	recombinant human erythropoietin (rHuEPO)	n/a	5/26/2011	Treatment of mutiple myeloma	XTL Biopharmaceuticals, Ltd
2070	Recombinant Human Factor VIIa Variant	n/a	11/30/2012	Routine prophylaxis to prevent bleeding episodes in patients with hemophilia A and B patients with inhibitors	Pfizer, Inc.
2071	Recombinant human fibrinogen	n/a	10/4/2007	Treatment of bleeding in patients deficient in fibrinogen	Pharming Technologies B.V.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2072	recombinant human galactocerebrosidase (rhGALC);	Galaczym	12/12/2011	Treatment of globoid cell leukodystrophy (Krabbe Disease)	ACE BioSciences A/S
2073	Recombinant human gelsolin	n/a	1/12/1994	Treatment of the respiratory symptoms of cystic fibrosis.	BioAegis Therapeutics, Inc.
2074	Recombinant human gelsolin	n/a	3/6/1995	Treatment of acute and chronic respiratory symptoms of bronchiectasis.	BioAegis, Therapeutics, Inc.
2075	Recombinant human glutamic acid decarboxylase 65KDa isoform	n/a	3/22/2010	Treatment of Type I diabetes with residual beta cell function	Diamyd Therapeutics AB
2076	recombinant human GM-CSF, molgramostim	n/a	10/31/2012	Treatment of pulmonary alveolar proteinosis	Serendex ApS
2077	recombinant human growth hormone in an ocular delivery system	n/a	12/3/2012	Treatment of persistent corneal epithelial defects	Jade Therapeutics LLC
2078	Recombinant human granulocyte colony stimulating factor	n/a	7/24/2006	Prevention of implantation failure	Nora Therapeutics, Inc.
2079	Recombinant human highly phosphorylated acid alpha-glucosidase	Tbd	9/20/2000	For enzyme replacement therapy in patients with all subtypes of glycogen storage disease type II (GSDII, Pompe Disease)	Novazyme Pharmaceuticals, Inc.
2080	Recombinant human highly phosphorylated alpha-L-iduronidase (rhHP-IDUA)	n/a	4/11/2001	Enzyme replacement therapy in patients with all subtypes of Mucopolysaccharidosis I.	Novazyme Pharmaceuticals, Inc.
2081	recombinant human histone H1.3; recombinant human N-bis-met-histone H1.3	Oncohist	10/20/2008	Treatment of acute myeloid leukemia	Xenetic Biosciences Plc
2082	recombinant human IgG1 monoclonal antibody	n/a	12/14/2009	Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets)	Ultragenyx Pharmaceutical, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2083	Recombinant human insulin-like growth factor-I	Pv802	2/16/2000	Treatment of short-bowel syndrome as a result of resection of the small bowel or as a result of congenital dysfunction of the intestines.	GroPep Pty Ltd.
2084	Recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein-3	n/a	6/15/1999	Treatment of major burns that require hospitalization.	Insmed, Inc.
2085	Recombinant human interleukin-12	n/a	10/20/1997	Treatment of renal cell carcinoma.	Genetics Institute, Inc.
2086	Recombinant Human Interleukin-21 (rIL-21)	n/a	10/4/2005	Treatment of stage II (T4), III or IV malignant melanoma.	Zymo Genetics, Inc
2087	Recombinant human keratinocyte growth factor	n/a	12/20/1999	Reducing the incidence and severity of radiation-induced xerostomia.	Swedish Orphan Biovitrum AB (publ) (SOBI)
2088	recombinant human lecithin:cholesterol acyltransferase (rhLCAT)	n/a	9/2/2010	Treatment of LCAT deficiency syndromes	AlphaCore Pharma, LLC
2089	Recombinant human luteinizing hormone	Luveris	10/7/1994	For use in association with recombinant human follicle stimulating hormone for the treatment of women with chronic anovulation due to hypogonadotropic hypogonadism.	EMD Serono, Inc.
2090	Recombinant human lysosomal acid lipase or cholesteryl ester hydrolase	Cholestase	7/14/2005	Treatment of lipase deficiencies, including Wolman Disease and cholesteryl ester storage disease	Lysosomal Acid Lipase, LLC
2091	Recombinant human microplasmin	n/a	1/23/2006	Treatment of peripheral arterial occlusion	ThromboGenics Ltd

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2092	recombinant human minibody against complement component	n/a	6/7/2011	Treatment of atypical hemolytic uremic syndrome associated with an inherited abnormality of the complement system.	Adienne S.r.l
2093	recombinant human minibody against complement component C5	Mubodina	2/4/2009	Treatment of primary membranoproliferative glomerulonephritis	Adienne S.r.l.
2094	recombinant human minibody against complement component C5 fused with RGD-motif	n/a	2/4/2009	Prevention of ischemia/reperfusion injury associated with solid organ transplantation.	Adienne S.r.l.
2095	recombinant human monoclonal antibody against activin receptors type II	n/a	6/18/2012	Treatment of inclusion body myositis	Novartis Pharmaceuticals Corp.
2096	recombinant human monoclonal antibody to hsp90	Mycograb	9/16/2002	Treatment of invasive candidiasis	Novartis Pharmaceuticals Corp.
2097	recombinant human monoclonal IgM antibody targeting glucose regulated protein 78	n/a	10/25/2013	Treatment of multiple myeloma	Patrys Ltd.
2098	recombinant human Naglu- insulin-like growth factor II	n/a	3/5/2013	Treatment of mucopolysaccharidosis type IIIB (Sanfilippo syndrome type B)	Shire Human Genetic Therapies, Inc.
2099	Recombinant human nerve growth factor	n/a	4/16/1999	Treatment of HIV-associated sensory neuropathy.	Genentech, Inc.
2100	recombinant human nerve growth factor	n/a	8/8/2013	Treatment of retinitis pigmentosa	Dompe s.p.a.
2101	recombinant human neutrophil inhibitor (hNE)	n/a	12/9/2003	Treatment of cystic fibrosis	Dyax Corporation
2102	recombinant human Pentraxin-2; recombinant human Serum Amyloid P	n/a	2/17/2012	Treatment of idiopathic pulmonary fibrosis.	Promedior, Inc.
2103	Recombinant human platelet derived growth factor BB	n/a	2/1/2007	Treatment of osteonecrosis of the jaws	Luitpold Pharmaceuticals, Inc.
2104	recombinant human platelet derived growth factor-BB	n/a	8/6/2010	Treatment of osteochondritis dissecans	Biomimetic Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2105	recombinant human porphobilinogen deaminase	Porphozyme	9/9/2002	Treatment of acute intermittent porphyria attacks	Zymenex A/S
2106	recombinant human porphobilinogen deaminase, erythropoetic form	n/a	7/11/2002	Treatment of acute intermittent porphyria preventing attacks	ZymenexA/S
2107	recombinant human proinsulin (Including rhPI-Methionine)	n/a	12/10/2008	Treatment of retinitis pigmentosa	ProRetina Therapeutics, S.L.
2108	recombinant human rod-derived cone viability factor	n/a	1/7/2008	Treatment of retinitis pigmentosa	Fovea Pharmaceuticals
2109	Recombinant Human soluble Fc-gamma Receptor IIb	n/a	3/22/2010	Treatment of idiopathic thrombocytopenic purpura	SuppreMol GmbH
2110	Recombinant human thrombopoietin	n/a	9/29/1997	For use in accelerating platelet recovery in patients undergoing hematopoietic stem cell transplantation.	Genentech, Inc.
2111	recombinant human tripeptidyl-peptidase 1 (rhTPP1)	n/a	4/1/2013	Treatment of neuronal ceroid lipofuscinosis type 2	BioMarin Pharmaceutical, Inc.
2112	recombinant human type I pancreatic elastase	n/a	4/3/2009	Prevention of arteriovenous fistula maturation and arteriovenous graft failure in patients with end stage renal disease who are receiving hemodialysis or preparing for hemodialysis	Proteon Therapeutics, Inc.
2113	recombinant human type VII collagen	n/a	6/18/2008	Treatment of hereditary dystrophic epidermolysis bullosa (DEB)	David T. Woodley, MD and Mei Chen, MD
2114	recombinant human vascular endothelial growth factor	n/a	6/7/2010	Treatment of amyotrophic lateral sclerosis	NeuroNova AB
2115	Recombinant humanized anti-LOXL2 monoclonal antibody	n/a	4/18/2011	Treatment of idiopathic pulmonary fibrosis	Gilead Sciences, Inc.
2116	Recombinant humanized anti-LOXL2 monoclonal antibody, IgG4(S241P)	n/a	6/1/2011	Treatment of myelofibrosis.	Gilead Sciences, Inc.
2117	recombinant humanized anti-LOXL2 monoclonal antibody, IgG4(S241P)	n/a	5/17/2011	Treatment of pancreatic cancer.	Gilead Sciences, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2118	recombinant humanized IgG1k monoclonal antibody to human invariant T cell receptor (iTCR)	n/a	4/12/2013	Treatment of sickle cell disease	NKT Therapeutics, Inc.
2119	Recombinant humanized MAb 5c8	n/a	3/22/1999	Prevention of rejection of pancreatic islet cell transplants.	Biogen, Inc.
2120	Recombinant humanized MAb 5c8	n/a	10/14/1998	Prevention and treatment of Factor VIII/Factor IX inhibitors in patients with hemophilia A or B.	Biogen, Inc.
2121	Recombinant humanized MAb 5c8	n/a	3/22/1999	Prevention of rejection of solid organ transplants.	Biogen, Inc.
2122	Recombinant humanized monoclonal antibody 5c8	n/a	2/3/1998	Treatment of immune thrombocytopenic purpura.	Biogen, Inc.
2123	Recombinant humanized monoclonal antibody 5c8	n/a	2/18/1998	Treatment of systemic lupus erythematosus.	Biogen, Inc.
2124	Recombinant humanized monoclonal antibody directed against an epidermal growth factor receptor	n/a	2/17/2012	Treatment of glioblastoma multiforme (GBM).	AbbVie, Inc.
2125	recombinant humanized monoclonal antibody of the immunoglobulin G1 subclass directed against colony stimulating factor-1 receptor expressed on macrophages	n/a	5/14/2014	Treatment of pigmented villonodular synovitis and tenosynovial giant cell tumor	Genentech, Inc.
2126	recombinant IgA protease of bacterium Heamophilus influenzae	n/a	4/18/2011	Treatment of immunoglobulin A nephropathy (IgAN, Berger's disease).	Shire Human Genetics Therapies
2127	Recombinant immunotoxin combining the functional components of antibody against mesothelin and the enzymatic activity of a pseudomonas exotoxin	n/a	2/11/2002	Treatment of epithelial ovarian cancer	National Institutes of Health
2128	Recombinant immunotoxin combining the functional components of antibody against mesothelin and the enzymatic activity of a pseudomonas exotoxin	n/a	2/11/2002	Treatment of malignant mesothelioma	National Institutes of Health

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2129	recombinant kallikrein inhibitor	n/a	11/23/2010	Treatment of Netherton Syndrome.	Dermadis SA
2130	recombinant lens epithelium derived growth factor 1-326	n/a	5/19/2014	Treatment of retinitis pigmentosa	Ocugen, Inc.
2131	Recombinant methionyl brain-derived neurotrophic factor	n/a	11/28/1994	Treatment of amyotrophic lateral sclerosis.	Amgen, Inc.
2132	recombinant ovine interferon tau	Tauferon	1/25/2005	Treatment of pediatric multiple sclerosis	PEPGEN Corporation
2133	Recombinant Porcine Factor VIII, B-domain Deleted	n/a	3/16/2004	Treatment and prevention of episodic bleeding in patients with inhibitor antibodies to human coagulation factor VIII	Baxter Healthcare Corporation, Baxter BioScience
2134	Recombinant P-Selectin glycoprotein ligand	n/a	3/29/2006	Prevention of delayed graft function in renal transplant patients	Y's Therapeutics, Inc.
2135	Recombinant P-selectin glycoprotein ligand-immunoglobulin Ig	n/a	7/26/2007	Prevention of ischemia reperfusion injury in all solid organ transplants	Y's Therapeutics, Inc.
2136	Recombinant replication deficient adenovirus vector carrying human p53 gene	n/a	4/12/1999	Treatment of primary ovarian cancer.	Schering Corporation
2137	Recombinant retroviral vector - glucocerebrosidase	n/a	11/15/1993	For use as enzyme replacement therapy for patients with types I, II, or III Gaucher disease.	Genetic Therapy, Inc.
2138	Recombinant secretory leucocyte protease inhibitor	n/a	3/29/1991	Treatment of cystic fibrosis.	Amgen, Inc.
2139	Recombinant soluble human CD4 (rCD4)	n/a	3/23/1989	Treatment of AIDS in patients infected with HIV virus.	Genentech, Inc.
2140	Recombinant T-cell receptor ligand	n/a	5/2/2003	Treatment of multiple sclerosis patients who are both HLA-DR2 positive and autoreactive to myelin oligodendrocyte glycoprotein residues 35-55	Artielle ImmunoTherapeutics, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2141	recombinant thymidine phosphorylase encapsulated with autologous erythrocytes	n/a	12/13/2010	Treatment of mitochondrial neurogastrointestinal encephalomyopathy due to thymidine phosphorylase deficiency.	St. George's University of London
2142	Recombinant truncated SPINT2 protease inhibitor	n/a	6/24/2005	Treatment of cystic fibrosis	Aerovance, Inc.
2143	Recombinant urate oxidase	n/a	10/11/2000	Prophylaxis of chemotherapy-induced hyperuricemia.	Sanofi-Synthelabo Research
2144	recombinant von Willebrand factor (rhVWF)	n/a	11/23/2010	Treatment of von Willebrand disease.	Baxter Healthcare Corporation
2145	Reduced L-glutathione	Cachexon	2/14/1994	Treatment of AIDS-associated cachexia.	Telluride Pharmaceutical Corporation
2146	refanalina	n/a	5/25/2010	To improve renal function and prevent delayed graft function following renal transplantation	Angion Biomedica Corporation
2147	regorafenib	Stivarga	1/12/2011	Treatment gastrointestinal stromal tumors	Bayer HealthCare Pharmaceuticals, Inc.
2148	REMUNE HIV 1	n/a	2/14/2014	Treatment of pediatric HIV/AIDS (age through 16 years)	Immune Response BioPharma, Inc.
2149	reparixin	n/a	9/25/2012	Prevention of graft loss in pancreatic islet transplantation	Dompe S.p.A.
2150	reparixin	n/a	1/27/2003	Prevention of delayed graft function in solid organ transplant	Dompe S.p.A.
2151	Replication defective recombinant adenovirus serotype 5 vector carrying the p53 gene in its E1 deleted region	Advexin	1/27/2003	Treatment of head and neck cancer	Introgen Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2152	replication-deficient recombinant serotype 2 adeno-associated viral vector containing hAQP1 cDNA	n/a	5/3/2013	Treatment of symptoms of Grade 2 and Grade 3 late xerostomia from parotid gland hypofunction caused by radiotherapy for cancer of the oral cavity.	John A. Chiorini, PhD
2153	Replication-incompetent GM-CSF-expressing gene-modified allogeneic acute myeloid leukemia cancer cell lines	Gvax Acute Myeloid Leukemia	3/2/2010	Treatment of acute myeloid leukemia	Aduro BioTech, Inc.
2154	Replication-incompetent GM-CSF-expressing gene-modified allogeneic chronic myeloid leukemia cancer cell lines	Gvax Chronic Myeloid Leukemia	4/30/2010	Treatment of chronic myeloid leukemia	Aduro BioTech, Inc.
2155	Replication-incompetent GM-CSF-expressing gene-modified allogeneic pancreatic cancer cell lines	Gvax Pancreas	3/1/2010	Treatment of pancreatic cancer.	Aduro BioTech, Inc.
2156	repository corticotropin injection	H.P. Acthar Gel	6/28/2013	Treatment of amyotrophic lateral sclerosis	Questor Pharmaceuticals, Inc.
2157	repository corticotropin or adrenocorticotrophic hormone	H.P. Acthar Gel	5/21/2003	Treatment of infantile spasms	Questcor Pharmaceuticals, Inc.
2158	resiniferatoxin	n/a	5/13/2003	Treatment of intractable pain at end-stage disease	Sorrento Therapeutics, Inc.
2159	reslizumab	Cinquil	1/12/2011	Treatment of hypereosinophilic syndrome	Teva Pharmaceuticals, Inc.
2160	reslizumab	n/a	12/19/2007	Treatment of children with eosinophilic esophagitis	Cephalon, Inc.
2161	resminostat	n/a	9/16/2011	Treatment of Hodgkin's lymphoma.	4SC AG
2162	resminostat	n/a	6/29/2011	Treatment of hepatocellular carcinoma	4SC AG
2163	Respiratory Syncytial Virus Immune Globulin (human)	Hyperimmune Rsv	9/27/1990	Treatment of respiratory syncytial virus lower respiratory tract infections in hospitalized infants and young children.	MedImmune, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2164	Respiratory syncytial virus immune globulin (Human)	Respigam	9/27/1990	Prophylaxis of respiratory syncytial virus lower respiratory tract infections in infants and young children at high risk of RSV disease.	MedImmune & Massachusetts Public Health Biologics Labs.
2165	retroviral gamma-c cDNA containing vector	n/a	4/29/2002	Treatment of X linked severe combined immune deficiency disease	AVAX technologies, Inc.
2166	Reversal agent linked to chloroquine-like moiety	n/a	3/26/2010	Treatment of malaria	DesignMedix
2167	Revimmune	n/a	2/18/2011	Treatment of autoimmune hemolytic anemia.	Accentia Biopharmaceuticals
2168	Reviparin sodium	Clivarine	6/18/2001	Treatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients	Abbott
2169	Reviparin sodium	Clivarine	6/18/2001	Long-term treatment of acute deep vein trombosis with or without pulmonary embolism in pregnant patients	Abbott
2170	rhIGF-I/rhIGFBP-3	Somatokine	12/9/2003	Treatment of extreme insulin resistance syndromes (type A, Rabson-Mendenhall syndrome, Leprechaunism, Type B syndrome)	Insmmed, Inc.
2171	rh-microplasmin, ocriplasmin	Jetrea	3/16/2004	Adjunct to surgery in cases of pediatric vitrectomy	ThromboGenics Inc.
2172	Rho (D) immune globulin intravenous (human)	Winrho Sd	11/9/1993	Treatment of immune thrombocytopenic purpura.	Rh Pharmaceuticals, Inc.
2173	ribavirin	Virazole	4/12/1991	Treatment of hemorrhagic fever with renal syndrome	Valeant Pharmaceuticals International
2174	ribavirin	Rebetol	4/4/2003	Treatment of chronic hepatitis C in pediatric patients	Schering Corporation

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2175	ribavirin elaidate	n/a	9/2/2011	Treatment of follicular, medullary, and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer	Translational Therapeutics, Inc.
2176	riboflavin ophthalmic solution & ultraviolet A	n/a	9/2/2011	Treatment of keratoconus	Avedro, Inc.
2177	riboflavin ophthalmic solution ultraviolet-A (UVA) irradiation	n/a	12/2/2011	Treatment of corneal ectasia following refractive surgery	Avedro, Inc.
2178	Ricin (blocked) conjugated murine MCA (anti-B4)	n/a	11/17/1988	Treatment of B-cell leukemia and B-cell lymphoma.	ImmunoGen, Inc.
2179	Ricin (blocked) conjugated murine mca (anti-b4)	n/a	1/24/1991	For the ex-vivo purging of leukemic cells from the bone marrow of non-T cell acute lymphocytic leukemia patients who are in complete remission.	ImmunoGen, Inc.
2180	Ricin (blocked) conjugated murine MCA (anti-my9)	n/a	2/1/1990	For use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia.	ImmunoGen, Inc.
2181	Ricin (blocked) conjugated murine MCA (anti-my9)	n/a	8/3/1989	Treatment of myeloid leukemia, including AML, and blast crisis of CML.	ImmunoGen, Inc.
2182	Ricin (blocked) conjugated murine MCA (n901)	n/a	1/25/1991	Treatment of small cell lung cancer	ImmunoGen, Inc.
2183	Ricin (blocked) conjugated murine monoclonal antibody (CD6)	n/a	9/6/1994	Treatment of cutaneous T-cell lymphomas, acute T-cell leukemia-lymphoma, and related mature T-cell malignancies.	ImmunoGen, Inc.
2184	ricin vaccine	Rivax(R)	1/7/2011	Prevention of ricin intoxication.	Soligenix, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2185	Rifabutin	n/a	12/18/1989	Treatment of disseminated Mycobacterium avium complex disease.	Pfizer, Inc.
2186	Rifabutin	Mycobutin	12/18/1989	Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.	Adria Laboratories, Inc.
2187	Rifalazil	n/a	4/13/1999	Treatment of pulmonary tuberculosis.	PathoGenesis Corporation
2188	Rifampin	Rifadin I.V.	12/9/1985	For antituberculosis treatment where use of the oral form of the drug is not feasible.	Hoechst Marion Roussel
2189	Rifampin, isoniazid, pyrazinamide	Rifater	9/12/1985	For the short-course treatment of tuberculosis.	Hoechst Marion Roussel
2190	Rifapentine	Priftin	6/9/1995	Treatment of Mycobacterium avium complex in patients with AIDS.	Hoechst Marion Roussel , Inc.
2191	Rifapentine	Priftin	3/12/1996	Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.	Hoechst Marion Roussel, Inc.
2192	Rifapentine	Priftin	6/9/1995	Treatment of pulmonary tuberculosis.	Hoechst Marion Roussel
2193	rifaximin	Normix	2/10/1998	Treatment of hepatic encephalopathy	Salix Pharmaceuticals, Inc.
2194	rigisertib	n/a	3/18/2011	Treatment of pancreatic cancer.	Onconova Therapeutics, Inc
2195	rigisertib	n/a	9/3/2009	Treatment of myelodysplastic syndromes	Onconova Therapeutics, Inc.
2196	rigosertib	n/a	3/16/2012	Treatment of ovarian cancer	Onconova Therapeutics, Inc.
2197	RII retinamide	n/a	5/6/1993	Treatment of myelodysplastic syndromes.	Sparta Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2198	rilonacept	Arcalyst	1/9/2013	Treatment of familial Mediterranean fever	Philip J Hashkes, MD, MSc.
2199	Rilonacept	Arcalyst	12/20/2004	Treatment of CIAS1-Associated Periodic Syndromes	Regeneron Pharmaceuticals, Inc.
2200	rilotumumab	n/a	6/18/2012	Treatment of gastric cancer including gastroesophageal junction adenocarcinoma	Amgen, Inc.
2201	Riluzole	Rilutek	10/15/1996	Treatment of Huntington's disease.	Rhone-Poulenc Rorer Pharmaceuticals, Inc.
2202	Riluzole	Rilutek	3/16/1993	Treatment of amyotrophic lateral sclerosis.	Rhone-Poulenc Rorer Pharmaceuticals, Inc.
2203	rindopepimut	n/a	11/19/2007	Treatment of EGFRvIII-expressing glioblastoma multiforme	CellDex Therapeutics, Inc.
2204	riociguat	Adempas	9/19/2013	Treatment of chronic thromboembolic pulmonary hypertension	Bayer HealthCare Pharmaceuticals, Inc.
2205	riociguat	Adempas	9/19/2013	Treatment of pulmonary arterial hypertension.	Bayer HealthCare Pharmaceuticals, Inc.
2206	rituximab	Rituxan	3/12/2002	Treatment of immune thrombocytopenic purpura	Genentech, Inc.
2207	rituximab	Rituxan	2/14/2006	Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)	Genentech, Inc.
2208	rituximab	Rituxan	1/29/2004	Treatment of chronic lymphocytic leukemia	Genentech, Inc.
2209	rituximab	Rituxan	6/13/1994	Treatment of non-Hodgkin's B-cell lymphoma	Genentech, Inc.
2210	rofecoxib	Vioxx	3/16/2004	Treatment of juvenile rheumatoid arthritis	MERCK & Co., Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2211	romidepsin	Istodax	9/30/2004	Treatment of non-Hodgkin T-cell lymphomas	Celgene Corporation
2212	romiplostim	n/a	10/31/2007	Treatment of thrombocytopenia associated with myelodysplasia syndrome	Amgen Inc.
2213	romiplostim	Nplate	3/27/2003	Treatment of immune thrombocytopenic purpura	Amgen, Inc.
2214	Rose Bengal Disodium	n/a	12/20/2006	Treatment of metastatic melanoma	Provectus Pharmaceuticals, Inc.
2215	rosuvastatin	Crestor	2/14/2014	For the treatment of pediatric homozygous familial hypercholesterolemia	AstraZeneca Pharmaceuticals LP
2216	rozrolimupab	n/a	9/13/2010	Treatment of primary immune thrombocytopenia.	Symphogen A/S
2217	rsATP7A cDNA	n/a	1/10/2014	Treatment of Menkes disease	Stephen G. Kaler, MD
2218	rSP-C lung surfactant	Venticute	4/3/2000	Treatment of adult respiratory distress syndrome.	Byk Gulden Pharmaceuticals
2219	rSP-C surfactant	Venticute	9/18/2006	For use in patients with pneumonia or aspiration of gastric contents leading to intubation, mechanical ventilation, and severe oxygen impairment	Altana Pharma
2220	rubitecan	n/a	7/17/2002	Treatment of pediatric patients infected with human immunodeficiency virus and acquired immunodeficiency syndrome	SuperGen, Inc.
2221	rucaparib	n/a	7/31/2012	Treatment of ovarian cancer	Clovis Oncology, Inc.
2222	rufinamide	Banzel	10/8/2004	Treatment of Lennox-Gastaut Syndrome.	Eisai, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2223	ruxolitinib	Jakafi	8/16/2013	Treatment of pancreatic cancer	Incyte Corporation
2224	ruxolitinib phosphate	Jakafi	3/26/2010	Treatment of polycythemia vera	Incyte Corporation
2225	ruxolitinib phosphate	Jakafi	3/22/2010	Treatment of essential thrombocythemia	Incyte Corporation
2226	ruxolitinib phosphate	Jakafi	9/5/2008	Treatment of myelofibrosis	Incyte Corporation
2227	rVIIa-FP	n/a	12/22/2011	Treatment and prophylaxis of bleeding episodes in patients with congenital hemophilia and inhibitors to coagulation factor VIII or IX	CSL Behring
2228	S(-)-3-[3-amino-phthalimido]-glutaramide	n/a	3/14/2002	Treatment of multiple myeloma	EntreMed Incorporated
2229	S-[2,3-bispalmitoyloxy-(2R)-propyl]-cysteinyl-GNNDENISFKEK	n/a	10/20/2009	Treatment of pancreatic cancer	MBiotec GmbH
2230	S-59 treated FFP (plasma treated with amotosalen hydrochloride & ultraviolet A light	Intercept Blood System For	2/14/2011	Treatment of thrombotic thrombocytopenic purpura	Cerus Corporation
2231	Sacrosidase	Sucraid	12/10/1993	Treatment of congenital sucrase-isomaltase deficiency	QOL Medical, LLC
2232	S-adenosylmethionine	n/a	4/30/1998	Treatment of AIDS-myelopathy.	Genopia USA, Inc.
2233	salicylic acid 6%	n/a	2/17/2012	Treatment of rare congenital ichthyoses.	Orenova Group, LLC
2234	salirasib	n/a	12/18/2006	Treatment of pancreatic cancer.	Kadmon Corporation, LLC
2235	salmeterol xinafoate/fluticasone propionate	n/a	10/29/2009	Treatment of symptomatic exophthalmos associated with thyroid related eye disease.	Lithera, Inc.
2236	sapropterin	Kuvan	1/29/2004	Treatment of hyperphenylalaninemia	Biomarin Pharmaceutical Inc.
2237	Sar9, Met(O2)11-Substance P	Homspera	3/16/2011	Treatment of idiopathic pulmonary fibrosis	ImmuneRegen BioSciences, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2238	sarcosine	n/a	10/12/2011	Treatment of obsessive compulsive disorder in pediatric patients (0 to 16 years of age)	Guochuan Emil Tsai, MD, PhD
2239	Sargramostim	Leukine	3/6/1995	To reduce neutropenia and leukopenia and decrease the incidence of death due to infection in patients with acute myelogenous leukemia.	Immunex Corporation
2240	Sargramostim	Leukine	5/3/1990	Treatment of neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment.	Immunex Corporation
2241	Satumomab pendetide	Oncoscint Cr/Ov	9/25/1989	Detection of ovarian carcinoma.	Cytogen Corporation
2242	SC-1 monoclonal antibody	n/a	11/12/2003	Treatment of patients with CD55 (sc-1) positive gastric tumors	Patrys Limited
2243	SDF-1 (108) Lysine Dimer	n/a	7/7/2005	Treatment of osteogenic sarcoma	Chemokine Therapeutics Corporation
2244	sdTD-K6a.513a.12; small interfering RNA composed of 2 strands of hybridized RNAs	n/a	4/15/2013	Treatment of pachyonychia congenita	TransDerm, Inc.
2245	Secalciferol	Osteo-D	7/26/1993	Treatment of familial hypophosphatemic rickets.	Teva Pharmaceuticals USA
2246	Secretory leukocyte protease inhibitor	n/a	6/30/1992	Treatment of bronchopulmonary dysplasia.	Synergen, Inc.
2247	secukinumab	n/a	3/26/2010	Adjunctive treatment of chronic non-infectious uveitis requiring systemic immunosuppression	Novartis Pharmaceutical Corporation

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2248	selective antagonist of the chemokine receptor type 4	n/a	9/5/2013	Treatment of acute myeloid leukemia	BioLineRx, Ltd.
2249	selective deacylglycerol acyltransferase 1 inhibitor	n/a	3/28/2011	Treatment of hypertriglyceridemia in te setting of Type I hyperlipoproteinemia, also known as Familial Chylomicronema Syndrome	Novartis Pharmaceuticals Corporation
2250	Selective inhibitor of polymorphonuclear leukocyte (PMN) elastase	n/a	6/4/1996	Therapeutic management of patients with lung disease attributable to cystic fibrosis.	DuPont Pharmaceuticals Company
2251	Selegiline HCl	Eldepryl	11/7/1984	As an adjuvant to levodopa and carbidopa treatment of idiopathic Parkinson's disease (paralysis agitans), postencephalitic Parkinsonism, and symptomatic Parkinsonism.	Somerset Pharmaceuticals, Inc.
2252	self-complimentary adeno-associated virus vector, serotype 9, packaging the full lenght GAN gene in the viral capsid	n/a	9/27/2013	Treatment of Giant Axonal Neuropathy	Hannah's Hope Fund
2253	Selinexor; (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(pyrazin-2-yl)acrylohydrazide	n/a	5/14/2014	Treatment of acute myeloid leukemia	Karyopharm Therapeutics, Inc.
2254	selisistat	n/a	12/7/2009	Treatment of Huntington's disease	Siena Biotech SpA
2255	Seneca Valley virus	n/a	8/22/2008	Treatment of neuroendocrine tumors	Neotropix, Inc.
2256	Sermorelin acetate	Geref	9/14/1988	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	EMD Serono, Inc.
2257	Serratia marcescens extract (polyribosomes)	Imuvert	9/7/1988	Treatment of primary brain malignancies.	Cell Technology, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2258	Short chain fatty acid enema	Colomed	8/19/1997	Treatment of chronic radiation proctitis.	Richard I. Breuer, M.D.
2259	Short chain fatty acid solution	Colomed	5/29/1990	Treatment of the active phase of ulcerative colitis with involvement restricted to the left side of the colon.	Richard I. Breuer
2260	sialic acid	n/a	9/23/2011	Treatment of hereditary inclusion body myopathy.	Ultragenyx Pharmaceutical, Inc.
2261	sildenafil	Revatio	7/28/2011	Treatment of pediatric (defined as children less than 17 years of age) pulmonary arterial hypertension	Pfizer, Inc.
2262	Silibinin-C-2',3-dihydrogensuccinate, disodium salt	Legalon Sil	2/17/2012	Prevention of recurrent hepatitis C in liver transplant patients	Rottapharm S.p.A.
2263	siltuximab	n/a	10/11/2005	Treatment of multiple myeloma	Janssen Research & Development, LLC
2264	siltuximab	Sylvant	5/26/2006	Treatment of Castleman's disease	Janssen Biotech, Inc.
2265	Silver sulfadiazine and cerium nitrate	Flammacerium	11/17/1999	Treatment of patients with severe dermal burns	Sinclair Pharmaceuticals Ltd
2266	Siponimod	n/a	11/26/2013	Treatment of polymyositis	Novartis Pharmaceuticals Corporation
2267	sirolimus	n/a	3/18/2013	Treatment of pachyonychia congenita	TransDerm, Inc.
2268	sirolimus	Rapamune(R)	10/31/2012	Treatment of lymphangioleiomyomatosis	Pfizer, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2269	sirolimus	n/a	11/4/2011	Treatment of chronic/refractory anterior noninfectious uveitis, noninfectious intermediate uveitis, noninfectious panuveitis and non-infectious, uveitis affecting the posterior of the eye (NICUPS).	Santen Inc.
2270	sirolimus in an implantable collagen matrix	Coll-R, Sirogen	5/10/2012	Prevention of arteriovenous(AV) fistula or AV graft failure in patients with end stage renal disease, receiving hemodialysis or preparing for hemodialysis	Vascular Therapies, LLC
2271	Sitaxsentan Sodium	n/a	11/2/2004	For the treatment of pulmonary arterial hypertension in the absence of chronic obstructive pulmonary disease or congestive heart failure.	Pfizer Global Research and Development
2272	siimagene ceradenovec	Cerepro	7/31/2001	Use with gancyclovir in the treatment of malignant glioma	Finvector Vision Therapies Ltd
2273	skin tissue	Stratagraft	5/21/2012	Treatment of hospitalized patients with complex skin defects resulting from partial and full thickness skin burns requiring excision and grafting	Stratatech Corporation
2274	small molecule inhibitor of histone methyltransferase DOT1L	n/a	8/8/2013	Treatment of acute lymphoblastic leukemia (ALL)	Epizyme Inc.
2275	small molecule inhibitor of phosphodiesterase 10	n/a	9/26/2013	Treatment of Huntington's disease	Omeros Corporation

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2276	smilagenin	Cogane	7/21/2011	Treatment of amyotrophic lateral sclerosis	Junaxo, Inc.
2277	S-nitroglutathione	n/a	5/12/2009	Management of cystic fibrosis patients to improve airway clearance and to improve or stabilize pulmonary function	N30 PHARMAceuticals, LLC
2278	S-nitrosoglutathione	n/a	12/28/2012	Treatment of severe pre-eclampsia	Salupont Consulting Ltd
2279	sobetirome	n/a	4/29/2011	Treatment of X-linked adrenoleukodystrophy	EndoChem, Inc.
2280	sodium 2, 2 dimethylbutyrate	n/a	7/25/2008	Treatment of sickle cell disease.	HemaQuest Pharmaceuticals, Inc.
2281	sodium 4-{ [9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-d] [2] benzazepin-2-yl]-2-methoxybenzoate	n/a	4/3/2009	Treatment of ovarian cancer	Millennium Pharmaceuticals, Inc.
2282	sodium 4-phenylbutyrate	n/a	10/18/2011	Treatment of spinal muscular atrophy	GMP-Orphan SAS
2283	Sodium aluminosilicate	n/a	3/4/2005	Treatment of chronic hepatic encephalopathy	Framework Therapeutics, LLC
2284	Sodium ascorbate and menadione sodium bisulfite	Apatone	7/31/2007	Treatment of metastatic or locally advanced inoperable transitional cell carcinoma of the urothelium (stage III and IV bladder cancer)	IC-MedTech Corporation
2285	sodium ascorbate and menadione sodium bisulfite	Apatone(R)	4/15/2013	Treatment of autosomal dominant polycystic liver disease	IC-Medtech Corporation
2286	sodium ascorbate and menadione sodium bisulfite	Apatone	4/15/2013	Treatment of autosomal dominant polycystic kidney disease	IC-MedTech Corporation
2287	sodium benzoate and clozapine	n/a	12/22/2011	Treatment of treatment-resistant schizophrenia	Guochuan Emil Tsai, MD, PhD
2288	sodium chlorite	n/a	8/22/2011	For slowing the progression of amyotrophic lateral sclerosis.	Neuraltus Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2289	Sodium dichloroacetate	n/a	11/10/1994	Treatment of lactic acidosis in patients with severe malaria.	Stacpoole, Peter W. M.D., Ph.D.
2290	Sodium dichloroacetate	n/a	6/11/1990	Treatment of congenital lactic acidosis	Stacpoole, Peter W. M.D., Ph.D.
2291	Sodium dichloroacetate	n/a	6/11/1990	Treatment of homozygous familial hypercholesterolemia.	Stacpoole, Peter W. M.D., Ph.D.
2292	sodium dichloroacetate	n/a	7/3/2003	Use as an antidote in the management of systemic monochloroacetic acid poisoning	EBD Group
2293	sodium dichloroacetate	n/a	11/29/2010	For pulmonary arterial hypertension.	Peter W. Stackpoole, PhD, MD
2294	sodium fusidate	n/a	10/23/2013	Treatment of patients with prosthetic joint infections	Cempra Pharmaceuticals, Inc.
2295	Sodium Monomercaptoundecahydro-closododecaborate	Borocell	4/15/1992	For use in boron neutron capture therapy (BNCT) in the treatment of glioblastoma multiforme.	Neutron Technology Corp.& Neutron R&D Partner
2296	sodium nitrate	n/a	1/9/2012	Treatment of chlorine gas poisoning	Hope Pharmaceuticals
2297	Sodium nitrite	n/a	1/17/2007	Prevention of vasospasm associated with subarachnoid hemorrhage	Hope Pharmaceuticals
2298	Sodium nitrite	n/a	4/18/2007	Treatment of cyanide poisoning	Hope Pharmaceuticals
2299	Sodium nitrite	n/a	4/2/2007	Treatment of vaso-occlusive crisis associated with sickle cell disease	Hope Pharmaceuticals
2300	sodium nitrite	n/a	9/3/2009	Prevention of ischemia reperfusion injury to donor organ tissue associated with solid organ transplantation	Hope Pharmaceuticals
2301	sodium nitrite	n/a	7/8/2008	Treatment of pulmonary arterial hypertension	Aires Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2302	sodium nitrite and sodium thiosulfate	Nithiodote	4/9/2008	Treatment of known or suspected cyanide poisoning	Hope Pharmaceuticals
2303	Sodium nitrite/sodium thiosulfate	Cyanide Antidote Package	3/23/2007	Treatment of cyanide poisoning	Keystone Pharmaceuticals, Inc.
2304	Sodium phenylacetate/sodium benzoate 10%/10% Injection	Ammonul(R)	6/3/2005	Treatment of grade III and IV hepatic encephalopathy	Ucyclyd Pharma, Inc.
2305	Sodium phenylbutyrate	n/a	4/24/1998	For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Elan Drug Delivery, Inc.
2306	Sodium phenylbutyrate	n/a	3/20/2007	Treatment of spinal muscular atrophy	Tikvah Therapeutics, Inc.
2307	Sodium phenylbutyrate	Buphenyl	1/25/2007	Treatment of spinal muscular atrophy	OrphaMed, Inc.
2308	sodium phenylbutyrate	n/a	1/19/2010	Treatment of urea cycle disorder.	Navinta LLC
2309	sodium phenylbutyrate	n/a	7/2/1992	Treatment for sickling disorders, which include S-S hemoglobinopathy, S-C hemoglobinopathy, and S-thalassemia hemoglobinopathy.	Medicis Pharmaceutical Corp.
2310	sodium phenylbutyrate	Pheburane	6/6/2013	Treatment of urea cycle disorders	Lucane Pharma SA
2311	sodium phenylbutyrate	Buphenyl	11/22/1993	Treatment of urea cycle disorders: carbamylphosphate synthetase deficiency, ornithine transcarbamylase deficiency, and arginiosuccinic acid synthetase deficiency.	Medicis Pharmaceutical Corp.
2312	Sodium pyruvate	n/a	3/31/2003	Treatment of cystic fibrosis	Cellular Sciences, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2313	Sodium stibogluconate	n/a	6/16/2006	Treatment of cutaneous leishmaniasis	VioQuest Pharmaceuticals, Inc.
2314	sodium stibogluconate	n/a	10/28/2009	Treatment of cutaneous leishmaniasis	Surgeon General of the US Army
2315	sodium sulfate, potassium sulfate, and magnesium sulfate	Suprep	10/31/2012	For cleansing of the colon in preparation for colonoscopic diagnosis of colonic disease in children and adolescents	Braintree Laboratories, Inc.
2316	sodium sulfate, potassium sulfate, and magnesium sulfate; PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride	Suclear	9/4/2013	For use in cleansing of the colon in preparation for colonoscopy in children and adolescents	Braintree Laboratories, Inc.
2317	Sodium tetradecyl sulfate	Sotradecol	6/10/1986	Treatment of bleeding esophageal varices.	Elkins-Sinn, Inc.
2318	Sodium Thiosulfate	n/a	2/16/2012	Treatment of uremic and non-uremic calciphylaxis	Luitpold Pharmaceuticals, Inc.
2319	Sodium thiosulfate	n/a	3/17/2004	Prevention of platinum-induced ototoxicity in pediatric patients	Adherex Technologies, Inc.
2320	sodium thiosulfate	n/a	11/9/2011	Treatment of uremic and non-uremic calciphylaxis	Hope Pharmaceuticals
2321	sodium thiosulfate	n/a	12/2/2010	Treatment of extravasation of meclorethamine hydrochloride into subcutaneous tissues.	Hope Pharmaceuticals
2322	sodium thiosulfate	n/a	3/3/2011	Treatment of sulfur mustard poisoning	Hope Pharmaceuticals
2323	sodium thiosulfate	n/a	10/13/2011	Prevention of platinum-induced ototoxicity in pediatric patients	Hope Pharmaceuticals
2324	sodium thiosulfate	n/a	11/19/2012	Treatment of calciphylaxis	Edinburg BioQuarter
2325	Sodium thiosulfate and sodium nitrite	n/a	12/18/2006	Treatment of cyanide poisoning	Akorn, Inc.
2326	Sodium thiosulfate, sodium nitrite, amyl nitrite	Cyanide Antidote Package	6/16/2006	Treatment of cyanide poisoning	Keystone Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2327	Solasonine and solamargine	Coramsine	11/2/2005	Treatment of renal cell carcinoma	Solbec Pharmaceuticals Limited
2328	Solasonine and solamargine	Coramsine	2/6/2006	Treatment of high risk stage II, stage III and stage IV melanoma	Solbec Pharmaceuticals Limited
2329	Soluble complement receptor type 1	n/a	3/6/2000	Prevention of post-cardiopulmonary bypass syndrome in children undergoing cardiopulmonary bypass.	Avant Immunotherapeutics, Inc.
2330	Soluble recombinant human complement receptor type 1	n/a	11/21/1994	Prevention or reduction of adult respiratory distress syndrome.	T Cell Sciences, Inc.
2331	solvent/detergent treated non-blood-group specific human coagulation active plasma	Uniplas	12/12/2005	Treatment of thrombotic thrombocytopenic purpura	Octapharma USA, Inc.
2332	somatorelin	Somatrel	8/8/1989	Diagnostic measure of the capacity of the pituitary gland to release growth hormone.	Ferring Laboratories, Inc.
2333	Somatostatin	Zecnil	6/20/1988	Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or pancreas.	Ferring Laboratories, Inc.
2334	Somatostatin	n/a	12/22/1994	Treatment of bleeding esophageal varices.	Eumetica Pharmaceuticals A.G. (Schweiz)
2335	Somatrem for injection	Protropin	12/9/1985	Treatment of short stature associated with Turner's syndrome.	Genentech, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2336	Somatrem for injection	Protropin	12/9/1985	For long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc.
2337	Somatropin	Serostim	3/16/2004	Treatment of patients with HIV-associated adipose redistribution syndrome	EMD Serono, Inc.
2338	Somatropin	Norditropin	8/9/2006	Treatment of short stature in patients with Noonan syndrome	Novo Nordisk Inc.
2339	Somatropin	Nutropin	3/6/1987	For use in the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc.
2340	Somatropin	Humatrope	5/8/1990	Treatment of short stature associated with Turner syndrome.	Eli Lilly and Company
2341	Somatropin	Genotropin	9/6/1994	Treatment of adults with growth hormone deficiency.	Pharmacia & Upjohn
2342	Somatropin	Humatrope	12/15/2005	Treatment of short stature in pediatric patients with short stature homeobox-containing gene (SHOX) deficiency	Eli Lilly and Company
2343	Somatropin (rDNA origin)	Nutropin Depot	10/28/1999	Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc.
2344	Somatropin (rDNA origin)	Saizen	3/6/1987	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	EMD Serono, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2345	Somatropin (rDNA origin) injection	Norditropin	7/10/1987	Treatment of growth failure in children due to inadequate growth hormone secretion.	Novo Nordisk Pharmaceuticals
2346	Somatropin (rDNA)	Saizen	5/3/1989	For the enhancement of nitrogen retention in hospitalized patients suffering from severe burns.	EMD Serono, Inc.
2347	Somatropin (r-DNA)	Zorbtive	3/6/1995	For use alone or in combination with glutamine in the treatment of short bowel syndrome.	EMD Serono, Inc.
2348	Somatropin (r-DNA) for injection	Serostim	3/26/1996	Treatment of children with AIDS-associated failure-to-thrive including AIDS-associated wasting.	EMD Serono, Inc.
2349	Somatropin [rDNA]	Genotropin	7/6/1999	Treatment of short stature in patients with Prader-Willi syndrome.	Pharmacia & Upjohn
2350	somatropin [rDNA]	Genotropin	12/27/2000	Treatment of growth failure in children who were born small for gestational age.	Pharmacia and Upjohn Company
2351	Somatropin for injection	Nutropin	8/4/1989	Treatment of growth retardation associated with chronic renal failure.	Genentech, Inc.
2352	Somatropin for injection	Nutropin	3/23/1989	Treatment of short stature associated with Turner's syndrome.	Genentech, Inc.
2353	Somatropin for injection	Humatrope	6/12/1986	For the long-term treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone.	Eli Lilly and Company

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2354	Somatropin for injection	Nutropin	11/18/1996	As replacement therapy for growth hormone deficiency in adults after epiphyseal closure.	Genentech, Inc.
2355	Somatropin for injection	Serostim	11/15/1991	Treatment of AIDS-associated catabolism/weight loss.	EMD Serono, Inc.
2356	Sorafenib	Nexavar	4/20/2006	Treatment of hepatocellular carcinoma	Bayer Pharmaceuticals Corporation
2357	Sorafenib	Nexavar	10/8/2004	Treatment of renal cell carcinoma.	Bayer Pharmaceutical Corporation
2358	sorafenib	Nexavar	12/12/2011	Treatment of medullary thyroid cancer, anaplastic thyroid cancer, and recurrent or metastatic follicular or papillary thyroid cancer	Bayer HealthCare Pharmaceuticals, Inc.
2359	sotalol (IV)	So-Aqueous	7/25/2008	For ventricular tachycardia, ventricular fibrillation, or the maintenance of sinus rhythm in patients converted from atrial fibrillation or atrial flutter when oral administration is not possible.	Academic Pharmaceuticals
2360	Sotalol HCl	Betapace	9/23/1988	Treatment of life-threatening ventricular tachyarrhythmias.	Berlex Laboratories, Inc.
2361	sotalol hydrochloride	n/a	2/10/2014	Treatment of life-threatening ventricular arrhythmias in pediatric patients	Arbor Pharmaceuticals, LLC

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2362	sotatercept	n/a	4/28/2014	Treatment of anemias associated with myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasms.	Celgene Corporation
2363	sotatercept	n/a	12/5/2013	Treatment of beta-thalassemia intermedia and major	Celgene Corporation
2364	spherical carbon adsorbent	n/a	12/19/2007	Treatment of chronic pouchitis	Ocera Therapeutics, Inc.
2365	squalamine lactate	n/a	5/11/2001	Treatment of ovarian cancer refractory or resistant to standard chemotherapy	Genaera Corporation
2366	Staphylococcus aureus Immune Globulin (Human)	Altastaph	1/29/2004	Prophylaxis against Staphylococcus aureus infections in low birth weight neonates	Biotest Pharmaceuticals Corporation
2367	Stem and progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood	Stemex	3/4/2005	For use as hematopoietic support in patients with relapsed or refractory hematologic malignancies who are receiving high-dose therapy	Gamida Cell Ltd - Teva Joint Venture
2368	Sterile Bicarbonate Infusate, Hemofiltration, Hemodiafiltration, and Hemodialysis Solution	Accusol	5/29/2009	For use as a replacement solution in adults and children during Continuous Renal Replacement Therapy	Baxter Healthcare Corporation
2369	Sterile talc	Steritalc	12/8/1997	Treatment of malignant pleural effusion.	Novatech SA
2370	Sterile talc	Steritalc	12/8/1997	Treatment of pneumothorax.	Novatech SA
2371	Sterile talc powder	Sclerosol Intrapleural Aerosol	9/18/1995	Treatment of malignant pleural effusion.	Bryan Corporation
2372	stiripentol	Diacomit	10/30/2008	Treatment of Dravet syndrome	Biocodex

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2373	Succimer	Chemet	11/5/1990	Prevention of cystine kidney stone formation in patients with homozygous cystinuria who are prone to stone development.	Sanofi Winthrop, Inc.
2374	Succimer	Chemet	3/22/1991	Treatment of mercury intoxication.	Sanofi Winthrop, Inc.
2375	Succimer	Chemet Capsules	5/9/1984	Treatment of lead poisoning in children.	Bock Pharmacal Company
2376	Sucralfate suspension	n/a	3/12/1990	Treatment of oral complications of chemotherapy in bone marrow transplant patients.	Darby Pharmaceuticals, Inc.
2377	Sucralfate suspension	n/a	3/4/1991	Treatment of oral ulcerations and dysphagia in patients with epidermolysis bullosa.	Darby Pharmaceuticals, Inc.
2378	Sulfadiazine	n/a	3/14/1994	For use in combination with pyrimethamine for the treatment of Toxoplasma gondii encephalitis in patients with and without AIDS.	Eon Labs Manufacturing, Inc.
2379	sulfamidase	n/a	5/22/2008	For treatment of Sanfilippo Syndrome (MPS IIIA)	Shire Human Genetic Therapies, Inc.
2380	Sulfapyridine	n/a	9/10/1990	Treatment of dermatitis herpetiformis.	Jacobus Pharmaceutical Company
2381	sulfonated monophosphorylated mannose oligosaccharide	n/a	2/17/2012	Treatment of hepatocellular carcinoma	Medigen Biotechnology Corporation
2382	sulthiame	n/a	7/25/2013	Treatment of patients with benign epilepsy of childhood with centrotemporal spikes (BECTS) also known as rolandic epilepsy	Marathon Pharmaceuticals, LLC

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2383	Superoxide dismutase (human)	n/a	3/6/1985	For protection of donor organ tissue from damage or injury mediated by oxygen-derived free radicals that are generated during the necessary periods of ischemia (hypoxia, anoxia), and especially reperfusion, associated with the operative procedure.	Pharmacia-Chiron Partnership
2384	superoxide dismutase, gliadin	Etr019	4/30/2010	Treatment of amyotrophic lateral sclerosis	Verius Limited
2385	Suramin	Metaret	5/6/1997	Treatment of hormone-refractory prostate cancer.	Warner-Lambert Company
2386	Surface active extract of saline lavage of bovine lungs	Infasurf	6/7/1985	Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.	ONY, Inc.
2387	Synsorb Pk	n/a	7/17/1995	Treatment of verocytotoxogenic E. coli infections.	Synsorb Biotech Inc.
2388	Synthetic derivative of 16-hydroxy-9Z, 12Z, 14E-octadecatrienoic acid	Drepanol	10/24/1991	Prophylactic treatment of sickle cell disease.	Omex International, Inc.
2389	synthetic double-stranded siRNA oligonucleotide against antithrombin (AT) mRNA	n/a	8/16/2013	Treatment of hemophilia A	Alnylam Pharmaceuticals
2390	synthetic double-stranded siRNA oligonucleotide against antithrombin mRNA	n/a	8/12/2013	Treatment of hemophilia B	Alnylam Pharmaceuticals
2391	Synthetic double-stranded siRNA oligonucleotide against caspase 2 mRNA	n/a	9/25/2012	Treatment of ischemic optic neuropathy	Quark Pharmaceuticals, Inc.
2392	synthetic double-stranded siRNA oligonucleotide against p53 mRNA	n/a	12/23/2009	Prophylaxis of delayed graft function in renal transplant patients	Quark Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2393	synthetic double-stranded siRNA oligonucleotide against transthyretin (TTR) mRNA	n/a	6/14/2012	Treatment of familial amyloidotic polyneuropathy	Alnylam Pharmaceuticals, Inc.
2394	Synthetic human secretin	n/a	6/16/1999	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc.
2395	Synthetic human secretin	n/a	9/18/2006	For use in conjunction with diagnostic procedures (excluding ERCP) for pancreatic disorders to increase pancreatic fluid secretion	Repligen Corporation
2396	Synthetic human secretin	n/a	6/16/1999	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc.
2397	Synthetic human secretin	n/a	3/7/2000	For use in conjunction with diagnostic, therapeutic, or combined diagnostic/therapeutic procedures for pancreatic disorders to increase pancreatic fluid secretion.	ChiRhoClin, Inc.
2398	Synthetic human secretin	Chirostim	6/16/1999	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc.
2399	synthetic peptide H-D-Ala-Ser-Pro-Met-Leu-Val-Ala-Tyr-Asp-D-Ala-OH	n/a	10/12/2011	Treatment of necrotizing soft tissue infections (NSTI)	Atox Bio, Inc.
2400	synthetic peptide; cyclo-Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-ALA-Lys-Pro-Trp-Tyr-Cys	n/a	1/15/2013	Treatment of high altitude pulmonary edema	Apeptico Forschung und Entwicklung GmbH
2401	Synthetic porcine secretin	n/a	6/18/1999	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2402	Synthetic porcine secretin	Secreflo	6/18/1999	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc.
2403	Synthetic porcine secretin	Secreflo	3/7/2000	For use in conjunction with diagnostic, therapeutic, or combined diagnostic/therapeutic procedures for pancreatic disorders to increase pancreatic fluid secretion.	ChiRhoClin, Inc.
2404	Synthetic porcine secretin	Secreflo	6/18/1999	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc.
2405	synthetic surfactant comprised of DPPC, POPG Na, synthetic SP-C analogue and synthetic SP-B analogue	n/a	3/16/2012	Treatment of preterm neonatal respiratory distress syndrome	Chiesi Pharmaceuticals, Inc.
2406	T cell receptor (TCR) peptide (BV5S2, BV6S5, BV13S1) vaccine	Neurovax	2/6/2014	Treatment of Pediatric Multiple Sclerosis	Immune Response BioPharma, Inc.
2407	T4 endonuclease V, liposome encapsulated	n/a	6/27/1989	To prevent cutaneous neoplasms and other skin abnormalities in xeroderma pigmentosum.	AGI Dermatics
2408	tabalumab	n/a	11/19/2012	Treatment of multiple myeloma	Eli Lilly and Company
2409	taberminogene vadenovec	Trinam	10/24/2000	Prevention of complications due to neointimal hyperplasia disease in certain vascular anastomoses.	Finvector Vision Therapies, Ltd.
2410	Tacrolimus	Prograf	4/6/1998	Prophylaxis of graft-versus-host-disease.	Fujisawa USA, Inc.
2411	Tacrolimus	n/a	12/20/2013	Prophylaxis of organ rejection in patients receiving allogeneic kidney transplant	Veloxis Pharmaceuticals, Inc.
2412	tacrolimus	n/a	7/6/2012	Treatment of hemorrhagic cystitis	Lipella Pharmaceuticals Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2413	Tacrolimus	Prograf	6/6/2005	Prophylaxis of organ rejection in patients receiving heart transplants.	Astellas Pharma US, Inc.
2414	tadalafil	Adcirca	12/18/2006	Treatment of pulmonary arterial hypertension	Eli Lilly and Company
2415	tafamidis	n/a	5/23/2006	Treatment of familial amyloid polyneuropathy	Pfizer, Inc.
2416	tafamidis meglumine	n/a	2/17/2012	Treatment of symptomatic transthyretin (TTR) amyloid cardiomyopathy.	Pfizer, Inc.
2417	tafenoquine	n/a	1/15/2013	Treatment of malaria	Glaxo Group Limited, England
2418	talactoferrin alfa	n/a	8/20/2003	For the prevention of graft-versus-host disease	Agennix, Inc.
2419	talactoferrin alfa	n/a	8/20/2003	For the treatment of graft versus host disease	Agennix, Inc.
2420	talarazole	n/a	3/16/2012	Treatment of congenital ichthyosis	Stiefel Laboratories, Inc.
2421	Taliglucerase alfa	Ellelyso For Injection	9/3/2009	Treatment of Gaucher's disease	Pfizer, Inc.
2422	Tamibarotene	n/a	10/11/2007	Treatment of acute promyelocytic leukemia (APL).	CytRx Corporation
2423	Tanespimycin	n/a	9/9/2004	Treatment of multiple myeloma	Bristol-Myers Squibb
2424	Targeted Gastrin 17 Complexed Peptide	n/a	5/14/2014	Treatment of pancreatic cancer	Tyg Oncology Ltd
2425	tasimelteon	n/a	4/30/2010	Treatment of sleep-wake disorder in Smith-Magenis syndrome associated with diurnal melatonin secretion	Vanda Pharmaceuticals, Inc.
2426	tasimelteon	Hetlioz	1/19/2010	Non-24-hour sleepwake disorder in blind individuals without light perception	Vanda Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2427	taurine	n/a	3/22/2010	Treatment of cystathionine beta-synthase deficient homocystinuria	Johan L. Van Hove, MD, PhD
2428	T-cell depleted stem cell enriched cellular product from peripheal b lood stem cells	n/a	11/1/2001	Treatment of chronic granulomatous disease	Nexell Therapeutics Inc.
2429	TD-K6a.513a.12	Reveker	6/15/2006	Treatment of pachyonychia congenita	TransDerm, Inc.
2430	Technetium Tc99m murine monoclonal antibody (IgG2a) to B cell	Lymphoscan	4/7/1992	Diagnostic imaging in the evaluation of the extent of disease in patients with histologically confirmed diagnosis of non-Hodgkin's B-cell lymphoma, acute B-cell lymphoblastic leukemia (in children and adults), and chronic B-cell lymphocytic leukemia.	Immunomedics, Inc.
2431	Technetium Tc99m rh-Annexin V	Apomate	11/3/2000	Diagnosis or assessment of rejection status in heart, heart-lung, single lung, or bilateral lung transplants.	Theseus Imaging Corporation
2432	Technetium Tc99m sulfur colloid injection, lyophilized	Technetium Tc99m Sulfur Colloi	3/17/2009	For localization of sentinel lymph nodes in patients with melanoma.	Pharmalucence, Inc.
2433	tecovirimat	n/a	12/27/2006	Treatment of smallpox.	SIGA Technologies, Inc.
2434	tecovirimat	n/a	12/18/2006	post exposure prophylaxis against smallpox	SIGA Technologies, Inc.
2435	tecovirimat	n/a	9/29/2010	Treatment of orthopoxvirus infections.	SIGA Technologies, Inc.
2436	teduglutide [rDNA origin]	Gattex	6/29/2000	Treatment of short bowel syndrome.	NPS Pharmaceuticals, Inc.
2437	Tegafur/gimeracil/oteracil	n/a	7/20/2006	Treatment of gastric cancer	Taiho Pharma USA, Inc.
2438	telatinib	n/a	5/17/2010	Treatment of gastric cancer	ACT Biotech Inc.
2439	temocillin sodium	Negaban	4/21/2004	Treatment of pulmonary infections caused by Burkholderia cepacia	Belpharma S.A.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2440	Temoporfin	Foscan	10/28/1999	Palliative treatment of recurrent, refractory or second primary squamous cell carcinomas of the head and neck in patients considered to be incurable with surgery or radiotherapy.	Biolitec Pharma Ireland Ltd.
2441	Temozolomide	Temodal	10/18/2004	Treatment of newly diagnosed high grade glioma	Schering-Plough Research Institute
2442	Temozolomide	Temodal	10/14/1998	Treatment of advanced metastatic melanoma.	Schering-Plough Research Institute
2443	temozolomide	Temodar	10/5/1998	Treatment of recurrent malignant glioma.	Schering-Plough Research Institute
2444	Temsirolimus	Torisel	12/16/2004	Treatment of renal cell carcinoma	Wyeth Pharmaceuticals, Inc.
2445	Teniposide	Vumon For Injection	11/1/1984	Treatment of refractory childhood acute lymphocytic leukemia.	Bristol-Myers Squibb Pharmaceutical Research Institute
2446	tenofovir	Viread	3/17/2009	Treatment of pediatric HIV infection.	Gilead Sciences, Inc.
2447	teprotumumab	n/a	5/6/2013	Treatment of active (dynamic) phase Grave's orbitopathy	River Vision, Inc.
2448	terguride	Mysalfon, Teluron	5/17/2013	Treatment of systemic sclerosis	Serodapharm UG
2449	Teriparatide	Parathar	10/28/1999	Treatment of idiopathic osteoporosis.	Biomeasure, Inc.
2450	teriparatide	Forteo	4/18/2014	Treatment of hypoparathyroidism	Entera Bio, Ltd.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2451	Teriparatide	Parathar	1/9/1987	Diagnostic agent to assist in establishing the diagnosis in patients presenting with clinical and laboratory evidence of hypocalcemia due to either hypoparathyroidism or pseudohypoparathyroidism.	Rhone-Poulenc Rorer Pharmaceuticals, Inc.
2452	Terlipressin	Glypressin	3/6/1986	Treatment of bleeding esophageal varices.	Ferring Laboratories, Inc.
2453	terlipressin	n/a	10/29/2004	Treatment of Hepatorenal Syndrome	Ikaria (INO Therapeutics)
2454	tesetaxel	n/a	12/22/2008	Treatment of gastric cancer	Genta Inc.
2455	tesetaxel	n/a	11/21/2008	Treatment of stages IIB, IIC, III, and stage IV melanoma	Genta, Inc.
2456	Testosterone	Theraderm Testosterone Transdermal System	9/22/1997	For use as physiologic testosterone replacement in androgen deficient HIV+ patients with an associated weight loss.	Watson Laboratories
2457	Testosterone propionate ointment 2%	n/a	7/31/1991	Treatment of vulvar dystrophies.	Star Pharmaceuticals, Inc.
2458	testosterone undecanoate (oral)	n/a	2/13/2013	Treatment of constitutional delay in growth and puberty in adolescent boys (14-17 yrs of age)	SOV Therapeutics, Inc.
2459	tetra substituted prophyrin derivative containing manganese (III)	n/a	1/17/2014	For use in patients exposed to radiation following a nuclear accident or detonation in order to treat or mitigate acute radiation syndrome.	Aeolus Pharmaceuticals, Inc.
2460	Tetrabenazine	n/a	5/12/1998	Treatment of moderate/severe tardive dyskinesia.	Prestwick Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2461	tetrabenazine	n/a	7/1/2009	Treatment of Tourette's Syndrome in school-age children, ages 5-16	Valeant International (Barbados) SRL
2462	Tetrabenazine	Xenazine	12/11/1997	Treatment of Huntington's disease	Prestwick Pharmaceuticals, Inc
2463	tetracosactide hexaacetate (beta 1-24-corticotrophin)	Synacthen Depot, S. Retard	10/31/2012	Treatment of infantile spasms	Cerium Pharmaceuticals, Inc.
2464	Tetraiodothyroacetic acid	n/a	5/1/2000	Suppression of thyroid stimulating hormone in patients with well-differentiated cancer of the thyroid gland.	Danforth, Jr., MD, Elliot
2465	Tezacitabine	n/a	1/27/2003	Treatment of adenocarcinoma of the esophagus and stomach	Sanofi-Aventis US, Inc.
2466	Thalidomide	n/a	5/1/1995	Treatment of severe recurrent aphthous stomatitis in severely, terminally immunocompromised patients.	Celgene Corporation
2467	Thalidomide	Synovir	3/11/1996	Treatment of HIV-associated wasting syndrome.	Celgene Corporation
2468	Thalidomide	n/a	5/15/1995	Treatment and prevention of recurrent aphthous ulcers in severely, terminally immunocompromised patients.	Andrulis Research Corporation
2469	Thalidomide	Thalomid	4/6/1999	Treatment of Crohn's disease.	Celgene Corporation
2470	Thalidomide	n/a	7/29/1998	Treatment of Kaposi's sarcoma.	Celgene Corporation
2471	Thalidomide	n/a	2/27/1998	Treatment of primary brain malignancies.	Celgene Corporation

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2472	Thalidomide	n/a	11/15/1988	Treatment and maintenance of reactional lepromatous leprosy.	Pediatric Pharmaceuticals, Inc.
2473	Thalidomide	n/a	9/19/1988	Treatment of graft versus host disease in patients receiving bone marrow transplantation.	Pediatric Pharmaceuticals, Inc.
2474	Thalidomide	n/a	9/19/1988	Prevention of graft versus host disease in patients receiving bone marrow transplantation.	Pediatric Pharmaceuticals, Inc.
2475	Thalidomide	n/a	3/5/1990	Prevention of graft versus host disease.	Andrulis Research Corporation
2476	Thalidomide	n/a	3/5/1990	Treatment of graft versus host disease.	Andrulis Research Corporation
2477	Thalidomide	n/a	1/12/1993	Treatment of the clinical manifestations of mycobacterial infection caused by Mycobacterium tuberculosis and non-tuberculous mycobacteria.	Celgene Corporation
2478	Thalidomide	Thalomid	9/27/2004	Treatment of myelodysplastic syndrome	Celgene Corporation
2479	Thalidomide	Thalomid	7/26/1995	Treatment of erythema nodosum leprosum.	Celgene Corporation
2480	Thalidomide	Thalomid	10/14/1998	Treatment of multiple myeloma	Celgene Corporation
2481	Thawed donor matched banked umbilical cord blood enriched by cell sorting to produce a subpopulation expressing high levels of intracellular aldehyde dehydrogenase	n/a	10/23/2008	To improve patient outcomes by decreasing time to platelet and neutrophil engraftment in patients with inherited metabolic diseases (IMD) undergoing umbilical cord blood transplantation.	Aldagen, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2482	Thiotepa	Tepadina	4/2/2007	Conditioning treatment prior to hematopoietic stem cell transplantation	Adienne S.r.l.
2483	Thymalfasin	Zadaxin	1/8/1998	Treatment of DiGeorge anomaly with immune defects.	SciClone Pharmaceuticals, Inc.
2484	Thymalfasin	Zadaxin	3/6/2000	Treatment of hepatocellular carcinoma.	SciClone Pharmaceuticals, Inc.
2485	Thymalfasin	Zadaxin	3/13/2006	Treatment of stage IIb through Stage IV malignant melanoma	SciClone Pharmaceuticals, Inc.
2486	Thymalfasin	Zadaxin	5/3/1991	Treatment of chronic active hepatitis B.	SciClone Pharmaceuticals, Inc.
2487	thymopentin	n/a	2/4/2011	Treatment of sarcoidosis.	mondoBIOTECH Laboratories, AG
2488	Thymosin beta 4	n/a	5/28/2004	Treatment of epidermolysis bullosa.	RegeneRx Biopharmaceuticals, Inc.
2489	thymosin beta 4	n/a	12/31/2013	Treatment of patients with neurotrophic keratopathy	RegeneRx Biopharmaceuticals, Inc.
2490	Thyrotropin alfa	Thyrogen	8/3/2001	Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid	Genzyme Corporation
2491	Thyrotropin alpha	Thyrogen	2/24/1992	As an adjunct in the diagnosis of thyroid cancer.	Genzyme Corporation
2492	Tiazofurin (2-Beta-D-ribofuranosyl-4-thiazolecarboxamide)	n/a	12/27/2000	Chronic myelogenous leukemia (CML)	Valeant Pharmaceuticals North America
2493	tigecycline	n/a	10/23/2013	Treatment of acute myeloid leukemia.	Stem Cell Therapeutics Corporation
2494	Tilarginine acetate	n/a	4/11/2005	Treatment of cardiogenic shock	Arginox Pharmceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2495	tin ethyl etiopurpurin	n/a	11/4/2003	Prevention of access graft disease in hemodialysis patients	Miravant Medical Technologies
2496	Tinidazole	Tindamax	8/20/2003	Treatment of amebiasis	Presutti Laboratories, Inc.
2497	tinidazole	Tindamax	4/18/2002	Treatment of giardiasis	Presutti Laboratories, Inc.
2498	Tiopronin	Thiola	1/17/1986	Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.	Pak, Charles Y.C. M.D.
2499	Tiotropium bromide	Spiriva	1/8/2008	To improve pulmonary function in conjunction with standard therapy in the management of patients with cystic fibrosis	Boehringer Ingelheim Pharmaceuticals, Inc.
2500	Tipifarnib	Zarnestra	7/6/2004	Treatment of acute myeloid leukemia	Johnson & Johnson Pharmaceutical Research & Dev.
2501	tiptorelin pamoate	n/a	8/20/2012	Treatment of central precocious puberty	Debiopharm
2502	tirapazamine	n/a	10/23/2002	Treatment of head and neck cancer	Sanofi-Aventis US, Inc.
2503	Tiratricol	Triacana	8/13/1991	For use in combination with levo-thyroxine to suppress thyroid stimulating hormone in patients with well-differentiated thyroid cancer who are intolerant to adequate doses of levo-thyroxine alone.	Laphal Laboratoires
2504	Tissue Plasminogen activator	n/a	4/18/2011	Treatment of acute ischemic stroke (AIS) in children age 16 years and younger.	Catherine Amlie-Lefond, MD
2505	Tissue repair cells obtained from autologous bone marrow expanded ex vivo with a cell production system	n/a	1/25/2007	Treatment of dilated cardiomyopathy	Aastrom Biosciences, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2506	Tissue repair cells obtained from autologous bone marrow expanded ex vivo with a cell production system	n/a	3/13/2006	Treatment of osteonecrosis.	Aastrom Biosciences, Inc.
2507	tivantinib	n/a	10/16/2013	Treatment of hepatocellular carcinoma	Daiichi Sankyo Pharma Development
2508	Tizanidine HCl	Zanaflex	1/31/1994	Treatment of spasticity associated with multiple sclerosis and spinal cord injury.	Athena Neurosciences, Inc.
2509	Tobramycin	Tobi	6/18/1999	Treatment of bronchiectasis patients infected with Pseudomonas aeruginosa.	Novartis Pharmaceuticals Corp.
2510	Tobramycin for inhalation	Tobi	10/13/1994	Treatment of bronchopulmonary infections of Pseudomonas aeruginosa in cystic fibrosis patients.	Novartis Pharmaceuticals Corp
2511	tocilizumab	Actemra	4/17/2013	Treatment of systemic sclerosis	Genentech, Inc.
2512	tocilizumab	Actemra	7/31/2012	Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis	Genentech, Inc.
2513	Tolcapone	n/a	12/24/2013	Treatment of transthyretin amyloidosis	SOM Innovation Biotech SL (SOM Biotech)
2514	tolvaptan	Samsca	4/6/2012	Treatment of autosomal dominant polycystic kidney disease	Otsuka Pharmaceuticals Co., Ltd.
2515	Topiramate	Topamax	11/25/1992	Treatment of Lennox-Gastaut syndrome.	Johnson & Johnson Pharmaceutical R & D, LLC

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2516	topiramate injection	n/a	7/24/2013	Treatment of partial onset or primary generalized tonic-clonic seizures for hospitalized epilepsy patients or epilepsy patients being treated in an emergency care setting who are unable to take oral topiramate	Ligand Pharmaceuticals, Inc.
2517	Toremifene	n/a	8/17/1993	Treatment of desmoid tumors.	Orion Corporation
2518	Toremifene	Fareston	9/19/1991	Hormonal therapy of metastatic carcinoma of the breast.	Orion Corporation
2519	Tosedostat	n/a	12/10/2008	Treatment of acute myeloid leukemia	Cell Therapeutics Inc.
2520	Tositumomab and iodine I 131 tositumomab	Bexxar	5/16/1994	Treatment of non-Hodgkin's B-cell lymphoma.	GlaxoSmithKline LLC
2521	trabectedin	Yondelis	9/30/2004	Treatment of soft tissue sarcoma.	Janssen Research & Development, LLC
2522	trabectedin	Yondelis	3/29/2005	Treatment of patients with ovarian cancer	Janssen Research & Development, LLC
2523	trabedersen	n/a	8/22/2011	Treatment of Stage IIB through Stage IV malignant melanoma.	Isarna Therapeutics GmbH
2524	trabedersen	n/a	7/21/2009	Treatment of pancreatic cancer.	Antisense Pharma GmbH
2525	trabedersen	Oncomun	6/5/2002	Treatment of malignant glioma	Antisense Pharma GmbH
2526	tralokinumab (recombinant human anti-interleukin-13 monoclonal antibody)	n/a	7/24/2012	Treatment of idiopathic pulmonary fibrosis	MedImmune Ltd.
2527	Tramadol hydrochloride	n/a	1/28/2005	Treatment of painful HIV-associated neuropathy	TheraQuest Biosciences, LLC
2528	Tramadol hydrochloride	n/a	4/26/2005	Management of postherpetic neuralgia	TheraQuest Biosciences, LLC

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2529	trametinib	Mekinist	12/20/2010	Treatment of Stage IIb through Stage IV melanoma	GlaxoSmithKline, LLC
2530	trametinib and dabrafenib	Mekinist And Tafinlar	9/20/2012	Treatment of Stage IIb through IV melanoma.	GlaxoSmithKline, LLC
2531	Tranilast	Rizaben	12/2/2003	For the treatment of malignant glioma	Angiogen Pharmaceuticals, Pty. Ltd.
2532	tranilast	Rizaben	12/23/2010	Prevention of scarring following glaucoma filtration surgery	Altacor Ltd
2533	trans sodium crocetin	n/a	12/3/2012	Treatment of brain metastasis	Diffusion Pharmaceuticals, LLC
2534	trans sodium crocetin	n/a	7/21/2011	Treatment of glioblastoma in conjunction with radiotherapy	Diffusion Pharmaceuticals, LLC
2535	Transforming growth factor-beta 2	n/a	12/18/1992	Treatment of full thickness macular holes.	Celtrix Pharmaceuticals, Inc.
2536	transforming growth factor-beta receptor 1 kinase inhibitor	n/a	4/1/2013	Treatment of hepatocellular carcinoma	Eli Lilly and Company
2537	transforming growth factor-beta receptor 1 kinase inhibitor	n/a	3/11/2013	Treatment of glioma	Eli Lilly and Company
2538	Transgenic human alpha 1 antitrypsin	n/a	5/19/1999	Treatment of emphysema secondary to alpha 1 antitrypsin deficiency.	PPL Therapeutics (Scotland) Limited
2539	trastuzumab	Herceptin	12/14/1999	Treatment of patients with pancreatic cancer that overexpress p185HER2.	Genentech, Inc.
2540	trastuzumab	Herceptin	10/13/2009	Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction	Genentech, Inc.
2541	trastuzumab emtansine	Kadcyla Trastuzumab emtansine	10/25/2013	For the treatment of gastric cancer including gastroesophageal junction cancer.	Genentech, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2542	trebananib	n/a	8/30/2013	Treatment of ovarian cancer	Amgen, Inc.
2543	trehalose	Cabaletta	10/25/2013	Treatment of oculopharyngeal muscular dystrophy	BIOBLAST PHARMA LTD.
2544	tremelimumab	n/a	9/18/2006	Treatment of stage IIb to stage IV metastatic melanoma	MedImmune
2545	Treosulfan	Ovastat	5/16/1994	Treatment of ovarian cancer.	Medac GmbH
2546	treprostinil	Remodulin	6/4/1997	Treatment of pulmonary arterial hypertension.	United Therapeutics Corp.
2547	treprostinil (inhalational)	Tyvaso	6/17/2010	Treatment of pulmonary arterial hypertension	LungRx, Inc.
2548	Tretinoin	Atra-lv	4/11/2003	Treatment of T-cell non-Hodgkin's lymphoma	Antigenics, Inc.
2549	Tretinoin	Atra-lv	1/14/1993	Treatment of acute and chronic leukemia.	Antigenics, Inc.
2550	Tretinoin	n/a	4/15/1985	Treatment of squamous metaplasia of the ocular surface epithelia (conjunctiva and/or cornea) with mucous deficiency and keratinization.	Hannan Ophthalmic Marketing Services, Inc
2551	Tretinoin	Vesanoid	10/24/1990	Treatment of acute promyelocytic leukemia.	Hoffmann-La Roche, Inc.
2552	tri-antennary glycotripeptide derivative of 5-fluorodeoxyuridine monophosphate	n/a	11/23/2001	Treatment for hepatocellular carcinoma	Cell Works Inc.
2553	tricitabine	n/a	2/1/2008	Treatment of multiple myeloma	VioQuest Pharmaceuticals, Inc.
2554	Trientine HCl	Syprine	12/24/1984	Treatment of patients with Wilson's disease who are intolerant, or inadequately responsive to penicillamine.	Merck Sharp & Dohme Research
2555	trientine hydrochloride	Syprine(R)	11/2/2010	Treatment of manganism.	Cerberus Princeton, LLC

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2556	Triheptanoin	Triheptanoin-Sasol Special Oil	2/1/2008	Treatment of glycogen storage disorder II (Pompe disease)	Baylor Research Institute
2557	Triheptanoin	Triheptanoim-Sasol Special Oil	5/26/2006	Treatment of fatty acid disorders	Baylor Research Institute
2558	Trimetrexate glucuronate	Neutrexin	5/15/1986	Treatment of Pneumocystis carinii pneumonia in AIDS patients.	Medimmune Oncology, Inc.
2559	Trisaccharides A and B	Biosynject	4/20/1987	For use in ABO-incompatible solid organ transplantation, including kidney, heart, liver and pancreas.	Chembiomed, Ltd.
2560	Trisaccharides A and B	Biosynject	4/12/1987	Treatment of moderate to severe clinical forms of hemolytic disease of the newborn arising from placental transfer of antibodies against blood group substances A and B.	Chembiomed, Ltd.
2561	Trisaccharides A and B	Biosynject	4/15/1988	Prevention of ABO medical hemolytic reactions arising from ABO-incompatible bone marrow transplantation.	Chembiomed, Ltd.
2562	Trisodium citrate concentration	Hemocitrate	6/15/1995	For use in leukapheresis procedures.	Hemotec Medical Products, Inc.
2563	Trisodium zinc Diethylenetriaminepentaacetate	n/a	2/27/2004	Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rate of elimination.	CustomCare Pharmacy
2564	Trypan blue	Membraneblue	8/2/2006	Selectively staining epiretinal membranes during ophthalmic surgical vitrectomy procedures	Dutch Ophthalmic Research Center Int'l BV

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2565	tryptophan hydroxylase (TPH) inhibitor	n/a	3/9/2012	Management of symptoms of carcinoid syndrome associated with carcinoid tumor	Lexicon Pharmaceuticals, Inc.
2566	Tumor necrosis factor-binding protein 1	n/a	1/6/1993	Treatment of symptomatic patients with AIDS including all patients with CD4 counts less than 200 cells per mm3.	EMD Serono, Inc.
2567	Tumor necrosis factor-binding protein II	n/a	1/6/1993	Treatment of symptomatic patients with the AIDS including all patients with CD4 T-cell counts less than 200 cells per mm3.	EMD Serono, Inc.
2568	TXA127	n/a	10/25/2013	Treatment of acute radiation syndrome	US Biotest, Inc.
2569	Tyloxapol	Supervent	3/8/1995	Treatment of cystic fibrosis.	Kennedy & Hoidal, M.D.'s
2570	Type 1 native bovine skin collagen	n/a	2/1/2008	Treatment of diffuse systemic sclerosis	arGentis Pharmaceuticals, LLC
2571	tyrosine kinase inhibitor	n/a	9/14/2005	Treatment of mastocytosis	AB Science
2572	Ubiquinol	Ubi-Q-Nol, Li-Q-Nol	4/12/2004	Treatment of Huntington's Disease	Gel-Tec, Division of Tishcon Corp
2573	Ubiquinol, coenzyme Q10, ubiquinone	Ubi-Q-Nol	4/12/2004	Treatment of pediatric congestive heart failure	Gel-Tec, Division of TISHCON Corporation
2574	Ubiquinone	Ubi-Q-Gel	12/14/1999	Treatment of mitochondrial cytopathies.	Gel-Tec, Division of Tishcon Corp.
2575	ublituximab	n/a	9/5/2013	Treatment of Nodal marginal zone lymphoma	TG Therapeutics, Inc.
2576	ublituximab	n/a	8/6/2010	Treatment of chronic lymphocytic leukemia	TG Therapeutics, Inc.
2577	ublituximab	n/a	9/5/2013	Treatment of Extranodal marginal zone lymphoma (mucosa-associated lymphatic tissue, MALT)	TG Therapeutics, Inc.
2578	Unconjugated Chimeric (human-murine) G250 IgG monoclonal antibody	n/a	3/22/2001	Treatment of renal cell carcinoma.	Wilex Biotechnology GmbH

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2579	unoprostone isopropyl	Rescula	9/16/2010	Treatment of retinitis pigmentosa	Sucampo Pharma Americas, LLC
2580	urea	n/a	11/7/2011	Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosiform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis).	Orenova Group, LLC
2581	Urea for intravitreal injection	Neurosolve	12/14/2005	Treatment of retinitis pigmentosa	Vitreo Retinal Technologies, Inc
2582	uridine triacetate	n/a	8/9/2013	Treatment of hereditary orotic aciduria	Wellstat Therapeutics, Inc.
2583	uridine triacetate	n/a	9/3/2009	Treatment of mitchondrial disease	Wellstat Therapeutics Corporation
2584	uridine triacetate	n/a	5/1/2009	An antidote in the treatment of 5-fluorouracil poisoning	Wellstat Therapeutics Corp.
2585	Urofollitropin	Metrodin	11/25/1987	For induction of ovulation in patients with polycystic ovarian disease who have an elevated LH/FSH ratio and who have failed to respond to adequate clomiphene citrate therapy.	EMD Serono, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2586	Urogastrone	n/a	11/1/1984	For acceleration of corneal epithelial regeneration and healing of stromal incisions from corneal transplant surgery.	Chiron Vision
2587	ursodiol	Ursofalk Suspension	10/23/2007	Treatment of cystic fibrosis liver disease	Asklepiion Pharmaceuticals, LLC
2588	Ursodiol	Urso 250	6/20/1991	Treatment of patients with primary biliary cirrhosis	Aptalis Pharma US, Inc.
2589	ustekinumab	Stelara	11/29/2010	Treatment of type 1 diabetes mellitus patients with residual beta-cell function.	Johnson & Johnson Pharmaceutical & Development LLC
2590	Vaccinia Immune Globulin (Human) Intravenous	n/a	6/18/2004	Treatment of severe complications from the smallpox vaccine	DynPort Vaccine Company LLC
2591	Vaccinia Immune Globulin (Human) Intravenous	Cnj-016	6/18/2004	Treatment of complications of vaccinia vaccination	Cangene Corporation
2592	Valine, isoleucine and leucine	Vil	1/5/1996	Treatment of hyperphenylalaninemia	Leas Research Products
2593	valine-valine-ganciclovir	n/a	5/21/2007	Treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HSV1 and HSV2.	Verenta Pharmaceuticals, Inc.
2594	Valproate	n/a	5/5/2008	Treatment of fragile X syndrome	Neuropharm Ltd,
2595	Valrubicin	Valstar	5/23/1994	Treatment of carcinoma in situ of the urinary bladder.	Anthra Pharmaceuticals, Inc.
2596	vancomycin	n/a	12/27/2012	Treatment of endophthalmitis	Fera Pharmaceuticals, LLC
2597	vancomycin hydrochloride (inhalational)	n/a	9/20/2012	Treatment of persistent methicillin-resistant S. aureus lung infection in patients with cystic fibrosis	Savara Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2598	vandetanib	Caprelsa(R)	10/21/2005	Treatment of patients with follicular thyroid carcinoma, medullary thyroid carcinoma, anaplastic thyroid carcinoma, and locally advanced and metastatic papillary thyroid carcinoma	AstraZeneca Pharmaceutical LP
2599	Vapreotide	Sanvar	4/6/2004	Treatment of symptomatic carcinoid tumors	H3 Pharma, Inc.
2600	vapreotide	Octastatin	1/10/2000	Treatment of gastrointestinal and pancreatic fistulas.	Debiopharm S.A.
2601	vapreotide	Sanvar	1/10/2000	Treatment of esophageal variceal hemorrhage patients with portal hypertension.	Debiovision, Inc.
2602	vapreotide	Octastatin	3/6/2000	Prevention of early postoperative complications following pancreatic resection.	Debiopharm S.A.
2603	vapreotide	Sanvar	11/4/2003	Treatment of acromegaly	H3 Pharma, Inc.
2604	Varbulin	Azixa	11/5/2009	Treatment of glioblastoma multiforme.	Myrexix, Inc.
2605	Varicella Zoster Immune Globulin (Human)	Varizig	11/7/2006	Passive immunization for the treatment of exposed, susceptible individuals who are at risk of complications from varicella	Cangene bioPharma, Inc.
2606	vascular endothelial growth factor 165b	n/a	6/24/2008	Treatment of advanced melanoma stages IIb through IV.	PhiloGene, Inc.
2607	Vasoactive intestinal peptide	n/a	3/9/2001	Treatment of Acute Respiratory Distress Syndrome.	mondoBIOTECH
2608	vasoactive intestinal peptide (VIP)-elastin-like peptide (ELP) fusion protein	n/a	5/13/2014	Treatment of pulmonary arterial hypertension, WHO Group 1	PhaseBio Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2609	Vasoactive intestinal polypeptide	n/a	6/23/1993	Treatment of acute esophageal food impaction.	Research Triangle Pharmaceuticals
2610	vatiquinone	Vincerinone	1/31/2014	Treatment of Friedreich's ataxia	Edison Pharmaceuticals, Inc.
2611	velaglucerase-alfa	Vpriv	6/8/2009	Treatment of Gaucher disease	Shire Human Genetics Therapies, Inc.
2612	veliparib	n/a	11/20/2009	Treatment of hepatocellular carcinoma in combination with DNA-damaging agents	AbbVie, Inc.
2613	veliparib	n/a	5/9/2008	Treatment of glioblastoma multiforme when used in combination with DNA-damaging agents	AbbVie, Inc.
2614	veltuzumab	n/a	8/28/2008	Treatment of chronic lymphocytic leukemia	Immunomedics, Inc.
2615	vemurafenib	Zelboraf	11/26/2013	Treatment of anaplastic thyroid carcinoma and advanced papillary thyroid cancer whose tumors harbor a BRAF V600 mutation	Genentech, Inc.
2616	vemurafenib	Zelboraf	12/20/2010	Treatment of patients with IIb to Stage IV melanoma positive for the BRAF(v600) mutation	Hoffmann-La Roche, Inc.
2617	verteporfin	Visudyne(R)	3/9/2012	Treatment of chronic or recurrent central serous chorioretinopathy	Valeant Pharmaceuticals North America LLC
2618	vibriolysin	Vibrilase	6/16/2006	Debridement of severe, deep dermal burns in hospitalized patients	BioMarin Pharmaceutical Inc.
2619	vigabatrin	Sabril	6/12/2000	Treatment of infantile spasms.	H. Lundbeck A/S
2620	vinCRIStine sulfate LIPOSOME injection	Marqibo	1/8/2007	Treatment of acute lymphoblastic leukemia	Talon Therapeutics, Inc.
2621	vincristine sulfate liposomes	Marqibo	6/24/2008	Treatment of metastatic uveal melanoma.	Talon Therapeutics

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2622	vintafolide	n/a	12/16/2013	Treatment of ovarian cancer	Merck Sharp & Dohme Corp.
2623	Virulizin	Virulizin	2/1/2001	Treatment of pancreatic cancer.	ZOR Pharmaceuticals, LLC
2624	volasertib	n/a	4/14/2014	Treatment of acute myeloid leukemia	Boehringer Ingelheim Pharmaceuticals, Inc.
2625	vorinostat	Zolinza	3/16/2004	Treatment of T-cell non-Hodgkin's lymphoma	Merck & Co., Inc.
2626	vosaroxin	n/a	10/28/2009	Treatment of acute myeloid leukemia	Sunesis Pharmaceuticals, Inc.
2627	Water-miscible vitamin A palmitate	Aquasol A Parenteral	3/26/2010	Prevention of bronchopulmonary dysplasia.	Fox Pharma, Inc.
2628	Xenogeneic hepatocytes	Hepatassist Liver Assist System	11/27/1998	Treatment of severe liver failure.	Circe Biomedical, Inc.
2629	Yttrium (90Y) antiferritin polyclonal antibodies	Ferritarg P	9/18/2006	Treatment of Hodgkin's disease.	MAT Biopharma
2630	Yttrium(90Y)-DTPA-radiolabelled chimeric monoclonal antibody against frizzled homologue 10	n/a	12/3/2012	Treatment of soft tissue sarcoma	OncoTherapy Science, Inc.
2631	Yttrium-90 radiolabeled humanized monoclonal anti-carcinoembryonic antigen IgG antibody	Cea-Cide	8/3/1999	Treatment of ovarian carcinoma.	Immunomedics, Inc.
2632	Zalcitabine	n/a	12/9/1986	Treatment of AIDS.	National Cancer Institute, DCT
2633	Zalcitabine	Hivid	6/28/1988	Treatment of AIDS.	Hoffmann-La Roche, Inc.
2634	Zidovudine	Retrovir	7/17/1985	Treatment of AIDS related complex.	Glaxo Wellcome Inc.
2635	zidovudine	Retrovir	7/17/1985	Treatment of AIDS	Glaxo Wellcome Inc.
2636	Zinc acetate	Galzin	11/6/1985	Treatment of Wilson's disease.	Lemmon Company
2637	Zoledronate	Zometa, Zabel	8/18/2000	Treatment of tumor induced hypercalcemia.	Novartis Pharmaceuticals Corp.

Orphan Drug Designations and Approvals List as of 06-02-2014
Governs July 1, 2014 - September 30, 2014

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2638	zoledronic acid	Zometa, Reclast, Aclasta	5/6/2013	Treatment of complex regional pain syndrome (CRPS).	Axsome Therapeutics, Inc.
2639	Zosuquidar trihydrochloride	n/a	12/15/2005	Treatment of acute myeloid leukemia	Kanisa Pharmaceuticals, Inc.
2640		Dysport(R)	12/5/1991	Treatment of essential blepharospasm.	Ipsen Biopharmaceuticals, Inc.
2641		Nicord	4/28/2014	For the treatment of acute myeloid leukemia	Gamida Cell Ltd
2642		Biothrax	4/11/2014	For post-exposure prophylaxis of anthrax disease resulting from suspected or confirmed Bacillus anthracis exposure	Emergent Product Development Gaithersburg, Inc.